WO2024086644A1 - Cereblon ligands and uses thereof - Google Patents
Cereblon ligands and uses thereof Download PDFInfo
- Publication number
- WO2024086644A1 WO2024086644A1 PCT/US2023/077191 US2023077191W WO2024086644A1 WO 2024086644 A1 WO2024086644 A1 WO 2024086644A1 US 2023077191 W US2023077191 W US 2023077191W WO 2024086644 A1 WO2024086644 A1 WO 2024086644A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- carbocyclyl
- alkynyl
- alkenyl
- aryl
- Prior art date
Links
- 101000941994 Homo sapiens Protein cereblon Proteins 0.000 title claims abstract description 42
- 102100032783 Protein cereblon Human genes 0.000 title claims abstract description 42
- 239000003446 ligand Substances 0.000 title claims description 23
- 150000001875 compounds Chemical class 0.000 claims abstract description 262
- 150000003839 salts Chemical class 0.000 claims abstract description 81
- 239000012453 solvate Substances 0.000 claims abstract description 71
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 34
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 34
- 230000000593 degrading effect Effects 0.000 claims abstract description 13
- 125000000623 heterocyclic group Chemical group 0.000 claims description 276
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 261
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 189
- 229910052739 hydrogen Inorganic materials 0.000 claims description 144
- 239000001257 hydrogen Substances 0.000 claims description 144
- 125000000217 alkyl group Chemical group 0.000 claims description 127
- 125000003118 aryl group Chemical group 0.000 claims description 116
- 125000001072 heteroaryl group Chemical group 0.000 claims description 114
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 111
- 150000002431 hydrogen Chemical group 0.000 claims description 110
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 109
- 125000004432 carbon atom Chemical group C* 0.000 claims description 109
- 125000000304 alkynyl group Chemical group 0.000 claims description 108
- 125000003342 alkenyl group Chemical group 0.000 claims description 105
- 229910052736 halogen Inorganic materials 0.000 claims description 101
- 150000002367 halogens Chemical group 0.000 claims description 100
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 98
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 94
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 94
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 93
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 91
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 91
- 125000003545 alkoxy group Chemical group 0.000 claims description 85
- 125000003282 alkyl amino group Chemical group 0.000 claims description 84
- 238000000034 method Methods 0.000 claims description 46
- 229910052760 oxygen Inorganic materials 0.000 claims description 39
- 125000006706 (C3-C6) carbocyclyl group Chemical group 0.000 claims description 34
- 229910052757 nitrogen Inorganic materials 0.000 claims description 32
- 125000001424 substituent group Chemical group 0.000 claims description 32
- 239000012472 biological sample Substances 0.000 claims description 30
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 23
- 125000004429 atom Chemical group 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 230000027455 binding Effects 0.000 claims description 18
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 15
- 229910052770 Uranium Inorganic materials 0.000 claims description 15
- 229910052727 yttrium Inorganic materials 0.000 claims description 15
- 108010080146 androgen receptors Proteins 0.000 claims description 11
- 108010038795 estrogen receptors Proteins 0.000 claims description 11
- 108010017324 STAT3 Transcription Factor Proteins 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 9
- 102100029895 Bromodomain-containing protein 4 Human genes 0.000 claims description 8
- 101710126815 Bromodomain-containing protein 4 Proteins 0.000 claims description 8
- 102100038885 Histone acetyltransferase p300 Human genes 0.000 claims description 8
- 102000001712 STAT5 Transcription Factor Human genes 0.000 claims description 8
- 108010029477 STAT5 Transcription Factor Proteins 0.000 claims description 8
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 claims description 8
- 102200006539 rs121913529 Human genes 0.000 claims description 8
- 102100032187 Androgen receptor Human genes 0.000 claims description 7
- 101000702559 Homo sapiens Probable global transcription activator SNF2L2 Proteins 0.000 claims description 7
- 102100031021 Probable global transcription activator SNF2L2 Human genes 0.000 claims description 7
- 125000006244 carboxylic acid protecting group Chemical group 0.000 claims description 7
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 6
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 6
- 229910052805 deuterium Inorganic materials 0.000 claims description 6
- 102000014914 Carrier Proteins Human genes 0.000 claims description 5
- 108091008324 binding proteins Proteins 0.000 claims description 5
- 108010040163 CREB-Binding Protein Proteins 0.000 claims description 4
- 102100021975 CREB-binding protein Human genes 0.000 claims description 4
- 101710204864 Tyrosine-protein phosphatase 2 Proteins 0.000 claims description 4
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 claims description 4
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 claims description 4
- 101000702545 Homo sapiens Transcription activator BRG1 Proteins 0.000 claims description 3
- 102100031027 Transcription activator BRG1 Human genes 0.000 claims description 3
- 102100038595 Estrogen receptor Human genes 0.000 claims 2
- 239000001064 degrader Substances 0.000 abstract description 5
- 230000001588 bifunctional effect Effects 0.000 abstract description 4
- 239000011230 binding agent Substances 0.000 abstract description 3
- -1 n- propyl Chemical group 0.000 description 331
- 125000005842 heteroatom Chemical group 0.000 description 105
- 239000000203 mixture Substances 0.000 description 103
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 100
- 239000000243 solution Substances 0.000 description 94
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 80
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 67
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 60
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 58
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 58
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 57
- 239000011541 reaction mixture Substances 0.000 description 48
- 229910001868 water Inorganic materials 0.000 description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 46
- 239000007787 solid Substances 0.000 description 40
- 238000005160 1H NMR spectroscopy Methods 0.000 description 39
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 38
- 201000010099 disease Diseases 0.000 description 37
- 235000019439 ethyl acetate Nutrition 0.000 description 35
- 239000012267 brine Substances 0.000 description 34
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 34
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 33
- 239000000741 silica gel Substances 0.000 description 33
- 229910002027 silica gel Inorganic materials 0.000 description 33
- 238000003818 flash chromatography Methods 0.000 description 32
- 229910052717 sulfur Inorganic materials 0.000 description 32
- 239000007832 Na2SO4 Substances 0.000 description 30
- 125000004404 heteroalkyl group Chemical group 0.000 description 30
- 229910052938 sodium sulfate Inorganic materials 0.000 description 30
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 29
- 239000012043 crude product Substances 0.000 description 29
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 28
- 239000012044 organic layer Substances 0.000 description 28
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 25
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- 235000018102 proteins Nutrition 0.000 description 24
- 239000003208 petroleum Substances 0.000 description 23
- 239000000126 substance Substances 0.000 description 23
- 239000001301 oxygen Substances 0.000 description 22
- 239000002904 solvent Substances 0.000 description 22
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 21
- 208000035475 disorder Diseases 0.000 description 21
- 229920006395 saturated elastomer Polymers 0.000 description 21
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 20
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 20
- 150000003254 radicals Chemical class 0.000 description 20
- 235000011152 sodium sulphate Nutrition 0.000 description 20
- 239000011593 sulfur Substances 0.000 description 20
- 125000004043 oxo group Chemical group O=* 0.000 description 19
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 238000003786 synthesis reaction Methods 0.000 description 17
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 17
- 229910052796 boron Inorganic materials 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 16
- 239000000706 filtrate Substances 0.000 description 16
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 16
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 16
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 16
- 238000006467 substitution reaction Methods 0.000 description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 15
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- 239000012230 colorless oil Substances 0.000 description 14
- 125000004122 cyclic group Chemical group 0.000 description 14
- 239000003921 oil Substances 0.000 description 14
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 14
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 13
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 13
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 13
- 229910052799 carbon Inorganic materials 0.000 description 12
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 11
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 11
- 229940024606 amino acid Drugs 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 238000001704 evaporation Methods 0.000 description 11
- 230000008020 evaporation Effects 0.000 description 11
- 238000001914 filtration Methods 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 11
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 10
- 239000002585 base Substances 0.000 description 10
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 10
- 125000000524 functional group Chemical group 0.000 description 10
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 10
- 230000001404 mediated effect Effects 0.000 description 10
- 125000002950 monocyclic group Chemical group 0.000 description 10
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 10
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
- 102000015694 estrogen receptors Human genes 0.000 description 9
- 125000003003 spiro group Chemical group 0.000 description 9
- 229960003433 thalidomide Drugs 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 8
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 8
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 8
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 125000004450 alkenylene group Chemical group 0.000 description 8
- 125000001309 chloro group Chemical group Cl* 0.000 description 8
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 8
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 8
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 8
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 8
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 8
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 8
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 125000001624 naphthyl group Chemical group 0.000 description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 8
- 125000006017 1-propenyl group Chemical group 0.000 description 7
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 7
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 7
- YCPULGHBTPQLRH-UHFFFAOYSA-N 3-aminopiperidine-2,6-dione;hydron;chloride Chemical compound Cl.NC1CCC(=O)NC1=O YCPULGHBTPQLRH-UHFFFAOYSA-N 0.000 description 7
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 7
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 7
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 7
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 7
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 7
- 125000002947 alkylene group Chemical group 0.000 description 7
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 7
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 7
- BVCRERJDOOBZOH-UHFFFAOYSA-N bicyclo[2.2.1]heptanyl Chemical group C1C[C+]2CC[C-]1C2 BVCRERJDOOBZOH-UHFFFAOYSA-N 0.000 description 7
- 125000001246 bromo group Chemical group Br* 0.000 description 7
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 7
- 125000002188 cycloheptatrienyl group Chemical group C1(=CC=CC=CC1)* 0.000 description 7
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 7
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 7
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 7
- 125000004090 cyclononenyl group Chemical group C1(=CCCCCCCC1)* 0.000 description 7
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 7
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 7
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 7
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 7
- 125000005508 decahydronaphthalenyl group Chemical group 0.000 description 7
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 7
- 125000006038 hexenyl group Chemical group 0.000 description 7
- 125000005980 hexynyl group Chemical group 0.000 description 7
- 150000007524 organic acids Chemical class 0.000 description 7
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 7
- 125000005981 pentynyl group Chemical group 0.000 description 7
- 229910052698 phosphorus Inorganic materials 0.000 description 7
- 239000011574 phosphorus Substances 0.000 description 7
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 7
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 7
- WNZQDUSMALZDQF-UHFFFAOYSA-N 2-benzofuran-1(3H)-one Chemical compound C1=CC=C2C(=O)OCC2=C1 WNZQDUSMALZDQF-UHFFFAOYSA-N 0.000 description 6
- UZBLIXHRHKMMPY-UHFFFAOYSA-N 5-bromo-4-hydroxy-3h-2-benzofuran-1-one Chemical compound C1=C(Br)C(O)=C2COC(=O)C2=C1 UZBLIXHRHKMMPY-UHFFFAOYSA-N 0.000 description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 6
- 125000004419 alkynylene group Chemical group 0.000 description 6
- 150000001721 carbon Chemical group 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 6
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 6
- TZIHFWKZFHZASV-UHFFFAOYSA-N methyl formate Chemical compound COC=O TZIHFWKZFHZASV-UHFFFAOYSA-N 0.000 description 6
- 150000007522 mineralic acids Chemical class 0.000 description 6
- 125000006606 n-butoxy group Chemical group 0.000 description 6
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 6
- 125000006574 non-aromatic ring group Chemical group 0.000 description 6
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 229910052710 silicon Inorganic materials 0.000 description 6
- 239000010703 silicon Substances 0.000 description 6
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 5
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 5
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 5
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 5
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 5
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 5
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 5
- 125000005647 linker group Chemical group 0.000 description 5
- 238000002953 preparative HPLC Methods 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 5
- DBGVGMSCBYYSLD-UHFFFAOYSA-N tributylstannane Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 4
- 150000001412 amines Chemical group 0.000 description 4
- 235000019270 ammonium chloride Nutrition 0.000 description 4
- 102000001307 androgen receptors Human genes 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 125000005549 heteroarylene group Chemical group 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 229960004942 lenalidomide Drugs 0.000 description 4
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 4
- TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical group OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 125000003367 polycyclic group Chemical group 0.000 description 4
- 239000011698 potassium fluoride Substances 0.000 description 4
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical group OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 3
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 3
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 3
- OITBAMYZXSPIPR-UHFFFAOYSA-N 2-methylidene-5-phenylmethoxypentanal Chemical compound O=CC(=C)CCCOCC1=CC=CC=C1 OITBAMYZXSPIPR-UHFFFAOYSA-N 0.000 description 3
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000005711 Benzoic acid Substances 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 3
- 125000005915 C6-C14 aryl group Chemical group 0.000 description 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 3
- 239000005977 Ethylene Substances 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 235000010233 benzoic acid Nutrition 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthene Chemical compound C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 125000004474 heteroalkylene group Chemical group 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 125000005394 methallyl group Chemical group 0.000 description 3
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 150000002894 organic compounds Chemical class 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 3
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 125000000547 substituted alkyl group Chemical group 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 3
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- 125000006585 (C6-C10) arylene group Chemical group 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- AMMPLVWPWSYRDR-UHFFFAOYSA-N 1-methylbicyclo[2.2.2]oct-2-ene-4-carboxylic acid Chemical compound C1CC2(C(O)=O)CCC1(C)C=C2 AMMPLVWPWSYRDR-UHFFFAOYSA-N 0.000 description 2
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical group C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 2
- WJRFMEFSYATRFI-UHFFFAOYSA-N 2-methylidene-4-phenylmethoxybutan-1-ol Chemical compound OCC(=C)CCOCC1=CC=CC=C1 WJRFMEFSYATRFI-UHFFFAOYSA-N 0.000 description 2
- XECYWBLONQYPGQ-UHFFFAOYSA-N 2-methylidene-4-phenylmethoxybutanal Chemical compound O=CC(=C)CCOCC1=CC=CC=C1 XECYWBLONQYPGQ-UHFFFAOYSA-N 0.000 description 2
- XLZYKTYMLBOINK-UHFFFAOYSA-N 3-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(C(=O)C=2C=CC(O)=CC=2)=C1 XLZYKTYMLBOINK-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- JUJHZOVDCJJUJK-UHFFFAOYSA-N 3-methylidenepentane-1,5-diol Chemical compound OCCC(=C)CCO JUJHZOVDCJJUJK-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 2
- RZVDPWSEPVHOPU-UHFFFAOYSA-N 5-phenylmethoxypentan-1-ol Chemical compound OCCCCCOCC1=CC=CC=C1 RZVDPWSEPVHOPU-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- AXICIBPYBONRSP-UHFFFAOYSA-N Anofinic acid Chemical compound C1=C(C(O)=O)C=C2C=CC(C)(C)OC2=C1 AXICIBPYBONRSP-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- 102000011045 Chloride Channels Human genes 0.000 description 2
- 108010062745 Chloride Channels Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 2
- 101710159242 Cullin-4A Proteins 0.000 description 2
- 102100028907 Cullin-4A Human genes 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Chemical group OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 2
- 102100023877 E3 ubiquitin-protein ligase RBX1 Human genes 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Chemical group OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001111722 Homo sapiens E3 ubiquitin-protein ligase RBX1 Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 244000062939 Leptospermum ericoides Species 0.000 description 2
- 229910010084 LiAlH4 Inorganic materials 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Chemical group OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 102000004495 STAT3 Transcription Factor Human genes 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 125000000732 arylene group Chemical group 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- WDECIBYCCFPHNR-UHFFFAOYSA-N chrysene Chemical compound C1=CC=CC2=CC=C3C4=CC=CC=C4C=CC3=C21 WDECIBYCCFPHNR-UHFFFAOYSA-N 0.000 description 2
- 235000013985 cinnamic acid Nutrition 0.000 description 2
- 229930016911 cinnamic acid Natural products 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- VPUGDVKSAQVFFS-UHFFFAOYSA-N coronene Chemical compound C1=C(C2=C34)C=CC3=CC=C(C=C3)C4=C4C3=CC=C(C=C3)C4=C2C3=C1 VPUGDVKSAQVFFS-UHFFFAOYSA-N 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000174 gluconic acid Chemical group 0.000 description 2
- 235000012208 gluconic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Chemical group 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- CPJRRXSHAYUTGL-UHFFFAOYSA-N isopentenyl alcohol Chemical compound CC(=C)CCO CPJRRXSHAYUTGL-UHFFFAOYSA-N 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 229960002510 mandelic acid Drugs 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- GPKUICFDWYEPTK-UHFFFAOYSA-N methoxycyclohexatriene Chemical compound COC1=CC=C=C[CH]1 GPKUICFDWYEPTK-UHFFFAOYSA-N 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 2
- 230000036457 multidrug resistance Effects 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Chemical group OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- GBROPGWFBFCKAG-UHFFFAOYSA-N picene Chemical compound C1=CC2=C3C=CC=CC3=CC=C2C2=C1C1=CC=CC=C1C=C2 GBROPGWFBFCKAG-UHFFFAOYSA-N 0.000 description 2
- 229960000688 pomalidomide Drugs 0.000 description 2
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 229940121649 protein inhibitor Drugs 0.000 description 2
- 239000012268 protein inhibitor Substances 0.000 description 2
- 238000011865 proteolysis targeting chimera technique Methods 0.000 description 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
- 229940107700 pyruvic acid Drugs 0.000 description 2
- 238000005956 quaternization reaction Methods 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 150000003384 small molecules Chemical group 0.000 description 2
- 108010026668 snake venom protein C activator Proteins 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000008117 stearic acid Chemical group 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 238000003419 tautomerization reaction Methods 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- UAYWVJHJZHQCIE-UHFFFAOYSA-L zinc iodide Chemical compound I[Zn]I UAYWVJHJZHQCIE-UHFFFAOYSA-L 0.000 description 2
- JLIDBLDQVAYHNE-YKALOCIXSA-N (+)-Abscisic acid Chemical compound OC(=O)/C=C(/C)\C=C\[C@@]1(O)C(C)=CC(=O)CC1(C)C JLIDBLDQVAYHNE-YKALOCIXSA-N 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- OWTSKJPRWFIYHU-SFHVURJKSA-N (2s)-5-hydroxy-2-(4-hydroxyphenyl)-7-methoxy-8-(3-methylbut-2-enyl)-2,3-dihydrochromen-4-one Chemical compound C1([C@@H]2CC(=O)C3=C(O)C=C(C(=C3O2)CC=C(C)C)OC)=CC=C(O)C=C1 OWTSKJPRWFIYHU-SFHVURJKSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 1
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 description 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- 125000006545 (C1-C9) alkyl group Chemical group 0.000 description 1
- 125000006649 (C2-C20) alkynyl group Chemical group 0.000 description 1
- 125000006592 (C2-C3) alkenyl group Chemical group 0.000 description 1
- 125000006593 (C2-C3) alkynyl group Chemical group 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 1
- FPLKPCUDKVEJDK-UHFFFAOYSA-N 1-(2,3-dimethoxy-5-prop-2-enylphenyl)-2,3-dimethoxy-5-prop-2-enylbenzene Chemical compound COC1=CC(CC=C)=CC(C=2C(=C(OC)C=C(CC=C)C=2)OC)=C1OC FPLKPCUDKVEJDK-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- LJCZNYWLQZZIOS-UHFFFAOYSA-N 2,2,2-trichlorethoxycarbonyl chloride Chemical compound ClC(=O)OCC(Cl)(Cl)Cl LJCZNYWLQZZIOS-UHFFFAOYSA-N 0.000 description 1
- HMBHAQMOBKLWRX-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxine-3-carboxylic acid Chemical compound C1=CC=C2OC(C(=O)O)COC2=C1 HMBHAQMOBKLWRX-UHFFFAOYSA-N 0.000 description 1
- YXYOLVAXVPOIMA-UHFFFAOYSA-N 2,3-dihydro-1-benzofuran-5-carboxylic acid Chemical compound OC(=O)C1=CC=C2OCCC2=C1 YXYOLVAXVPOIMA-UHFFFAOYSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- 125000006516 2-(benzyloxy)ethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 1
- GNNSSYYFBOBGRB-UHFFFAOYSA-N 2-(phenylmethoxymethyl)prop-2-en-1-ol Chemical compound OCC(=C)COCC1=CC=CC=C1 GNNSSYYFBOBGRB-UHFFFAOYSA-N 0.000 description 1
- NRFSKDSNWWTEJH-UHFFFAOYSA-N 2-(phenylmethoxymethyl)prop-2-enal Chemical compound O=CC(=C)COCC1=CC=CC=C1 NRFSKDSNWWTEJH-UHFFFAOYSA-N 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 1
- MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 description 1
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- MNURPFVONZPVLA-UHFFFAOYSA-N 2-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1Cl MNURPFVONZPVLA-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- USEGQJLHQSTGHW-UHFFFAOYSA-N 3-bromo-2-methylprop-1-ene Chemical compound CC(=C)CBr USEGQJLHQSTGHW-UHFFFAOYSA-N 0.000 description 1
- XJFZOSUFGSANIF-UHFFFAOYSA-N 3-chloro-2-(chloromethyl)prop-1-ene Chemical compound ClCC(=C)CCl XJFZOSUFGSANIF-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- 108010091324 3C proteases Proteins 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- OOXNYFKPOPJIOT-UHFFFAOYSA-N 5-(3-bromophenyl)-7-(6-morpholin-4-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-4-amine;dihydrochloride Chemical compound Cl.Cl.C=12C(N)=NC=NC2=NC(C=2C=NC(=CC=2)N2CCOCC2)=CC=1C1=CC=CC(Br)=C1 OOXNYFKPOPJIOT-UHFFFAOYSA-N 0.000 description 1
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 1
- QJEJYBQYGQJKSK-UHFFFAOYSA-N 5-hydroxy-3h-2-benzofuran-1-one Chemical compound OC1=CC=C2C(=O)OCC2=C1 QJEJYBQYGQJKSK-UHFFFAOYSA-N 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- QREBEZZOILCJEP-UHFFFAOYSA-N 6-(3-methoxyphenyl)hex-1-en-3-one Chemical compound COC1=CC=CC(CCCC(=O)C=C)=C1 QREBEZZOILCJEP-UHFFFAOYSA-N 0.000 description 1
- TYNSUEXNGLNQSS-UHFFFAOYSA-N 6-carbamoyl-5-hydroxy-4-methoxy-7,8-dihydro-3h-pyrrolo[3,2-e]indole-2-carboxylic acid Chemical compound C1=2C=C(C(O)=O)NC=2C(OC)=C(O)C2=C1CCN2C(N)=O TYNSUEXNGLNQSS-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 102000006267 AMP Deaminase Human genes 0.000 description 1
- 108700016228 AMP deaminases Proteins 0.000 description 1
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 description 1
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102100032534 Adenosine kinase Human genes 0.000 description 1
- 108010076278 Adenosine kinase Proteins 0.000 description 1
- 102000009346 Adenosine receptors Human genes 0.000 description 1
- 108050000203 Adenosine receptors Proteins 0.000 description 1
- 108010056443 Adenylosuccinate synthase Proteins 0.000 description 1
- 102100024085 Alpha-aminoadipic semialdehyde dehydrogenase Human genes 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 102000005590 Anaphylatoxin C5a Receptor Human genes 0.000 description 1
- 108010059426 Anaphylatoxin C5a Receptor Proteins 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 1
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 108010018763 Biotin carboxylase Proteins 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 description 1
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 description 1
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 description 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 108091007914 CDKs Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000003846 Carbonic anhydrases Human genes 0.000 description 1
- 108090000209 Carbonic anhydrases Proteins 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108090000426 Caspase-1 Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 101150065749 Churc1 gene Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 101710094481 Cullin-4 Proteins 0.000 description 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
- 108010037464 Cyclooxygenase 1 Proteins 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- 102100037799 DNA-binding protein Ikaros Human genes 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 102000010180 Endothelin receptor Human genes 0.000 description 1
- 108050001739 Endothelin receptor Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 102000007317 Farnesyltranstransferase Human genes 0.000 description 1
- 108010007508 Farnesyltranstransferase Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 102000011714 Glycine Receptors Human genes 0.000 description 1
- 108010076533 Glycine Receptors Proteins 0.000 description 1
- 102000007390 Glycogen Phosphorylase Human genes 0.000 description 1
- 108010046163 Glycogen Phosphorylase Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 102000000543 Histamine Receptors Human genes 0.000 description 1
- 108010002059 Histamine Receptors Proteins 0.000 description 1
- 101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 description 1
- 101000599038 Homo sapiens DNA-binding protein Ikaros Proteins 0.000 description 1
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
- 101001033312 Homo sapiens Interleukin-4 receptor subunit alpha Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 101000606741 Homo sapiens Phosphoribosylglycinamide formyltransferase Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 description 1
- 101000599042 Homo sapiens Zinc finger protein Aiolos Proteins 0.000 description 1
- 108010016183 Human immunodeficiency virus 1 p16 protease Proteins 0.000 description 1
- 108700020129 Human immunodeficiency virus 1 p31 integrase Proteins 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- GRSZFWQUAKGDAV-KQYNXXCUSA-N IMP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-N 0.000 description 1
- 108091069197 Ikaros C2H2-type zinc-finger protein family Proteins 0.000 description 1
- 102000039995 Ikaros C2H2-type zinc-finger protein family Human genes 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102100022337 Integrin alpha-V Human genes 0.000 description 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 102100039078 Interleukin-4 receptor subunit alpha Human genes 0.000 description 1
- 108010018951 Interleukin-8B Receptors Proteins 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 108010002481 Lymphocyte Specific Protein Tyrosine Kinase p56(lck) Proteins 0.000 description 1
- 102000036243 Lymphocyte Specific Protein Tyrosine Kinase p56(lck) Human genes 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 102000004722 NADPH Oxidases Human genes 0.000 description 1
- 108010002998 NADPH Oxidases Proteins 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 101150111783 NTRK1 gene Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 108050002826 Neuropeptide Y Receptor Proteins 0.000 description 1
- 102000012301 Neuropeptide Y receptor Human genes 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 102100027069 Odontogenic ameloblast-associated protein Human genes 0.000 description 1
- 101710091533 Odontogenic ameloblast-associated protein Proteins 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 102100028139 Oxytocin receptor Human genes 0.000 description 1
- 108090000876 Oxytocin receptors Proteins 0.000 description 1
- 102100037600 P2Y purinoceptor 1 Human genes 0.000 description 1
- 108050008996 P2Y purinoceptor 1 Proteins 0.000 description 1
- 102100028045 P2Y purinoceptor 2 Human genes 0.000 description 1
- 101710096700 P2Y purinoceptor 2 Proteins 0.000 description 1
- 102100028070 P2Y purinoceptor 4 Human genes 0.000 description 1
- 108050009478 P2Y purinoceptor 4 Proteins 0.000 description 1
- 102100028074 P2Y purinoceptor 6 Human genes 0.000 description 1
- 101710096702 P2Y purinoceptor 6 Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 244000025272 Persea americana Species 0.000 description 1
- 235000008673 Persea americana Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 102100039654 Phosphoribosylglycinamide formyltransferase Human genes 0.000 description 1
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 1
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710101148 Probable 6-oxopurine nucleoside phosphorylase Proteins 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 102100038239 Protein Churchill Human genes 0.000 description 1
- 108020001991 Protoporphyrinogen Oxidase Proteins 0.000 description 1
- 102000005135 Protoporphyrinogen oxidase Human genes 0.000 description 1
- 102000030764 Purine-nucleoside phosphorylase Human genes 0.000 description 1
- 102000000033 Purinergic Receptors Human genes 0.000 description 1
- 108010080192 Purinergic Receptors Proteins 0.000 description 1
- 108090000944 RNA Helicases Proteins 0.000 description 1
- 102000004409 RNA Helicases Human genes 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108091006731 SLCO1B1 Proteins 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- 101800001838 Serine protease/helicase NS3 Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 239000004280 Sodium formate Substances 0.000 description 1
- 102100027233 Solute carrier organic anion transporter family member 1B1 Human genes 0.000 description 1
- 229940119502 Squalene cyclase inhibitor Drugs 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 1
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 206010043275 Teratogenicity Diseases 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000005497 Thymidylate Synthase Human genes 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- SLGBZMMZGDRARJ-UHFFFAOYSA-N Triphenylene Natural products C1=CC=C2C3=CC=CC=C3C3=CC=CC=C3C2=C1 SLGBZMMZGDRARJ-UHFFFAOYSA-N 0.000 description 1
- 102000001400 Tryptase Human genes 0.000 description 1
- 108060005989 Tryptase Proteins 0.000 description 1
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 1
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 108010005705 Ubiquitinated Proteins Proteins 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 101710135349 Venom phosphodiesterase Proteins 0.000 description 1
- 108010048673 Vitronectin Receptors Proteins 0.000 description 1
- ZZXDRXVIRVJQBT-UHFFFAOYSA-M Xylenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-M 0.000 description 1
- 102100037798 Zinc finger protein Aiolos Human genes 0.000 description 1
- QVXFGVVYTKZLJN-KHPPLWFESA-N [(z)-hexadec-7-enyl] acetate Chemical compound CCCCCCCC\C=C/CCCCCCOC(C)=O QVXFGVVYTKZLJN-KHPPLWFESA-N 0.000 description 1
- JDPAVWAQGBGGHD-UHFFFAOYSA-N aceanthrylene Chemical group C1=CC=C2C(C=CC3=CC=C4)=C3C4=CC2=C1 JDPAVWAQGBGGHD-UHFFFAOYSA-N 0.000 description 1
- 125000004054 acenaphthylenyl group Chemical group C1(=CC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- SQFPKRNUGBRTAR-UHFFFAOYSA-N acephenanthrylene Chemical group C1=CC(C=C2)=C3C2=CC2=CC=CC=C2C3=C1 SQFPKRNUGBRTAR-UHFFFAOYSA-N 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- HXGDTGSAIMULJN-UHFFFAOYSA-N acetnaphthylene Natural products C1=CC(C=C2)=C3C2=CC=CC3=C1 HXGDTGSAIMULJN-UHFFFAOYSA-N 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 102000005130 adenylosuccinate synthetase Human genes 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- KNNXFYIMEYKHBZ-UHFFFAOYSA-N as-indacene Chemical compound C1=CC2=CC=CC2=C2C=CC=C21 KNNXFYIMEYKHBZ-UHFFFAOYSA-N 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 229940075419 choline hydroxide Drugs 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 102000022604 damaged DNA binding proteins Human genes 0.000 description 1
- 108091013406 damaged DNA binding proteins Proteins 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000004582 dihydrobenzothienyl group Chemical group S1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 230000008406 drug-drug interaction Effects 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 108010068613 ecdysone 20-hydroxylase Proteins 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- VVDUZZGYBOWDSQ-UHFFFAOYSA-M eschenmoser's salt Chemical compound [I-].C[N+](C)=C VVDUZZGYBOWDSQ-UHFFFAOYSA-M 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 1
- HQVFCQRVQFYGRJ-UHFFFAOYSA-N formic acid;hydrate Chemical compound O.OC=O HQVFCQRVQFYGRJ-UHFFFAOYSA-N 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 125000002686 geranylgeranyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000004475 heteroaralkyl group Chemical group 0.000 description 1
- KKLGDUSGQMHBPB-UHFFFAOYSA-N hex-2-ynedioic acid Chemical compound OC(=O)CCC#CC(O)=O KKLGDUSGQMHBPB-UHFFFAOYSA-N 0.000 description 1
- QSQIGGCOCHABAP-UHFFFAOYSA-N hexacene Chemical compound C1=CC=CC2=CC3=CC4=CC5=CC6=CC=CC=C6C=C5C=C4C=C3C=C21 QSQIGGCOCHABAP-UHFFFAOYSA-N 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 239000004312 hexamethylene tetramine Substances 0.000 description 1
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- PKIFBGYEEVFWTJ-UHFFFAOYSA-N hexaphene Chemical compound C1=CC=C2C=C3C4=CC5=CC6=CC=CC=C6C=C5C=C4C=CC3=CC2=C1 PKIFBGYEEVFWTJ-UHFFFAOYSA-N 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 235000013902 inosinic acid Nutrition 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 229940127215 low-molecular weight heparin Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- IZDROVVXIHRYMH-UHFFFAOYSA-N methanesulfonic anhydride Chemical compound CS(=O)(=O)OS(C)(=O)=O IZDROVVXIHRYMH-UHFFFAOYSA-N 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- VYOFPLOREOHCDP-UHFFFAOYSA-N methyl 4-bromo-3-hydroxybenzoate Chemical compound COC(=O)C1=CC=C(Br)C(O)=C1 VYOFPLOREOHCDP-UHFFFAOYSA-N 0.000 description 1
- UPIJOAFHOIWPLT-UHFFFAOYSA-N methyl 4-tert-butylbenzoate Chemical compound COC(=O)C1=CC=C(C(C)(C)C)C=C1 UPIJOAFHOIWPLT-UHFFFAOYSA-N 0.000 description 1
- IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- TZJOIDXKFOTKCW-UHFFFAOYSA-N n-cyclohexylcyclohexanamine;5-[(2-methylpropan-2-yl)oxy]-5-oxo-2-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound C1CCCCC1NC1CCCCC1.CC(C)(C)OC(=O)CCC(C(O)=O)NC(=O)OCC1=CC=CC=C1 TZJOIDXKFOTKCW-UHFFFAOYSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- VLZLOWPYUQHHCG-UHFFFAOYSA-N nitromethylbenzene Chemical compound [O-][N+](=O)CC1=CC=CC=C1 VLZLOWPYUQHHCG-UHFFFAOYSA-N 0.000 description 1
- 230000000966 norepinephrine reuptake Effects 0.000 description 1
- 125000001736 nosyl group Chemical group S(=O)(=O)(C1=CC=C([N+](=O)[O-])C=C1)* 0.000 description 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
- PFTXKXWAXWAZBP-UHFFFAOYSA-N octacene Chemical compound C1=CC=CC2=CC3=CC4=CC5=CC6=CC7=CC8=CC=CC=C8C=C7C=C6C=C5C=C4C=C3C=C21 PFTXKXWAXWAZBP-UHFFFAOYSA-N 0.000 description 1
- OVPVGJFDFSJUIG-UHFFFAOYSA-N octalene Chemical compound C1=CC=CC=C2C=CC=CC=CC2=C1 OVPVGJFDFSJUIG-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- WTFQBTLMPISHTA-UHFFFAOYSA-N octaphene Chemical compound C1=CC=C2C=C(C=C3C4=CC5=CC6=CC7=CC=CC=C7C=C6C=C5C=C4C=CC3=C3)C3=CC2=C1 WTFQBTLMPISHTA-UHFFFAOYSA-N 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 150000002905 orthoesters Chemical class 0.000 description 1
- LSQODMMMSXHVCN-UHFFFAOYSA-N ovalene Chemical compound C1=C(C2=C34)C=CC3=CC=C(C=C3C5=C6C(C=C3)=CC=C3C6=C6C(C=C3)=C3)C4=C5C6=C2C3=C1 LSQODMMMSXHVCN-UHFFFAOYSA-N 0.000 description 1
- 125000005882 oxadiazolinyl group Chemical group 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003551 oxepanyl group Chemical group 0.000 description 1
- 125000003585 oxepinyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- PMJHHCWVYXUKFD-UHFFFAOYSA-N penta-1,3-diene Chemical compound CC=CC=C PMJHHCWVYXUKFD-UHFFFAOYSA-N 0.000 description 1
- SLIUAWYAILUBJU-UHFFFAOYSA-N pentacene Chemical compound C1=CC=CC2=CC3=CC4=CC5=CC=CC=C5C=C4C=C3C=C21 SLIUAWYAILUBJU-UHFFFAOYSA-N 0.000 description 1
- GUVXZFRDPCKWEM-UHFFFAOYSA-N pentalene Chemical compound C1=CC2=CC=CC2=C1 GUVXZFRDPCKWEM-UHFFFAOYSA-N 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- JQQSUOJIMKJQHS-UHFFFAOYSA-N pentaphene Chemical compound C1=CC=C2C=C3C4=CC5=CC=CC=C5C=C4C=CC3=CC2=C1 JQQSUOJIMKJQHS-UHFFFAOYSA-N 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 125000002080 perylenyl group Chemical group C1(=CC=C2C=CC=C3C4=CC=CC5=CC=CC(C1=C23)=C45)* 0.000 description 1
- CSHWQDPOILHKBI-UHFFFAOYSA-N peryrene Natural products C1=CC(C2=CC=CC=3C2=C2C=CC=3)=C3C2=CC=CC3=C1 CSHWQDPOILHKBI-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NQFOGDIWKQWFMN-UHFFFAOYSA-N phenalene Chemical compound C1=CC([CH]C=C2)=C3C2=CC=CC3=C1 NQFOGDIWKQWFMN-UHFFFAOYSA-N 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- DIJNSQQKNIVDPV-UHFFFAOYSA-N pleiadene Chemical compound C1=C2[CH]C=CC=C2C=C2C=CC=C3[C]2C1=CC=C3 DIJNSQQKNIVDPV-UHFFFAOYSA-N 0.000 description 1
- BITYAPCSNKJESK-UHFFFAOYSA-N potassiosodium Chemical compound [Na].[K] BITYAPCSNKJESK-UHFFFAOYSA-N 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 125000006410 propenylene group Chemical group 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-M propynoate Chemical compound [O-]C(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-M 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- LNKHTYQPVMAJSF-UHFFFAOYSA-N pyranthrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC3=C(C=CC=C4)C4=CC4=CC=C1C2=C34 LNKHTYQPVMAJSF-UHFFFAOYSA-N 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000007154 radical cyclization reaction Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- FMKFBRKHHLWKDB-UHFFFAOYSA-N rubicene Chemical compound C12=CC=CC=C2C2=CC=CC3=C2C1=C1C=CC=C2C4=CC=CC=C4C3=C21 FMKFBRKHHLWKDB-UHFFFAOYSA-N 0.000 description 1
- WEMQMWWWCBYPOV-UHFFFAOYSA-N s-indacene Chemical compound C=1C2=CC=CC2=CC2=CC=CC2=1 WEMQMWWWCBYPOV-UHFFFAOYSA-N 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- VFWRGKJLLYDFBY-UHFFFAOYSA-N silver;hydrate Chemical compound O.[Ag].[Ag] VFWRGKJLLYDFBY-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 description 1
- 235000019254 sodium formate Nutrition 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000004426 substituted alkynyl group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000003390 teratogenic effect Effects 0.000 description 1
- 231100000211 teratogenicity Toxicity 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000005207 tetraalkylammonium group Chemical group 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000005305 thiadiazolinyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000005458 thianyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000001583 thiepanyl group Chemical group 0.000 description 1
- 125000003777 thiepinyl group Chemical group 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 125000005323 thioketone group Chemical group 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 125000004665 trialkylsilyl group Chemical group 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000005881 triazolinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 1
- 125000005580 triphenylene group Chemical group 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 102000008538 voltage-gated sodium channel activity proteins Human genes 0.000 description 1
- 108040002416 voltage-gated sodium channel activity proteins Proteins 0.000 description 1
- 229940071104 xylenesulfonate Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
Definitions
- thalidomide-cerebellar protein binding in vivo may be the cause of thalidomide teratogenicity.
- the compound and related structures can be used as anti-inflammatory agents, anti- angiogenic agents and anti-cancer agents.
- Lenalidomide and pomalidomide obtained by further modification of the structure of thalidomide have greatly improved their safety and significantly reduced their teratogenic effects. Lenalidomide has been approved by the FDA in 2006 for marketing.
- Ikaros family zinc finger structural proteins 1 and 3 Ikaros family zinc finger structural proteins 1 and 3 (IKZF1 and IKZF3), which further reveals the structure of thalidomide may be combined with the E3 ubiquitin ligase protein complex of the cerebellar protein to further play a role in degrading the target protein (Science, 2014, 343, 301; Science, 2014, 343, 305).
- CRBN ligands are widely used in protein degradation, and a series of PROTACs molecules based on CRBN ligands have been developed. Due to the influence of CRBN ligand itself on the target point, it may additionally degrade zinc finger domain protein.
- the present disclosure provides compounds or conjugates of Formula I: and pharmaceutically acceptable salts, solvates, or stereoisomers thereof, wherein each of the variables are defined, described, and exemplified herein.
- methods of binding cereblon E3 ubiquitin ligase protein complex in a subject or biological sample comprising administering a compound described herein to the subject or contacting the biological sample with a compound described herein.
- provided herein are uses of a compound described herein in the manufacture of a medicament for binding cereblon E3 ubiquitin ligase protein complex in a subject or biological sample.
- compounds described herein for use in binding cereblon E3 ubiquitin ligase protein complex in a subject or biological sample are compounds described herein for use in binding cereblon E3 ubiquitin ligase protein complex in a subject or biological sample.
- the present disclosure provides pharmaceutical compositions comprising a conjugate disclosed herein, and a pharmaceutically acceptable excipient.
- methods of degrading a protein in a subject or biological sample comprising administering a conjugate described herein to the subject or contacting the biological sample with a conjugate described herein.
- provided herein are uses of a conjugate described herein in the manufacture of a medicament for degrading a protein in a subject or biological sample.
- conjugates described herein for use in degrading a protein in a subject or biological sample are methods of treating or preventing a disease or disorder a subject in need thereof, comprising administering to the subject a conjugate described herein.
- methods of treating or preventing a disease or disorder a subject in need thereof comprising administering to the subject a conjugate described herein.
- provided herein are uses of a conjugate described herein in the manufacture of a medicament for treating or preventing a disease or disorder in a subject in need thereof.
- conjugates described herein for use in treating or preventing a disease or disorder in a subject in need thereof.
- DETAILED DESCRIPTION [00016] The present disclosure relates to compounds that show cereblon-binding activity, and compounds that bifunctional degraders comprising such compound, as well as pharmaceutical compositions thereof.
- the present disclosure further relates to methods of degrading a protein in a subject or biological sample comprising administering a compound described herein to the subject or contacting the biological sample with a compound described herein.
- the present disclosure also relates to methods of treating or preventing a disease or disorder a subject in need thereof, comprising administering to the subject a compound described herein.
- Ring A is 6 275501297 v3 or , [00019] In certain embodiments, the compound is not or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. [00021] In certain embodiments, the compound of Formula I is a compound of Formula I-2 or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
- U is hydrogen or C1-6 alkyl (e.g., methyl (C1), ethyl (C2), n- propyl (C3), i-propyl (C3), n-butyl (C4), i-butyl (C4), s-butyl (C4), t-butyl (C4), pentyl (C5), or hexyl (C 6 )).
- Y is N.
- Y is CR Y .
- R Y is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C 1-6 alkoxy, C 1-6 alkylamino, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, or 3- to 12-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl is optionally substituted with one or more R u .
- R Y is hydrogen, halogen (e.g., -F, -Cl, -Br, or -I), -CN, -NO2, -OH, -NH2, C1-6 alkyl (e.g., methyl (C1), ethyl (C2), n-propyl (C3), i-propyl (C3), n-butyl (C4), i-butyl (C 4 ), s-butyl (C 4 ), t-butyl (C 4 ), pentyl (C 5 ), or hexyl (C 6 )), C 1-6 alkoxy (e.g., methoxy (C 1 ), ethoxy (C 2 ), n-propoxy (C 3 ), i-propoxy (C 3 ), n-butoxy (C 4 ), i-butoxy (C 4 ), s-butoxy (C 4 ), 7 275501297 v
- C1-6 alkyl
- R Y is hydrogen, halogen, -CN, -NO 2 , -OH, -NH 2 , C 1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C3-12 carbocyclyl, 3- to 12-membered heterocyclyl, C 6-10 aryl, 5- to 10-membered heteroaryl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more R u .
- R Y is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C3-6 carbocyclyl, 3- to 6-membered heterocyclyl, C 6 aryl, 5- to 6-membered heteroaryl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more R u .
- R Y is hydrogen, halogen, -CN, -NO 2 , -OH, -NH 2 , C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkylamino, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 carbocyclyl, or 3- to 6-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, or heterocyclyl, is optionally substituted with one or more R u .
- R Y is hydrogen, halogen, -CN, -NO 2 , -OH, -NH 2 , C 1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C3-6 carbocyclyl, or 3- to 6-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, carbocyclyl, or heterocyclyl, is optionally substituted with one or more R u .
- R Y is hydrogen.
- R 1 and R 2 together with the intervening carbon atoms, form Ring A.
- the compound of Formula I-1 is a compound of Formula I-1- I’, I-1-ii’, I-1-iii’, or I-1-iv’: or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
- the compound of Formula I-1 is a compound of Formula I-1- i, I-1-ii, I-1-iii, or I-1-iv: 9 275501297 v3 (I-1-i), (I-1-ii), (I-1-iii), or (I-1-iv), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
- the compound of Formula I-2 is a compound of Formula I- 2-i’, I-2-ii’, I-2-iii’, or I-2-iv’: or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
- the compound of Formula I-2 is a compound of Formula I- 2-i, I-2-ii, I-2-iii, or I-2-iv: iv), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
- Y is N.
- Y is CR 3 .
- R 3 is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered 10 275501297 v3 heteroaryl, C3-12 carbocyclyl, or 3- to 12-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl is optionally substituted with one or more R u .
- R 3 is hydrogen, halogen (e.g., -F, -Cl, -Br, or -I), -CN, -NO2, -OH, -NH2, C1-6 alkyl (e.g., methyl (C1), ethyl (C2), n-propyl (C3), i-propyl (C3), n-butyl (C4), i-butyl (C 4 ), s-butyl (C 4 ), t-butyl (C 4 ), pentyl (C 5 ), or hexyl (C 6 )), C 1-6 alkoxy (e.g., methoxy (C 1 ), ethoxy (C 2 ), n-propoxy (C 3 ), i-propoxy (C 3 ), n-butoxy (C 4 ), i-butoxy (C 4 ), s-butoxy (C 4 ), t-butoxy (C4)
- C1-6 alkyl
- R 3 is hydrogen, halogen, -CN, -NO 2 , -OH, -NH 2 , C 1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C3-12 carbocyclyl, 3- to 12-membered heterocyclyl, C6-10 aryl, 5- to 10-membered heteroaryl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more R u .
- R 3 is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C 1-6 alkoxy, C 1-6 alkylamino, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 carbocyclyl, 3- to 6-membered heterocyclyl, C 6 aryl, 5- to 6-membered heteroaryl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more R u .
- R 3 is hydrogen, halogen, -CN, -NO 2 , -OH, -NH 2 , C 1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C3-6 carbocyclyl, or 3- to 6-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, or heterocyclyl, is optionally substituted with one or more R u .
- R 3 is hydrogen, halogen, -CN, -NO 2 , -OH, -NH 2 , C 1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C3-6 carbocyclyl, or 3- to 6-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, carbocyclyl, or heterocyclyl, is optionally substituted with one or more R u .
- R 3 is hydrogen.
- R 2 and R 3 together with the intervening carbon atoms, form Ring A.
- the compound of Formula I-1 is a compound of Formula I-1- v’, I-1-vi’, I-1-vii’, or I-1-viii’: 12 275501297 v3 or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
- the compound of Formula I-1 is a compound of Formula I-1- v, I-1-vi, I-1-vii, or I-1-viii: or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
- the compound of Formula I-2 is a compound of Formula I- 2-v’, I-2-vi’, I-2-vii’, or I-2-viii’: or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
- the compound of Formula I-2 is a compound of Formula I- 2-v, I-2-vi, I-2-vii, or I-2-viii: 13 275501297 v3 (I-2-v), (I-2-vi), (I-2-vii), or (I-2-viii), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
- R 1 is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C 1-6 alkoxy, C 1-6 alkylamino, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, or 3- to 12-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl is optionally substituted with one or more R u .
- R 1 is hydrogen, halogen (e.g., -F, -Cl, -Br, or -I), -CN, -NO2, -OH, -NH2, C1-6 alkyl (e.g., methyl (C1), ethyl (C2), n-propyl (C3), i-propyl (C3), n-butyl (C4), i-butyl (C 4 ), s-butyl (C 4 ), t-butyl (C 4 ), pentyl (C 5 ), or hexyl (C 6 )), C 1-6 alkoxy (e.g., methoxy (C 1 ), ethoxy (C 2 ), n-propoxy (C 3 ), i-propoxy (C 3 ), n-butoxy (C 4 ), i-butoxy (C 4 ), s-butoxy (C 4 ), t-butoxy (C4)
- C1-6 alkyl
- R 1 is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C 1-6 alkoxy, C 1-6 alkylamino, C 2-6 alkenyl, C 2-6 alkynyl, C 3-12 carbocyclyl, 3- to 12-membered heterocyclyl, C 6-10 aryl, 5- to 10-membered heteroaryl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more R u .
- R 1 is hydrogen, halogen, -CN, -NO 2 , -OH, -NH 2 , C 1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C3-6 carbocyclyl, 3- to 6-membered heterocyclyl, C 6 aryl, 5- to 6-membered heteroaryl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more R u .
- R 1 is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C 1-6 alkoxy, C 1-6 alkylamino, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 carbocyclyl, or 3- to 6-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, or heterocyclyl, is optionally substituted with one or more R u .
- R 1 is hydrogen, halogen, -CN, -NO 2 , -OH, -NH 2 , C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkylamino, C 3-6 carbocyclyl, or 3- to 6-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, carbocyclyl, or heterocyclyl, is optionally substituted with one or more R u .
- R 1 is hydrogen.
- Y’ is N. 15 275501297 v3
- Y’ is CR Y’ .
- R Y’ is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C 1-6 alkoxy, C 1-6 alkylamino, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, or 3- to 12-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl is optionally substituted with one or more R u .
- R Y’ is hydrogen, halogen (e.g., -F, -Cl, -Br, or -I), -CN, -NO 2 , -OH, -NH2, C1-6 alkyl (e.g., methyl (C1), ethyl (C2), n-propyl (C3), i-propyl (C3), n-butyl (C4), i-butyl (C 4 ), s-butyl (C 4 ), t-butyl (C 4 ), pentyl (C 5 ), or hexyl (C 6 )), C 1-6 alkoxy (e.g., methoxy (C 1 ), ethoxy (C 2 ), n-propoxy (C 3 ), i-propoxy (C 3 ), n-butoxy (C 4 ), i-butoxy (C 4 ), s-butoxy (C 4 ), t-butoxy (C 4 ), t
- R Y’ is hydrogen, halogen, -CN, -NO 2 , -OH, -NH 2 , C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkylamino, C 2-6 alkenyl, C 2-6 alkynyl, C 3-12 carbocyclyl, 3- to 12-membered heterocyclyl, C6-10 aryl, 5- to 10-membered heteroaryl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more R u .
- R Y’ is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C3-6 carbocyclyl, 3- to 6-membered heterocyclyl, C 6 aryl, 5- to 6-membered heteroaryl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more R u .
- R Y’ is hydrogen, halogen, -CN, -NO 2 , -OH, -NH 2 , C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkylamino, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 carbocyclyl, or 3- to 6-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, or heterocyclyl, is optionally substituted with one or more R u .
- R Y’ is hydrogen, halogen, -CN, -NO 2 , -OH, -NH 2 , C 1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C3-6 carbocyclyl, or 3- to 6-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, carbocyclyl, or heterocyclyl, is optionally substituted with one or more R u .
- R Y’ is hydrogen.
- Ring A is 5- to 7-membered heterocycle comprising one oxygen atom.
- Ring A is 5- to 7-membered heterocycle comprising one oxygen atom and no double bond.
- Ring A is 5- to 7-membered heterocycle comprising one oxygen atom and a double bond.
- Ring A is [00072]
- R end is -OR H1 or -N(R H2 ) 2 .
- R H1 is hydrogen.
- C1-6 alkyl e.g., methyl (C1), ethyl (C2), n- propyl (C 3 ), i-propyl (C
- R H2 is hydrogen.
- C 1-6 alkyl e.g., methyl (C 1 ), ethyl (C 2 ), n- propyl (C3), i-propyl (C3), n-butyl (C4), i-butyl (C4), s-butyl (C4), t-
- R H3 is hydrogen.
- R H4 is hydrogen, C1-6 alkyl (e.g., methyl (C1), ethyl (C2), n- propyl (C 3 ), i-propyl (C 3 ), n-butyl (C 4 ), i-butyl (C 4 ), s-butyl (C 4 ), t-butyl (C 4 ), pentyl (C 5 ), or hexyl (C6)), or a carboxylic acid-protecting group, wherein the C1-6 alkyl is optionally substituted with one or more R u .
- R H4 is hydrogen.
- each R G1 is independently hydrogen, halogen, -CN, -NO2, - OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C 3-12 carbocyclyl, or 3- to 12-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl is optionally substituted with one or more R u .
- each R G1 is hydrogen, halogen (e.g., -F, -Cl, -Br, or -I), -CN, -NO2, -OH, -NH2, C1-6 alkyl (e.g., methyl (C1), ethyl (C2), n-propyl (C3), i-propyl (C3), n-butyl (C 4 ), i-butyl (C 4 ), s-butyl (C 4 ), t-butyl (C 4 ), pentyl (C 5 ), or hexyl (C 6 )), C 1-6 alkoxy (e.g., methoxy (C1), ethoxy (C2), n-propoxy (C3), i-propoxy (C3), n-butoxy (C4), i-butoxy (C4), s- butoxy (C4), t-butoxy (C4), t-butoxy (C4), t
- each R G1 is independently hydrogen, halogen, -CN, -NO2, - OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C3-12 carbocyclyl, 3- to 12-membered heterocyclyl, C 6-10 aryl, 5- to 10-membered heteroaryl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more R u .
- each R G1 is independently hydrogen, halogen, -CN, -NO 2 , - OH, -NH 2 , C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkylamino, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 carbocyclyl, 3- to 6-membered heterocyclyl, C6 aryl, 5- to 6-membered heteroaryl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more R u .
- each R G1 is independently hydrogen, halogen, -CN, -NO2, - OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C3-6 carbocyclyl, or 3- to 6-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, or heterocyclyl, is optionally substituted with one or more R u .
- each R G1 is independently hydrogen, halogen, -CN, -NO2, - OH, -NH 2 , C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkylamino, C 3-6 carbocyclyl, or 3- to 6-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, carbocyclyl, or heterocyclyl, is optionally substituted with one or more R u .
- each R G1 is independently hydrogen, halogen, or C 1-6 alkyl (e.g., methyl (C 1 ), ethyl (C 2 ), n-propyl (C 3 ), i-propyl (C 3 ), n-butyl (C 4 ), i-butyl (C 4 ), s-butyl (C4), t-butyl (C4), pentyl (C5), or hexyl (C6)) optionally substituted with one or more R u .
- C 1-6 alkyl e.g., methyl (C 1 ), ethyl (C 2 ), n-propyl (C 3 ), i-propyl (C 3 ), n-butyl (C 4 ), i-butyl (C 4 ), s-butyl (C4), t-butyl (C4), pentyl (C5), or hexyl (C6)
- R cp is -(CH 2 ) n OH, or -(CH 2 ) n NH 2 , wherein n is an integer selected from 0 to 4.
- R cp is -CH2OH.
- each R i is independently oxo, halogen, -CN, -NO2, -OH, - NH 2 , C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkylamino, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, 5- to 10- membered heteroaryl, C3-12 carbocyclyl, or 3- to 12-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl is optionally substituted with one or more R u .
- each R i is independently oxo, halogen (e.g., -F, -Cl, -Br, or - I), -CN, -NO2, -OH, -NH2, C1-6 alkyl (e.g., methyl (C1), ethyl (C2), n-propyl (C3), i-propyl (C3), n-butyl (C 4 ), i-butyl (C 4 ), s-butyl (C 4 ), t-butyl (C 4 ), pentyl (C 5 ), or hexyl (C 6 )), C 1-6 alkoxy (e.g., methoxy (C 1 ), ethoxy (C 2 ), n-propoxy (C 3 ), i-propoxy (C 3 ), n-butoxy (C 4 ), i-butoxy (C 4 ), s- butoxy (C4), t
- each R i is independently oxo, halogen, -CN, -NO 2 , -OH, - NH 2 , C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkylamino, C 2-6 alkenyl, C 2-6 alkynyl, C 3-12 carbocyclyl, 3- to 12-membered heterocyclyl, C6-10 aryl, 5- to 10-membered heteroaryl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more R u .
- each R i is independently oxo, halogen, -CN, -NO2, -OH, - NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C3-6 carbocyclyl, 3- to 6-membered heterocyclyl, C 6 aryl, 5- to 6-membered heteroaryl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more R u .
- each R i is independently oxo, halogen, -CN, -NO 2 , -OH, - NH 2 , C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkylamino, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 carbocyclyl, or 3- to 6-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, or heterocyclyl, is optionally substituted with one or more R u .
- each R i is independently oxo, halogen, -CN, -NO 2 , -OH, - NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C3-6 carbocyclyl, or 3- to 6-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, carbocyclyl, or heterocyclyl, is optionally substituted with one or more R u .
- at least one R i is oxo. In certain embodiments, at least one R i is oxo. In certain embodiments, at least one R i is -CN. In certain embodiments, at least one R i is -OH. In certain embodiments, at least one R i is -NH 2 .
- s is an integer selected from 0 to 8, as valency permits. In certain embodiments, s is an integer selected from 0 to 7, as valency permits. In certain embodiments, s is an integer selected from 0 to 6, as valency permits. In certain embodiments, s is an integer selected from 0 to 5, as valency permits. In certain embodiments, s is an integer selected from 0 to 4, as valency permits.
- s is an integer selected from 0 to 3, as valency permits. In certain embodiments, s is an integer selected from 0 to 2, as valency permits. In certain embodiments, s is 0 or 1, as valency permits. [000101] In certain embodiments, s is 0. In certain embodiments, s is 1. In certain embodiments, s is 2. In certain embodiments, s is 3. In certain embodiments, s is 4. In certain embodiments, s is 5. In certain embodiments, s is 6. In certain embodiments, s is 7. In certain embodiments, s is 8. [000102] In certain embodiments, R 4 is hydrogen. In certain embodiments, R 4 is deuterium. In certain embodiments, R 4 is C1-6 haloalkyl.
- R 4 is C1-6 alkyl. 23 275501297 v3 [000103] In certain embodiments, q is 0. In certain embodiments, q is 1. In certain embodiments, q is 2. In certain embodiments, q is 0 or 1. In certain embodiments, q is 0 or 2. In certain embodiments, q is 1 or 2. Bifunctional Degraders [000104] In certain aspects, the present disclosure provides conjugates comprising a compound disclosed herein being connected to a ligand for a protein (e.g., via a linker).
- Ring A’ is .
- R v is -O- or -N(R G3 )-.
- R v is -O-.
- R G3 is hydrogen or C 1-6 alkyl (e.g., methyl (C 1 ), ethyl (C 2 ), n-propyl (C3), i-propyl (C3), n-butyl (C4), i-butyl (C4), s-butyl (C4), t-butyl (C4), pentyl (C5), or hexyl (C6)) optionally substituted with one or more R u .
- C 1-6 alkyl e.g., methyl (C 1 ), ethyl (C 2 ), n-propyl (C3), i-propyl (C3), n-butyl (C4), i-butyl (C4), s-butyl (C4), t-butyl (C4), pentyl (C5), or hexyl (C6)
- -R V -[G] p - is *-(CH 2 ) n O- or *-(CH 2 ) n NH-, wherein n is an integer selected from 0 to 4, and * denotes attachment to Ring A’.
- -R V -[G]p- is *-CH2O-.
- the conjugate of Formula I is a conjugate of Formula I-1 or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
- the conjugate of Formula I is a conjugate of Formula I-2 or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
- the conjugate of Formula I-1 is a conjugate of Formula I’- 1-i’ or I’-1-ii’: or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
- the conjugate of Formula I-1 is a conjugate of Formula I’- 1-i or I’-1-ii: or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. 25 275501297 v3
- the conjugate of Formula I-2 is a conjugate of Formula I’- 2-i’ or I’-2-ii’: or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
- the conjugate of Formula I-2 is a conjugate of Formula I’- 2-i or I’-2-ii: or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
- the conjugate of Formula I-1 is a conjugate of Formula I’- 1-iii’ or I’-1-iv’: or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
- the conjugate of Formula I-1 is a conjugate of Formula I’- 1-iii or I’-1-iv: iv), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
- the conjugate of Formla I-2 is a conjugate of Formula I’-2- iii’ or I’-2-iv’: 26 275501297 v3 (I’-2-iii’) or (I’-2-iv’), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
- the conjugate of Formla I-2 is a conjugate of Formula I’-2- iii or I’-2-iv: or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
- L, the linker is a chemical moiety that connects the ligand of a protein with the cereblon ligand disclosed herein.
- L configures the ligand and the cereblon ligand such that the construct functions as a bifunctional degrader which binds the cereblon ligand and selectively degrades the target protein.
- L is a linker comprising 6- to 10-membered heteroarylene, C 6-10 arylene, C 3-12 membered carbocyclylene, or 3- to 12-membered heterocyclylene, wherein the arylene, heteroarylene, carbocyclylene, or heterocyclylene is optionally substituted by one or more R u , and is directly attached to T.
- T a ligand of a protein
- the protein is B7.1 and B7, TINFRlm, TNFR2, NADPH oxidase, BclIBax and other partners in the apotosis pathway, C5a receptor, HMG-CoA reductase, PDE V phosphodiesterase type, PDE IV phosphodiesterase type 4, PDE I, PDEII, PDEIII, squalene cyclase inhibitor, CXCR1, CXCR2, nitric oxide (NO) synthase, cyclo- oxygenase 1, cyclo-oxygenase 2, 5HT receptors, dopamine receptors, G Proteins, i.e., Gq, histamine receptors, 5 -lipoxygenase, tryptase serine protease, thymidylate synthase,
- Additional protein targets include, for example, ecdysone 20-monooxygenase, ion channel of the GABA gated chloride channel, acetylcholinesterase, voltage-sensitive sodium channel protein, calcium release channel, and chloride channels. Still further target proteins include Acetyl-CoA carboxylase, adenylosuccinate synthetase, protoporphyrinogen oxidase, and enolpyruvylshikimate- phosphate synthase.
- the protein is an androgen receptor (AR), an estrogen receptor (ER), signal transducer and activator of transcription 3 (STAT3), signal transducer and activator of transcription 5 (STAT5), CREB-binding protein/EP300(E1A) binding protein (CBP/p300), SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A, Member 2/4 (SMARCA2/4), Kirsten rat sarcoma viral oncogene homolog G12D (KRAS G12D), Src homology region 2-containing protein tyrosine phosphatase 2 (SHP2), or bromodomain-containing protein 4 (BRD4).
- AR androgen receptor
- ER estrogen receptor
- STAT5 signal transducer and activator of transcription 3
- STAT5 signal transducer and activator of transcription 5
- CBP/p300 CREB-binding protein/EP300(E1A) binding protein
- SWI/SNF Related Matr
- T is a small molecule.
- T is a peptide.
- the peptide has about 5 amino acids. In certain embodiments, the peptide has about 10 amino acids. In certain embodiments, the peptide has about 15 amino acids. In certain embodiments, the peptide has about 20 amino acids. In certain embodiments, the peptide has about 25 amino acids. In certain embodiments, the peptide has about 30 amino acids. In certain embodiments, the peptide has about 35 amino acids. In certain embodiments, the peptide has about 40 amino acids. In certain embodiments, the peptide has about 45 amino acids. In certain embodiments, the peptide has about 50 amino acids.
- T is an antibody.
- T is a ligand for an estrogen receptor.
- T is ligand for an androgen receptor.
- T is ligand for a STAT3 protein.
- T is an estrogen receptor inhibitor.
- T is an androgen receptor inhibitor.
- T is a STAT3 protein inhibitor.
- the compound is selected from the compounds in Table 1, or a pharmaceutically acceptable salt thereof.
- the compound is selected from the compounds in Table 1. Table 1.
- Exemplary Embodiment 2 The compound of any one of the preceding Exemplary Embodiments, wherein the compound is not Exemplary Embodiment 3.
- R cp is -(CH2)nOH, or -(CH2)nNH2, wherein n is an integer selected from 0 to 4.
- Exemplary Embodiment 7 The conjugate of any one of the preceding Exemplary Embodiments, wherein R v is -O- or -N(R G3 )-.
- Y is CR Y
- R Y is hydrogen, halogen, -CN, -NO2, -OH, -NH 2 , C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkylamino, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, 5- to 10- membered heteroaryl, C 3-12 carbocyclyl, or 3- to 12-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl is optionally substituted with one or more R u .
- Exemplary Embodiment 15 The compound or conjugate of any one of the preceding Exemplary Embodiments, wherein R Y is hydrogen.
- Exemplary Embodiment 16 The compound or conjugate of any one of the preceding Exemplary Embodiments, wherein R 1 and R 2 , together with the intervening carbon atoms, form Ring A or Ring A’. 39 275501297 v3 Exemplary Embodiment 17.
- Y is CR 3
- R 3 is hydrogen, halogen, -CN, -NO 2 , -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10- membered heteroaryl, C3-12 carbocyclyl, or 3- to 12-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl is optionally substituted with one or more R u .
- Exemplary Embodiment 20 The compound or conjugate of any one of the preceding Exemplary Embodiments, wherein Y” is CR 3 , and R 3 is hydrogen.
- Exemplary Embodiment 21 The compound or conjugate of any one of the preceding Exemplary Embodiments, wherein R 2 and R 3 , together with the intervening carbon atoms, form Ring A or Ring A’.
- Exemplary Embodiment 22 The compound or conjugate of any one of the preceding Exemplary Embodiments, wherein R 2 and R 3 , together with the intervening carbon atoms, form Ring A or Ring A’.
- the compound of Formula I-2 is a compound of Formula I-2-v’, I-2-vi’, I-2-vii’, or I-2-viii’: 41 275501297 v3 (I-2-v’), (I-2-vi’), (I-2-vii’), or (I-2-viii’), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, or the conjugate of Formula I-2 is a conjugate of Formula I’-2-iii’ or I’-2-iv’ or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
- Exemplary Embodiment 24 Exemplary Embodiment 24.
- R 1 is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C 1-6 alkoxy, C 1-6 alkylamino, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, or 3- to 12-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl is optionally substituted with one or more R u .
- R 1 is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C 1-6 alkoxy, C 1-6 alkylamino, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl
- R 1 is hydrogen.
- exemplary Embodiment 26 The compound or conjugate of any one of the preceding Exemplary Embodiments, wherein R 1 is hydrogen.
- Y’ is CR Y’
- R Y’ is hydrogen, halogen, -CN, -NO 2 , - OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C 3-12 carbocyclyl, or 3- to 12-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl is optionally substituted with one or more R u .
- Exemplary Embodiment 27 The compound or conjugate of any one of the preceding Exemplary Embodiments, wherein R Y’ is hydrogen.
- Exemplary Embodiment 28 The compound or conjugate of any one of the preceding Exemplary Embodiments, wherein each R i is independently oxo, halogen, -CN, -NO2, -OH, - 42 275501297 v3 NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10- membered heteroaryl, C3-12 carbocyclyl, or 3- to 12-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl is optionally substituted with one or more R u .
- Exemplary Embodiment 30 The compound or conjugate of any one of the preceding Exemplary Embodiments, wherein s is 0.
- Exemplary Embodiment 31 The compound or conjugate of any one of the preceding Exemplary Embodiments, wherein R 4 is hydrogen.
- Exemplary Embodiment 32 The compound or conjugate of any one of the preceding Exemplary Embodiments, wherein R 4 is hydrogen.
- Exemplary Embodiment 33 A compound selected from the compounds in Table 1 and pharmaceutically acceptable salts thereof.
- Exemplary Embodiment 34 A pharmaceutical composition comprising the compound or conjugate of any one of the preceding Exemplary Embodiments, and a pharmaceutically acceptable excipient.
- Exemplary Embodiment 35 A method of binding cereblon E3 ubiquitin ligase protein complex in a subject or biological sample comprising administering the compound of any one of the preceding Exemplary Embodiments to the subject or contacting the biological sample with the compound of any one of the preceding Exemplary Embodiments.
- Exemplary Embodiment 36 A method of binding cereblon E3 ubiquitin ligase protein complex in a subject or biological sample comprising administering the compound of any one of the preceding Exemplary Embodiments to the subject or contacting the biological sample with the compound of any one of the preceding Exemplary Embodiments.
- Exemplary Embodiment 37 A compound of any one of the preceding Exemplary Embodiments for use in binding cereblon E3 ubiquitin ligase protein complex in a subject or biological sample.
- the compounds of the present disclosure possess advantageous characteristics, as compared to known compounds, such as known cereblon-binding agents or known degraders comprising cereblon-binding agents.
- the compounds of the present disclosure display more potent cereblon-binding activity or more potent degradation activity against 43 275501297 v3 certain proteins, more favorable pharmacokinetic properties (e.g., as measured by Cmax, Tmax, and/or AUC), and/or less interaction with other cellular targets (e.g., hepatic cellular transporter such as OATP1B1) and accordingly improved safety (e.g., drug-drug interaction).
- beneficial properties of the compounds of the present disclosure can be measured according to methods commonly available in the art, such as methods exemplified herein.
- the compounds of the present disclosure may be in cis or trans, or Z or E, configuration.
- a compound of the present disclosure e.g., a compound of any of the formulae or any individual compounds disclosed herein
- a pharmaceutically acceptable salt e.g., a compound of any of the formulae or any individual compounds disclosed herein
- a compound of the present disclosure e.g., a compound of any of the formulae or any individual compounds disclosed herein
- a solvate e.g., a compound of any of the formulae or any individual compounds disclosed herein
- a compound of the present disclosure (e.g., a compound of any of the formulae or any individual compounds disclosed herein) is a hydrate.
- compositions comprising: a pharmaceutically acceptable salt.
- the compounds disclosed herein exist as their pharmaceutically acceptable salts.
- the methods disclosed herein include methods of treating diseases by administering such pharmaceutically acceptable salts. 44 275501297 v3
- the methods disclosed herein include methods of treating diseases by administering such pharmaceutically acceptable salts as pharmaceutical compositions.
- the compounds described herein possess acidic or basic groups and therefor react with any of a number of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt.
- these salts are prepared in situ during the final isolation and purification of the compounds disclosed herein, or by separately reacting a purified compound in its free form with a suitable acid or base, and isolating the salt thus formed.
- suitable acid or base examples include those salts prepared by reaction of the compounds described herein with a mineral, organic acid, or inorganic base, such salts including acetate, acrylate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, bisulfite, bromide, butyrate, butyn-1,4-dioate, camphorate, camphorsulfonate, caproate, caprylate, chlorobenzoate, chloride, citrate, cyclopentanepropionate, decanoate, digluconate, dihydrogenphosphate, dinitrobenzoate, dodecylsulfate, ethanesulfonate, formate, fumarate
- the compounds described herein can be prepared as pharmaceutically acceptable salts formed by reacting the free base form of the compound with a pharmaceutically acceptable inorganic or organic acid, including, but not limited to, inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid metaphosphoric acid, and the like; and organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, p-toluenesulfonic acid, tartaric acid, trifluoroacetic acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, arylsulfonic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-
- those compounds described herein which comprise a free acid group react with a suitable base, such as the hydroxide, carbonate, bicarbonate, or sulfate of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary, tertiary, or quaternary amine.
- a suitable base such as the hydroxide, carbonate, bicarbonate, or sulfate of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary, tertiary, or quaternary amine.
- Representative salts include the alkali or alkaline earth salts, like lithium, sodium, potassium, calcium, and magnesium, and aluminum salts and the like.
- bases include sodium hydroxide, potassium hydroxide, choline hydroxide, sodium carbonate, N + (C1-4 alkyl)4, and the like.
- Organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, and the like. It should be understood that the compounds described herein also include the quaternization of any basic nitrogen-containing groups they contain. In certain embodiments, water or oil-soluble or dispersible products are obtained by such quaternization. Solvates [000146] Those skilled in the art of organic chemistry will appreciate that many organic compounds can form complexes with solvents in which they are reacted or from which they are precipitated or crystallized. These complexes are known as “solvates”. For example, a complex with water is known as a “hydrate”.
- Solvates are within the scope of the invention. [000147] It will also be appreciated by those skilled in organic chemistry that many organic compounds can exist in more than one crystalline form. For example, crystalline form may vary from solvate to solvate. Thus, all crystalline forms or the pharmaceutically acceptable solvates thereof are contemplated and are within the scope of the present invention. [000148] In certain embodiments, the compounds described herein exist as solvates. The present disclosure provides for methods of treating diseases by administering such solvates. The present disclosure further provides for methods of treating diseases by administering such solvates as pharmaceutical compositions. [000149] Solvates contain either stoichiometric or non-stoichiometric amounts of a solvent, such as water, ethanol, and the like.
- a solvent such as water, ethanol, and the like.
- Solvates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol.
- Solvates of the compounds described herein 46 275501297 v3 can be conveniently prepared or formed during the processes described herein.
- the compounds provided herein can exist in unsolvated as well as solvated forms. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the compounds and methods provided herein.
- the compounds disclosed herein possess one or more chiral centers and each center exists in the R configuration or S configuration.
- the compounds disclosed herein include all diastereomeric, enantiomeric, and epimeric forms as well as the corresponding mixtures thereof. All diastereomeric, enantiomeric, and epimeric forms of the compounds disclosed herein are contemplated and are within the scope of the invention.
- mixtures of enantiomers and/or diastereoisomers, resulting from a single preparative step, combination, or interconversion are useful for the applications described herein.
- the compounds described herein are prepared as their individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereoisomeric compounds, separating the diastereomers, and recovering the optically pure enantiomers.
- dissociable complexes are preferred.
- the diastereomers have distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) and are separated by taking advantage of these dissimilarities.
- the diastereomers are separated by chiral chromatography, or preferably, by separation/resolution techniques based upon differences in 47 275501297 v3 solubility.
- the optically pure enantiomer is then recovered, along with the resolving agent.
- Tautomers [000154]
- compounds described herein exist as tautomers.
- the compounds described herein include all possible tautomers within the formulas described herein.
- Tautomers are compounds that are interconvertible by migration of a hydrogen atom, accompanied by a switch of a single bond and an adjacent double bond. In bonding arrangements where tautomerization is possible, a chemical equilibrium of the tautomers will exist. All tautomeric forms of the compounds disclosed herein are contemplated and are within the scope of the invention. The exact ratio of the tautomers depends on several factors, including temperature, solvent, and pH.
- compositions [000156]
- the compound described herein is administered as a pure chemical.
- the compound described herein is combined with a pharmaceutically suitable or acceptable carrier (also referred to herein as a pharmaceutically suitable (or acceptable) excipient, physiologically suitable (or acceptable) excipient, or physiologically suitable (or acceptable) carrier) selected on the basis of a chosen route of administration and standard pharmaceutical practice as described, for example, in Remington: The Science and Practice of Pharmacy (Gennaro, 21 st Ed. Mack Pub. Co., Easton, PA (2005)).
- compositions comprising a compound described herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, and a pharmaceutically acceptable excipient.
- the compound provided herein is substantially pure, in that it contains less than about 5%, less than about 1%, or less than about 0.1% of other organic small molecules, such as unreacted intermediates or synthesis by-products that are created, for example, in one or more of the steps of a synthesis method.
- Pharmaceutical compositions are administered in a manner appropriate to the disease to be treated (or prevented).
- an appropriate dose and a suitable duration and frequency of administration will be determined by such factors as the condition of the patient, the type and severity of the patient's disease, the particular form of the active ingredient, and the method of 48 275501297 v3 administration.
- an appropriate dose and treatment regimen provides the composition(s) in an amount sufficient to provide therapeutic and/or prophylactic benefit (e.g., an improved clinical outcome, such as more frequent complete or partial remissions, or longer disease-free and/or overall survival, or a lessening of symptom severity.
- Optimal doses are generally determined using experimental models and/or clinical trials. The optimal dose depends upon the body mass, weight, or blood volume of the patient.
- the pharmaceutical composition is formulated for oral, topical (including buccal and sublingual), rectal, vaginal, transdermal, parenteral, intrapulmonary, intradermal, intrathecal and epidural and intranasal administration.
- Parenteral administration includes intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration.
- the pharmaceutical composition is formulated for intravenous injection, oral administration, inhalation, nasal administration, topical administration, or ophthalmic administration.
- the pharmaceutical composition is formulated for oral administration.
- the pharmaceutical composition is formulated for intravenous injection.
- the pharmaceutical composition is formulated as a tablet, a pill, a capsule, a liquid, an inhalant, a nasal spray solution, a suppository, a suspension, a gel, a colloid, a dispersion, a suspension, a solution, an emulsion, an ointment, a lotion, an eye drop, or an ear drop.
- the pharmaceutical composition is formulated as a tablet.
- the compounds of the present disclosure can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art.
- the compounds of the present disclosure i.e., a compound of the present application (e.g., a compound of any of the formulae or any individual compounds disclosed herein)
- a lactone compound of formula (VI) is reacted with a suitable base such as LiOH, NaOH, and the like; in a suitable solvent such as THF, MeOH, and the like; in a co-solvent such as water; at temperatures ranging from 25 °C to 80 °C, preferably at 50 °C; to provide an acid compound of formula (VII).
- a suitable base such as LiOH, NaOH, and the like
- a suitable solvent such as THF, MeOH, and the like
- a co-solvent such as water
- An acid compound of formula (VII) is oxidized in the presence of an oxidant such as MnO2, Dess-Martin periodinane, and the like; in a suitable solvent such as DCM, acetonitrile, and the like; at temperatures ranging from 0 °C to 50 °C, preferably at 25 °C; to provide a compound of formula (VIII).
- An aldehyde compound of formula (VIII) is reacted with a commercially available or synthetically accessible amine of formula (IX), in the presence of a suitable reductant such as NaBH(OAc)3, NaCNBH3 and the like; in a suitable solvent such as DCM, THF and the like; at temperatures ranging from 0 °C to about 60 °C, preferably 25 °C; to afford a compound of formula (X).
- a suitable reductant such as NaBH(OAc)3, NaCNBH3 and the like
- a suitable solvent such as DCM, THF and the like
- a compound of formula (X) is cyclized with a coupling agent such as HTAU, EDCI and the like; in the presence of a suitable base such as TEA, DIPEA and the like; in a suitable solvent such as DCM, THF and the like; at temperatures ranging from 0 °C to about 60 °C, preferably 25 °C; to afford an cyclized compound of formula (I-1-iii);
- a compound of formula (X) is cyclized in the presence of a suitable acid such as AcOH, TFA, pTSA and the like; in a suitable solvent such as DMF, THF, dioxane and the like; at temperatures ranging from 0 °C to about 80 °C, preferably 25 °C; to afford an cyclized compound of formula (I-1-iii).
- a stereocenter exists in the compounds of the present dislosure (e.g., a compound of any of the formulae or any individual compounds disclosed herein). Accordingly, the present disclosure includes both possible stereoisomers (unless specified in the synthesis) and includes not only racemic compound but the individual enantiomers and/or diastereomers as well.
- a compound When a compound is desired as a single enantiomer or diastereomer, it may be obtained by stereospecific synthesis or by resolution of the final product or any convenient intermediate. Resolution of the final product, an intermediate, or a starting material may be affected by any suitable method known in the art.
- a typical assay in a HTRF assay, compounds are diluted in DMSO and react with His tagged CRBN+DDB-DLS7+CXU4 followed by addition of Fluorescent probe Cy5-labeled Thalidomide, and MAb Anti-6HIS Tb cryptate Gold. After a certain period of incubation at room temperature, the HTRF signals are read on Envision reader (e.g., Perkin Elemer). Data is analyzed using XLfit using four parameters dose response curve to determine IC50s.
- Envision reader e.g., Perkin Elemer
- provided herein are methods of binding cereblon E3 ubiquitin ligase protein complex in a subject or biological sample comprising administering a compound described herein to the subject or contacting the biological sample with a compound described herein (e.g., in a therapeutically effective amount).
- a compound described herein in the manufacture of a medicament for binding cereblon E3 ubiquitin ligase protein complex in a subject or biological sample.
- compounds described herein for use in binding cereblon E3 ubiquitin ligase protein complex in a subject or biological sample are compounds described herein for use in binding cereblon E3 ubiquitin ligase protein complex in a subject or biological sample.
- kits for degrading a protein in a subject or biological sample comprising administering a conjugate described herein to the subject or contacting the biological sample with a conjugate described herein (e.g., in a therapeutically effective amount).
- a conjugate described herein in the manufacture of a medicament for degrading a protein in a subject or biological sample.
- conjugates described herein for use in degrading a protein in a subject or biological sample are provided herein for use in degrading a protein in a subject or biological sample.
- the protein is an androgen receptor (AR), an estrogen receptor (ER), signal transducer and activator of transcription 3 (STAT3), signal transducer and activator of transcription 5 (STAT5), CREB-binding protein/EP300(E1A) binding protein (CBP/p300), SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, 54 275501297 v3 Subfamily A, Member 2/4 (SMARCA2/4), Kirsten rat sarcoma viral oncogene homolog G12D (KRAS G12D), Src homology region 2-containing protein tyrosine phosphatase 2 (SHP2), or bromodomain-containing protein 4 (BRD4).
- AR androgen receptor
- ER estrogen receptor
- STAT5 signal transducer and activator of transcription 3
- STAT5 signal transducer and activator of transcription 5
- CBP/p300 CREB-binding protein/EP300(E1A) binding protein
- provided herein are methods of treating or preventing a disease or disorder a subject in need thereof, comprising administering to the subject a conjugate described herein (e.g., in a therapeutically effective amount).
- a conjugate described herein in the manufacture of a medicament for treating or preventing a disease or disorder in a subject in need thereof.
- conjugates described herein for use in treating or preventing a disease or disorder in a subject in need thereof are provided herein for use in treating or preventing a disease or disorder in a subject in need thereof.
- the disease or disorder is an androgen receptor (AR)- mediated disease or disorder, an estrogen receptor (ER)-mediated disease or disorder, signal transducer and activator of transcription 3 (STAT3)-mediated disease or disorder, signal transducer and activator of transcription 5 (STAT5)-mediated disease or disorder, CREB- binding protein/EP300(E1A) binding protein (CBP/p300)-mediated disease or disorder, SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A, Member 2/4 (SMARCA2/4)-mediated disease or disorder, Kirsten rat sarcoma viral oncogene homolog G12D (KRAS G12D)-mediated disease or disorder, Src homology region 2-containing protein tyrosine phosphatase 2 (SHP2)-mediated disease or disorder, or bromodomain-containing protein 4 (BRD4)-mediated disease or disorder.
- AR androgen receptor
- ER estrogen receptor
- STAT5 signal transducer and activator of
- the subject is a mammal.
- the subject is a human.
- the compounds described herein can be in the form of an individual enantiomer, diastereomer or geometric isomer, or can be in the form of a mixture of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomer.
- Isomers can be isolated from mixtures by methods known to those skilled in the art, including chiral high pressure liquid chromatography (HPFC) and the formation and crystallization of chiral salts; or preferred isomers can be prepared by asymmetric syntheses.
- C 1-6 alkyl is intended to encompass, C 1 , C 2 , C 3 , C 4 , C 5 , C6, C1-6, C1-5, C1-4, C1-3, C1-2, C2-6, C2-5, C2-4, C2-3, C3-6, C3-5, C3-4, C4-6, C4-5, and C5-6 alkyl.
- alkyl refers to a radical of a straight-chain or branched saturated hydrocarbon group having from 1 to 20 carbon atoms (“C1-20 alkyl”). In certain embodiments, an alkyl group has 1 to 12 carbon atoms (“C 1-12 alkyl”). In certain embodiments, an alkyl group has 1 to 10 carbon atoms (“C1-10 alkyl”).
- an alkyl group has 1 to 9 carbon atoms (“C1-9 alkyl”). In certain embodiments, an alkyl group has 1 to 8 carbon atoms (“C 1-8 alkyl”). In certain embodiments, an alkyl group has 1 to 7 carbon atoms (“C 1-7 alkyl”). In certain embodiments, an alkyl group has 1 to 6 carbon atoms (“C 1-6 alkyl”, which is also referred to herein as “lower alkyl”). In certain embodiments, an alkyl group has 1 to 5 carbon atoms (“C 1-5 alkyl”). In certain embodiments, an alkyl group has 1 to 4 carbon atoms (“C 1-4 alkyl”).
- an alkyl group has 1 to 3 carbon atoms (“C 1-3 alkyl”). In certain embodiments, an alkyl group has 1 to 2 carbon atoms (“C1-2 alkyl”). In certain embodiments, an alkyl group has 1 carbon atom (“C1 alkyl”).
- C1-6 alkyl groups include methyl (C 1 ), ethyl (C 2 ), n-propyl (C 3 ), isopropyl (C 3 ), n-butyl (C 4 ), tert-butyl (C 4 ), sec-butyl (C 4 ), isobutyl (C4), n-pentyl (C5), 3-pentanyl (C5), amyl (C5), neopentyl (C5), 3-methyl-2-butanyl (C5), tertiary amyl (C5), and n-hexyl (C6).
- alkyl groups include n-heptyl (C 7 ), n-octyl (C 8 ) and the like.
- each instance of an alkyl group is independently optionally substituted, i.e., unsubstituted (an “unsubstituted alkyl”) or substituted (a “substituted alkyl”) with one or more substituents; e.g., for instance from 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.
- the alkyl group is unsubstituted C 1-10 alkyl (e.g., -CH 3 ).
- the alkyl group is substituted C 1- 10 alkyl.
- Alkylene refers to an alkyl group wherein two hydrogens are removed to provide a divalent radical. When a range or number of carbons is provided for a particular “alkylene” group, it is understood that the range or number refers to the range or number of carbons in the linear carbon divalent chain.
- alkelene may be substituted or unsubstituted with one or more substituents as described herein.
- exemplary unsubstituted divalent alkylene groups include, but are not limited to, methylene (-CH2-), ethylene (- CH 2 CH 2 -), propylene (-CH 2 CH 2 CH 2 -), butylene (-CH 2 CH 2 CH 2 CH 2 -), pentylene (- CH 2 CH 2 CH 2 CH 2 CH 2 -), hexylene (-CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 -), and the like.
- Exemplary substituted divalent alkylene groups include but are not limited to, substituted methylene (-CH(CH 3 )-, (-C(CH 3 ) 2 -), substituted ethylene (-CH(CH 3 )CH 2 -,-CH 2 CH(CH 3 )-, -C(CH 3 ) 2 CH 2 -,-CH 2 C(CH 3 ) 2 -), substituted 57 275501297 v3 propylene (-CH(CH3)CH2CH2-, -CH2CH(CH3)CH2-, -CH2CH2CH(CH3)-, -C(CH3)2CH2CH2-, -CH2C(CH3)2CH2-, -CH2CH2C(CH3)2-), and the like.
- alkenyl refers to a radical of a straight-chain or branched hydrocarbon group having from 2 to 20 carbon atoms, one or more carbon-carbon double bonds (e.g., 1, 2, 3, or 4 carbon-carbon double bonds), and optionally one or more carbon-carbon triple bonds (e.g., 1, 2, 3, or 4 carbon-carbon triple bonds) (“C 2-20 alkenyl”). In certain embodiments, alkenyl does not contain any triple bonds. In certain embodiments, an alkenyl group has 2 to 10 carbon atoms (“C2-10 alkenyl”). In certain embodiments, an alkenyl group has 2 to 9 carbon atoms (“C 2-9 alkenyl”).
- an alkenyl group has 2 to 8 carbon atoms (“C 2-8 alkenyl”). In certain embodiments, an alkenyl group has 2 to 7 carbon atoms (“C 2- 7 alkenyl”). In certain embodiments, an alkenyl group has 2 to 6 carbon atoms (“C2-6 alkenyl”). In certain embodiments, an alkenyl group has 2 to 5 carbon atoms (“C2-5 alkenyl”). In certain embodiments, an alkenyl group has 2 to 4 carbon atoms (“C 2-4 alkenyl”). In certain embodiments, an alkenyl group has 2 to 3 carbon atoms (“C2-3 alkenyl”).
- an alkenyl group has 2 carbon atoms (“C2 alkenyl”).
- the one or more carbon- carbon double bonds can be internal (such as in 2-butenyl) or terminal (such as in 1-butenyl).
- Examples of C 2-4 alkenyl groups include ethenyl (C 2 ), 1-propenyl (C 3 ), 2-propenyl (C 3 ), 1- butenyl (C4), 2-butenyl (C4), butadienyl (C4), and the like.
- C2-6 alkenyl groups include the aforementioned C 2-4 alkenyl groups as well as pentenyl (C 5 ), pentadienyl (C 5 ), hexenyl (C 6 ), and the like. Additional examples of alkenyl include heptenyl (C 7 ), octenyl (C 8 ), octatrienyl (C8), and the like.
- each instance of an alkenyl group is independently optionally substituted, i.e., unsubstituted (an “unsubstituted alkenyl”) or substituted (a “substituted alkenyl”) with one or more substituents e.g., for instance from 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.
- the alkenyl group is unsubstituted C2-10 alkenyl.
- the alkenyl group is substituted C2-10 alkenyl.
- Alkenylene refers to an alkenyl group wherein two hydrogens are removed to provide a divalent radical.
- alkenylene When a range or number of carbons is provided for a particular “alkenylene” group, it is understood that the range or number refers to the range or number of carbons in the linear carbon divalent chain.
- Alkynyl refers to a radical of a straight-chain or branched hydrocarbon group having from 2 to 20 carbon atoms, one or more carbon-carbon triple bonds (e.g., 1, 2, 3, or 4 carbon-carbon triple bonds), and optionally one or more carbon-carbon double bonds (e.g., 1, 2, 3, or 4 carbon-carbon double bonds) (“C 2-20 alkynyl”). In certain embodiments, alkynyl does not contain any double bonds. In certain embodiments, an alkynyl group has 2 to 10 carbon atoms (“C 2-10 alkynyl”). In certain embodiments, an alkynyl group has 2 to 9 carbon atoms (“C 2-9 alkynyl”).
- an alkynyl group has 2 to 8 carbon atoms (“C2-8 alkynyl”). In certain embodiments, an alkynyl group has 2 to 7 carbon atoms (“C2-7 alkynyl”). In certain embodiments, an alkynyl group has 2 to 6 carbon atoms (“C2- 6 alkynyl”). In certain embodiments, an alkynyl group has 2 to 5 carbon atoms (“C 2-5 alkynyl”). In certain embodiments, an alkynyl group has 2 to 4 carbon atoms (“C2-4 alkynyl”). In certain embodiments, an alkynyl group has 2 to 3 carbon atoms (“C2-3 alkynyl”).
- an alkynyl group has 2 carbon atoms (“C 2 alkynyl”).
- the one or more carbon- carbon triple bonds can be internal (such as in 2-butynyl) or terminal (such as in 1-butynyl).
- Examples of C2-4 alkynyl groups include, without limitation, ethynyl (C2), 1-propynyl (C3), 2- propynyl (C 3 ), 1-butynyl (C 4 ), 2-butynyl (C 4 ), and the like.
- Examples of C 2-6 alkenyl groups include the aforementioned C 2-4 alkynyl groups as well as pentynyl (C 5 ), hexynyl (C 6 ), and the like.
- alkynyl examples include heptynyl (C7), octynyl (C8), and the like.
- each instance of an alkynyl group is independently optionally substituted, i.e., unsubstituted (an “unsubstituted alkynyl”) or substituted (a “substituted alkynyl”) with one or more substituents; e.g., for instance from 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.
- the alkynyl group is unsubstituted C2-10 alkynyl.
- the alkynyl group is substituted C 2-10 alkynyl.
- Alkynylene refers to a linear alkynyl group wherein two hydrogens are removed to provide a divalent radical.
- alkynylene refers to the range or number of carbons in the linear carbon divalent chain.
- An “alkynylene” group may be substituted or unsubstituted with one or more substituents as described herein.
- Exemplary divalent alkynylene groups include, but are not limited to, substituted or unsubstituted ethynylene, substituted or unsubstituted propynylene, and the like.
- heteroalkyl refers to an alkyl group, as defined herein, which further comprises 1 or more (e.g., 1, 2, 3, or 4) heteroatoms (e.g., oxygen, sulfur, nitrogen, boron, silicon, phosphorus) within the parent chain, wherein the one or more heteroatoms is inserted between adjacent carbon atoms within the parent carbon chain and/or one or more heteroatoms is inserted between a carbon atom and the parent molecule, i.e., between the point of attachment.
- 1 or more heteroatoms e.g., oxygen, sulfur, nitrogen, boron, silicon, phosphorus
- a heteroalkyl group refers to a saturated group having from 1 to 10 carbon atoms and 1, 2, 3, or 4 heteroatoms (“C 1-10 heteroalkyl”). In certain embodiments, a heteroalkyl group is a saturated group having 1 to 9 carbon atoms and 1, 2, 3, or 4 heteroatoms (“C 1-9 heteroalkyl”). In certain embodiments, a heteroalkyl group is a saturated group having 1 to 8 carbon atoms and 1, 2, 3, or 4 heteroatoms (“C1-8 heteroalkyl”). In certain embodiments, a heteroalkyl group is a saturated group having 1 to 7 carbon atoms and 1, 2, 3, or 4 heteroatoms (“C1-7 heteroalkyl”).
- a heteroalkyl group is a group having 1 to 6 carbon atoms and 1, 2, or 3 heteroatoms (“C 1-6 heteroalkyl”). In certain embodiments, a heteroalkyl group is a saturated group having 1 to 5 carbon atoms and 1 or 2 heteroatoms (“C1-5 heteroalkyl”). In certain embodiments, a heteroalkyl group is a saturated group having 1 to 4 carbon atoms and/or 2 heteroatoms (“C 1-4 heteroalkyl”). In certain embodiments, a heteroalkyl group is a saturated group having 1 to 3 carbon atoms and 1 heteroatom (“C1-3 heteroalkyl”).
- a heteroalkyl group is a saturated group having 1 to 2 carbon atoms and 1 heteroatom (“C 1-2 heteroalkyl”). In certain embodiments, a heteroalkyl group is a saturated group having 1 carbon atom and 1 heteroatom (“C1 heteroalkyl”). In certain embodiments, a heteroalkyl group is a saturated group having 2 to 6 carbon atoms and 1 or 2 heteroatoms (“C 2-6 heteroalkyl”). Unless otherwise specified, each instance of a heteroalkyl group is independently unsubstituted (an “unsubstituted heteroalkyl”) or substituted (a “substituted heteroalkyl”) with one or more substituents.
- heteroalkyl group is an unsubstituted C1-10 heteroalkyl. In certain embodiments, the heteroalkyl group is a substituted C 1-10 heteroalkyl.
- heteroalkenyl refers to an alkenyl group, as defined herein, which further comprises one or more (e.g., 1, 2, 3, or 4) heteroatoms (e.g., oxygen, sulfur, nitrogen, boron, silicon, phosphorus) wherein the one or more heteroatoms is inserted between adjacent carbon atoms within the parent carbon chain and/or one or more heteroatoms is inserted between a carbon atom and the parent molecule, i.e., between the point of attachment.
- one or more heteroatoms e.g., oxygen, sulfur, nitrogen, boron, silicon, phosphorus
- a heteroalkenyl group refers to a group having from 2 to 10 carbon atoms, at least one double bond, and 1, 2, 3, or 4 heteroatoms (“C 2-10 heteroalkenyl”). In certain embodiments, a heteroalkenyl group has 2 to 9 carbon atoms at least one double 60 275501297 v3 bond, and 1, 2, 3, or 4 heteroatoms (“C2-9 heteroalkenyl”). In certain embodiments, a heteroalkenyl group has 2 to 8 carbon atoms, at least one double bond, and 1, 2, 3, or 4 heteroatoms (“C 2-8 heteroalkenyl”).
- a heteroalkenyl group has 2 to 7 carbon atoms, at least one double bond, and 1, 2, 3, or 4 heteroatoms (“C2-7 heteroalkenyl”). In certain embodiments, a heteroalkenyl group has 2 to 6 carbon atoms, at least one double bond, and 1, 2, or 3 heteroatoms (“C 2-6 heteroalkenyl”). In certain embodiments, a heteroalkenyl group has 2 to 5 carbon atoms, at least one double bond, and 1 or 2 heteroatoms (“C 2-5 heteroalkenyl”). In certain embodiments, a heteroalkenyl group has 2 to 4 carbon atoms, at least one double bond, and l or 2 heteroatoms (“C 2-4 heteroalkenyl”).
- a heteroalkenyl group has 2 to 3 carbon atoms, at least one double bond, and 1 heteroatom (“C 2- 3 heteroalkenyl”). In certain embodiments, a heteroalkenyl group has 2 to 6 carbon atoms, at least one double bond, and 1 or 2 heteroatoms (“C2-6 heteroalkenyl”). Unless otherwise specified, each instance of a heteroalkenyl group is independently unsubstituted (an “unsubstituted heteroalkenyl”) or substituted (a “substituted heteroalkenyl”) with one or more substituents. In certain embodiments, the heteroalkenyl group is an unsubstituted C2-10 heteroalkenyl.
- the heteroalkenyl group is a substituted C 2-10 heteroalkenyl.
- heteroalkynyl refers to an alkynyl group, as defined herein, which further comprises one or more (e.g., 1, 2, 3, or 4) heteroatoms (e.g., oxygen, sulfur, nitrogen, boron, silicon, phosphorus) wherein the one or more heteroatoms is inserted between adjacent carbon atoms within the parent carbon chain and/or one or more heteroatoms are inserted between a carbon atom and the parent molecule, i.e., between the point of attachment.
- one or more heteroatoms e.g., oxygen, sulfur, nitrogen, boron, silicon, phosphorus
- a heteroalkynyl group refers to a group having from 2 to 10 carbon atoms, at least one triple bond, and 1, 2, 3, or 4 heteroatoms (“C2-10 heteroalkynyl”). In certain embodiments, a heteroalkynyl group has 2 to 9 carbon atoms, at least one triple bond, and 1, 2, 3, or 4 heteroatoms (“C 2-9 heteroalkynyl”). In certain embodiments, a heteroalkynyl group has 2 to 8 carbon atoms, at least one triple bond, and 1, 2, 3, or 4 heteroatoms (“C2-8 heteroalkynyl”).
- a heteroalkynyl group has 2 to 7 carbon atoms, at least one triple bond, and 1, 2, 3, or 4 heteroatoms (“C 2-7 heteroalkynyl”).
- a heteroalkynyl group has 2 to 6 carbon atoms, at least one triple bond, and 1, 2, or 3 heteroatoms (“C2-6 heteroalkynyl”).
- a heteroalkynyl group has 2 to 5 carbon atoms, at least one triple bond, and 1 or 2 heteroatoms (“C 2-5 heteroalkynyl”).
- a heteroalkynyl group has 2 to 4 carbon atoms, at least one triple bond, and lor 2 heteroatoms (“C2-4 heteroalkynyl”).
- a heteroalkynyl group 61 275501297 v3 has 2 to 3 carbon atoms, at least one triple bond, and 1 heteroatom (“C2-3 heteroalkynyl”). In certain embodiments, a heteroalkynyl group has 2 to 6 carbon atoms, at least one triple bond, and 1 or 2 heteroatoms (“C 2-6 heteroalkynyl”). Unless otherwise specified, each instance of a heteroalkynyl group is independently unsubstituted (an “unsubstituted heteroalkynyl”) or substituted (a “substituted heteroalkynyl”) with one or more substituents.
- the heteroalkynyl group is an unsubstituted C 2-10 heteroalkynyl. In certain embodiments, the heteroalkynyl group is a substituted C 2-10 heteroalkynyl.
- “alkylene,” “alkenylene,” and “alkynylene” as defined above, “heteroalkylene,” “heteroalkenylene,” and “heteroalkynylene,” as used herein, refer to a divalent radical of heteroalkyl, heteroalkenyl, and heteroalkynyl group respectively.
- heteroalkylene When a range or number of carbons is provided for a particular “heteroalkylene,” “heteroalkenylene,” or “heteroalkynylene,” group, it is understood that the range or number refers to the range or number of carbons in the linear divalent chain.
- “Heteroalkylene,” “heteroalkenylene,” and “heteroalkynylene” groups may be substituted or unsubstituted with one or more substituents as described herein.
- Aryl refers to a radical of a monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 ⁇ electrons shared in a cyclic array) having 6-14 ring carbon atoms and zero heteroatoms provided in the aromatic ring system (“C6-14 aryl”).
- an aryl group has six ring carbon atoms (“C 6 aryl”; e.g., phenyl).
- an aryl group has ten ring carbon atoms (“C 10 aryl”; e.g., naphthyl such as 1-naphthyl and 2-naphthyl). In some embodiments, an aryl group has fourteen ring carbon atoms (“C 14 aryl”; e.g., anthracyl).
- Typical aryl groups include, but are not limited to, groups derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, coronene, fluoranthene, fluorene, hexacene, hexaphene, hexalene, as-indacene, s-indacene, indane, indene, naphthalene, octacene, octaphene, octalene, ovalene, penta-2,4-diene, pentacene, pentalene, pentaphene, perylene, phenalene, phenanthrene, picene, pleiadene, pyrene, pyranthrene, rubicene, triphenylene, and trinaphthalene.
- aryl groups include phenyl, naphthyl, indenyl, and tetrahydronaphthyl.
- each instance of an aryl group is independently optionally substituted, i.e., unsubstituted (an “unsubstituted aryl”) or substituted (a “substituted aryl”) with one or more substituents.
- the aryl group is unsubstituted C 6-14 aryl.
- the aryl group is substituted C 6-14 aryl.
- Alkyl is a subset of alkyl and aryl, as defined herein, and refers to an optionally substituted alkyl group substituted by an optionally substituted aryl group.
- “Heteroaryl” refers to a radical of a 5- to 14-membered monocyclic or polycyclic 4n+2 aromatic ring system (e.g., having 6, 10, or 14 ⁇ electrons shared in a cyclic array) having ring carbon atoms and 1-8 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen and sulfur (“5- to 14-membered heteroaryl”).
- Heteroaryl bicyclic ring systems can include one or more heteroatoms in one or both rings.
- “Heteroaryl” also includes ring systems wherein the heteroaryl group, as defined above, is fused with one or more aryl groups wherein the point of attachment is either on the heteroaryl or the one or more aryl groups, and in such instances, the number of ring members designates the total number of ring members in the fused (aryl/heteroaryl) ring system. When substitution is indicated in such instances, unless otherwise specified, substitution can occur on either the heteroaryl or the one or more aryl groups.
- Bicyclic heteroaryl groups wherein one ring does not contain a heteroatom e.g., indolyl, quinolinyl, carbazolyl, and the like
- the point of attachment can be on either ring, i.e., either the ring bearing a heteroatom (e.g., 2-indolyl) or the ring that does not contain a heteroatom (e.g., 5-indolyl).
- a heteroaryl is a 5- to 10-membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5- to 10-membered heteroaryl”).
- a heteroaryl is a 5- to 9-membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5- to 9-membered heteroaryl”).
- a heteroaryl is a 5- to 8-membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5- to 8-membered heteroaryl”).
- a heteroaryl group is a 5- to 6-membered aromatic ring system having ring carbon atoms and 1- 4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5- to 6-membered heteroaryl”).
- the 5- to 6-membered heteroaryl has 1-3 ring heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- the 5- to 6-membered heteroaryl has 1-2 ring heteroatoms independently selected from nitrogen, oxygen, and sulfur. 63 275501297 v3
- the 5- to 6-membered heteroaryl has 1 ring heteroatom selected from nitrogen, oxygen, and sulfur.
- each instance of a heteroaryl group is independently optionally substituted, i.e., unsubstituted (an “unsubstituted heteroaryl”) or substituted (a “substituted heteroaryl”) with one or more substituents.
- the heteroaryl group is unsubstituted 5- to 14-membered heteroaryl.
- the heteroaryl group is substituted 5- to 14-membered heteroaryl.
- Exemplary 5-membered heteroaryl containing one heteroatom include, without limitation, pyrrolyl, furanyl and thiophenyl.
- Exemplary 5-membered heteroaryl containing two heteroatoms include, without limitation, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl.
- Exemplary 5-membered heteroaryl containing three heteroatoms include, without limitation, triazolyl, oxadiazolyl, and thiadiazolyl.
- Exemplary 5-membered heteroaryl containing four heteroatoms include, without limitation, tetrazolyl.
- Exemplary 6-membered heteroaryl containing one heteroatom include, without limitation, pyridinyl.
- Exemplary 6- membered heteroaryl containing two heteroatoms include, without limitation, pyridazinyl, pyrimidinyl, and pyrazinyl.
- Exemplary 6-membered heteroaryl containing three or four heteroatoms include, without limitation, triazinyl and tetrazinyl, respectively.
- Exemplary 7- membered heteroaryl containing one heteroatom include, without limitation, azepinyl, oxepinyl, and thiepinyl.
- Exemplary 5,6-bicyclic heteroaryl include, without limitation, indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzoisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzthiazolyl, benzisothiazolyl, benzthiadiazolyl, indolizinyl, and purinyl.
- Exemplary 6,6- bicyclic heteroaryl include, without limitation, naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl.
- Heteroaralkyl is a subset of alkyl and heteroaryl, as defined herein, and refers to an optionally substituted alkyl group substituted by an optionally substituted heteroaryl group.
- Carbocyclyl refers to a radical of a non-aromatic cyclic hydrocarbon group having from 3 to 12 ring carbon atoms (“C3-12 carbocyclyl”) and zero heteroatoms in the nonaromatic ring system.
- a carbocyclyl group has 3 to 10 ring carbon atoms (“C3- 10 carbocyclyl”).
- a carbocyclyl group has 3 to 8 ring carbon atoms (“C 3-8 carbocyclyl”).
- a carbocyclyl group has 3 to 6 ring carbon atoms (“C3-6 carbocyclyl”).
- a carbocyclyl group has 5 to 12 ring carbon atoms (“C 5-12 carbocyclyl”). In certain embodiments, a carbocyclyl group has 5 to 10 ring carbon atoms (“C 5-10 carbocyclyl”). In certain embodiments, a carbocyclyl group has 5 to 8 ring carbon atoms (“C5-8 carbocyclyl”). In certain embodiments, a carbocyclyl group has 5 or 6 ring carbon 64 275501297 v3 atoms (“C5-6 carbocyclyl”).
- Exemplary C3-6 carbocyclyl include, without limitation, cyclopropyl (C3), cyclopropenyl (C3), cyclobutyl (C4), cyclobutenyl (C4), cyclopentyl (C5), cyclopentenyl (C 5 ), cyclohexyl (C 6 ), cyclohexenyl (C 6 ), cyclohexadienyl (C 6 ), and the like.
- Exemplary C3-8 carbocyclyl include, without limitation, the aforementioned C3-6 carbocyclyl groups as well as cycloheptyl (C7), cycloheptenyl (C7), cycloheptadienyl (C7), cycloheptatrienyl (C 7 ), cyclooctyl (C 8 ), cyclooctenyl (C 8 ), bicyclo[2.2.1]heptanyl (C 7 ), bicyclo[2.2.2]octanyl (C 8 ), and the like.
- Exemplary C 3-10 carbocyclyl include, without limitation, the aforementioned C3-8 carbocyclyl groups as well as cyclononyl (C9), cyclononenyl (C 9 ), cyclodecyl (C 10 ), cyclodecenyl (C 10 ), octahydro-1H-indenyl (C 9 ), decahydronaphthalenyl (C 10 ), spiro[4.5]decanyl (C 10 ), and the like.
- “carbocyclyl” is a monocyclic, saturated carbocyclyl group having from 3 to 12 ring carbon atoms (“C3-12 carbocyclyl”).
- “carbocyclyl” is a monocyclic, saturated carbocyclyl group having from 3 to 10 ring carbon atoms (“C3-10 carbocyclyl”). In certain embodiments, “carbocyclyl” is a monocyclic, saturated carbocyclyl group having from 3 to 8 ring carbon atoms (“C3-8 carbocyclyl”). In certain embodiments, “carbocyclyl” is a monocyclic, saturated carbocyclyl group having from 3 to 6 ring carbon atoms (“C 3-6 carbocyclyl”). In certain embodiments, “carbocyclyl” is a monocyclic, saturated carbocyclyl group having from 5 to 12 ring carbon atoms (“C5-12 carbocyclyl”).
- a carbocyclyl group has 5 to 10 ring carbon atoms (“C 5-10 carbocyclyl”). In certain embodiments, a carbocyclyl group has 5 to 8 ring carbon atoms (“C 5-8 carbocyclyl”). In certain embodiments, “carbocyclyl” is a monocyclic, saturated carbocyclyl group having 5 or 6 ring carbon atoms (“C 5-6 carbocyclyl”). Examples of C 5-6 carbocyclyl include cyclopentyl (C 5 ) and cyclohexyl (C 5 ).
- C 3-6 carbocyclyl examples include the aforementioned C 5-6 carbocyclyl groups as well as cyclopropyl (C3) and cyclobutyl (C4).
- Examples of C3-8 carbocyclyl include the aforementioned C3-6 carbocyclyl groups as well as cycloheptyl (C7) and cyclooctyl (C 8 ).
- each instance of a carbocyclyl group is independently unsubstituted (an “unsubstituted carbocyclyl”) or substituted (a “substituted carbocyclyl”) with one or more substituents.
- the carbocyclyl group is unsubstituted C 3-12 carbocyclyl.
- the carbocyclyl group is substituted C 3-12 carbocyclyl.
- the carbocyclyl group is either monocyclic (“monocyclic carbocyclyl”) or polycyclic (“polycyclic carbocyclyl”) that contains a fused, bridged or spiro ring system and can be saturated or can be partially unsaturated.
- each instance of a carbocyclyl group is independently 65 275501297 v3 optionally substituted, i.e., unsubstituted (an “unsubstituted carbocyclyl”) or substituted (a “substituted carbocyclyl”) with one or more substituents.
- the carbocyclyl group is unsubstituted C 3-12 carbocyclyl. In certain embodiments, the carbocyclyl group is a substituted C3-12 carbocyclyl.
- “Fused carbocyclyl” or “fused carbocycle” refers to ring systems wherein the carbocyclyl group, as defined above, is fused with, i.e., share one common bond with, one or more carbocyclyl groups, as defined above, wherein the point of attachment is on any of the fused rings. In such instances, the number of carbons designates the total number of carbons in the fused ring system. When substitution is indicated, unless otherwise specified, substitution can occur on any of the fused rings.
- “Spiro carbocyclyl” or or “spiro carbocycle” refers to ring systems wherein the carbocyclyl group, as defined above, form spiro structure with, i.e., share one common atom with, one or more carbocyclyl groups, as defined above, wherein the point of attachment is on the carbocyclyl rings in which the spiro structure is embeded.
- the number of carbons designates the total number of carbons of the carbocyclyl rings in which the spiro structure is embeded.
- Bridged carbocyclyl or or “bridged carbocycle” refers to ring systems wherein the carbocyclyl group, as defined above, form bridged structure with, i.e., share more than one atoms (as such, share more than one bonds) with, one or more carbocyclyl groups, as defined above, wherein the point of attachment is on any of the carbocyclyl rings in which the bridged structure is embeded.
- the number of carbons designates the total number of carbons of the bridged rings.
- Heterocyclyl refers to a radical of a 3- to 12-membered non-aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus, and silicon (“3- to 12-membered heterocyclyl”).
- the point of attachment can be a carbon or nitrogen atom, as valency permits.
- Exemplary 3- membered heterocyclyl groups containing one heteroatom include, without limitation, azirdinyl, oxiranyl, thiorenyl.
- Exemplary 4-membered heterocyclyl groups containing one heteroatom include, without limitation, azetidinyl, oxetanyl and thietanyl.
- Exemplary 5membered heterocyclyl groups containing one heteroatom include, without limitation, 66 275501297 v3 tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, pyrrolidinyl, dihydropyrrolyl and pyrrolyl-2,5-dione.
- Exemplary 5-membered heterocyclyl groups containing two heteroatoms include, without limitation, dioxolanyl, oxasulfuranyl, disulfuranyl, and oxazolidin-2-one.
- Exemplary 5-membered heterocyclyl groups containing three heteroatoms include, without limitation, triazolinyl, oxadiazolinyl, and thiadiazolinyl.
- Exemplary 6-membered heterocyclyl groups containing one heteroatom include, without limitation, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl.
- Exemplary 6- membered heterocyclyl groups containing two heteroatoms include, without limitation, piperazinyl, morpholinyl, dithianyl, dioxanyl. Exemplary 6-membered heterocyclyl groups containing two heteroatoms include, without limitation, triazinanyl. Exemplary 7-membered heterocyclyl groups containing one heteroatom include, without limitation, azepanyl, oxepanyl and thiepanyl. Exemplary 8-membered heterocyclyl groups containing one heteroatom include, without limitation, azocanyl, oxecanyl and thiocanyl.
- Exemplary 5-membered heterocyclyl groups fused to a C6 aryl ring include, without limitation, indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, benzoxazolinonyl, and the like.
- Exemplary 6-membered heterocyclyl groups fused to an aryl ring include, without limitation, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and the like.
- a heterocyclyl group is a 5- to 12-membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus, and silicon (“5- to 12-membered heterocyclyl”).
- a heterocyclyl group is a 5- to 10- membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus, and silicon (“5- to 10-membered heterocyclyl”).
- a heterocyclyl group is a 5- to 8-membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5- to 8-membered heterocyclyl”).
- a heterocyclyl group is a 5- to 6-membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5- to 6-membered heterocyclyl”).
- the 5- to 6-membered heterocyclyl has 1-3 ring heteroatoms selected from nitrogen, oxygen, and sulfur.
- the 5- to 6-membered heterocyclyl has 1-2 ring heteroatoms selected from 67 275501297 v3 nitrogen, oxygen, and sulfur. In certain embodiments, the 5- to 6-membered heterocyclyl has one ring heteroatom selected from nitrogen, oxygen, and sulfur.
- a heterocyclyl group can either be monocyclic (“monocyclic heterocyclyl”) or polycyclic (“polycyclic heterocyclyl”) that contains a fused, bridged or spiro ring system, and can be saturated or can be partially unsaturated.
- Heterocyclyl polycyclic ring systems can include one or more heteroatoms in one or both rings.
- Heterocyclyl also includes ring systems wherein the heterocyclyl group, as defined above, is fused with one or more carbocyclyl groups wherein the point of attachment is either on the carbocyclyl or heterocyclyl ring, and in such instances, the number of ring members designates the total number of ring members in the entire ring system. When substitution is indicated in such instances, unless otherwise specified, substitution can occur on either the heterocyclyl or the one or more carbocyclyl groups.
- each instance of heterocyclyl is independently optionally substituted, i.e., unsubstituted (an “unsubstituted heterocyclyl”) or substituted (a “substituted heterocyclyl”) with one or more substituents.
- the heterocyclyl group is unsubstituted 3- to 12-membered heterocyclyl. In certain embodiments, the heterocyclyl group is substituted 3- to 12-membered heterocyclyl.
- “Fused heterocyclyl” or “fused heterocycle” refers to ring systems wherein the heterocyclyl group, as defined above, is fused with, i.e., share one common bond with, one or more heterocyclyl or carbocyclyl groups, as defined above, wherein the point of attachment is on any of the fused rings.
- the number of carbons designates the total number of ring members in the fused ring system.
- “Spiro heterocyclyl” or “spiro heterocycle” refers to ring systems wherein the heterocyclyl group, as defined above, form spiro structure with, i.e., share one common atom with, one or more heterocyclyl or carbocyclyl groups, as defined above, wherein the point of attachment is on the heterocyclyl or carbocyclyl rings in which the spiro structure is embeded.
- the number of ring members designates the total number of ring members of the heterocyclyl or carbocyclyl rings in which the spiro structure is embeded.
- “Bridged heterocyclyl” or “bridged heterocycle” refers to ring systems wherein the heterocyclyl group, as defined above, form bridged structure with, i.e., share more than one atoms (as such, share more than one bonds) with, one or more heterocyclyl or carbocyclyl 68 275501297 v3 groups, as defined above, wherein the point of attachment is on the heterocyclyl or carbocyclyl rings in which the bridged structure is embeded.
- the number of ring members designates the total number of ring members of the heterocyclyl or carbocyclyl rings in which the bridged structure is embeded.
- substitution can occur on any of the bridged rings.
- “Hetero” when used to describe a compound or a group present on a compound means that one or more carbon atoms in the compound or group have been replaced by a nitrogen, oxygen, sulfur, boron, phosphorus, and silicon heteroatom, as valency permits. Hetero may be applied to any of the hydrocarbyl groups described above having from 1 to 5, and particularly from 1 to 3 heteroatoms.
- Alkoxy refers to the group -OR, wherein R is alkyl as defined herein.
- C1-6 alkoxy refers to the group -OR, wherein each R is C1-6 alkyl, as defined herein.
- Exemplary C 1-6 alkyl is set forth above.
- Alkylamino refers to the group -NHR or -NR2, wherein each R is independently alkyl, as defined herein.
- C1-6 alkylamino refers to the group -NHR or -NR2, wherein each R is independently C 1-6 alkyl, as defined herein.
- Exemplary C 1-6 alkyl is set forth above.
- a group other than aryl and heteroaryl or an atom is substituted with an oxo, it is meant to indicate that two geminal radicals on that group or atom form a double bond with an oxygen radical.
- a heteroaryl is substituted with an oxo, it is meant to indicate that a resonance structure/tautomer involving a heteroatom provides a carbon atom that is able to form two geminal radicals, which form a double bond with an oxygen radical.
- “Azido” refers to the radical -N3.
- Amino refers to the radical -NH2.
- “Hydroxy” refers to the radical -OH.
- “Cyano” refers to the radical -CN.
- Halo or “halogen” refers to fluoro (F), chloro (Cl), bromo (Br), and iodo (I). In certain embodiments, the halo group is either fluoro or chloro.
- “Nitro” refers to the radical -NO 2 .
- Protecting group refers to a chemical moiety introduced into a molecule by chemical modification of a functional group (e.g., hydroxyl, 69 275501297 v3 amino, thio, and carboxylic acid) to obtain chemoselectivity in a subsequent chemical reaction, during which the unmodified functional group may not survive or may interfere with the chemical reaction.
- a functional group e.g., hydroxyl, 69 275501297 v3 amino, thio, and carboxylic acid
- Common functional groups that need to be protected include but not limited to hydroxyl, amino, thiol, and carboxylic acid. Accordingly, the protecting groups are termed hydroxyl-protecting groups, amino-protecting groups, thiol-protecting groups, and carboxylic acid-protecting groups, respectively.
- hydroxyl-protecting groups include but not limited to ethers (e.g., methoxymethyl (MOM), ⁇ -Methoxyethoxymethyl (MEM), tetrahydropyranyl (THP), p- methoxyphenyl (PMP), t-butyl, triphenylmethyl (Trityl), allyl, and benzyl ether (Bn)), silyl ethers (e.g., t-butyldiphenylsilyl (TBDPS), trimethylsilyl (TMS), triisopropylsilyl (TIPS), tri- iso-propylsilyloxymethyl (TOM), and t-butyldimethylsilyl (TBDMS)), and esters (e.g., pivalic acid ester (Piv) and benzoic acid ester (benzoate; Bz)).
- ethers e.g., methoxymethyl (MOM), ⁇ -Methoxyeth
- amino-protecting groups include but not limited to carbamates (e.g., t-butyloxycarbonyl (Boc), 9-fluorenylmethyloxycarbonyl (Fmoc), p-methoxybenzyl carbonyl (Moz or MeOZ), 2,2,2-trichloroehtoxycarbonyl (Troc), and benzyl carbamate (Cbz)), esters (e.g., acetyl (Ac); benzoyl (Bz), trifluoroacetyl, and phthalimide), amines (e.g, benzyl (Bn), p-methoxybenzyl (PMB), p-methoxyphenyl (PMP), and triphenylmethyl (trityl)), and sulfonamides (e.g., tosyl (Ts), N-alkyl nitrobenzenesulfonamides (Nosyl), and 2- nitro
- Common types of thiol-protecting groups include but not limited to sulfide (e.g., p- methylbenzyl (Meb), t-butyl, acetamidomethyl (Acm), and triphenylmethyl (Trityl)).
- Common types of carboxylic acid-protecting groups include but not limited to esters (e.g., methyl ester, triphenylmethyl (Trityl), t-butyl ester, benzyl ester (Bn), S-t-butyl ester, silyl esters, and orthoesters) and oxazoline.
- “Pharmaceutically acceptable salt” refers to a salt of a compound of the invention that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound.
- such salts are non-toxic may be inorganic or organic acid addition salts and base addition salts.
- such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2- hydroxyethanesulfonic acid, benzenesulfonic acid, chlorobenzenesulfonic acid, 2- naphthalenesulfonic acid, 4-toluenesulfonic acid
- Salts further include, by way of example only, sodium potassium, calcium, magnesium, ammonium, tetraalkylammonium, and the like; and when the compound contains a basic functionality, salts of nontoxic organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate and the like.
- pharmaceutically acceptable cation refers to an acceptable cationic counterion of an acidic functional group. Such cations are exemplified by sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium cations, and the like (see, e.g., Berge, et al., J.
- “Pharmaceutically acceptable vehicle” refers to a diluent, adjuvant, excipient or carrier with which a compound of the invention is administered.
- “Pharmaceutically acceptable metabolically cleavable group” refers to a group which is cleaved in vivo to yield the parent molecule of the structural formula indicated herein.
- metabolically cleavable groups include -COR, -COOR, -CONR2 and -CH2OR radicals, where R is selected independently at each occurrence from alkyl, trialkylsilyl, carbocyclic aryl or carbocyclic aryl substituted with one or more of alkyl, halogen, hydroxy or 71 275501297 v3 alkoxy.
- Specific examples of representative metabolically cleavable groups include acetyl, methoxycarbonyl, benzoyl, methoxymethyl and trimethylsilyl groups.
- Solvate refers to forms of the compound that are associated with a solvent or water (also referred to as “hydrate”), usually by a solvolysis reaction.
- This physical association includes hydrogen bonding.
- Conventional solvents include water, ethanol, acetic acid and the like.
- the compounds of the invention may be prepared e.g., in crystalline form and may be solvated or hydrated.
- Suitable solvates include pharmaceutically acceptable solvates, such as hydrates, and further include both stoichiometric solvates and non-stoichiometric solvates.
- the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid.
- “Solvate” encompasses both solution-phase and isolable solvates.
- Representative solvates include hydrates, ethanolates and methanolates.
- a “subject” to which administration is contemplated includes, but is not limited to, humans (i.e., a male or female of any age group, e.g., a pediatric subject (e.g, infant, child, adolescent) or an adult subject (e.g., young adult, middle aged adult or senior adult) and/or a non-human animal, e.g., a mammal such as primates (e.g., cynomolgus monkeys, rhesus monkeys), cattle, pigs, horses, sheep, goats, rodents, cats, and/or dogs.
- the subject is a human.
- the subject is a non-human animal.
- an “effective amount” means the amount of a compound that, when administered to a subject for treating or preventing a disease, is sufficient to effect such treatment or prevention.
- the “effective amount” can vary depending on the compound, the disease and its severity, and the age, weight, etc., of the subject to be treated.
- a “therapeutically effective amount” refers to the effective amount for therapeutic treatment.
- a “prophylatically effective amount” refers to the effective amount for prophylactic treatment.
- “Preventing”, “prevention” or “prophylactic treatment” refers to a reduction in risk of acquiring or developing a disease or disorder (i.e., causing at least one of the clinical symptoms of the disease not to develop in a subject not yet exposed to a disease-causing agent, or in a subject who is predisposed to the disease in advance of disease onset).
- the term “prophylaxis” is related to “prevention,” and refers to a measure or procedure the purpose of which is to prevent, rather than to treat or cure a disease.
- Non limiting examples of prophylactic measures may include the administration of vaccines; the administration of low molecular weight heparin to hospital patients at risk for thrombosis due, for example, to immobilization, and the administration of an anti-malarial agent such as 72 275501297 v3 chloroquine, in advance of a visit to a geographical region where malaria is endemic or the risk of contracting malaria is high.
- “Treating” or “treatment” or “therapeutic treatment” of any disease or disorder refers, in one embodiment, to ameliorating the disease or disorder (i.e., arresting the disease or reducing the manifestation, extent or severity of at least one of the clinical symptoms thereof).
- treating refers to ameliorating at least one physical parameter, which may not be discernible by the subject.
- treating or “treatment” refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both.
- treating or “treatment” relates to slowing the progression of the disease.
- Cyclon E3 ubiquitin ligase protein complex is art recognized and refers to an association of proteins in which CRBN, a 442-amino acid protein, forms a Cullin-4-RING E3 ubiquitin ligase (CRL4) complex and interacts with the adaptor protein damaged DNA–binding protein 1 (DDB1), Cullin-4A (CUL4A), and regulator of cullins 1 (ROC1). Within the CRL4 complex, CRBN acts as a substrate-specificity receptor.
- DDB1 DNA–binding protein 1
- CUL4A Cullin-4A
- ROC1 regulator of cullins 1
- An enantiomer can be characterized by the absolute configuration of its asymmetric center and is described by the R - and S - sequencing rules of Cahn and Prelog, or by the manner in which the molecule rotates the plane of polarized light and designated as dextrorotatory or levorotatory (i.e., as (+)- or (-)- isomers respectively).
- a chiral compound can exist as either individual enantiomer or as a mixture thereof.
- a mixture containing equal proportions of the enantiomers is termed a “racemic mixture”.
- “Tautomers” refer to compounds that are interchangeable forms of a particular compound structure, and that vary in the displacement of hydrogen atoms and electrons.
- enols and ketones are tautomers because they are rapidly interconverted by treatment with either acid or base.
- Another example of tautomerism is the 73 275501297 v3 aci- and nitro-forms of phenylnitromethane, that are likewise formed by treatment with acid or base.
- Tautomeric forms may be relevant to the attainment of the optimal chemical reactivity and biological activity of a compound of interest.
- a pure enantiomeric compound is substantially free from other enantiomers or stereoisomers of the compound (i.e., in enantiomeric excess).
- an “S” form of the compound is substantially free from the “R” form of the compound and is, thus, in enantiomeric excess of the “R” form.
- enantiomerically pure or “pure enantiomer” denotes that the compound comprises more than 95% by weight, more than 96% by weight, more than 97% by weight, more than 98% by weight, more than 98.5% by weight, more than 99% by weight, more than 99.2% by weight, more than 99.5% by weight, more than 99.6% by weight, more than 99.7% by weight, more than 99.8% by weight or more than 99.9% by weight, of the enantiomer.
- the weights are based upon total weight of all enantiomers or stereoisomers of the compound.
- the term “enantiomerically pure (R)- compound” refers to at least about 95% by weight (R)-compound and at most about 5% by weight (S)-compound, at least about 99% by weight (R)-compound and at most about 1% by weight (S)-compound, or at least about 99.9 % by weight (R)-compound and at most about 0.1% by weight (S)-compound.
- the weights are based upon total weight of compound.
- the term “enantiomerically pure (S)- compound” refers to at least about 95% by weight (S)-compound and at most about 5% by weight (R)-compound, at least about 99% by weight (S)-compound and at most about 1% by weight (R)-compound or at least about 99.9% by weight (S)-compound and at most about 0.1% by weight (R)-compound. In certain embodiments, the weights are based upon total weight of compound. [000255] In the compositions provided herein, an enantiomerically pure compound or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof can be present with other active or inactive ingredients.
- a pharmaceutical composition comprising enantiomerically pure (R)-compound can comprise, for example, about 90% excipient and about 10% enantiomerically pure (R)-compound.
- the enantiomerically pure (R)-compound in such compositions can, for example, comprise, at least about 95% by weight (R)-compound and at most about 5% by weight (S)-compound, by total weight of the compound.
- a pharmaceutical composition comprising enantiomerically pure (S)- compound can comprise, for example, about 90% excipient and about 10% enantiomerically 74 275501297 v3 pure (S)-compound.
- the enantiomerically pure (S)-compound in such compositions can, for example, comprise, at least about 95% by weight (S)-compound and at most about 5% by weight (R)-compound, by total weight of the compound.
- the active ingredient can be formulated with little or no excipient or carrier.
- the term “about” when referring to a number or a numerical range means that the number or numerical range referred to is an approximation within experimental variability or within statistical experimental error, and thus the number or numerical range, in some instances, will vary between 1% and 15% of the stated number or numerical range. In certain embodiments, the number or numerical range vary by 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, or 15% of the stated number or numerical range.
- the term “or” as used herein shall only be interpreted as indicating exclusive alternatives (i.e., “one or the other but not both”) when preceded by terms of exclusivity, such as “either,” “one of,” “only one of,” or “exactly one of.” “Consisting essentially of,” when used in the claims, shall have its ordinary meaning as used in the field of patent law. [000261] As used herein in the specification and in the claims, the phrase “at least one,” in reference to a list of one or more elements, should be understood to mean at least one element selected from any one or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed within the list of elements and not excluding any combinations of elements in the list of elements.
- At least one of A and B may refer, in one embodiment, to at least one, optionally including more than one, A, with no B present (and optionally including elements other than B); in another embodiment, to at least one, optionally including more than one, B, with no A present (and optionally including elements other than A); in yet another embodiment, to at least one, optionally including more than one, A, and at least one, optionally including more than one, B (and optionally including other elements); etc.
- Step B 4-((2-((benzyloxy)methyl)allyl)oxy)-5-bromoisobenzofuran-1(3H)-one
- 5-bromo-4-hydroxyisobenzofuran-1(3H)-one 5 g, 21.83 mmol, 1.0 eq
- DMF 50 mL
- K2CO3 5.43 g, 39.29 mmol, 1.8 eq
- the mixture was stirred at 80 o C for 5 h.
- Step C 3-((benzyloxy)methyl)-3-methyl-2,3-dihydrobenzo[2,1-b:3,4-c']difuran-6(8H)-one [000268]
- 4-((2-((benzyloxy)methyl)allyl)oxy)-5-bromoisobenzofuran-1(3H)- one (4.3 g, 11.05 mmol, 1.0 eq) in Toluene (40 mL) were added tributylstannane (14.89 mL, 55.23 mmol, 4.5 eq) and AIBN (0.36 g, 2.21 mmol, 0.2 eq).
- the mixture was stirred at 110 o C in a sealed tube overnight. After cooled to room temperature, the mixture was diluted with aqueous KF solution (2 N) (100 mL) and stirred for 1 h. After separation, the aqueous layer was extracted with ethyl acetate (40 mL x 3). The combined extracts were washed with water (40 mL x 3), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure.
- Step E 3-((benzyloxy)methyl)-7-formyl-3-methyl-2,3-dihydrobenzofuran-6-carboxylic acid [000271] To a solution of 3-((benzyloxy)methyl)-7-(hydroxymethyl)-3-methyl-2,3- dihydrobenzofuran-6-carboxylic acid (2.8 g, 8.53 mmol, 1.0 eq) in DCM (50 mL) was added Dess-Martin Periodinane (7.24 g, 17.06 mmol, 2.0 eq). The mixture was stirred at room temperature overnight.
- Step F 3-(3-((benzyloxy)methyl)-3-methyl-6-oxo-2,3,6,8-tetrahydro-7H-furo[2,3-e]isoindol- 7-yl)piperidine-2,6-dione [000272]
- 3-[(benzyloxy)methyl]-7-formyl-3-methyl-2,3-dihydro-1- benzofuran-6-carboxylic acid 1.3 g, 3.98 mmol, 1.0 eq
- DMF 30 mL
- AcOH 10 mL
- 3-aminopiperidine-2,6-dione hydrochloride (0.56 g, 4.38 mmol, 1.5 eq
- NaBH(OAc) 3 (1.68 g, 7.97 mmol, 2.0 eq).
- Step G 3-(3-(hydroxymethyl)-3-methyl-6-oxo-2,3,6,8-tetrahydro-7H-furo[2,3-e]isoindol-7- yl)piperidine-2,6-dione [000273] To a solution of 3- ⁇ 3-[(benzyloxy)methyl]-3-methyl-6-oxo-2H,3H,6H,7H,8H- furo[2,3-e]isoindol-7-yl ⁇ piperidine-2,6-dione (1 g, 2.38 mmol, 1.0 eq) in Ethyl acetate (10 mL) was added 10% Pd/C (200 mg).
- Step B 5-bromo-4-hydroxyisobenzofuran-1(3H)-one [000275] To a solution of methyl 4-bromo-2-formyl-3-hydroxybenzoate (3 g, 11.58 mmol, 1.0 eq) in MeOH (30 mL) was added NaBH4 (1.17 g, 34.74 mmol, 3.0 eq) in portions at 0 o C.
- Step C 4-(benzyloxy)-2-methylenebutanal [000276] To a solution of oxalic dichloride (2.859 mL, 33.287 mmol, 1.5 eq) in anhydrous DCM (160 mL) was added dropwise DMSO (4.73 mL, 66.57 mmol, 3.0 eq) under N2 at - 78 o C. After stirring for 20 min, a solution of 5-(benzyloxy)pentan-1-ol (4.0 g, 22.19 mmol, 1.0 eq) in DCM (30 mL) was added dropwise to above solution over 20 min and the resulting mixture was stirred at -78 o C for 1 h.
- Step D 4-(benzyloxy)-2-methylenebutan-1-ol [000277] To a solution of 2-[(benzyloxy)methyl]prop-2-enal (1.7 g, 9.64 mmol, 1.0 eq) in THF (50 mL) was added LiAlH 4 (0.55 g, 14.47 mmol, 1.5 eq) in small portions over 5 min at 0 o C and the mixture was stirred at 0 o C for 30 min. The reaction mixture was cautiously quenched with saturated aqueous NH4Cl solution (50 mL) and extracted with EtOAc (200 mL x 2). The combined organic extracts were dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure.
- Step E 4-(4-(benzyloxy)-2-methylenebutoxy)-5-bromoisobenzofuran-1(3H)-one
- Step F 3-(2-(benzyloxy)ethyl)-3-methyl-2,3-dihydrobenzo[2,1-b:3,4-c']difuran-6(8H)-one and 3-(2-(benzyloxy)ethyl)-3,4-dihydro-2H-furo[3,4-h]chromen-7(9H)-one [000279]
- 4-(4-(benzyloxy)-2-methylenebutoxy)-5-bromoisobenzofuran- 1(3H)-one 7.7 g, 19.09 mmol, 1.0 eq) in toluene (100 mL) were added AIBN (627.3 mg, 3.82 mmol, 0.2 eq) and tributyltin hydride (15.4 mL, 57.28 mmol, 3.0 eq).
- the mixture was stirred under N 2 at 110 o C in a sealed tube overnight. After cooled to room temperature, the mixture was quenched with saturated aqueous potassium fluoride solution (150 mL) and stirred for 2 h. Then the mixture was extracted with EA (150 mL x 3). The organic layer was washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure.
- Step G 3-(2-(benzyloxy)ethyl)-7-(hydroxymethyl)-3-methyl-2,3-dihydrobenzofuran-6- carboxylic acid [000282] To a solution of 3-(2-(benzyloxy)ethyl)-3-methyl-2,3-dihydrobenzo[2,1-b:3,4- c']difuran-6(8H)-one (100 mg, 0.307 mmol, 1.0 eq) in THF/MeOH/H2O (3/3/1, 7 mL) was added NaOH (49 mg, 1.233 mmol, 4.0 eq) and the mixture was stirred at room temperature for 0.5 h.
- Step H 3-(2-(benzyloxy)ethyl)-7-formyl-3-methyl-2,3-dihydrobenzofuran-6-carboxylic acid
- DCM dihydrobenzofuran-6-carboxylic acid
- Dess-Martin periodinane (680 mg, 1.603 mmol, 2.0 eq) in portions at 0 o C and the mixture was stirred for 1 h, After evaporation, the residue was purified by flash silica gel column chromatography (ethyl acetate in petroleum ether, from 0% to 30%) to give 3-(2- (benzyloxy)ethyl)-7-(hydroxy
- Step K 3-(3-(2-hydroxyethyl)-3-methyl-6-oxo-2,3,6,8-tetrahydro-7H-furo[2,3-e]isoindol-7- yl)piperidine-2,6-dione
- Step B 5-(benzyloxy)-2-methylenepentan-1-ol
- Step C 4-((5-(benzyloxy)-2-methylenepentyl)oxy)-5-bromoisobenzofuran-1(3H)-one [000289] To a solution of 5-bromo-4-hydroxy-1,3-dihydro-2-benzofuran-1-one (3.87 g, 16.9 mmol, 1.0 eq) and 5-(benzyloxy)-2-methylidenepentan-1-ol (3.49 g, 16.9 mmol, 1.0 eq), and PPh 3 (5.32 g, 20.3 mmol, 1.2 eq) in dry THF (40 mL) was added dropwise DIAD (4.10 g, 85 275501297 v3 20.3 mmol, 1.2 eq) and the reaction mixture was stirred under N2 at room temperature for 16 h.
- DIAD 4.10 g, 85 275501297 v3 20.3 mmol, 1.2 eq
- Step D 3-(3-(benzyloxy)propyl)-3-methyl-2,3-dihydrobenzo[2,1-b:3,4-c']difuran-6(8H)-one
- 4-((5-(benzyloxy)-2-methylenepentyl)oxy)-5-bromoisobenzofuran- 1(3H)-one 1.0 g, 2.4 mmol, 1.0 eq
- Bu3SnH (2.38 g, 9.6 mmol, 4.0 eq
- AIBN 80 mg, 479 ⁇ mol, 0.2 eq.
- the mixture was stirred at 100 o C in a sealed tube for 16 h. After cooled to room temperature, the reaction mixture was quenched with aqueous KF solution (20 mL), stirred for 2 h, and extracted with EA (20 mL x 3). The organic layer was washed with brine (40 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure.
- Step E 3-(3-(benzyloxy)propyl)-7-(hydroxymethyl)-3-methyl-2,3-dihydrobenzofuran-6- carboxylic acid
- 3-(3-(benzyloxy)propyl)-3-methyl-2,3-dihydrobenzo[2,1-b:3,4- c']difuran-6(8H)-one 370 mg, 1.1 mmol, 1.0 eq
- THF 3 mL
- water 1.5 mL
- NaOH 17.4.9 mg, 4.4 mmol, 4.0 eq
- Step F 3-(3-(benzyloxy)propyl)-7-formyl-3-methyl-2,3-dihydrobenzofuran-6-carboxylic acid [000292] To a solution of 3-(3-(benzyloxy)propyl)-7-(hydroxymethyl)-3-methyl-2,3- dihydrobenzofuran-6-carboxylic acid (210 mg, 589 ⁇ mol, 1.0 eq) in DCM (10 mL) were added MnO 2 (1.02 g, 11.7 mmol, 20.0 eq). The mixture was stirred at room temperature for 1 h.
- Step G 3-(3-(3-(benzyloxy)propyl)-3-methyl-6-oxo-2,3,6,8-tetrahydro-7H-furo[2,3- e]isoindol-7-yl)piperidine-2,6-dione [000293] To a solution of 3-(3-(benzyloxy)propyl)-7-formyl-3-methyl-2,3- dihydrobenzofuran-6-carboxylic acid (250 mg, 705 ⁇ mol, 1.0 eq) in DMF (2.5 mL) and AcOH (0.2 mL) were added 3-aminopiperidine-2,6-dione hydrochloride (135.5 mg, 1.06 mmol, 1.5 eq) and the mixture was stirred at 30 o C for 30 min.
- 3-aminopiperidine-2,6-dione hydrochloride 135.5 mg, 1.06 mmol, 1.5 eq
- Step H 3-(3-(3-hydroxypropyl)-3-methyl-6-oxo-2,3,6,8-tetrahydro-7H-furo[2,3-e]isoindol-7- yl)piperidine-2,6-dione [000294] To a solution of 3-(3-(3-(benzyloxy)propyl)-3-methyl-6-oxo-2,3,6,8-tetrahydro-7H- furo[2,3-e]isoindol-7-yl)piperidine-2,6-dione (40 mg, 89 ⁇ mol, 1.0 eq) in 2,2,2- trifluoroethanol (2 mL) was added 10% Pd/C (630 mg).
- Step B 4-((5-(benzyloxy)-3-methylenepentyl)oxy)-5-bromoisobenzofuran-1(3H)-one [000296] To a mixture of 5-bromo-4-hydroxy-1,3-dihydro-2-benzofuran-1-one (200 mg, 0.9 mmol, 1.0 eq) in DMF (5 mL) was added (((5-bromo-3-methylenepentyl)oxy)methyl)benzene (234.99 mg, 0.9 mmol, 1.0 eq) and K 2 CO 3 (362 mg, 2.6 mmol, 3.0 eq) at room temperature. The reaction mixture was stirred at 80 o C overnight.
- Step C 4-(2-(benzyloxy)ethyl)-2,3,4,5-tetrahydrooxepino[2,3-e]isobenzofuran-8(10H)-one [000297] To a mixture of 4- ⁇ [5-(benzyloxy)-3-methylidenepentyl]oxy ⁇ -5-bromo-1,3-dihydro- 2-benzofuran-1-one (2.2 g, 5.272 mmol, 1.0 eq) and AIBN (1.73 g, 10.544 mmol, 2.0 eq) in Toluene (30 mL) was added Bu 3 SnH (5.37 mL, 10.544 mmol, 2.0 eq) at room temperature.
- reaction mixture was stirred under N2 at 100 o C in a sealed tube overnight.
- the reaction mixture was cooled to room temperature, quenched with aqueous KF solution (50 mL), stirred for 2 h, and extracted with EtOAc (30 mL x 3). The organic layer was washed with brine (30 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure.
- Step D 4-(2-(benzyloxy)ethyl)-9-(hydroxymethyl)-2,3,4,5-tetrahydrobenzo[b]oxepine-8- carboxylic acid [000298] To a solution of 4-(2-(benzyloxy)ethyl)-2,3,4,5-tetrahydrooxepino[2,3- e]isobenzofuran-8(10H)-one (1.5 g, 4.433 mmol, 1.0 eq) in THF (20 mL) and MeOH (20 mL) was added dropwise aqueous NaOH solution (886.5 mg, 22.163 mmol, 5.0 eq) in water (10 mL) and the resulting mixture was stirred at 40 °C for 2 h.
- Step E 4-(2-(benzyloxy)ethyl)-9-formyl-2,3,4,5-tetrahydrobenzo[b]oxepine-8-carboxylic acid [000299] To a solution of 4-[2-(benzyloxy)ethyl]-9-(hydroxymethyl)-2,3,4,5-tetrahydro-1- 89 275501297 v3 benzoxepine-8-carboxylic acid (1.5 g, 4.489 mmol,1.0 eq) in DCM (50 mL) was added active manganese dioxide (7.8 g, 89.782 mmol, 20.0 eq) in one portion at room temperature.
- Step F 3-(4-(2-(benzyloxy)ethyl)-8-oxo-2,3,4,5,8,10-hexahydro-9H-oxepino[2,3-e]isoindol-9- yl)piperidine-2,6-dione [000300] To a solution of 4-[2-(benzyloxy)ethyl]-9-formyl-2,3,4,5-tetrahydro-1-benzoxepine- 8-carboxylic acid (1.3 g, 3.668 mmol, 1.0 eq) and 3-aminopiperidine-2,6-dione hydrochloride (0.71 g, 5.502 mmol, 1.5 eq) in DMF (20 mL) was added AcOH (2.11 mL, 37 mmol, 10.0 eq).
- Step G 3-(4-(2-hydroxyethyl)-8-oxo-2,3,4,5,8,10-hexahydro-9H-oxepino[2,3-e]isoindol-9- yl)piperidine-2,6-dione
- 3-(4-(2-(benzyloxy)ethyl)-8-oxo-2,3,4,5,8,10-hexahydro-9H- oxepino[2,3-e]isoindol-9-yl)piperidine-2,6-dione 610 mg, 1.360 mmol, 1.0 eq
- 2,2,2- trifluoroethanol 20 mL
- Step B 3-(2-(benzyloxy)ethyl)-8-formylchromane-7-carboxylic acid
- 3-(2-(benzyloxy)ethyl)-8-(hydroxymethyl)chromane-7-carboxylic acid 338 mg, 0.987 mmol, 1.0 eq
- Dess-Martin periodinane 837 mg, 1.974 mmol, 2.0 eq
- the residue was purified by flash silica gel column chromatography (ethyl acetate in petroleum ether, from 0% to 30%) to give 3-(2-(benzyloxy)ethyl)-8-formylchromane-7- carboxylic acid (180 mg, yield 54%) as a colorless oil.
- Step E 3-(3-(2-hydroxyethyl)-7-oxo-3,4,7,9-tetrahydropyrano[2,3-e]isoindol-8(2H)- yl)piperidine-2,6-dione
- a mixture of 3-(3-(2-(benzyloxy)ethyl)-7-oxo-3,4,7,9-tetrahydropyrano[2,3- e]isoindol-8(2H)-yl)piperidine-2,6-dione (30 mg, 0.069 mmol, 1 equiv) and 10% Pd/C (10 mg) in 2,2,2-trifluoroethanol (10 mL) was stirred under H2 (1 atm) at room temperature for 1 h.
- reaction mixture was stirred at 40 °C for 3 h. After cooled to room temperature, the reaction mixture was diluted with EA (30 mL) and quenched with water (10 mL). The organic layer was washed with brine (10 mL x 3), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure.
- reaction mixture was stirred under N2 at 70 °C for 3 h. After cooled to room temperature, the reaction mixture was evaporated and the residue was diluted with EA (100 mL). The organic layer was washed with saturated NH4Cl solution (20 mL x 3) and brine(20 mL x 3), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure.
- Step B 3-(4-amino-2,2-dimethyl-7-oxo-3,4,7,9-tetrahydropyrano[2,3-e]isoindol-8(2H)- yl)piperidine-2,6-dione [000310] To a solution of (E)-3-(4-(hydroxyimino)-2,2-dimethyl-7-oxo-3,4,7,9- tetrahydropyrano[2,3-e]isoindol-8(2H)-yl)piperidine-2,6-dione (342 mg, 0.96 mmol, 1.0 eq) in AcOH (10 mL) was added Zn powder (936 mg, 14.4 mmol, 15.0 eq).
- reaction mixture was stirred at 120 °C for 1.5 h. After cooled to room temperature, the reaction mixture was filtered and the filtrate was concentrated under reduced pressure. The residue was diluted with EA (100 mL), washed with saturated aqueous NaHCO3 solution (20 mL x 3) and brine (20 mL), dried 94 275501297 v3 over anhydrous sodium sulfate, filtered and concentrated under reduced pressure.
- reaction mixture was stirred under N2 at room temperature for 36 h.
- the reaction mixture was diluted with EA (150 mL), washed with saturated aqueous NaHCO 3 solution (15 mL x 2) and brine (15 mL x 3), dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure.
- Step B 3-(4-(aminomethyl)-2,2-dimethyl-7-oxo-3,4,7,9-tetrahydropyrano[2,3-e]isoindol- 8(2H)-yl)piperidine-2,6-dione [000314] To a solution of 8-(2,6-dioxopiperidin-3-yl)-2,2-dimethyl-7-oxo-4- ((trimethylsilyl)oxy)-2,3,4,7,8,9-hexahydropyrano[2,3-e]isoindole-4-carbonitrile (50.0 mg, 113 ⁇ mol, 1.0 eq) in EtOH (4.00 mL) were added con.
- Step B 5-hydroxy-4-(2- methylallyl)isobenzofuran-1(3H)-one [000317] A solution of 5-((2-methylallyl)oxy)isobenzofuran-1(3H)-one (220 mg, 1.08 mmol, 1.0 eq) in 1-methylpyrrolidin-2-one (6.00 mL) was stirred under microwave at 150 oC for 1 h. After cooled to room temperature, the reaction mixture was diluted with EA (30 mL), washed with brine (30 mL x 3), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure.
- Step D (7-methyl-3-oxo-1,3,7,8-tetrahydrobenzo[1,2-b:3,4-c']difuran-7-yl)methyl formate
- Step E 2,4-bis(hydroxymethyl)-2-methyl-2,3-dihydrobenzofuran-5- carboxylic acid
- 7-methyl-3-oxo-1,3,7,8-tetrahydrobenzo[1,2-b:3,4-c']difuran-7- yl)methyl formate (680 mg, 2.74 mmol, 1.0 eq) and NaOH (0.55 g, 13.7 mmol, 5.0 eq) in THF/MeOH/H 2 O (7.0 mL 3 mL/3 mL/1 mL) and the reaction mixture was stirred at 50 o C for 1 h.
- Step F 1-hydroxy-7-(hydroxymethyl)-7-methyl-7,8-dihydrobenzo[1,2-b:3,4-c']difuran-3(1H)- one [000321]
- MnO 2 4.38 g, 13.7 mmol, 20.0 eq. The mixture was stirred at room temperature for 12 h. After filtration, the filtrate was collected and concentrated under reduced pressure.
- Step G 3-(7- (hydroxymethyl)-7-methyl-3-oxo-1,3,7,8-tetrahydro-2H-furo[3,2-e]isoindol-2- yl)piperidine-2,6-dione [000322] To a solution of 3-aminopiperidine-2,6-dione hydrochloride (418 mg, 2.54 mmol, 1.5 eq) in DMF (10.0 mL) was added TEA (257 mg, 2.54 mmol, 0.35 mL, 2.0 eq) and the reaction mixture was stirred at 40 o C for 10 min.
- Step D methyl 4-(2-(benzyloxy)ethyl)-4,6-dimethylchromane-7-carboxylate
- methyl 5-((5-(benzyloxy)-3-methylenepentyl)oxy)-4-bromo-2- methylbenzoate 6.6 g, 15.2 mmol, 1.0 eq
- DMF 66 mL
- NaOAc 3.37 g, 41.1 mmol, 2.7 eq
- sodium formate (1.35 g, 19.8 mmol, 1.3 eq
- Tetraethylammonium chloride monohydrate 3.64 g, 19.8 mmol, 1.3 eq
- Pd(OAc) 2 340 mg, 1.5 mmol, 0.1 eq.
- Step E methyl 4-(2-hydroxyethyl)-4,6-dimethylchromane-7-carboxylate [000327] To a solution of methyl 4-(2-(benzyloxy)ethyl)-4,6-dimethylchroman-7-carboxylate (3.0 g, 8.5 mmol, 1.0 eq) in MeOH (30 mL) was added 10% Pd/C (300 mg). The mixture was stirred under H2 (1 atm) at room temperature for 10 h. After filtration, the filtrate was 102 275501297 v3 concentrated under reduced pressure to afford methyl 4-(2-hydroxyethyl)-4,6- dimethylchroman-7-carboxylate (2.0 g, yield 89%) as a colorless oil.
- Step G methyl 4-(2-azidoethyl)-4,6-dimethylchroman-7-carboxylate
- methyl 4-(2-bromoethyl)-4,6-dimethylchroman-7-carboxylate 1.5 g, 4.60 mmol, 1.0 eq
- NaN3 598 mg, 9.2 mmol, 2.0 eq
- the reaction mixture was stirred at 60 o C for 12 h.
- the reaction mixture was cooled to room temperature, quenched with water (60 mL), and extracted with EtOAc (60 mL x 3).
- Step H methyl 4-(2-aminoethyl)-4,6-dimethylchroman-7-carboxylate
- MeOH MeOH
- 10% Pd/C 110 mg
- the mixture was stirred under H 2 (1 atm) at room temperature for 10 h. After filtration, the filtrate was concentrated under reduced pressure to afford methyl 4-(2-aminoethyl)-4,6-dimethylchroman-7-carboxylate (940 mg, yield 94%) as a colorless oil.
- Step I methyl 4-(2-((tert-butoxycarbonyl)amino)ethyl)-4,6-dimethylchroman-7-carboxylate [000331] To a solution of methyl 4-(2-aminoethyl)-4,6-dimethylchroman-7-carboxylate (940 mg, 3.56 mmol, 1.0 eq) in DCM (25 mL) were added Boc2O (1.1 g, 5.34 mmol, 1.5 eq), DMAP (43 mg, 0.356 mmol, 0.1 eq), and TEA (719 mg, 7.12 mmol, 2.0 eq).
- Step J methyl 6-(bromomethyl)-4-(2-((tert-butoxycarbonyl)amino)ethyl)-4-methyl chroman- 7-carboxylate
- NBS NBS
- BPO 100 mg, 0.413 mmol, 0.3 eq
- Step K tert-butyl(2-(7-(2,6-dioxopiperidin-3-yl)-4-methyl-8-oxo-2,3,4,6,7,8-hexahy dropyrano[2,3-f]isoindol-4-yl)ethyl)carbamate
- DIEA 2-((tert-butoxycarbonyl)amino)ethyl)- 4-methylchroman-7-carboxylate
- Step L 3-(4-(2-aminoethyl)-4-methyl-8-oxo-3,4-dihydropyrano[2,3-f]isoindol-7(2H,6H,8H)- yl)piperidine-2,6-dione hydrochloride [000335] To a solution of tert-butyl (2-(7-(2,6-dioxopiperidin-3-yl)-4-methyl-8-oxo - 2,3,4,6,7,8-hexahydropyrano[2,3-f]isoindol-4-yl)ethyl)carbamate (200 mg, 0.437 mmol, 1.0 eq) in 1,4-dioxane (5 mL) was added HCl-dioxane (4 M) (5 mL, 20 mmol, 45 eq).
- the reaction was conducted in total volume of 20 ⁇ L with addition of 2 nM His tagged CRBN+DDB-DLS7+CXU4 (Wuxi, catalogue # RP210521GA) to compounds followed by addition of 60 nM Fluorescent probe Cy5-labeled Thalidomide (Tenova Pharma, catalogue # T52461), and 0.4 nM of MAb Anti-6HIS Tb cryptate Gold (Cisbio, catalogue # 61HI2TLA in the assay buffer (50 mM HEPES pH 7.5, 1 mM TCEP, 0.01% Brij-35, 50 mM NaCl, and 0.1% BSA).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Described herein are compounds or conjugates of Formula I and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as cereblon-binding agents or bifunctional degraders for degrading certain proteins).
Description
CEREBLON LIGANDS AND USES THEREOF RELATED APPLICATIONS [0001] This application claims the benefit of and priority to U.S. Provisional Application No. 63/417,198, filed October 18, 2022, the contents of which are incorporated herein by reference in their entireties. BACKGROUND [0002] Cereblon (CRBN), a component of the DDBl-CUL4a-Rocl ubiquitin ligase complex, is a molecular target of immunomodulatory agents such as thalidomide, lenalidomide, and pomalidomide. Inhibition of CRBN ubiquitination by these agents may allow CRBN to accumulate, leading to the increased cullin-4 RING E3 ligase-mediated degradation of target proteins. [0003] The discovery process of CRBN type E3 ligase ligand is related to the study of thalidomide's mechanism of action. In 2010, while studying the toxicity of thalidomide, scientists discovered that cereblon is a binding protein of thalidomide (Science 2010, 327, 1345). Cerebellar protein is part of the E3 ubiquitin ligase protein complex, which acts as a substrate receptor to select ubiquitinated proteins. The study shows that thalidomide-cerebellar protein binding in vivo may be the cause of thalidomide teratogenicity. Subsequent studies found that the compound and related structures can be used as anti-inflammatory agents, anti- angiogenic agents and anti-cancer agents. Lenalidomide and pomalidomide obtained by further modification of the structure of thalidomide have greatly improved their safety and significantly reduced their teratogenic effects. Lenalidomide has been approved by the FDA in 2006 for marketing. Two groundbreaking papers published in Science in 2014 pointed out that lenalidomide works by degrading two special B cell transcription factors, Ikaros family zinc finger structural proteins 1 and 3 (IKZF1 and IKZF3), which further reveals the structure of thalidomide may be combined with the E3 ubiquitin ligase protein complex of the cerebellar protein to further play a role in degrading the target protein (Science, 2014, 343, 301; Science, 2014, 343, 305). [0004] On this basis, CRBN ligands are widely used in protein degradation, and a series of PROTACs molecules based on CRBN ligands have been developed. Due to the influence of CRBN ligand itself on the target point, it may additionally degrade zinc finger domain protein. Therefore, the design and synthesis of new and highly selective CRBN ligands is also particularly important in the synthesis of PROTACs molecules. 1 275501297 v3
SUMMARY [0005] In certain aspects, the present disclosure provides compounds or conjugates of Formula I:
and pharmaceutically acceptable salts, solvates, or stereoisomers thereof, wherein each of the variables are defined, described, and exemplified herein. [0006] In certain aspects, provided herein are methods of binding cereblon E3 ubiquitin ligase protein complex in a subject or biological sample comprising administering a compound described herein to the subject or contacting the biological sample with a compound described herein. [0007] In certain aspects, provided herein are uses of a compound described herein in the manufacture of a medicament for binding cereblon E3 ubiquitin ligase protein complex in a subject or biological sample. [0008] In certain aspects, provided herein are compounds described herein for use in binding cereblon E3 ubiquitin ligase protein complex in a subject or biological sample. [0009] In certain aspects, the present disclosure provides pharmaceutical compositions comprising a conjugate disclosed herein, and a pharmaceutically acceptable excipient. [00010] In certain aspects, provided herein are methods of degrading a protein in a subject or biological sample comprising administering a conjugate described herein to the subject or contacting the biological sample with a conjugate described herein. [00011] In certain aspects, provided herein are uses of a conjugate described herein in the manufacture of a medicament for degrading a protein in a subject or biological sample. [00012] In certain aspects, provided herein are conjugates described herein for use in degrading a protein in a subject or biological sample. [00013] In certain aspects, provided herein are methods of treating or preventing a disease or disorder a subject in need thereof, comprising administering to the subject a conjugate described herein. [00014] In certain aspects, provided herein are uses of a conjugate described herein in the manufacture of a medicament for treating or preventing a disease or disorder in a subject in need thereof. 2 275501297 v3
[00015] In certain aspects, provided herein are conjugates described herein for use in treating or preventing a disease or disorder in a subject in need thereof. DETAILED DESCRIPTION [00016] The present disclosure relates to compounds that show cereblon-binding activity, and compounds that bifunctional degraders comprising such compound, as well as pharmaceutical compositions thereof. The present disclosure further relates to methods of degrading a protein in a subject or biological sample comprising administering a compound described herein to the subject or contacting the biological sample with a compound described herein. The present disclosure also relates to methods of treating or preventing a disease or disorder a subject in need thereof, comprising administering to the subject a compound described herein. Compounds of the Application Cereblon Ligands [00017] In certain aspects, the present disclosure provides compounds of Formula I:
and pharmaceutically acceptable salts, solvates, or stereoisomers thereof, wherein: R1 is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, 3- to 12- membered heterocyclyl, -SRb, -S(=O)Ra, -S(=O)2Ra, -S(=O)2ORb, -S(=O)2NRcRd, - NRcS(=O)2Ra, -NRcS(=O)Ra, -NRcS(=O)2ORb, -NRcS(=O)2NRcRd, -NRbC(=O)NRcRd, - NRbC(=O)Ra, -NRbC(=O)ORb, -OS(=O)2Ra, -OS(=O)2ORb, -OS(=O)2NRcRd, -OC(=O)Ra, -OC(=O)ORb, -OC(=O)NRcRd, -C(=O)Ra, -C(=O)ORb, or -C(=O)NRcRd, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more Ru; R1 and R2, together with the intervening carbon atoms, form Ring A; Y” is N or CR3; R3 is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, 3- to 12- membered heterocyclyl, -SRb, -S(=O)Ra, -S(=O)2Ra, -S(=O)2ORb, -S(=O)2NRcRd, - 3 275501297 v3
NRcS(=O)2Ra, -NRcS(=O)Ra, -NRcS(=O)2ORb, -NRcS(=O)2NRcRd, -NRbC(=O)NRcRd, - NRbC(=O)Ra, -NRbC(=O)ORb, -OS(=O)2Ra, -OS(=O)2ORb, -OS(=O)2NRcRd, -OC(=O)Ra, -OC(=O)ORb, -OC(=O)NRcRd, -C(=O)Ra, -C(=O)ORb, or -C(=O)NRcRd, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more Ru; or R2 and R3, together with the intervening carbon atoms, form Ring A; provided that either R1 and R2 or R2 and R3 form Ring A, Y’ is N or CRY’; RY’ is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, or 3- to 12-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl is optionally substituted with one or more Ru; denotes an optional covalent bond between Y and U; when the bond between Y and U is absent: r is 0 or 1; X is O or N; wherein when X is O, then U is absent; Y is N or CRY; RY is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, or 3- to 12-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl is optionally substituted with one or more Ru; and U is absent, hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, 3- to 12-membered heterocyclyl, -S(=O)Ra, -S(=O)2Ra, - S(=O)2ORb, -S(=O)2NRcRd, -C(=O)Ra, -C(=O)ORb, or -C(=O)NRcRd, wherein the alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more Ru; when the bond between Y and U is present: r is 1; X is N; Y is C; and U is -CH2- or -C(=O)- R4 is hydrogen, deuterium, C1-6 haloalkyl, or C1-6 alkyl; q is an integer from 0 to 2, 4 275501297 v3
Ring A is
wherein: each Ri independently is oxo, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, 3- to 12-membered heterocyclyl, -SRb, -S(=O)Ra, -S(=O)2Ra, -S(=O)2ORb, - S(=O)2NRcRd, -NRcS(=O)2Ra, -NRcS(=O)Ra, -NRcS(=O)2ORb, -NRcS(=O)2NRcRd, - NRbC(=O)NRcRd, -NRbC(=O)Ra, -NRbC(=O)ORb, -OS(=O)2Ra, -OS(=O)2ORb, - OS(=O)2NRcRd, -OC(=O)Ra, -OC(=O)ORb, -OC(=O)NRcRd, -C(=O)Ra, -C(=O)ORb, or - C(=O)NRcRd, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more Ru; s is an integer selected from 0 to 5; m is an integer selected from 0 to 2; Rcp is , wherein: Rend is -ORH1, -N(RH2)2, -SRH3, or -C(=O)ORH4; RH1 is hydrogen, C1-6 alkyl, -S(=O)2Ra, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, or a hydroxyl- protecting group, wherein the C1-6 alkyl is optionally substituted with one or more Ru; RH2 is hydrogen, C1-6 alkyl, -S(=O)2Ra, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, or an amino- protecting group, wherein the C1-6 alkyl is optionally substituted with one or more Ru; RH3 is hydrogen, C1-6 alkyl, -C(=O)Ra, or a thiol-protecting group, wherein the C1-6 alkyl is optionally substituted with one or more Ru; RH4 is hydrogen, C1-6 alkyl, or a carboxylic acid-protecting group, wherein the C1-6 alkyl is optionally substituted with one or more Ru; each occurrence of G is independently -C(RG1)2-, -O-, -NRG2-, -C(=O)-, -S-, or -S(=O)2-; each RG1 is independently hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, or 3- to 12-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl is optionally substituted with one or more Ru; 5 275501297 v3
each RG2 is independently hydrogen or C1-6 alkyl optionally substituted with one or more Ru; and p is an integer selected from 0 to 5, wherein: each Ru is independently oxo, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, 3- to 12-membered heterocyclyl, -SRb, -S(=O)Ra, -S(=O)2Ra, -S(=O)2ORb, - S(=O)2NRcRd, -NRcS(=O)2Ra, -NRcS(=O)Ra, -NRcS(=O)2ORb, -NRcS(=O)2NRcRd, - NRbC(=O)NRcRd, -NRbC(=O)Ra, -NRbC(=O)ORb, -OS(=O)2Ra, -OS(=O)2ORb, - OS(=O)2NRcRd, -OC(=O)Ra, -OC(=O)ORb, -OC(=O)NRcRd, -C(=O)Ra, -C(=O)ORb, or - C(=O)NRcRd; wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more substituents selected from oxo, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C3-6 carbocyclyl, and 3- to 6-membered heterocyclyl; or two Ru, together with the one or more intervening atoms, form C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl or 3- to 12-membered heterocyclyl; each Ra is independently C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-12 carbocyclyl, 3- to 12- membered heterocyclyl, C6-10 aryl, or 5- to 10-membered heteroaryl; each Rb is independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-12 carbocyclyl, 3- to 12-membered heterocyclyl, C6-10 aryl, or 5- to 10-membered heteroaryl; and each Rc and Rd is independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-12 carbocyclyl, 3- to 12-membered heterocyclyl, C6-10 aryl, or 5- to 10-membered heteroaryl; or Rc and Rd, together with the nitrogen atom to which they are attached, form 3- to 12-membered heterocyclyl, wherein each occurrence of Ra, Rb, Rc, and Rd is independently and optionally substituted with one or more Rz; and each Rz is independently oxo, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C3-6 carbocyclyl, or 3- to 6-memberred heterocyclyl. [00018] In certain embodiments, Ring A is 6 275501297 v3
or , [00019] In certain embodiments, the compound is not
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. [00021] In certain embodiments, the compound of Formula I is a compound of Formula I-2
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. [00022] In certain embodiments, U is hydrogen or C1-6 alkyl (e.g., methyl (C1), ethyl (C2), n- propyl (C3), i-propyl (C3), n-butyl (C4), i-butyl (C4), s-butyl (C4), t-butyl (C4), pentyl (C5), or hexyl (C6)). [00023] In certain embodiments, Y is N. [00024] In certain embodiments, Y is CRY. [00025] In certain embodiments, RY is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, or 3- to 12-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl is optionally substituted with one or more Ru. [00026] In certain embodiments, RY is hydrogen, halogen (e.g., -F, -Cl, -Br, or -I), -CN, -NO2, -OH, -NH2, C1-6 alkyl (e.g., methyl (C1), ethyl (C2), n-propyl (C3), i-propyl (C3), n-butyl (C4), i-butyl (C4), s-butyl (C4), t-butyl (C4), pentyl (C5), or hexyl (C6)), C1-6 alkoxy (e.g., methoxy (C1), ethoxy (C2), n-propoxy (C3), i-propoxy (C3), n-butoxy (C4), i-butoxy (C4), s-butoxy (C4), 7 275501297 v3
t-butoxy (C4), pentoxy (C5), or hexoxy (C6)), C1-6 alkylamino (e.g., dimethylamino, diethylamino, di-n-propylamino, di-i-propylamino, di-n-butylamino, di-i-butylamino, di-s- butylamino, di-t-butylamino, dipentylamino, dihexylamino, methylethylamino, methyl-n- propylamino, methyl-i-propylamino, methyl-n-butylamino, methyl-i-butylamino, methyl-s- butylamino, methyl-t-butylamino, methylpentylamino, methylhexylamino, ethyl-n- propylamino, ethyl-i-propylamino, ethyl-n-butylamino, ethyl-s-butylamino, ethyl-i- butylamino, ethyl-t-butylamino, ethylpentylamino, ethylhexylamino, propyl-n-butylamino, propyl-i-butylamino, propyl-s-butylamino, propyl-t-butylamino, propylpentylylamino, propylhexylamino, n-butylpentylamino, i-butylpentylamino, s-butylpentylamino, t- butylpentylamino, n-butylhexylamino, i-butylhexylamino, s-butylhexylamino, t- butylhexylamino, or pentylhexylamino), C2-6 alkenyl (e.g., ethenyl (C2), 1-propenyl (C3), 2- propenyl (C3), 1-butenyl (C4), 2-butenyl (C4), butadienyl (C4), pentenyl (C5), pentadienyl (C5), or hexenyl (C6)), C2-6 alkynyl (e.g., ethynyl (C2), 1-propynyl (C3), 2-propynyl (C3), 1-butynyl (C4), 2-butynyl (C4), pentynyl (C5), or hexynyl (C6)), C3-12 carbocyclyl (e.g., cyclopropyl (C3), cyclopropenyl (C3), cyclobutyl (C4), cyclobutenyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclohexyl (C6), cyclohexenyl (C6), cyclohexadienyl (C6), cycloheptyl (C7), cycloheptenyl (C7), cycloheptadienyl (C7), cycloheptatrienyl (C7), cyclooctyl (C8), cyclooctenyl (C8), bicyclo[2.2.1]heptanyl (C7), bicyclo[2.2.2]octanyl (C8), cyclononyl (C9), cyclononenyl (C9), cyclodecyl (C10), cyclodecenyl (C10), octahydro-1H-indenyl (C9), decahydronaphthalenyl (C10), or spiro[4.5]decanyl (C10)), 3- to 12-membered heterocyclyl (e.g., heterocyclyl comprising one or two 3- to 8-membered rings and 1-5 heteroatoms selected from N, O, and S), C6-10 aryl (e.g., phenyl or naphthyl), 5- to 10-membered heteroaryl (e.g., heteroaryl comprising one or two 5- or 6-membered rings and 1-5 heteroatoms selected from N, O, and S), -SRb, -S(=O)Ra, -S(=O)2Ra, -S(=O)2ORb, -S(=O)2NRcRd, -NRcS(=O)2Ra, -NRcS(=O)Ra, - NRcS(=O)2ORb, -NRcS(=O)2NRcRd, -NRbC(=O)NRcRd, -NRbC(=O)Ra, -NRbC(=O)ORb, - OS(=O)2Ra, -OS(=O)2ORb, -OS(=O)2NRcRd, -OC(=O)Ra, -OC(=O)ORb, -OC(=O)NRcRd, - C(=O)Ra, -C(=O)ORb, or -C(=O)NRcRd, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more Ru. [00027] In certain embodiments, RY is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C3-12 carbocyclyl, 3- to 12-membered heterocyclyl, C6-10 aryl, 5- to 10-membered heteroaryl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more Ru. 8 275501297 v3
[00028] In certain embodiments, RY is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C3-6 carbocyclyl, 3- to 6-membered heterocyclyl, C6 aryl, 5- to 6-membered heteroaryl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more Ru. [00029] In certain embodiments, RY is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C3-6 carbocyclyl, or 3- to 6-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, or heterocyclyl, is optionally substituted with one or more Ru. [00030] In certain embodiments, RY is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C3-6 carbocyclyl, or 3- to 6-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, carbocyclyl, or heterocyclyl, is optionally substituted with one or more Ru. [00031] In certain embodiments, RY is hydrogen. [00032] In certain embodiments, R1 and R2, together with the intervening carbon atoms, form Ring A. [00033] In certain embodiments, the compound of Formula I-1 is a compound of Formula I-1- I’, I-1-ii’, I-1-iii’, or I-1-iv’:
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. [00034] In certain embodiments, the compound of Formula I-1 is a compound of Formula I-1- i, I-1-ii, I-1-iii, or I-1-iv: 9 275501297 v3
(I-1-i), (I-1-ii), (I-1-iii), or (I-1-iv), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. [00035] In certain embodiments, the compound of Formula I-2 is a compound of Formula I- 2-i’, I-2-ii’, I-2-iii’, or I-2-iv’:
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. [00036] In certain embodiments, the compound of Formula I-2 is a compound of Formula I- 2-i, I-2-ii, I-2-iii, or I-2-iv:
iv), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. [00037] In certain embodiments, Y” is N. [00038] In certain embodiments, Y” is CR3. [00039] In certain embodiments, R3 is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered 10 275501297 v3
heteroaryl, C3-12 carbocyclyl, or 3- to 12-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl is optionally substituted with one or more Ru. [00040] In certain embodiments, R3 is hydrogen, halogen (e.g., -F, -Cl, -Br, or -I), -CN, -NO2, -OH, -NH2, C1-6 alkyl (e.g., methyl (C1), ethyl (C2), n-propyl (C3), i-propyl (C3), n-butyl (C4), i-butyl (C4), s-butyl (C4), t-butyl (C4), pentyl (C5), or hexyl (C6)), C1-6 alkoxy (e.g., methoxy (C1), ethoxy (C2), n-propoxy (C3), i-propoxy (C3), n-butoxy (C4), i-butoxy (C4), s-butoxy (C4), t-butoxy (C4), pentoxy (C5), or hexoxy (C6)), C1-6 alkylamino (e.g., dimethylamino, diethylamino, di-n-propylamino, di-i-propylamino, di-n-butylamino, di-i-butylamino, di-s- butylamino, di-t-butylamino, dipentylamino, dihexylamino, methylethylamino, methyl-n- propylamino, methyl-i-propylamino, methyl-n-butylamino, methyl-i-butylamino, methyl-s- butylamino, methyl-t-butylamino, methylpentylamino, methylhexylamino, ethyl-n- propylamino, ethyl-i-propylamino, ethyl-n-butylamino, ethyl-s-butylamino, ethyl-i- butylamino, ethyl-t-butylamino, ethylpentylamino, ethylhexylamino, propyl-n-butylamino, propyl-i-butylamino, propyl-s-butylamino, propyl-t-butylamino, propylpentylylamino, propylhexylamino, n-butylpentylamino, i-butylpentylamino, s-butylpentylamino, t- butylpentylamino, n-butylhexylamino, i-butylhexylamino, s-butylhexylamino, t- butylhexylamino, or pentylhexylamino), C2-6 alkenyl (e.g., ethenyl (C2), 1-propenyl (C3), 2- propenyl (C3), 1-butenyl (C4), 2-butenyl (C4), butadienyl (C4), pentenyl (C5), pentadienyl (C5), or hexenyl (C6)), C2-6 alkynyl (e.g., ethynyl (C2), 1-propynyl (C3), 2-propynyl (C3), 1-butynyl (C4), 2-butynyl (C4), pentynyl (C5), or hexynyl (C6)), C3-12 carbocyclyl (e.g., cyclopropyl (C3), cyclopropenyl (C3), cyclobutyl (C4), cyclobutenyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclohexyl (C6), cyclohexenyl (C6), cyclohexadienyl (C6), cycloheptyl (C7), cycloheptenyl (C7), cycloheptadienyl (C7), cycloheptatrienyl (C7), cyclooctyl (C8), cyclooctenyl (C8), bicyclo[2.2.1]heptanyl (C7), bicyclo[2.2.2]octanyl (C8), cyclononyl (C9), cyclononenyl (C9), cyclodecyl (C10), cyclodecenyl (C10), octahydro-1H-indenyl (C9), decahydronaphthalenyl (C10), or spiro[4.5]decanyl (C10)), 3- to 12-membered heterocyclyl (e.g., heterocyclyl comprising one or two 3- to 8-membered rings and 1-5 heteroatoms selected from N, O, and S), C6-10 aryl (e.g., phenyl or naphthyl), 5- to 10-membered heteroaryl (e.g., heteroaryl comprising one or two 5- or 6-membered rings and 1-5 heteroatoms selected from N, O, and S), -SRb, -S(=O)Ra, -S(=O)2Ra, -S(=O)2ORb, -S(=O)2NRcRd, -NRcS(=O)2Ra, -NRcS(=O)Ra, - NRcS(=O)2ORb, -NRcS(=O)2NRcRd, -NRbC(=O)NRcRd, -NRbC(=O)Ra, -NRbC(=O)ORb, - OS(=O)2Ra, -OS(=O)2ORb, -OS(=O)2NRcRd, -OC(=O)Ra, -OC(=O)ORb, -OC(=O)NRcRd, - C(=O)Ra, -C(=O)ORb, or -C(=O)NRcRd, wherein the alkyl, alkoxy, alkylamino, alkenyl, 11 275501297 v3
alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more Ru. [00041] In certain embodiments, R3 is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C3-12 carbocyclyl, 3- to 12-membered heterocyclyl, C6-10 aryl, 5- to 10-membered heteroaryl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more Ru. [00042] In certain embodiments, R3 is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C3-6 carbocyclyl, 3- to 6-membered heterocyclyl, C6 aryl, 5- to 6-membered heteroaryl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more Ru. [00043] In certain embodiments, R3 is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C3-6 carbocyclyl, or 3- to 6-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, or heterocyclyl, is optionally substituted with one or more Ru. [00044] In certain embodiments, R3 is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C3-6 carbocyclyl, or 3- to 6-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, carbocyclyl, or heterocyclyl, is optionally substituted with one or more Ru. [00045] In certain embodiments, R3 is hydrogen. [00046] In certain embodiments, R2 and R3, together with the intervening carbon atoms, form Ring A. [00047] In certain embodiments, the compound of Formula I-1 is a compound of Formula I-1- v’, I-1-vi’, I-1-vii’, or I-1-viii’:
12 275501297 v3
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. [00048] In certain embodiments, the compound of Formula I-1 is a compound of Formula I-1- v, I-1-vi, I-1-vii, or I-1-viii:
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. [00049] In certain embodiments, the compound of Formula I-2 is a compound of Formula I- 2-v’, I-2-vi’, I-2-vii’, or I-2-viii’:
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. [00050] In certain embodiments, the compound of Formula I-2 is a compound of Formula I- 2-v, I-2-vi, I-2-vii, or I-2-viii: 13 275501297 v3
(I-2-v), (I-2-vi), (I-2-vii), or (I-2-viii), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. [00051] In certain embodiments, R1 is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, or 3- to 12-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl is optionally substituted with one or more Ru. [00052] In certain embodiments, R1 is hydrogen, halogen (e.g., -F, -Cl, -Br, or -I), -CN, -NO2, -OH, -NH2, C1-6 alkyl (e.g., methyl (C1), ethyl (C2), n-propyl (C3), i-propyl (C3), n-butyl (C4), i-butyl (C4), s-butyl (C4), t-butyl (C4), pentyl (C5), or hexyl (C6)), C1-6 alkoxy (e.g., methoxy (C1), ethoxy (C2), n-propoxy (C3), i-propoxy (C3), n-butoxy (C4), i-butoxy (C4), s-butoxy (C4), t-butoxy (C4), pentoxy (C5), or hexoxy (C6)), C1-6 alkylamino (e.g., dimethylamino, diethylamino, di-n-propylamino, di-i-propylamino, di-n-butylamino, di-i-butylamino, di-s- butylamino, di-t-butylamino, dipentylamino, dihexylamino, methylethylamino, methyl-n- propylamino, methyl-i-propylamino, methyl-n-butylamino, methyl-i-butylamino, methyl-s- butylamino, methyl-t-butylamino, methylpentylamino, methylhexylamino, ethyl-n- propylamino, ethyl-i-propylamino, ethyl-n-butylamino, ethyl-s-butylamino, ethyl-i- butylamino, ethyl-t-butylamino, ethylpentylamino, ethylhexylamino, propyl-n-butylamino, propyl-i-butylamino, propyl-s-butylamino, propyl-t-butylamino, propylpentylylamino, propylhexylamino, n-butylpentylamino, i-butylpentylamino, s-butylpentylamino, t- butylpentylamino, n-butylhexylamino, i-butylhexylamino, s-butylhexylamino, t- butylhexylamino, or pentylhexylamino), C2-6 alkenyl (e.g., ethenyl (C2), 1-propenyl (C3), 2- propenyl (C3), 1-butenyl (C4), 2-butenyl (C4), butadienyl (C4), pentenyl (C5), pentadienyl (C5), or hexenyl (C6)), C2-6 alkynyl (e.g., ethynyl (C2), 1-propynyl (C3), 2-propynyl (C3), 1-butynyl (C4), 2-butynyl (C4), pentynyl (C5), or hexynyl (C6)), C3-12 carbocyclyl (e.g., cyclopropyl (C3), cyclopropenyl (C3), cyclobutyl (C4), cyclobutenyl (C4), cyclopentyl (C5), cyclopentenyl (C5), 14 275501297 v3
cyclohexyl (C6), cyclohexenyl (C6), cyclohexadienyl (C6), cycloheptyl (C7), cycloheptenyl (C7), cycloheptadienyl (C7), cycloheptatrienyl (C7), cyclooctyl (C8), cyclooctenyl (C8), bicyclo[2.2.1]heptanyl (C7), bicyclo[2.2.2]octanyl (C8), cyclononyl (C9), cyclononenyl (C9), cyclodecyl (C10), cyclodecenyl (C10), octahydro-1H-indenyl (C9), decahydronaphthalenyl (C10), or spiro[4.5]decanyl (C10)), 3- to 12-membered heterocyclyl (e.g., heterocyclyl comprising one or two 3- to 8-membered rings and 1-5 heteroatoms selected from N, O, and S), C6-10 aryl (e.g., phenyl or naphthyl), 5- to 10-membered heteroaryl (e.g., heteroaryl comprising one or two 5- or 6-membered rings and 1-5 heteroatoms selected from N, O, and S), -SRb, -S(=O)Ra, -S(=O)2Ra, -S(=O)2ORb, -S(=O)2NRcRd, -NRcS(=O)2Ra, -NRcS(=O)Ra, - NRcS(=O)2ORb, -NRcS(=O)2NRcRd, -NRbC(=O)NRcRd, -NRbC(=O)Ra, -NRbC(=O)ORb, - OS(=O)2Ra, -OS(=O)2ORb, -OS(=O)2NRcRd, -OC(=O)Ra, -OC(=O)ORb, -OC(=O)NRcRd, - C(=O)Ra, -C(=O)ORb, or -C(=O)NRcRd, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more Ru. [00053] In certain embodiments, R1 is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C3-12 carbocyclyl, 3- to 12-membered heterocyclyl, C6-10 aryl, 5- to 10-membered heteroaryl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more Ru. [00054] In certain embodiments, R1 is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C3-6 carbocyclyl, 3- to 6-membered heterocyclyl, C6 aryl, 5- to 6-membered heteroaryl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more Ru. [00055] In certain embodiments, R1 is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C3-6 carbocyclyl, or 3- to 6-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, or heterocyclyl, is optionally substituted with one or more Ru. [00056] In certain embodiments, R1 is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C3-6 carbocyclyl, or 3- to 6-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, carbocyclyl, or heterocyclyl, is optionally substituted with one or more Ru. [00057] In certain embodiments, R1 is hydrogen. [00058] In certain embodiments, Y’ is N. 15 275501297 v3
[00059] In certain embodiments, Y’ is CRY’. [00060] In certain embodiments, RY’ is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, or 3- to 12-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl is optionally substituted with one or more Ru. [00061] In certain embodiments, RY’ is hydrogen, halogen (e.g., -F, -Cl, -Br, or -I), -CN, -NO2, -OH, -NH2, C1-6 alkyl (e.g., methyl (C1), ethyl (C2), n-propyl (C3), i-propyl (C3), n-butyl (C4), i-butyl (C4), s-butyl (C4), t-butyl (C4), pentyl (C5), or hexyl (C6)), C1-6 alkoxy (e.g., methoxy (C1), ethoxy (C2), n-propoxy (C3), i-propoxy (C3), n-butoxy (C4), i-butoxy (C4), s-butoxy (C4), t-butoxy (C4), pentoxy (C5), or hexoxy (C6)), C1-6 alkylamino (e.g., dimethylamino, diethylamino, di-n-propylamino, di-i-propylamino, di-n-butylamino, di-i-butylamino, di-s- butylamino, di-t-butylamino, dipentylamino, dihexylamino, methylethylamino, methyl-n- propylamino, methyl-i-propylamino, methyl-n-butylamino, methyl-i-butylamino, methyl-s- butylamino, methyl-t-butylamino, methylpentylamino, methylhexylamino, ethyl-n- propylamino, ethyl-i-propylamino, ethyl-n-butylamino, ethyl-s-butylamino, ethyl-i- butylamino, ethyl-t-butylamino, ethylpentylamino, ethylhexylamino, propyl-n-butylamino, propyl-i-butylamino, propyl-s-butylamino, propyl-t-butylamino, propylpentylylamino, propylhexylamino, n-butylpentylamino, i-butylpentylamino, s-butylpentylamino, t- butylpentylamino, n-butylhexylamino, i-butylhexylamino, s-butylhexylamino, t- butylhexylamino, or pentylhexylamino), C2-6 alkenyl (e.g., ethenyl (C2), 1-propenyl (C3), 2- propenyl (C3), 1-butenyl (C4), 2-butenyl (C4), butadienyl (C4), pentenyl (C5), pentadienyl (C5), or hexenyl (C6)), C2-6 alkynyl (e.g., ethynyl (C2), 1-propynyl (C3), 2-propynyl (C3), 1-butynyl (C4), 2-butynyl (C4), pentynyl (C5), or hexynyl (C6)), C3-12 carbocyclyl (e.g., cyclopropyl (C3), cyclopropenyl (C3), cyclobutyl (C4), cyclobutenyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclohexyl (C6), cyclohexenyl (C6), cyclohexadienyl (C6), cycloheptyl (C7), cycloheptenyl (C7), cycloheptadienyl (C7), cycloheptatrienyl (C7), cyclooctyl (C8), cyclooctenyl (C8), bicyclo[2.2.1]heptanyl (C7), bicyclo[2.2.2]octanyl (C8), cyclononyl (C9), cyclononenyl (C9), cyclodecyl (C10), cyclodecenyl (C10), octahydro-1H-indenyl (C9), decahydronaphthalenyl (C10), or spiro[4.5]decanyl (C10)), 3- to 12-membered heterocyclyl (e.g., heterocyclyl comprising one or two 3- to 8-membered rings and 1-5 heteroatoms selected from N, O, and S), C6-10 aryl (e.g., phenyl or naphthyl), 5- to 10-membered heteroaryl (e.g., heteroaryl comprising one or two 5- or 6-membered rings and 1-5 heteroatoms selected from N, O, and S), -SRb, -S(=O)Ra, -S(=O)2Ra, -S(=O)2ORb, -S(=O)2NRcRd, -NRcS(=O)2Ra, -NRcS(=O)Ra, - 16 275501297 v3
NRcS(=O)2ORb, -NRcS(=O)2NRcRd, -NRbC(=O)NRcRd, -NRbC(=O)Ra, -NRbC(=O)ORb, - OS(=O)2Ra, -OS(=O)2ORb, -OS(=O)2NRcRd, -OC(=O)Ra, -OC(=O)ORb, -OC(=O)NRcRd, - C(=O)Ra, -C(=O)ORb, or -C(=O)NRcRd, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more Ru. [00062] In certain embodiments, RY’ is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C3-12 carbocyclyl, 3- to 12-membered heterocyclyl, C6-10 aryl, 5- to 10-membered heteroaryl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more Ru. [00063] In certain embodiments, RY’ is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C3-6 carbocyclyl, 3- to 6-membered heterocyclyl, C6 aryl, 5- to 6-membered heteroaryl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more Ru. [00064] In certain embodiments, RY’ is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C3-6 carbocyclyl, or 3- to 6-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, or heterocyclyl, is optionally substituted with one or more Ru. [00065] In certain embodiments, RY’ is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C3-6 carbocyclyl, or 3- to 6-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, carbocyclyl, or heterocyclyl, is optionally substituted with one or more Ru. [00066] In certain embodiments, RY’ is hydrogen. [00067] In certain embodiments, Ring A is 5- to 7-membered heterocycle comprising one oxygen atom. [00068] In certain embodiments, Ring A is 5- to 7-membered heterocycle comprising one oxygen atom and no double bond. [00069] In certain embodiments, Ring A is 5- to 7-membered heterocycle comprising one oxygen atom and a double bond. [00070] In certain embodiments, Ring A is
17 275501297 v3
wherein: each Ri independently is oxo, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, 3- to 12-membered heterocyclyl, -SRb, -S(=O)Ra, -S(=O)2Ra, -S(=O)2ORb, - S(=O)2NRcRd, -NRcS(=O)2Ra, -NRcS(=O)Ra, -NRcS(=O)2ORb, -NRcS(=O)2NRcRd, - NRbC(=O)NRcRd, -NRbC(=O)Ra, -NRbC(=O)ORb, -OS(=O)2Ra, -OS(=O)2ORb, - OS(=O)2NRcRd, -OC(=O)Ra, -OC(=O)ORb, -OC(=O)NRcRd, -C(=O)Ra, -C(=O)ORb, or - C(=O)NRcRd, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more Ru; s is an integer selected from 0 to 5; m is an integer selected from 0 to 2; Rcp is
, wherein: Rend is -ORH1, -N(RH2)2, -SRH3, or -C(=O)ORH4; RH1 is hydrogen, C1-6 alkyl, -S(=O)2Ra, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, or a hydroxyl- protecting group, wherein the C1-6 alkyl is optionally substituted with one or more Ru; RH2 is hydrogen, C1-6 alkyl, -S(=O)2Ra, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, or an amino- protecting group, wherein the C1-6 alkyl is optionally substituted with one or more Ru; RH3 is hydrogen, C1-6 alkyl, -C(=O)Ra, or a thiol-protecting group, wherein the C1-6 alkyl is optionally substituted with one or more Ru; RH4 is hydrogen, C1-6 alkyl, or a carboxylic acid-protecting group, wherein the C1-6 alkyl is optionally substituted with one or more Ru; each occurrence of G is independently -C(RG1)2-, -O-, -NRG2-, -C(=O)-, -S-, or -S(=O)2-; each RG1 is independently hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, or 3- to 12-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl is optionally substituted with one or more Ru; each RG2 is independently hydrogen or C1-6 alkyl optionally substituted with one or more Ru; and p is an integer selected from 0 to 5. 18 275501297 v3
[00071] In certain embodiments, Ring A is
[00072] In certain embodiments, Rend is -ORH1 or -N(RH2)2. [00073] In certain embodiments, RH1 is hydrogen, C1-6 alkyl (e.g., methyl (C1), ethyl (C2), n- propyl (C3), i-propyl (C3), n-butyl (C4), i-butyl (C4), s-butyl (C4), t-butyl (C4), pentyl (C5), or hexyl (C6)), -S(=O)2Ra, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, or a hydroxyl-protecting group, wherein the C1-6 alkyl is optionally substituted with one or more Ru. [00074] In certain embodiments, RH1 is hydrogen. [00075] In certain embodiments, RH2 is hydrogen, C1-6 alkyl (e.g., methyl (C1), ethyl (C2), n- propyl (C3), i-propyl (C3), n-butyl (C4), i-butyl (C4), s-butyl (C4), t-butyl (C4), pentyl (C5), or hexyl (C6)), -S(=O)2Ra, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, or an amino-protecting group, wherein the C1-6 alkyl is optionally substituted with one or more Ru. [00076] In certain embodiments, RH2 is hydrogen. [00077] In certain embodiments, RH3 is hydrogen, C1-6 alkyl (e.g., methyl (C1), ethyl (C2), n- propyl (C3), i-propyl (C3), n-butyl (C4), i-butyl (C4), s-butyl (C4), t-butyl (C4), pentyl (C5), or hexyl (C6)), -C(=O)Ra, or a thiol-protecting group, wherein the C1-6 alkyl is optionally substituted with one or more Ru. [00078] In certain embodiments, RH3 is hydrogen. [00079] In certain embodiments, RH4 is hydrogen, C1-6 alkyl (e.g., methyl (C1), ethyl (C2), n- propyl (C3), i-propyl (C3), n-butyl (C4), i-butyl (C4), s-butyl (C4), t-butyl (C4), pentyl (C5), or hexyl (C6)), or a carboxylic acid-protecting group, wherein the C1-6 alkyl is optionally substituted with one or more Ru. [00080] In certain embodiments, RH4 is hydrogen. [00081] In certain embodiments, each occurrence of G is independently -C(RG1)2-, -O-, -NRG2- , -C(=O)-, -S-, or -S(=O)2-. [00082] In certain embodiments, each occurrence of G is independently -C(RG1)2-, -O-, -NRG2- or -C(=O)-. [00083] In certain embodiments, each RG1 is independently hydrogen, halogen, -CN, -NO2, - OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, or 3- to 12-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl is optionally substituted with one or more Ru. 19 275501297 v3
[00084] In certain embodiments, each RG1 is hydrogen, halogen (e.g., -F, -Cl, -Br, or -I), -CN, -NO2, -OH, -NH2, C1-6 alkyl (e.g., methyl (C1), ethyl (C2), n-propyl (C3), i-propyl (C3), n-butyl (C4), i-butyl (C4), s-butyl (C4), t-butyl (C4), pentyl (C5), or hexyl (C6)), C1-6 alkoxy (e.g., methoxy (C1), ethoxy (C2), n-propoxy (C3), i-propoxy (C3), n-butoxy (C4), i-butoxy (C4), s- butoxy (C4), t-butoxy (C4), pentoxy (C5), or hexoxy (C6)), C1-6 alkylamino (e.g., dimethylamino, diethylamino, di-n-propylamino, di-i-propylamino, di-n-butylamino, di-i- butylamino, di-s-butylamino, di-t-butylamino, dipentylamino, dihexylamino, methylethylamino, methyl-n-propylamino, methyl-i-propylamino, methyl-n-butylamino, methyl-i-butylamino, methyl-s-butylamino, methyl-t-butylamino, methylpentylamino, methylhexylamino, ethyl-n-propylamino, ethyl-i-propylamino, ethyl-n-butylamino, ethyl-s- butylamino, ethyl-i-butylamino, ethyl-t-butylamino, ethylpentylamino, ethylhexylamino, propyl-n-butylamino, propyl-i-butylamino, propyl-s-butylamino, propyl-t-butylamino, propylpentylylamino, propylhexylamino, n-butylpentylamino, i-butylpentylamino, s- butylpentylamino, t-butylpentylamino, n-butylhexylamino, i-butylhexylamino, s- butylhexylamino, t-butylhexylamino, or pentylhexylamino), C2-6 alkenyl (e.g., ethenyl (C2), 1- propenyl (C3), 2-propenyl (C3), 1-butenyl (C4), 2-butenyl (C4), butadienyl (C4), pentenyl (C5), pentadienyl (C5), or hexenyl (C6)), C2-6 alkynyl (e.g., ethynyl (C2), 1-propynyl (C3), 2-propynyl (C3), 1-butynyl (C4), 2-butynyl (C4), pentynyl (C5), or hexynyl (C6)), C3-12 carbocyclyl (e.g., cyclopropyl (C3), cyclopropenyl (C3), cyclobutyl (C4), cyclobutenyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclohexyl (C6), cyclohexenyl (C6), cyclohexadienyl (C6), cycloheptyl (C7), cycloheptenyl (C7), cycloheptadienyl (C7), cycloheptatrienyl (C7), cyclooctyl (C8), cyclooctenyl (C8), bicyclo[2.2.1]heptanyl (C7), bicyclo[2.2.2]octanyl (C8), cyclononyl (C9), cyclononenyl (C9), cyclodecyl (C10), cyclodecenyl (C10), octahydro-1H-indenyl (C9), decahydronaphthalenyl (C10), or spiro[4.5]decanyl (C10)), 3- to 12-membered heterocyclyl (e.g., heterocyclyl comprising one or two 3- to 8-membered rings and 1-5 heteroatoms selected from N, O, and S), C6-10 aryl (e.g., phenyl or naphthyl), 5- to 10-membered heteroaryl (e.g., heteroaryl comprising one or two 5- or 6-membered rings and 1-5 heteroatoms selected from N, O, and S), -SRb, -S(=O)Ra, -S(=O)2Ra, -S(=O)2ORb, -S(=O)2NRcRd, -NRcS(=O)2Ra, - NRcS(=O)Ra, -NRcS(=O)2ORb, -NRcS(=O)2NRcRd, -NRbC(=O)NRcRd, -NRbC(=O)Ra, - NRbC(=O)ORb, -OS(=O)2Ra, -OS(=O)2ORb, -OS(=O)2NRcRd, -OC(=O)Ra, -OC(=O)ORb, - OC(=O)NRcRd, -C(=O)Ra, -C(=O)ORb, or -C(=O)NRcRd, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more Ru. 20 275501297 v3
[00085] In certain embodiments, each RG1 is independently hydrogen, halogen, -CN, -NO2, - OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C3-12 carbocyclyl, 3- to 12-membered heterocyclyl, C6-10 aryl, 5- to 10-membered heteroaryl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more Ru. [00086] In certain embodiments, each RG1 is independently hydrogen, halogen, -CN, -NO2, - OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C3-6 carbocyclyl, 3- to 6-membered heterocyclyl, C6 aryl, 5- to 6-membered heteroaryl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more Ru. [00087] In certain embodiments, each RG1 is independently hydrogen, halogen, -CN, -NO2, - OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C3-6 carbocyclyl, or 3- to 6-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, or heterocyclyl, is optionally substituted with one or more Ru. [00088] In certain embodiments, each RG1 is independently hydrogen, halogen, -CN, -NO2, - OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C3-6 carbocyclyl, or 3- to 6-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, carbocyclyl, or heterocyclyl, is optionally substituted with one or more Ru. [00089] In certain embodiments, each RG1 is independently hydrogen, halogen, or C1-6 alkyl (e.g., methyl (C1), ethyl (C2), n-propyl (C3), i-propyl (C3), n-butyl (C4), i-butyl (C4), s-butyl (C4), t-butyl (C4), pentyl (C5), or hexyl (C6)) optionally substituted with one or more Ru. [00090] In certain embodiments, Rcp is -(CH2)nOH, or -(CH2)nNH2, wherein n is an integer selected from 0 to 4. [00091] In certain embodiments, Rcp is -CH2OH. [00092] In certain embodiments, each Ri is independently oxo, halogen, -CN, -NO2, -OH, - NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10- membered heteroaryl, C3-12 carbocyclyl, or 3- to 12-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl is optionally substituted with one or more Ru. [00093] In certain embodiments, each Ri is independently oxo, halogen (e.g., -F, -Cl, -Br, or - I), -CN, -NO2, -OH, -NH2, C1-6 alkyl (e.g., methyl (C1), ethyl (C2), n-propyl (C3), i-propyl (C3), n-butyl (C4), i-butyl (C4), s-butyl (C4), t-butyl (C4), pentyl (C5), or hexyl (C6)), C1-6 alkoxy (e.g., methoxy (C1), ethoxy (C2), n-propoxy (C3), i-propoxy (C3), n-butoxy (C4), i-butoxy (C4), s- butoxy (C4), t-butoxy (C4), pentoxy (C5), or hexoxy (C6)), C1-6 alkylamino (e.g., 21 275501297 v3
dimethylamino, diethylamino, di-n-propylamino, di-i-propylamino, di-n-butylamino, di-i- butylamino, di-s-butylamino, di-t-butylamino, dipentylamino, dihexylamino, methylethylamino, methyl-n-propylamino, methyl-i-propylamino, methyl-n-butylamino, methyl-i-butylamino, methyl-s-butylamino, methyl-t-butylamino, methylpentylamino, methylhexylamino, ethyl-n-propylamino, ethyl-i-propylamino, ethyl-n-butylamino, ethyl-s- butylamino, ethyl-i-butylamino, ethyl-t-butylamino, ethylpentylamino, ethylhexylamino, propyl-n-butylamino, propyl-i-butylamino, propyl-s-butylamino, propyl-t-butylamino, propylpentylylamino, propylhexylamino, n-butylpentylamino, i-butylpentylamino, s- butylpentylamino, t-butylpentylamino, n-butylhexylamino, i-butylhexylamino, s- butylhexylamino, t-butylhexylamino, or pentylhexylamino), C2-6 alkenyl (e.g., ethenyl (C2), 1- propenyl (C3), 2-propenyl (C3), 1-butenyl (C4), 2-butenyl (C4), butadienyl (C4), pentenyl (C5), pentadienyl (C5), or hexenyl (C6)), C2-6 alkynyl (e.g., ethynyl (C2), 1-propynyl (C3), 2-propynyl (C3), 1-butynyl (C4), 2-butynyl (C4), pentynyl (C5), or hexynyl (C6)), C3-12 carbocyclyl (e.g., cyclopropyl (C3), cyclopropenyl (C3), cyclobutyl (C4), cyclobutenyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclohexyl (C6), cyclohexenyl (C6), cyclohexadienyl (C6), cycloheptyl (C7), cycloheptenyl (C7), cycloheptadienyl (C7), cycloheptatrienyl (C7), cyclooctyl (C8), cyclooctenyl (C8), bicyclo[2.2.1]heptanyl (C7), bicyclo[2.2.2]octanyl (C8), cyclononyl (C9), cyclononenyl (C9), cyclodecyl (C10), cyclodecenyl (C10), octahydro-1H-indenyl (C9), decahydronaphthalenyl (C10), or spiro[4.5]decanyl (C10)), 3- to 12-membered heterocyclyl (e.g., heterocyclyl comprising one or two 3- to 8-membered rings and 1-5 heteroatoms selected from N, O, and S), C6-10 aryl (e.g., phenyl or naphthyl), 5- to 10-membered heteroaryl (e.g., heteroaryl comprising one or two 5- or 6-membered rings and 1-5 heteroatoms selected from N, O, and S), -SRb, -S(=O)Ra, -S(=O)2Ra, -S(=O)2ORb, -S(=O)2NRcRd, -NRcS(=O)2Ra, - NRcS(=O)Ra, -NRcS(=O)2ORb, -NRcS(=O)2NRcRd, -NRbC(=O)NRcRd, -NRbC(=O)Ra, - NRbC(=O)ORb, -OS(=O)2Ra, -OS(=O)2ORb, -OS(=O)2NRcRd, -OC(=O)Ra, -OC(=O)ORb, - OC(=O)NRcRd, -C(=O)Ra, -C(=O)ORb, or -C(=O)NRcRd, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more Ru. [00094] In certain embodiments, each Ri is independently oxo, halogen, -CN, -NO2, -OH, - NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C3-12 carbocyclyl, 3- to 12-membered heterocyclyl, C6-10 aryl, 5- to 10-membered heteroaryl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more Ru. 22 275501297 v3
[00095] In certain embodiments, each Ri is independently oxo, halogen, -CN, -NO2, -OH, - NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C3-6 carbocyclyl, 3- to 6-membered heterocyclyl, C6 aryl, 5- to 6-membered heteroaryl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more Ru. [00096] In certain embodiments, each Ri is independently oxo, halogen, -CN, -NO2, -OH, - NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C3-6 carbocyclyl, or 3- to 6-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, or heterocyclyl, is optionally substituted with one or more Ru. [00097] In certain embodiments, each Ri is independently oxo, halogen, -CN, -NO2, -OH, - NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C3-6 carbocyclyl, or 3- to 6-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, carbocyclyl, or heterocyclyl, is optionally substituted with one or more Ru. [00098] In certain embodiments, each Ri is independently oxo, -CN, -OH, -NH2, C1-6 alkyl, - NRcS(=O)2Ra, or -NRbC(=O)Ra, wherein the alkyl is optionally substituted with one or more Ru. [00099] In certain embodiments, at least one Ri is oxo. In certain embodiments, at least one Ri is oxo. In certain embodiments, at least one Ri is -CN. In certain embodiments, at least one Ri is -OH. In certain embodiments, at least one Ri is -NH2. In certain embodiments, at least one Ri is C1-6 alkyl. In certain embodiments, at least one Ri is -NRcS(=O)2Ra. In certain embodiments, at least one Ri is -NRbC(=O)Ra. [000100] In certain embodiments, s is an integer selected from 0 to 8, as valency permits. In certain embodiments, s is an integer selected from 0 to 7, as valency permits. In certain embodiments, s is an integer selected from 0 to 6, as valency permits. In certain embodiments, s is an integer selected from 0 to 5, as valency permits. In certain embodiments, s is an integer selected from 0 to 4, as valency permits. In certain embodiments, s is an integer selected from 0 to 3, as valency permits. In certain embodiments, s is an integer selected from 0 to 2, as valency permits. In certain embodiments, s is 0 or 1, as valency permits. [000101] In certain embodiments, s is 0. In certain embodiments, s is 1. In certain embodiments, s is 2. In certain embodiments, s is 3. In certain embodiments, s is 4. In certain embodiments, s is 5. In certain embodiments, s is 6. In certain embodiments, s is 7. In certain embodiments, s is 8. [000102] In certain embodiments, R4 is hydrogen. In certain embodiments, R4 is deuterium. In certain embodiments, R4 is C1-6 haloalkyl. In certain embodiments, R4 is C1-6 alkyl. 23 275501297 v3
[000103] In certain embodiments, q is 0. In certain embodiments, q is 1. In certain embodiments, q is 2. In certain embodiments, q is 0 or 1. In certain embodiments, q is 0 or 2. In certain embodiments, q is 1 or 2. Bifunctional Degraders [000104] In certain aspects, the present disclosure provides conjugates comprising a compound disclosed herein being connected to a ligand for a protein (e.g., via a linker). [000105] In certain aspects, the present disclosure provides conjugates of Formula I:
and pharmaceutically acceptable salts, solvates, or stereoisomers thereof, wherein: R1 and R2, or R2 and R3, together with the intervening carbon atoms, form Ring A’; Ring A’ is
, wherein: Rcp’ is
, wherein: Rv is -O-, -N(RG3)-, -S-, or -C(=O)O-; RG3 is hydrogen or C1-6 alkyl optionally substituted with one or more Ru; L is a linker; and T is a ligand for a protein, wherein all other variables are defined herein. [000106] In certain embodiments, Ring A’ is
. [000107] In certain embodiments, Rv is -O-, -N(RG3)-, -S-, or -C(=O)O-. 24 275501297 v3
[000108] In certain embodiments, Rv is -O- or -N(RG3)-. [000109] In certain embodiments, Rv is -O-. [000110] In certain embodiments, RG3 is hydrogen or C1-6 alkyl (e.g., methyl (C1), ethyl (C2), n-propyl (C3), i-propyl (C3), n-butyl (C4), i-butyl (C4), s-butyl (C4), t-butyl (C4), pentyl (C5), or hexyl (C6)) optionally substituted with one or more Ru. [000111] In certain embodiments, -RV-[G]p- is *-(CH2)nO- or *-(CH2)nNH-, wherein n is an integer selected from 0 to 4, and * denotes attachment to Ring A’. [000112] In certain embodiments, -RV-[G]p- is *-CH2O-. [000113] In certain embodiments, the conjugate of Formula I is a conjugate of Formula I-1
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. [000114] In certain embodiments, the conjugate of Formula I is a conjugate of Formula I-2
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. [000115] In certain embodiments, the conjugate of Formula I-1 is a conjugate of Formula I’- 1-i’ or I’-1-ii’:
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. [000116] In certain embodiments, the conjugate of Formula I-1 is a conjugate of Formula I’- 1-i or I’-1-ii:
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. 25 275501297 v3
[000117] In certain embodiments, the conjugate of Formula I-2 is a conjugate of Formula I’- 2-i’ or I’-2-ii’:
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. [000118] In certain embodiments, the conjugate of Formula I-2 is a conjugate of Formula I’- 2-i or I’-2-ii:
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. [000119] In certain embodiments, the conjugate of Formula I-1 is a conjugate of Formula I’- 1-iii’ or I’-1-iv’:
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. [000120] In certain embodiments, the conjugate of Formula I-1 is a conjugate of Formula I’- 1-iii or I’-1-iv:
iv), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. [000121] In certain embodiments, the conjugate of Formla I-2 is a conjugate of Formula I’-2- iii’ or I’-2-iv’: 26 275501297 v3
(I’-2-iii’) or (I’-2-iv’), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. [000122] In certain embodiments, the conjugate of Formla I-2 is a conjugate of Formula I’-2- iii or I’-2-iv:
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. [000123] L, the linker, is a chemical moiety that connects the ligand of a protein with the cereblon ligand disclosed herein. L configures the ligand and the cereblon ligand such that the construct functions as a bifunctional degrader which binds the cereblon ligand and selectively degrades the target protein. [000124] In certain embodiments, L is a linker comprising 6- to 10-membered heteroarylene, C6-10 arylene, C3-12 membered carbocyclylene, or 3- to 12-membered heterocyclylene, wherein the arylene, heteroarylene, carbocyclylene, or heterocyclylene is optionally substituted by one or more Ru, and is directly attached to T. [000125] In certain embodiments, L is of formula
, wherein: * denotes attachment to T and ** denotes attachment to C; each occurrence of -W’- is independently C1-3 alkylene, C2 alkenylene, C2 alkynylene, C3-12 carbocycylene, 3- to 12-membered heterocyclylene, C6-10 arylene, 5- to 10-membered heteroarylene, -C(=O)-, -N(RL)-, -O-, -S-, or -S(=O)2-, wherein the alkylene, alkenylene, carbocyclylene, heterocyclylene, arylene, or heteroarylene is optionally substituted with one or more Ru; each occurrence of RL is independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, or 3- to 12-membered heterocyclyl, 27 275501297 v3
wherein the alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more Ru; and t is an integer selected from 1 to 15. [000126] T, a ligand of a protein, is a chemical entity that competitively or non-competitively a protein. [000127] In certain embodiments, the protein is B7.1 and B7, TINFRlm, TNFR2, NADPH oxidase, BclIBax and other partners in the apotosis pathway, C5a receptor, HMG-CoA reductase, PDE V phosphodiesterase type, PDE IV phosphodiesterase type 4, PDE I, PDEII, PDEIII, squalene cyclase inhibitor, CXCR1, CXCR2, nitric oxide (NO) synthase, cyclo- oxygenase 1, cyclo-oxygenase 2, 5HT receptors, dopamine receptors, G Proteins, i.e., Gq, histamine receptors, 5 -lipoxygenase, tryptase serine protease, thymidylate synthase, purine nucleoside phosphorylase, GAPDH trypanosomal, glycogen phosphorylase, Carbonic anhydrase, chemokine receptors, JAW STAT, RXR and similar, HIV 1 protease, HIV 1 integrase, influenza, neuramimidase, hepatitis B reverse transcriptase, sodium channel, multi drug resistance (MDR), protein P- glycoprotein (and MRP), tyrosine kinases, CD23, CD124, tyrosine kinase p56 lck, CD4, CD5, IL-2 receptor, IL-l receptor, TNF-alphaR, ICAM1, Cat+ channels, VC AM, VLA-4 integrin, selectins, CD40/CD40L, newokinins and receptors, inosine monophosphate dehydrogenase, p38 MAP Kinase, RaslRaflMEWERK pathway, interleukin- 1 converting enzyme, caspase, HCV, NS3 protease, HCV NS3 RNA helicase, glycinamide ribonucleotide formyl transferase, rhinovirus 3C protease, herpes simplex virus-l (HSV-I), protease, cytomegalovirus (CMV) protease, poly (ADP-ribose) polymerase, cyclin dependent kinases, vascular endothelial growth factor, oxytocin receptor, microsomal transfer protein inhibitor, bile acid transport inhibitor, 5 alpha reductase inhibitors, angiotensin 11, glycine receptor, noradrenaline reuptake receptor, endothelin receptors, neuropeptide Y and receptor, estrogen receptors, androgen receptors (AR), adenosine receptors, adenosine kinase and AMP deaminase, purinergic receptors (P2Y1, P2Y2, P2Y4, P2Y6, P2X1-7), farnesyl transferases, geranylgeranyl transferase, TrkA a receptor for NGF, beta-amyloid, tyrosine kinase Flk- IIKDR, vitronectin receptor, integrin receptor, Her-2l neu, telomerase inhibition, cytosolic phospholipaseA2 and EGF receptor tyrosine kinase. Additional protein targets include, for example, ecdysone 20-monooxygenase, ion channel of the GABA gated chloride channel, acetylcholinesterase, voltage-sensitive sodium channel protein, calcium release channel, and chloride channels. Still further target proteins include Acetyl-CoA carboxylase, adenylosuccinate synthetase, protoporphyrinogen oxidase, and enolpyruvylshikimate- phosphate synthase. 28 275501297 v3
[000128] In certain embodiments, the protein is an androgen receptor (AR), an estrogen receptor (ER), signal transducer and activator of transcription 3 (STAT3), signal transducer and activator of transcription 5 (STAT5), CREB-binding protein/EP300(E1A) binding protein (CBP/p300), SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A, Member 2/4 (SMARCA2/4), Kirsten rat sarcoma viral oncogene homolog G12D (KRAS G12D), Src homology region 2-containing protein tyrosine phosphatase 2 (SHP2), or bromodomain-containing protein 4 (BRD4). [000129] In certain embodiments, T is a small molecule. [000130] In certain embodiments, T is a peptide. In certain embodiments, the peptide has about 5 amino acids. In certain embodiments, the peptide has about 10 amino acids. In certain embodiments, the peptide has about 15 amino acids. In certain embodiments, the peptide has about 20 amino acids. In certain embodiments, the peptide has about 25 amino acids. In certain embodiments, the peptide has about 30 amino acids. In certain embodiments, the peptide has about 35 amino acids. In certain embodiments, the peptide has about 40 amino acids. In certain embodiments, the peptide has about 45 amino acids. In certain embodiments, the peptide has about 50 amino acids. [000131] In certain embodiments, T is an antibody. [000132] In certain embodiments, T is a ligand for an estrogen receptor. In certain embodiments, T is ligand for an androgen receptor. In certain embodiments, T is ligand for a STAT3 protein. [000133] In certain embodiments, T is an estrogen receptor inhibitor. In certain embodiments, T is an androgen receptor inhibitor. In certain embodiments, T is a STAT3 protein inhibitor. [000134] In certain embodiments, the compound is selected from the compounds in Table 1, or a pharmaceutically acceptable salt thereof. [000135] In certain embodiments, the compound is selected from the compounds in Table 1. Table 1.
29 275501297 v3
30 275501297 v3
EXEMPLARY EMBODIMENTS Exemplary Embodiment 1. A compound of Formula I:
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein: R1 is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, 3- to 12- membered heterocyclyl, -SRb, -S(=O)Ra, -S(=O)2Ra, -S(=O)2ORb, -S(=O)2NRcRd, - NRcS(=O)2Ra, -NRcS(=O)Ra, -NRcS(=O)2ORb, -NRcS(=O)2NRcRd, -NRbC(=O)NRcRd, - NRbC(=O)Ra, -NRbC(=O)ORb, -OS(=O)2Ra, -OS(=O)2ORb, -OS(=O)2NRcRd, -OC(=O)Ra, -OC(=O)ORb, -OC(=O)NRcRd, -C(=O)Ra, -C(=O)ORb, or -C(=O)NRcRd, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more Ru; or R1 and R2, together with the intervening carbon atoms, form Ring A; 31 275501297 v3
Y” is N or CR3; R3 is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, 3- to 12- membered heterocyclyl, -SRb, -S(=O)Ra, -S(=O)2Ra, -S(=O)2ORb, -S(=O)2NRcRd, - NRcS(=O)2Ra, -NRcS(=O)Ra, -NRcS(=O)2ORb, -NRcS(=O)2NRcRd, -NRbC(=O)NRcRd, - NRbC(=O)Ra, -NRbC(=O)ORb, -OS(=O)2Ra, -OS(=O)2ORb, -OS(=O)2NRcRd, -OC(=O)Ra, -OC(=O)ORb, -OC(=O)NRcRd, -C(=O)Ra, -C(=O)ORb, or -C(=O)NRcRd, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more Ru; or R2 and R3, together with the intervening carbon atoms, form Ring A; provided that either R1 and R2 or R2 and R3 form Ring A, Y’ is N or CRY’; RY’ is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, or 3- to 12-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl is optionally substituted with one or more Ru; denotes an optional covalent bond between Y and U; when the bond between Y and U is absent: r is 0 or 1; X is O or N; wherein when X is O, then U is absent; Y is N or CRY; RY is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, or 3- to 12-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl is optionally substituted with one or more Ru; and U is absent, hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, 3- to 12-membered heterocyclyl, -S(=O)Ra, -S(=O)2Ra, - S(=O)2ORb, -S(=O)2NRcRd, -C(=O)Ra, -C(=O)ORb, or -C(=O)NRcRd, wherein the alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more Ru; when the bond between Y and U is present: r is 1; X is N; 32 275501297 v3
Y is C; and U is -CH2- or -C(=O)- R4 is hydrogen, deuterium, C1-6 haloalkyl, or C1-6 alkyl; q is an integer from 0 to 2, Ring A is
wherein: each Ri independently is oxo, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, 3- to 12-membered heterocyclyl, -SRb, -S(=O)Ra, -S(=O)2Ra, -S(=O)2ORb, - S(=O)2NRcRd, -NRcS(=O)2Ra, -NRcS(=O)Ra, -NRcS(=O)2ORb, -NRcS(=O)2NRcRd, - NRbC(=O)NRcRd, -NRbC(=O)Ra, -NRbC(=O)ORb, -OS(=O)2Ra, -OS(=O)2ORb, - OS(=O)2NRcRd, -OC(=O)Ra, -OC(=O)ORb, -OC(=O)NRcRd, -C(=O)Ra, -C(=O)ORb, or - C(=O)NRcRd, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more Ru; s is an integer selected from 0 to 5; m is an integer selected from 0 to 2; Rcp is , wherein: Rend is -ORH1, -N(RH2)2, -SRH3, or -C(=O)ORH4; RH1 is hydrogen, C1-6 alkyl, -S(=O)2Ra, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, or a hydroxyl- protecting group, wherein the C1-6 alkyl is optionally substituted with one or more Ru; RH2 is hydrogen, C1-6 alkyl, -S(=O)2Ra, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, or an amino- protecting group, wherein the C1-6 alkyl is optionally substituted with one or more Ru; RH3 is hydrogen, C1-6 alkyl, -C(=O)Ra, or a thiol-protecting group, wherein the C1-6 alkyl is optionally substituted with one or more Ru; RH4 is hydrogen, C1-6 alkyl, or a carboxylic acid-protecting group, wherein the C1-6 alkyl is optionally substituted with one or more Ru; each occurrence of G is independently -C(RG1)2-, -O-, -NRG2-, -C(=O)-, -S-, or -S(=O)2-; 33 275501297 v3
each RG1 is independently hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, or 3- to 12-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl is optionally substituted with one or more Ru; each RG2 is independently hydrogen or C1-6 alkyl optionally substituted with one or more Ru; and p is an integer selected from 0 to 5, wherein: each Ru is independently oxo, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, 3- to 12-membered heterocyclyl, -SRb, -S(=O)Ra, -S(=O)2Ra, -S(=O)2ORb, - S(=O)2NRcRd, -NRcS(=O)2Ra, -NRcS(=O)Ra, -NRcS(=O)2ORb, -NRcS(=O)2NRcRd, - NRbC(=O)NRcRd, -NRbC(=O)Ra, -NRbC(=O)ORb, -OS(=O)2Ra, -OS(=O)2ORb, - OS(=O)2NRcRd, -OC(=O)Ra, -OC(=O)ORb, -OC(=O)NRcRd, -C(=O)Ra, -C(=O)ORb, or - C(=O)NRcRd; wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more substituents selected from oxo, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C3-6 carbocyclyl, and 3- to 6-membered heterocyclyl; or two Ru, together with the one or more intervening atoms, form C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl or 3- to 12-membered heterocyclyl; each Ra is independently C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-12 carbocyclyl, 3- to 12- membered heterocyclyl, C6-10 aryl, or 5- to 10-membered heteroaryl; each Rb is independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-12 carbocyclyl, 3- to 12-membered heterocyclyl, C6-10 aryl, or 5- to 10-membered heteroaryl; and each Rc and Rd is independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-12 carbocyclyl, 3- to 12-membered heterocyclyl, C6-10 aryl, or 5- to 10-membered heteroaryl; or Rc and Rd, together with the nitrogen atom to which they are attached, form 3- to 12-membered heterocyclyl, wherein each occurrence of Ra, Rb, Rc, and Rd is independently and optionally substituted with one or more Rz; and 34 275501297 v3
each Rz is independently oxo, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C3-6 carbocyclyl, or 3- to 6-memberred heterocyclyl. Exemplary Embodiment 2. The compound of any one of the preceding Exemplary Embodiments, wherein the compound is not
Exemplary Embodiment 3. The compound of any one of the preceding Exemplary Embodiments, wherein Rend is -ORH1 or -N(RH2)2. Exemplary Embodiment 4. The compound of any one of the preceding Exemplary Embodiments, wherein each occurrence of G is independently -C(RG1)2-, -O-, -NRG2- or - C(=O)-, and each RG1 is independently hydrogen, halogen, or C1-6 alkyl. Exemplary Embodiment 5. The compound of any one of the preceding Exemplary Embodiments, wherein Rcp is -(CH2)nOH, or -(CH2)nNH2, wherein n is an integer selected from 0 to 4. Exemplary Embodiment 6. A conjugate of Formula I:
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein: R1 is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, 3- to 12- membered heterocyclyl, -SRb, -S(=O)Ra, -S(=O)2Ra, -S(=O)2ORb, -S(=O)2NRcRd, - NRcS(=O)2Ra, -NRcS(=O)Ra, -NRcS(=O)2ORb, -NRcS(=O)2NRcRd, -NRbC(=O)NRcRd, - NRbC(=O)Ra, -NRbC(=O)ORb, -OS(=O)2Ra, -OS(=O)2ORb, -OS(=O)2NRcRd, -OC(=O)Ra, -OC(=O)ORb, -OC(=O)NRcRd, -C(=O)Ra, -C(=O)ORb, or -C(=O)NRcRd, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more Ru; R1 and R2, together with the intervening carbon atoms, form Ring A’; Y” is N or CR3; 35 275501297 v3
R3 is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, 3- to 12- membered heterocyclyl, -SRb, -S(=O)Ra, -S(=O)2Ra, -S(=O)2ORb, -S(=O)2NRcRd, - NRcS(=O)2Ra, -NRcS(=O)Ra, -NRcS(=O)2ORb, -NRcS(=O)2NRcRd, -NRbC(=O)NRcRd, - NRbC(=O)Ra, -NRbC(=O)ORb, -OS(=O)2Ra, -OS(=O)2ORb, -OS(=O)2NRcRd, -OC(=O)Ra, -OC(=O)ORb, -OC(=O)NRcRd, -C(=O)Ra, -C(=O)ORb, or -C(=O)NRcRd, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more Ru; or R2 and R3, together with the intervening carbon atoms, form Ring A’; provided that either R1 and R2, or R2 and R3, form Ring A’; Y’ is N or CRY’; RY’ is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, or 3- to 12-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl is optionally substituted with one or more Ru; denotes an optional covalent bond between Y and U; when the bond between Y and U is absent: r is 0 or 1; X is O or N; wherein when X is O, then U is absent; Y is N or CRY; RY is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, or 3- to 12-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl is optionally substituted with one or more Ru; and U is absent, hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, 3- to 12-membered heterocyclyl, -S(=O)Ra, -S(=O)2Ra, - S(=O)2ORb, -S(=O)2NRcRd, -C(=O)Ra, -C(=O)ORb, or -C(=O)NRcRd, wherein the alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more Ru; when the bond between Y and U is present: r is 1; X is N; Y is C; and 36 275501297 v3
U is -CH2- or -C(=O)-; R4 is hydrogen, deuterium, C1-6 haloalkyl, or C1-6 alkyl; q is an integer from 0 to 2, Ring A’ is
, wherein: each Ri independently is oxo, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, 3- to 12-membered heterocyclyl, -SRb, -S(=O)Ra, -S(=O)2Ra, -S(=O)2ORb, - S(=O)2NRcRd, -NRcS(=O)2Ra, -NRcS(=O)Ra, -NRcS(=O)2ORb, -NRcS(=O)2NRcRd, - NRbC(=O)NRcRd, -NRbC(=O)Ra, -NRbC(=O)ORb, -OS(=O)2Ra, -OS(=O)2ORb, - OS(=O)2NRcRd, -OC(=O)Ra, -OC(=O)ORb, -OC(=O)NRcRd, -C(=O)Ra, -C(=O)ORb, or - C(=O)NRcRd, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more Ru; s is an integer selected from 0 to 5; m is an integer selected from 0 to 2; Rcp’ is
, wherein: Rv is -O-, -N(RG3)-, -S-, or -C(=O)O-; RG3 is hydrogen or C1-6 alkyl optionally substituted with one or more Ru; each occurrence of G is independently -C(RG1)2-, -O-, -NRG2-, -C(=O)-, -S-, or -S(=O)2-; each RG1 is independently hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, or 3- to 12-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl is optionally substituted with one or more Ru; each RG2 is independently hydrogen or C1-6 alkyl optionally substituted with one or more Ru; p is an integer selected from 0 to 5, L is a linker, and 37 275501297 v3
T is a ligand for a protein, wherein: each Ru is independently oxo, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, 3- to 12-membered heterocyclyl, -SRb, -S(=O)Ra, -S(=O)2Ra, -S(=O)2ORb, - S(=O)2NRcRd, -NRcS(=O)2Ra, -NRcS(=O)Ra, -NRcS(=O)2ORb, -NRcS(=O)2NRcRd, - NRbC(=O)NRcRd, -NRbC(=O)Ra, -NRbC(=O)ORb, -OS(=O)2Ra, -OS(=O)2ORb, - OS(=O)2NRcRd, -OC(=O)Ra, -OC(=O)ORb, -OC(=O)NRcRd, -C(=O)Ra, -C(=O)ORb, or - C(=O)NRcRd; wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more substituents selected from oxo, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C3-6 carbocyclyl, and 3- to 6-membered heterocyclyl; or two Ru, together with the one or more intervening atoms, form C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl or 3- to 12-membered heterocyclyl; each Ra is independently C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-12 carbocyclyl, 3- to 12- membered heterocyclyl, C6-10 aryl, or 5- to 10-membered heteroaryl; each Rb is independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-12 carbocyclyl, 3- to 12-membered heterocyclyl, C6-10 aryl, or 5- to 10-membered heteroaryl; and each Rc and Rd is independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-12 carbocyclyl, 3- to 12-membered heterocyclyl, C6-10 aryl, or 5- to 10-membered heteroaryl; or Rc and Rd, together with the nitrogen atom to which they are attached, form 3- to 12-membered heterocyclyl, wherein each occurrence of Ra, Rb, Rc, and Rd is independently and optionally substituted with one or more Rz; and each Rz is independently oxo, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C3-6 carbocyclyl, or 3- to 6-memberred heterocyclyl. Exemplary Embodiment 7. The conjugate of any one of the preceding Exemplary Embodiments, wherein Rv is -O- or -N(RG3)-. Exemplary Embodiment 8. The conjugate of any one of the preceding Exemplary Embodiments, wherein each occurrence of G is independently -C(RG1)2-, -O-, -NRG2- or - C(=O)-, and each RG1 is independently hydrogen, halogen, or C1-6 alkyl. 38 275501297 v3
Exemplary Embodiment 9. The conjugate of any one of the preceding Exemplary Embodiments, wherein -RV-[G]p- is *-(CH2)nO- or *-(CH2)nNH-, wherein n is an integer selected from 0 to 4, and * denotes attachment to Ring A’. Exemplary Embodiment 10. The conjugate of any one of the preceding Exemplary Embodiments, wherein -RV-[G]p- is *-CH2O-. Exemplary Embodiment 11. The compound or conjugate of any one of the preceding Exemplary Embodiments, wherein the compound or conjugate of Formula I is a compound or conjugate of Formula I-1
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. Exemplary Embodiment 12. The compound or conjugate of any one of the preceding Exemplary Embodiments, wherein the compound or conjugate of Formula I is a compound or conjugate of Formula I-2
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. Exemplary Embodiment 13. The compound or conjugate of any one of the preceding Exemplary Embodiments, wherein U is hydrogen or C1-6 alkyl. Exemplary Embodiment 14. The compound or conjugate of any one of the preceding Exemplary Embodiments, wherein Y is CRY, and RY is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10- membered heteroaryl, C3-12 carbocyclyl, or 3- to 12-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl is optionally substituted with one or more Ru. Exemplary Embodiment 15. The compound or conjugate of any one of the preceding Exemplary Embodiments, wherein RY is hydrogen. Exemplary Embodiment 16. The compound or conjugate of any one of the preceding Exemplary Embodiments, wherein R1 and R2, together with the intervening carbon atoms, form Ring A or Ring A’. 39 275501297 v3
Exemplary Embodiment 17. The compound or conjugate of any one of the preceding Exemplary Embodiments, wherein the compound of Formula I-1 is a compound of Formula I-1-i’, I-1-ii’, I-1-iii’, or I-1-iv’:
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, or the conjugate of Formula I-1 is a conjugate of Formula I’-1-i’ or I’-1-ii’
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. Exemplary Embodiment 18. The compound or conjugate of any one of the preceding Exemplary Embodiments, wherein the compound of Formula I-2 is a compound of Formula I-2-i’, I-2-ii’, I-2-iii’, or I-2-iv’:
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, or the conjugate of Formula I-2 is a conjugate of Formula I’-2-i’ or I’-2-ii’
40 275501297 v3
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. Exemplary Embodiment 19. The compound or conjugate of any one of the preceding Exemplary Embodiments, wherein Y” is CR3, and R3 is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10- membered heteroaryl, C3-12 carbocyclyl, or 3- to 12-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl is optionally substituted with one or more Ru. Exemplary Embodiment 20. The compound or conjugate of any one of the preceding Exemplary Embodiments, wherein Y” is CR3, and R3 is hydrogen. Exemplary Embodiment 21. The compound or conjugate of any one of the preceding Exemplary Embodiments, wherein R2 and R3, together with the intervening carbon atoms, form Ring A or Ring A’. Exemplary Embodiment 22. The compound or conjugate of any one of the preceding Exemplary Embodiments, wherein the compound of Formula I-1 is a compound of Formula I-1-v’, I-1-vi’, I-1-vii’, or I-1-viii’:
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, or wherein the conjugate of Formula I-1 is a conjugate of Formula I’-1-iii’ or I’-1-iv’
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. Exemplary Embodiment 23. The compound or conjugate of any one of the preceding Exemplary Embodiments, wherein the compound of Formula I-2 is a compound of Formula I-2-v’, I-2-vi’, I-2-vii’, or I-2-viii’: 41 275501297 v3
(I-2-v’), (I-2-vi’), (I-2-vii’), or (I-2-viii’), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, or the conjugate of Formula I-2 is a conjugate of Formula I’-2-iii’ or I’-2-iv’
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. Exemplary Embodiment 24. The compound or conjugate of any one of the preceding Exemplary Embodiments, wherein R1 is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, or 3- to 12-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl is optionally substituted with one or more Ru. Exemplary Embodiment 25. The compound or conjugate of any one of the preceding Exemplary Embodiments, wherein R1 is hydrogen. Exemplary Embodiment 26. The compound or conjugate of any one of the preceding Exemplary Embodiments, wherein Y’ is CRY’, and RY’ is hydrogen, halogen, -CN, -NO2, - OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, or 3- to 12-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl is optionally substituted with one or more Ru. Exemplary Embodiment 27. The compound or conjugate of any one of the preceding Exemplary Embodiments, wherein RY’ is hydrogen. Exemplary Embodiment 28. The compound or conjugate of any one of the preceding Exemplary Embodiments, wherein each Ri is independently oxo, halogen, -CN, -NO2, -OH, - 42 275501297 v3
NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10- membered heteroaryl, C3-12 carbocyclyl, or 3- to 12-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl is optionally substituted with one or more Ru. Exemplary Embodiment 29. The compound or conjugate of any one of the preceding Exemplary Embodiments, wherein each Ri is independently oxo, -CN, -OH, -NH2, C1-6 alkyl, -NRcS(=O)2Ra, or -NRbC(=O)Ra, , wherein the alkyl is optionally substituted with one or more Ru. Exemplary Embodiment 30. The compound or conjugate of any one of the preceding Exemplary Embodiments, wherein s is 0. Exemplary Embodiment 31. The compound or conjugate of any one of the preceding Exemplary Embodiments, wherein R4 is hydrogen. Exemplary Embodiment 32. The compound or conjugate of any one of the preceding Exemplary Embodiments, wherein q is 1. Exemplary Embodiment 33. A compound selected from the compounds in Table 1 and pharmaceutically acceptable salts thereof. Exemplary Embodiment 34. A pharmaceutical composition comprising the compound or conjugate of any one of the preceding Exemplary Embodiments, and a pharmaceutically acceptable excipient. Exemplary Embodiment 35. A method of binding cereblon E3 ubiquitin ligase protein complex in a subject or biological sample comprising administering the compound of any one of the preceding Exemplary Embodiments to the subject or contacting the biological sample with the compound of any one of the preceding Exemplary Embodiments. Exemplary Embodiment 36. Use of the compound of any one of the preceding Exemplary Embodiments in the manufacture of a medicament for binding cereblon E3 ubiquitin ligase protein complex in a subject or biological sample. Exemplary Embodiment 37. A compound of any one of the preceding Exemplary Embodiments for use in binding cereblon E3 ubiquitin ligase protein complex in a subject or biological sample. [000136] The compounds of the present disclosure possess advantageous characteristics, as compared to known compounds, such as known cereblon-binding agents or known degraders comprising cereblon-binding agents. For example, the compounds of the present disclosure display more potent cereblon-binding activity or more potent degradation activity against 43 275501297 v3
certain proteins, more favorable pharmacokinetic properties (e.g., as measured by Cmax, Tmax, and/or AUC), and/or less interaction with other cellular targets (e.g., hepatic cellular transporter such as OATP1B1) and accordingly improved safety (e.g., drug-drug interaction). These beneficial properties of the compounds of the present disclosure can be measured according to methods commonly available in the art, such as methods exemplified herein. [000137] Due to the existence of double bonds, the compounds of the present disclosure may be in cis or trans, or Z or E, configuration. It is understood that although one configuration may be depicted in the structure of the compounds or formulae of the present disclosure, the present disclosure also encompasses the other configuration. For example, the compounds or formulae of the present disclosure may be depicted in cis or trans, or Z or E, configuration. [000138] In one embodiment, a compound of the present disclosure (e.g., a compound of any of the formulae or any individual compounds disclosed herein) is a pharmaceutically acceptable salt. In another embodiment, a compound of the present disclosure (e.g., a compound of any of the formulae or any individual compounds disclosed herein) is a solvate. In another embodiment, a compound of the present disclosure (e.g., a compound of any of the formulae or any individual compounds disclosed herein) is a hydrate. [000139] The details of the disclosure are set forth in the accompanying description below. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, illustrative methods and materials are now described. Other features, objects, and advantages of the disclosure will be apparent from the description and from the claims. In the specification and the appended claims, the singular forms also include the plural unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. All patents and publications cited in this specification are incorporated herein by reference in their entireties. Forms of Compounds Disclosed Herein Pharmaceutically acceptable salts [000140] In certain embodiments, the compounds disclosed herein exist as their pharmaceutically acceptable salts. In certain embodiments, the methods disclosed herein include methods of treating diseases by administering such pharmaceutically acceptable salts. 44 275501297 v3
In certain embodiments, the methods disclosed herein include methods of treating diseases by administering such pharmaceutically acceptable salts as pharmaceutical compositions. [000141] In certain embodiments, the compounds described herein possess acidic or basic groups and therefor react with any of a number of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt. In certain embodiments, these salts are prepared in situ during the final isolation and purification of the compounds disclosed herein, or by separately reacting a purified compound in its free form with a suitable acid or base, and isolating the salt thus formed. [000142] Examples of pharmaceutically acceptable salts include those salts prepared by reaction of the compounds described herein with a mineral, organic acid, or inorganic base, such salts including acetate, acrylate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, bisulfite, bromide, butyrate, butyn-1,4-dioate, camphorate, camphorsulfonate, caproate, caprylate, chlorobenzoate, chloride, citrate, cyclopentanepropionate, decanoate, digluconate, dihydrogenphosphate, dinitrobenzoate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptanoate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hexyne-1,6-dioate, hydroxybenzoate, γ-hydroxybutyrate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, iodide, isobutyrate, lactate, maleate, malonate, methanesulfonate, mandelate metaphosphate, methanesulfonate, methoxybenzoate, methylbenzoate, monohydrogenphosphate, 1-napthalenesulfonate, 2-napthalenesulfonate, nicotinate, nitrate, palmoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, pyrosulfate, pyrophosphate, propiolate, phthalate, phenylacetate, phenylbutyrate, propanesulfonate, salicylate, succinate, sulfate, sulfite, succinate, suberate, sebacate, sulfonate, tartrate, thiocyanate, tosylateundeconate, and xylenesulfonate. [000143] Further, the compounds described herein can be prepared as pharmaceutically acceptable salts formed by reacting the free base form of the compound with a pharmaceutically acceptable inorganic or organic acid, including, but not limited to, inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid metaphosphoric acid, and the like; and organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, p-toluenesulfonic acid, tartaric acid, trifluoroacetic acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, arylsulfonic acid, methanesulfonic acid, ethanesulfonic acid, 1,2- ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 2- 45 275501297 v3
naphthalenesulfonic acid, 4-methylbicyclo-[2.2.2]oct-2-ene-1-carboxylic acid, glucoheptonic acid, 4,4’-methylenebis-(3-hydroxy-2-ene-1-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, and muconic acid. [000144] In certain embodiments, those compounds described herein which comprise a free acid group react with a suitable base, such as the hydroxide, carbonate, bicarbonate, or sulfate of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary, tertiary, or quaternary amine. Representative salts include the alkali or alkaline earth salts, like lithium, sodium, potassium, calcium, and magnesium, and aluminum salts and the like. Illustrative examples of bases include sodium hydroxide, potassium hydroxide, choline hydroxide, sodium carbonate, N+(C1-4 alkyl)4, and the like. [000145] Representative organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, and the like. It should be understood that the compounds described herein also include the quaternization of any basic nitrogen-containing groups they contain. In certain embodiments, water or oil-soluble or dispersible products are obtained by such quaternization. Solvates [000146] Those skilled in the art of organic chemistry will appreciate that many organic compounds can form complexes with solvents in which they are reacted or from which they are precipitated or crystallized. These complexes are known as “solvates”. For example, a complex with water is known as a “hydrate”. Solvates are within the scope of the invention. [000147] It will also be appreciated by those skilled in organic chemistry that many organic compounds can exist in more than one crystalline form. For example, crystalline form may vary from solvate to solvate. Thus, all crystalline forms or the pharmaceutically acceptable solvates thereof are contemplated and are within the scope of the present invention. [000148] In certain embodiments, the compounds described herein exist as solvates. The present disclosure provides for methods of treating diseases by administering such solvates. The present disclosure further provides for methods of treating diseases by administering such solvates as pharmaceutical compositions. [000149] Solvates contain either stoichiometric or non-stoichiometric amounts of a solvent, such as water, ethanol, and the like. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol. Solvates of the compounds described herein 46 275501297 v3
can be conveniently prepared or formed during the processes described herein. In addition, the compounds provided herein can exist in unsolvated as well as solvated forms. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the compounds and methods provided herein. Isomers/Stereoisomers [000150] It is also to be understood that compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed “isomers.” Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers.” [000151] In certain embodiments, the compounds described herein exist as geometric isomers. In certain embodiments, the compounds described herein possess one or more double bonds. The compounds disclosed herein include all cis, trans, syn, anti, entgegen (E), and zusammen (Z) isomers as well as the corresponding mixtures thereof. All geometric forms of the compounds disclosed herein are contemplated and are within the scope of the invention. [000152] In certain embodiments, the compounds disclosed herein possess one or more chiral centers and each center exists in the R configuration or S configuration. The compounds disclosed herein include all diastereomeric, enantiomeric, and epimeric forms as well as the corresponding mixtures thereof. All diastereomeric, enantiomeric, and epimeric forms of the compounds disclosed herein are contemplated and are within the scope of the invention. [000153] In additional embodiments of the compounds and methods provided herein, mixtures of enantiomers and/or diastereoisomers, resulting from a single preparative step, combination, or interconversion are useful for the applications described herein. In certain embodiments, the compounds described herein are prepared as their individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereoisomeric compounds, separating the diastereomers, and recovering the optically pure enantiomers. In certain embodiments, dissociable complexes are preferred. In certain embodiments, the diastereomers have distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) and are separated by taking advantage of these dissimilarities. In certain embodiments, the diastereomers are separated by chiral chromatography, or preferably, by separation/resolution techniques based upon differences in 47 275501297 v3
solubility. In certain embodiments, the optically pure enantiomer is then recovered, along with the resolving agent. Tautomers [000154] In certain embodiments, compounds described herein exist as tautomers. The compounds described herein include all possible tautomers within the formulas described herein. [000155] Tautomers are compounds that are interconvertible by migration of a hydrogen atom, accompanied by a switch of a single bond and an adjacent double bond. In bonding arrangements where tautomerization is possible, a chemical equilibrium of the tautomers will exist. All tautomeric forms of the compounds disclosed herein are contemplated and are within the scope of the invention. The exact ratio of the tautomers depends on several factors, including temperature, solvent, and pH. Pharmaceutical Compositions [000156] In certain embodiments, the compound described herein is administered as a pure chemical. In certain embodiments, the compound described herein is combined with a pharmaceutically suitable or acceptable carrier (also referred to herein as a pharmaceutically suitable (or acceptable) excipient, physiologically suitable (or acceptable) excipient, or physiologically suitable (or acceptable) carrier) selected on the basis of a chosen route of administration and standard pharmaceutical practice as described, for example, in Remington: The Science and Practice of Pharmacy (Gennaro, 21st Ed. Mack Pub. Co., Easton, PA (2005)). [000157] Accordingly, the present disclosure provides pharmaceutical compositions comprising a compound described herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, and a pharmaceutically acceptable excipient. [000158] In certain embodiments, the compound provided herein is substantially pure, in that it contains less than about 5%, less than about 1%, or less than about 0.1% of other organic small molecules, such as unreacted intermediates or synthesis by-products that are created, for example, in one or more of the steps of a synthesis method. [000159] Pharmaceutical compositions are administered in a manner appropriate to the disease to be treated (or prevented). An appropriate dose and a suitable duration and frequency of administration will be determined by such factors as the condition of the patient, the type and severity of the patient's disease, the particular form of the active ingredient, and the method of 48 275501297 v3
administration. In general, an appropriate dose and treatment regimen provides the composition(s) in an amount sufficient to provide therapeutic and/or prophylactic benefit (e.g., an improved clinical outcome, such as more frequent complete or partial remissions, or longer disease-free and/or overall survival, or a lessening of symptom severity. Optimal doses are generally determined using experimental models and/or clinical trials. The optimal dose depends upon the body mass, weight, or blood volume of the patient. [000160] In certain embodiments, the pharmaceutical composition is formulated for oral, topical (including buccal and sublingual), rectal, vaginal, transdermal, parenteral, intrapulmonary, intradermal, intrathecal and epidural and intranasal administration. Parenteral administration includes intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration. In certain embodiments, the pharmaceutical composition is formulated for intravenous injection, oral administration, inhalation, nasal administration, topical administration, or ophthalmic administration. In certain embodiments, the pharmaceutical composition is formulated for oral administration. In certain embodiments, the pharmaceutical composition is formulated for intravenous injection. In certain embodiments, the pharmaceutical composition is formulated as a tablet, a pill, a capsule, a liquid, an inhalant, a nasal spray solution, a suppository, a suspension, a gel, a colloid, a dispersion, a suspension, a solution, an emulsion, an ointment, a lotion, an eye drop, or an ear drop. In certain embodiments, the pharmaceutical composition is formulated as a tablet. Preparation and Characterization of the Compounds [000161] The compounds of the present disclosure can be prepared in a number of ways well known to those skilled in the art of organic synthesis. By way of example, the compounds of the present disclosure can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art. The compounds of the present disclosure (i.e., a compound of the present application (e.g., a compound of any of the formulae or any individual compounds disclosed herein)) can be synthesized by following the general synthetic scheme below as well as the steps outlined in the examples, schemes, procedures, and/or synthesis described herein (e.g., Examples). 49 275501297 v3
General Synthetic Scheme Scheme 1
[000162] According to Scheme 1, commercially available or synthetically accessible lactone of formula II is brominated in the presence of a brominating agent such as Br2, NBS and the like; in the presence of an acid such as acetic acid, pTSA and the like; in an alcoholic solvent such as MeOH, EtOH and the like; at temperatures ranging from 0 °C to about 50 °C, preferably 25 °C; to afford a compound of formula (III). Bromo lactone of formula III is reacted with a compound of formula (IV) commercially available or synthetically accessible (where X = OH) under Mitsunobu condition, in the presence of a coupling agent such DIAD, DEAD, and the like; with a coupling co-agent such as Ph3P, Bu3P and the like; in a solvent such as diethyl ether, THF and the like; at temperatures ranging from -20 °C to about 50 °C, preferably 0 °C; to afford an ether compound of formula (V); Alternatively, bromo lactone of formula III is reacted with a compound of formula (IV) commercially available or synthetically accessible (where X = halogen) under coupling condition, in the presence of a base such K2CO3, NaH, Na2CO3, and 50 275501297 v3
the like; in a solvent such as THF, DMF, DMSO and the like; at temperatures ranging from 0 °C to about 100 °C, preferably 40 °C; to afford an ether compound of formula (V); a compound of formula (V) is cyclized under radical cyclization condition with a radical initiator such as BPO, AIBN and the like; in the presence of a suitable reductant such as Bu3SnH, (TMS)3SiH and the like; in a solvent such as benzene, toluene and the like; at temperatures ranging from 80 °C to about 120 °C, preferably 100 °C; to afford a compound of formula (VI). A lactone compound of formula (VI) is reacted with a suitable base such as LiOH, NaOH, and the like; in a suitable solvent such as THF, MeOH, and the like; in a co-solvent such as water; at temperatures ranging from 25 °C to 80 °C, preferably at 50 °C; to provide an acid compound of formula (VII). An acid compound of formula (VII) is oxidized in the presence of an oxidant such as MnO2, Dess-Martin periodinane, and the like; in a suitable solvent such as DCM, acetonitrile, and the like; at temperatures ranging from 0 °C to 50 °C, preferably at 25 °C; to provide a compound of formula (VIII). An aldehyde compound of formula (VIII) is reacted with a commercially available or synthetically accessible amine of formula (IX), in the presence of a suitable reductant such as NaBH(OAc)3, NaCNBH3 and the like; in a suitable solvent such as DCM, THF and the like; at temperatures ranging from 0 °C to about 60 °C, preferably 25 °C; to afford a compound of formula (X). A compound of formula (X) is cyclized with a coupling agent such as HTAU, EDCI and the like; in the presence of a suitable base such as TEA, DIPEA and the like; in a suitable solvent such as DCM, THF and the like; at temperatures ranging from 0 °C to about 60 °C, preferably 25 °C; to afford an cyclized compound of formula (I-1-iii); Alternatively, a compound of formula (X) is cyclized in the presence of a suitable acid such as AcOH, TFA, pTSA and the like; in a suitable solvent such as DMF, THF, dioxane and the like; at temperatures ranging from 0 °C to about 80 °C, preferably 25 °C; to afford an cyclized compound of formula (I-1-iii). [000163] Those skilled in the art will recognize if a stereocenter exists in the compounds of the present dislosure (e.g., a compound of any of the formulae or any individual compounds disclosed herein). Accordingly, the present disclosure includes both possible stereoisomers (unless specified in the synthesis) and includes not only racemic compound but the individual enantiomers and/or diastereomers as well. When a compound is desired as a single enantiomer or diastereomer, it may be obtained by stereospecific synthesis or by resolution of the final product or any convenient intermediate. Resolution of the final product, an intermediate, or a starting material may be affected by any suitable method known in the art. See, for example, 51 275501297 v3
"Stereochemistry of Organic Compounds" by E. L. Eliel, S. H. Wilen, and L. N. Mander (Wiley-lnterscience, 1994). [000164] The compounds used in the reactions described herein are made according to organic synthesis techniques known to those skilled in this art, starting from commercially available chemicals and/or from compounds described in the chemical literature. “Commercially available chemicals” are obtained from standard commercial sources including Acros Organics (Pittsburgh, PA), Aldrich Chemical (Milwaukee, WI, including Sigma Chemical and Fluka), Apin Chemicals Ltd. (Milton Park, UK), Avocado Research (Lancashire, U.K.), BDH, Inc. (Toronto, Canada), Bionet (Cornwall, U.K.), Chem Service Inc. (West Chester, PA), Crescent Chemical Co. (Hauppauge, NY), Eastman Organic Chemicals, Eastman Kodak Company (Rochester, NY), Fisher Scientific Co. (Pittsburgh, PA), Fisons Chemicals (Leicestershire, UK), Frontier Scientific (Logan, UT), ICN Biomedicals, Inc. (Costa Mesa, CA), Key Organics (Cornwall, U.K.), Lancaster Synthesis (Windham, NH), Maybridge Chemical Co. Ltd. (Cornwall, U.K.), Parish Chemical Co. (Orem, UT), Pfaltz & Bauer, Inc. (Waterbury, CN), Polyorganix (Houston, TX), Pierce Chemical Co. (Rockford, IL), Riedel de Haen AG (Hanover, Germany), Spectrum Quality Product, Inc. (New Brunswick, NJ), TCI America (Portland, OR), Trans World Chemicals, Inc. (Rockville, MD), and Wako Chemicals USA, Inc. (Richmond, VA). [000165] Suitable reference books and treatises that detail the synthesis of reactants useful in the preparation of compounds described herein, or provide references to articles that describe the preparation, include for example, “Synthetic Organic Chemistry”, John Wiley & Sons, Inc., New York; S. R. Sandler et al., “Organic Functional Group Preparations,” 2nd Ed., Academic Press, New York, 1983; H. O. House, “Modern Synthetic Reactions”, 2nd Ed., W. A. Benjamin, Inc. Menlo Park, Calif.1972; T. L. Gilchrist, “Heterocyclic Chemistry”, 2nd Ed., John Wiley & Sons, New York, 1992; J. March, “Advanced Organic Chemistry: Reactions, Mechanisms and Structure”, 4th Ed., Wiley-Interscience, New York, 1992. Additional suitable reference books and treatises that detail the synthesis of reactants useful in the preparation of compounds described herein, or provide references to articles that describe the preparation, include for example, Fuhrhop, J. and Penzlin G. “Organic Synthesis: Concepts, Methods, Starting Materials”, Second, Revised and Enlarged Edition (1994) John Wiley & Sons ISBN: 3-527- 29074-5; Hoffman, R.V. “Organic Chemistry, An Intermediate Text” (1996) Oxford University Press, ISBN 0-19-509618-5; Larock, R. C. “Comprehensive Organic Transformations: A Guide to Functional Group Preparations” 2nd Edition (1999) Wiley-VCH, 52 275501297 v3
ISBN: 0-471-19031-4; March, J. “Advanced Organic Chemistry: Reactions, Mechanisms, and Structure” 4th Edition (1992) John Wiley & Sons, ISBN: 0-471-60180-2; Otera, J. (editor) “Modern Carbonyl Chemistry” (2000) Wiley-VCH, ISBN: 3-527-29871-1; Patai, S. “Patai's 1992 Guide to the Chemistry of Functional Groups” (1992) Interscience ISBN: 0-471-93022- 9; Solomons, T. W. G. “Organic Chemistry” 7th Edition (2000) John Wiley & Sons, ISBN: 0- 471-19095-0; Stowell, J.C., “Intermediate Organic Chemistry” 2nd Edition (1993) Wiley- Interscience, ISBN: 0-471-57456-2; “Industrial Organic Chemicals: Starting Materials and Intermediates: An Ullmann's Encyclopedia” (1999) John Wiley & Sons, ISBN: 3-527-29645- X, in 8 volumes; “Organic Reactions” (1942-2000) John Wiley & Sons, in over 55 volumes; and “Chemistry of Functional Groups” John Wiley & Sons, in 73 volumes. [000166] Specific and analogous reactants are optionally identified through the indices of known chemicals prepared by the Chemical Abstract Service of the American Chemical Society, which are available in most public and university libraries, as well as through on-line. Chemicals that are known but not commercially available in catalogs are optionally prepared by custom chemical synthesis houses, where many of the standard chemical supply houses (e.g., those listed above) provide custom synthesis services. A reference for the preparation and selection of pharmaceutical salts of the compounds described herein is P. H. Stahl & C. G. Wermuth “Handbook of Pharmaceutical Salts”, Verlag Helvetica Chimica Acta, Zurich, 2002. Analytical Methods, Materials, and Instrumentation [000167] Unless otherwise noted, reagents and solvents were used as received from commercial suppliers. Proton nuclear magnetic resonance (NMR) spectra were obtained on either Bruker or Varian spectrometers at 400 MHz. Spectra are given in ppm (δ) and coupling constants, J, are reported in Hertz. Tetramethylsilane (TMS) was used as an internal standard. Liquid chromatography-mass spectrometry (LC/MS) were collected using a SHIMADZU LCMS-2020EV or Agilent 1260-6125B LCMS. Purity and low resolution mass spectral data were measured using Agilent 1260-6125B LCMS system (with Diode Array Detector, and Agilent G6125BA Mass spectrometer) or using Waters Acquity UPLC system (with Diode Array Detector, and Waters 3100 Mass Detector). The purity was characterized by UV wavelength 214 nm, 220 nm, 254 nm and ESI. Column: poroshell 120 EC-C182.7 μm 4.6 X 100 mm; Flow rate 0.8 mL/min; Solvent A (100/0.1 water/formic acid), Solvent B (100 acetonitrile); gradient: hold 5% B to 0.3 min, 5-95% B from 0.3 to 2 min, hold 95% B to 4.8 min, 95-5% B from 4.8 to 5.4 min, then hold 5% B to 6.5 min. Or, column: Acquity UPLC BEH C181.7 µm 2.1 X 50 mm; Flow rate 0.5 mL/min; Solvent A (0.1%formic acid water), 53 275501297 v3
Solvent B (acetonitrile); gradient: hold 5%B for 0.2 min, 5-95% B from 0.2 to 2.0 min, hold 95% B to 3.1 min, then 5% B at 3.5 min. Biological Assays [000168] The biological activities of the compounds of the present application can be assessed with methods and assays known in the art. [000169] The binding potency may be determined using HTRF assay technology (e.g., Perkin Elmer). In a typical assay, in a HTRF assay, compounds are diluted in DMSO and react with His tagged CRBN+DDB-DLS7+CXU4 followed by addition of Fluorescent probe Cy5-labeled Thalidomide, and MAb Anti-6HIS Tb cryptate Gold. After a certain period of incubation at room temperature, the HTRF signals are read on Envision reader (e.g., Perkin Elemer). Data is analyzed using XLfit using four parameters dose response curve to determine IC50s. Methods of Use [000170] In certain aspects, provided herein are methods of binding cereblon E3 ubiquitin ligase protein complex in a subject or biological sample comprising administering a compound described herein to the subject or contacting the biological sample with a compound described herein (e.g., in a therapeutically effective amount). [000171] In certain aspects, provided herein are uses of a compound described herein in the manufacture of a medicament for binding cereblon E3 ubiquitin ligase protein complex in a subject or biological sample. [000172] In certain aspects, provided herein are compounds described herein for use in binding cereblon E3 ubiquitin ligase protein complex in a subject or biological sample. [000173] In certain aspects, provided herein are methods of degrading a protein in a subject or biological sample comprising administering a conjugate described herein to the subject or contacting the biological sample with a conjugate described herein (e.g., in a therapeutically effective amount). [000174] In certain aspects, provided herein are uses of a conjugate described herein in the manufacture of a medicament for degrading a protein in a subject or biological sample. [000175] In certain aspects, provided herein are conjugates described herein for use in degrading a protein in a subject or biological sample. [000176] In certain embodiments, the protein is an androgen receptor (AR), an estrogen receptor (ER), signal transducer and activator of transcription 3 (STAT3), signal transducer and activator of transcription 5 (STAT5), CREB-binding protein/EP300(E1A) binding protein (CBP/p300), SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, 54 275501297 v3
Subfamily A, Member 2/4 (SMARCA2/4), Kirsten rat sarcoma viral oncogene homolog G12D (KRAS G12D), Src homology region 2-containing protein tyrosine phosphatase 2 (SHP2), or bromodomain-containing protein 4 (BRD4). [000177] In certain aspects, provided herein are methods of treating or preventing a disease or disorder a subject in need thereof, comprising administering to the subject a conjugate described herein (e.g., in a therapeutically effective amount). [000178] In certain aspects, provided herein are uses of a conjugate described herein in the manufacture of a medicament for treating or preventing a disease or disorder in a subject in need thereof. [000179] In certain aspects, provided herein are conjugates described herein for use in treating or preventing a disease or disorder in a subject in need thereof. [000180] In certain embodiments, the disease or disorder is an androgen receptor (AR)- mediated disease or disorder, an estrogen receptor (ER)-mediated disease or disorder, signal transducer and activator of transcription 3 (STAT3)-mediated disease or disorder, signal transducer and activator of transcription 5 (STAT5)-mediated disease or disorder, CREB- binding protein/EP300(E1A) binding protein (CBP/p300)-mediated disease or disorder, SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A, Member 2/4 (SMARCA2/4)-mediated disease or disorder, Kirsten rat sarcoma viral oncogene homolog G12D (KRAS G12D)-mediated disease or disorder, Src homology region 2-containing protein tyrosine phosphatase 2 (SHP2)-mediated disease or disorder, or bromodomain-containing protein 4 (BRD4)-mediated disease or disorder. [000181] In certain embodiments, the subject is a mammal. [000182] In certain embodiments, the subject is a human. Definitions [000183] As used in the specification and appended claims, unless specified to the contrary, the following terms have the meaning indicated below. Chemical Definitions [000184] Definitions of specific functional groups and chemical terms are described in more detail below. The chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th Ed., inside cover, and specific functional groups are generally defined as described therein. Additionally, general principles of organic chemistry, as well as specific functional moieties and reactivity, are described in Thomas Sorrell, Organic Chemistry, University Science Books, Sausalito, 1999; 55 275501297 v3
Smith and March, March’s Advanced Organic Chemistry, 5th Edition, John Wiley & Sons, Inc., New York, 2001; Larock, Comprehensive Organic Transformations, VCH Publishers, Inc., New York, 1989; and Carruthers, Some Modern Methods of Organic Synthesis, 3rd Edition, Cambridge University Press, Cambridge, 1987. [000185] Compounds described herein can comprise one or more asymmetric centers, and thus can exist in various isomeric forms, e.g., enantiomers and/or diastereomers. For example, the compounds described herein can be in the form of an individual enantiomer, diastereomer or geometric isomer, or can be in the form of a mixture of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomer. Isomers can be isolated from mixtures by methods known to those skilled in the art, including chiral high pressure liquid chromatography (HPFC) and the formation and crystallization of chiral salts; or preferred isomers can be prepared by asymmetric syntheses. See, for example, Jacques et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen et al., Tetrahedron 33:2725 (1977); Eliel, Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); and Wilen, Tables of Resolving Agents and Optical Resolutions p.268 (E.F. Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN 1972). [000186] The invention additionally encompasses compounds described herein as individual isomers substantially free of other isomers, and alternatively, as mixtures of various isomers. [000187] When a range of values is listed, it is intended to encompass each value and sub- range within the range. For example, “C1-6 alkyl” is intended to encompass, C1, C2, C3, C4, C5, C6, C1-6, C1-5, C1-4, C1-3, C1-2, C2-6, C2-5, C2-4, C2-3, C3-6, C3-5, C3-4, C4-6, C4-5, and C5-6 alkyl. [000188] The following terms are intended to have the meanings presented therewith below and are useful in understanding the description and intended scope of the present invention. When describing the invention, which may include compounds, pharmaceutical compositions containing such compounds and methods of using such compounds and compositions, the following terms, if present, have the following meanings unless otherwise indicated. It should also be understood that when described herein any of the moieties defined forth below may be substituted with a variety of substituents, and that the respective definitions are intended to include such substituted moieties within their scope as set out below. Unless otherwise stated, the term “substituted” is to be defined as set out below. It should be further understood that the terms “groups” and “radicals” can be considered interchangeable when used herein. The articles “a” and “an” may be used herein to refer to one or to more than one (i.e., at least one) of the grammatical objects of the article. By way of example “an analogue” means one analogue or more than one analogue. 56 275501297 v3
[000189] “Alkyl” as used herein, refers to a radical of a straight-chain or branched saturated hydrocarbon group having from 1 to 20 carbon atoms (“C1-20 alkyl”). In certain embodiments, an alkyl group has 1 to 12 carbon atoms (“C1-12 alkyl”). In certain embodiments, an alkyl group has 1 to 10 carbon atoms (“C1-10 alkyl”). In certain embodiments, an alkyl group has 1 to 9 carbon atoms (“C1-9 alkyl”). In certain embodiments, an alkyl group has 1 to 8 carbon atoms (“C1-8 alkyl”). In certain embodiments, an alkyl group has 1 to 7 carbon atoms (“C1-7 alkyl”). In certain embodiments, an alkyl group has 1 to 6 carbon atoms (“C1-6 alkyl”, which is also referred to herein as “lower alkyl”). In certain embodiments, an alkyl group has 1 to 5 carbon atoms (“C1-5 alkyl”). In certain embodiments, an alkyl group has 1 to 4 carbon atoms (“C1-4 alkyl”). In certain embodiments, an alkyl group has 1 to 3 carbon atoms (“C1-3 alkyl”). In certain embodiments, an alkyl group has 1 to 2 carbon atoms (“C1-2 alkyl”). In certain embodiments, an alkyl group has 1 carbon atom (“C1 alkyl”). Examples of C1-6 alkyl groups include methyl (C1), ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), isobutyl (C4), n-pentyl (C5), 3-pentanyl (C5), amyl (C5), neopentyl (C5), 3-methyl-2-butanyl (C5), tertiary amyl (C5), and n-hexyl (C6). Additional examples of alkyl groups include n-heptyl (C7), n-octyl (C8) and the like. Unless otherwise specified, each instance of an alkyl group is independently optionally substituted, i.e., unsubstituted (an “unsubstituted alkyl”) or substituted (a “substituted alkyl”) with one or more substituents; e.g., for instance from 1 to 5 substituents, 1 to 3 substituents, or 1 substituent. In certain embodiments, the alkyl group is unsubstituted C1-10 alkyl (e.g., -CH3). In certain embodiments, the alkyl group is substituted C1- 10 alkyl. Common alkyl abbreviations include Me (-CH3), Et (-CH2CH3), i-Pr (-CH(CH3)2), n- Pr (-CH2CH2CH3), n-Bu (-CH2CH2CH2CH3), or i-Bu (-CH2CH(CH3)2). [000190] “Alkylene” as used herein, refers to an alkyl group wherein two hydrogens are removed to provide a divalent radical. When a range or number of carbons is provided for a particular “alkylene” group, it is understood that the range or number refers to the range or number of carbons in the linear carbon divalent chain. An “alkelene” group may be substituted or unsubstituted with one or more substituents as described herein. Exemplary unsubstituted divalent alkylene groups include, but are not limited to, methylene (-CH2-), ethylene (- CH2CH2-), propylene (-CH2CH2CH2-), butylene (-CH2CH2CH2CH2-), pentylene (- CH2CH2CH2CH2CH2-), hexylene (-CH2CH2CH2CH2CH2CH2-), and the like. Exemplary substituted divalent alkylene groups, e.g., substituted with one or more alkyl (methyl) groups, include but are not limited to, substituted methylene (-CH(CH3)-, (-C(CH3)2-), substituted ethylene (-CH(CH3)CH2-,-CH2CH(CH3)-, -C(CH3)2CH2-,-CH2C(CH3)2-), substituted 57 275501297 v3
propylene (-CH(CH3)CH2CH2-, -CH2CH(CH3)CH2-, -CH2CH2CH(CH3)-, -C(CH3)2CH2CH2-, -CH2C(CH3)2CH2-, -CH2CH2C(CH3)2-), and the like. [000191] “Alkenyl” as used herein, refers to a radical of a straight-chain or branched hydrocarbon group having from 2 to 20 carbon atoms, one or more carbon-carbon double bonds (e.g., 1, 2, 3, or 4 carbon-carbon double bonds), and optionally one or more carbon-carbon triple bonds (e.g., 1, 2, 3, or 4 carbon-carbon triple bonds) (“C2-20 alkenyl”). In certain embodiments, alkenyl does not contain any triple bonds. In certain embodiments, an alkenyl group has 2 to 10 carbon atoms (“C2-10 alkenyl”). In certain embodiments, an alkenyl group has 2 to 9 carbon atoms (“C2-9 alkenyl”). In certain embodiments, an alkenyl group has 2 to 8 carbon atoms (“C2-8 alkenyl”). In certain embodiments, an alkenyl group has 2 to 7 carbon atoms (“C2- 7 alkenyl”). In certain embodiments, an alkenyl group has 2 to 6 carbon atoms (“C2-6 alkenyl”). In certain embodiments, an alkenyl group has 2 to 5 carbon atoms (“C2-5 alkenyl”). In certain embodiments, an alkenyl group has 2 to 4 carbon atoms (“C2-4 alkenyl”). In certain embodiments, an alkenyl group has 2 to 3 carbon atoms (“C2-3 alkenyl”). In certain embodiments, an alkenyl group has 2 carbon atoms (“C2 alkenyl”). The one or more carbon- carbon double bonds can be internal (such as in 2-butenyl) or terminal (such as in 1-butenyl). Examples of C2-4 alkenyl groups include ethenyl (C2), 1-propenyl (C3), 2-propenyl (C3), 1- butenyl (C4), 2-butenyl (C4), butadienyl (C4), and the like. Examples of C2-6 alkenyl groups include the aforementioned C2-4 alkenyl groups as well as pentenyl (C5), pentadienyl (C5), hexenyl (C6), and the like. Additional examples of alkenyl include heptenyl (C7), octenyl (C8), octatrienyl (C8), and the like. Unless otherwise specified, each instance of an alkenyl group is independently optionally substituted, i.e., unsubstituted (an “unsubstituted alkenyl”) or substituted (a “substituted alkenyl”) with one or more substituents e.g., for instance from 1 to 5 substituents, 1 to 3 substituents, or 1 substituent. In certain embodiments, the alkenyl group is unsubstituted C2-10 alkenyl. In certain embodiments, the alkenyl group is substituted C2-10 alkenyl. [000192] “Alkenylene” as used herein, refers to an alkenyl group wherein two hydrogens are removed to provide a divalent radical. When a range or number of carbons is provided for a particular “alkenylene” group, it is understood that the range or number refers to the range or number of carbons in the linear carbon divalent chain. An “alkenylene” group may be substituted or unsubstituted with one or more substituents as described herein. Exemplary unsubstituted divalent alkenylene groups include, but are not limited to, ethenylene (-CH=CH- ) and propenylene (e.g., - CH=CHCH2-, -CH2-CH=CH-). Exemplary substituted divalent alkenylene groups, e.g., substituted with one or more alkyl (methyl) groups, include but are not 58 275501297 v3
limited to, substituted ethylene (-C(CH3)=CH-, -CH=C(CH3)-), substituted propylene (e.g., - C(CH3)=CHCH2-, -CH=C(CH3)CH2-, -CH=CHCH(CH3)-, -CH=CHC(CH3)2-, -CH(CH3)- CH=CH-,-C(CH3)2-CH=CH-, -CH2-C(CH3)=CH-, -CH2-CH=C(CH3)-), and the like. [000193] “Alkynyl” as used herein, refers to a radical of a straight-chain or branched hydrocarbon group having from 2 to 20 carbon atoms, one or more carbon-carbon triple bonds (e.g., 1, 2, 3, or 4 carbon-carbon triple bonds), and optionally one or more carbon-carbon double bonds (e.g., 1, 2, 3, or 4 carbon-carbon double bonds) (“C2-20 alkynyl”). In certain embodiments, alkynyl does not contain any double bonds. In certain embodiments, an alkynyl group has 2 to 10 carbon atoms (“C2-10 alkynyl”). In certain embodiments, an alkynyl group has 2 to 9 carbon atoms (“C2-9 alkynyl”). In certain embodiments, an alkynyl group has 2 to 8 carbon atoms (“C2-8 alkynyl”). In certain embodiments, an alkynyl group has 2 to 7 carbon atoms (“C2-7 alkynyl”). In certain embodiments, an alkynyl group has 2 to 6 carbon atoms (“C2- 6 alkynyl”). In certain embodiments, an alkynyl group has 2 to 5 carbon atoms (“C2-5 alkynyl”). In certain embodiments, an alkynyl group has 2 to 4 carbon atoms (“C2-4 alkynyl”). In certain embodiments, an alkynyl group has 2 to 3 carbon atoms (“C2-3 alkynyl”). In certain embodiments, an alkynyl group has 2 carbon atoms (“C2 alkynyl”). The one or more carbon- carbon triple bonds can be internal (such as in 2-butynyl) or terminal (such as in 1-butynyl). Examples of C2-4 alkynyl groups include, without limitation, ethynyl (C2), 1-propynyl (C3), 2- propynyl (C3), 1-butynyl (C4), 2-butynyl (C4), and the like. Examples of C2-6 alkenyl groups include the aforementioned C2-4 alkynyl groups as well as pentynyl (C5), hexynyl (C6), and the like. Additional examples of alkynyl include heptynyl (C7), octynyl (C8), and the like. Unless otherwise specified, each instance of an alkynyl group is independently optionally substituted, i.e., unsubstituted (an “unsubstituted alkynyl”) or substituted (a “substituted alkynyl”) with one or more substituents; e.g., for instance from 1 to 5 substituents, 1 to 3 substituents, or 1 substituent. In certain embodiments, the alkynyl group is unsubstituted C2-10 alkynyl. In certain embodiments, the alkynyl group is substituted C2-10 alkynyl. [000194] “Alkynylene” as used herein, refers to a linear alkynyl group wherein two hydrogens are removed to provide a divalent radical. When a range or number of carbons is provided for a particular “alkynylene” group, it is understood that the range or number refers to the range or number of carbons in the linear carbon divalent chain. An “alkynylene” group may be substituted or unsubstituted with one or more substituents as described herein. Exemplary divalent alkynylene groups include, but are not limited to, substituted or unsubstituted ethynylene, substituted or unsubstituted propynylene, and the like. 59 275501297 v3
[000195] The term “heteroalkyl,” as used herein, refers to an alkyl group, as defined herein, which further comprises 1 or more (e.g., 1, 2, 3, or 4) heteroatoms (e.g., oxygen, sulfur, nitrogen, boron, silicon, phosphorus) within the parent chain, wherein the one or more heteroatoms is inserted between adjacent carbon atoms within the parent carbon chain and/or one or more heteroatoms is inserted between a carbon atom and the parent molecule, i.e., between the point of attachment. In certain embodiments, a heteroalkyl group refers to a saturated group having from 1 to 10 carbon atoms and 1, 2, 3, or 4 heteroatoms (“C1-10 heteroalkyl”). In certain embodiments, a heteroalkyl group is a saturated group having 1 to 9 carbon atoms and 1, 2, 3, or 4 heteroatoms (“C1-9 heteroalkyl”). In certain embodiments, a heteroalkyl group is a saturated group having 1 to 8 carbon atoms and 1, 2, 3, or 4 heteroatoms (“C1-8 heteroalkyl”). In certain embodiments, a heteroalkyl group is a saturated group having 1 to 7 carbon atoms and 1, 2, 3, or 4 heteroatoms (“C1-7 heteroalkyl”). In certain embodiments, a heteroalkyl group is a group having 1 to 6 carbon atoms and 1, 2, or 3 heteroatoms (“C1-6 heteroalkyl”). In certain embodiments, a heteroalkyl group is a saturated group having 1 to 5 carbon atoms and 1 or 2 heteroatoms (“C1-5 heteroalkyl”). In certain embodiments, a heteroalkyl group is a saturated group having 1 to 4 carbon atoms and/or 2 heteroatoms (“C1-4 heteroalkyl”). In certain embodiments, a heteroalkyl group is a saturated group having 1 to 3 carbon atoms and 1 heteroatom (“C1-3 heteroalkyl”). In certain embodiments, a heteroalkyl group is a saturated group having 1 to 2 carbon atoms and 1 heteroatom (“C1-2 heteroalkyl”). In certain embodiments, a heteroalkyl group is a saturated group having 1 carbon atom and 1 heteroatom (“C1 heteroalkyl”). In certain embodiments, a heteroalkyl group is a saturated group having 2 to 6 carbon atoms and 1 or 2 heteroatoms (“C2-6 heteroalkyl”). Unless otherwise specified, each instance of a heteroalkyl group is independently unsubstituted (an “unsubstituted heteroalkyl”) or substituted (a “substituted heteroalkyl”) with one or more substituents. In certain embodiments, the heteroalkyl group is an unsubstituted C1-10 heteroalkyl. In certain embodiments, the heteroalkyl group is a substituted C1-10 heteroalkyl. [000196] The term “heteroalkenyl,” as used herein, refers to an alkenyl group, as defined herein, which further comprises one or more (e.g., 1, 2, 3, or 4) heteroatoms (e.g., oxygen, sulfur, nitrogen, boron, silicon, phosphorus) wherein the one or more heteroatoms is inserted between adjacent carbon atoms within the parent carbon chain and/or one or more heteroatoms is inserted between a carbon atom and the parent molecule, i.e., between the point of attachment. In certain embodiments, a heteroalkenyl group refers to a group having from 2 to 10 carbon atoms, at least one double bond, and 1, 2, 3, or 4 heteroatoms (“C2-10 heteroalkenyl”). In certain embodiments, a heteroalkenyl group has 2 to 9 carbon atoms at least one double 60 275501297 v3
bond, and 1, 2, 3, or 4 heteroatoms (“C2-9 heteroalkenyl”). In certain embodiments, a heteroalkenyl group has 2 to 8 carbon atoms, at least one double bond, and 1, 2, 3, or 4 heteroatoms (“C2-8 heteroalkenyl”). In certain embodiments, a heteroalkenyl group has 2 to 7 carbon atoms, at least one double bond, and 1, 2, 3, or 4 heteroatoms (“C2-7 heteroalkenyl”). In certain embodiments, a heteroalkenyl group has 2 to 6 carbon atoms, at least one double bond, and 1, 2, or 3 heteroatoms (“C2-6 heteroalkenyl”). In certain embodiments, a heteroalkenyl group has 2 to 5 carbon atoms, at least one double bond, and 1 or 2 heteroatoms (“C2-5 heteroalkenyl”). In certain embodiments, a heteroalkenyl group has 2 to 4 carbon atoms, at least one double bond, and l or 2 heteroatoms (“C2-4 heteroalkenyl”). In certain embodiments, a heteroalkenyl group has 2 to 3 carbon atoms, at least one double bond, and 1 heteroatom (“C2- 3 heteroalkenyl”). In certain embodiments, a heteroalkenyl group has 2 to 6 carbon atoms, at least one double bond, and 1 or 2 heteroatoms (“C2-6 heteroalkenyl”). Unless otherwise specified, each instance of a heteroalkenyl group is independently unsubstituted (an “unsubstituted heteroalkenyl”) or substituted (a “substituted heteroalkenyl”) with one or more substituents. In certain embodiments, the heteroalkenyl group is an unsubstituted C2-10 heteroalkenyl. In certain embodiments, the heteroalkenyl group is a substituted C2-10 heteroalkenyl. [000197] The term “heteroalkynyl,” as used herein, refers to an alkynyl group, as defined herein, which further comprises one or more (e.g., 1, 2, 3, or 4) heteroatoms (e.g., oxygen, sulfur, nitrogen, boron, silicon, phosphorus) wherein the one or more heteroatoms is inserted between adjacent carbon atoms within the parent carbon chain and/or one or more heteroatoms are inserted between a carbon atom and the parent molecule, i.e., between the point of attachment. In certain embodiments, a heteroalkynyl group refers to a group having from 2 to 10 carbon atoms, at least one triple bond, and 1, 2, 3, or 4 heteroatoms (“C2-10 heteroalkynyl”). In certain embodiments, a heteroalkynyl group has 2 to 9 carbon atoms, at least one triple bond, and 1, 2, 3, or 4 heteroatoms (“C2-9 heteroalkynyl”). In certain embodiments, a heteroalkynyl group has 2 to 8 carbon atoms, at least one triple bond, and 1, 2, 3, or 4 heteroatoms (“C2-8 heteroalkynyl”). In certain embodiments, a heteroalkynyl group has 2 to 7 carbon atoms, at least one triple bond, and 1, 2, 3, or 4 heteroatoms (“C2-7 heteroalkynyl”). In certain embodiments, a heteroalkynyl group has 2 to 6 carbon atoms, at least one triple bond, and 1, 2, or 3 heteroatoms (“C2-6 heteroalkynyl”). In certain embodiments, a heteroalkynyl group has 2 to 5 carbon atoms, at least one triple bond, and 1 or 2 heteroatoms (“C2-5 heteroalkynyl”). In certain embodiments, a heteroalkynyl group has 2 to 4 carbon atoms, at least one triple bond, and lor 2 heteroatoms (“C2-4 heteroalkynyl”). In certain embodiments, a heteroalkynyl group 61 275501297 v3
has 2 to 3 carbon atoms, at least one triple bond, and 1 heteroatom (“C2-3 heteroalkynyl”). In certain embodiments, a heteroalkynyl group has 2 to 6 carbon atoms, at least one triple bond, and 1 or 2 heteroatoms (“C2-6 heteroalkynyl”). Unless otherwise specified, each instance of a heteroalkynyl group is independently unsubstituted (an “unsubstituted heteroalkynyl”) or substituted (a “substituted heteroalkynyl”) with one or more substituents. In certain embodiments, the heteroalkynyl group is an unsubstituted C2-10 heteroalkynyl. In certain embodiments, the heteroalkynyl group is a substituted C2-10 heteroalkynyl. [000198] Analogous to “alkylene,” “alkenylene,” and “alkynylene” as defined above, “heteroalkylene,” “heteroalkenylene,” and “heteroalkynylene,” as used herein, refer to a divalent radical of heteroalkyl, heteroalkenyl, and heteroalkynyl group respectively. When a range or number of carbons is provided for a particular “heteroalkylene,” “heteroalkenylene,” or “heteroalkynylene,” group, it is understood that the range or number refers to the range or number of carbons in the linear divalent chain. “Heteroalkylene,” “heteroalkenylene,” and “heteroalkynylene” groups may be substituted or unsubstituted with one or more substituents as described herein. [000199] “Aryl” refers to a radical of a monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 π electrons shared in a cyclic array) having 6-14 ring carbon atoms and zero heteroatoms provided in the aromatic ring system (“C6-14 aryl”). In some embodiments, an aryl group has six ring carbon atoms (“C6 aryl”; e.g., phenyl). In some embodiments, an aryl group has ten ring carbon atoms (“C10 aryl”; e.g., naphthyl such as 1-naphthyl and 2-naphthyl). In some embodiments, an aryl group has fourteen ring carbon atoms (“C14 aryl”; e.g., anthracyl). [000200] Typical aryl groups include, but are not limited to, groups derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, coronene, fluoranthene, fluorene, hexacene, hexaphene, hexalene, as-indacene, s-indacene, indane, indene, naphthalene, octacene, octaphene, octalene, ovalene, penta-2,4-diene, pentacene, pentalene, pentaphene, perylene, phenalene, phenanthrene, picene, pleiadene, pyrene, pyranthrene, rubicene, triphenylene, and trinaphthalene. Particular aryl groups include phenyl, naphthyl, indenyl, and tetrahydronaphthyl. Unless otherwise specified, each instance of an aryl group is independently optionally substituted, i.e., unsubstituted (an “unsubstituted aryl”) or substituted (a “substituted aryl”) with one or more substituents. In certain embodiments, the aryl group is unsubstituted C6-14 aryl. In certain embodiments, the aryl group is substituted C6-14 aryl. 62 275501297 v3
[000201] “Aralkyl” is a subset of alkyl and aryl, as defined herein, and refers to an optionally substituted alkyl group substituted by an optionally substituted aryl group. [000202] “Heteroaryl” refers to a radical of a 5- to 14-membered monocyclic or polycyclic 4n+2 aromatic ring system (e.g., having 6, 10, or 14 π electrons shared in a cyclic array) having ring carbon atoms and 1-8 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen and sulfur (“5- to 14-membered heteroaryl”). In heteroaryl groups that contain one or more nitrogen atoms, the point of attachment can be a carbon or nitrogen atom, as valency permits. Heteroaryl bicyclic ring systems can include one or more heteroatoms in one or both rings. [000203] “Heteroaryl” also includes ring systems wherein the heteroaryl group, as defined above, is fused with one or more aryl groups wherein the point of attachment is either on the heteroaryl or the one or more aryl groups, and in such instances, the number of ring members designates the total number of ring members in the fused (aryl/heteroaryl) ring system. When substitution is indicated in such instances, unless otherwise specified, substitution can occur on either the heteroaryl or the one or more aryl groups. Bicyclic heteroaryl groups wherein one ring does not contain a heteroatom (e.g., indolyl, quinolinyl, carbazolyl, and the like) the point of attachment can be on either ring, i.e., either the ring bearing a heteroatom (e.g., 2-indolyl) or the ring that does not contain a heteroatom (e.g., 5-indolyl). [000204] In certain embodiments, a heteroaryl is a 5- to 10-membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5- to 10-membered heteroaryl”). In certain embodiments, a heteroaryl is a 5- to 9-membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5- to 9-membered heteroaryl”). In certain embodiments, a heteroaryl is a 5- to 8-membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5- to 8-membered heteroaryl”). In certain embodiments, a heteroaryl group is a 5- to 6-membered aromatic ring system having ring carbon atoms and 1- 4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5- to 6-membered heteroaryl”). In certain embodiments, the 5- to 6-membered heteroaryl has 1-3 ring heteroatoms independently selected from nitrogen, oxygen, and sulfur. In certain embodiments, the 5- to 6-membered heteroaryl has 1-2 ring heteroatoms independently selected from nitrogen, oxygen, and sulfur. 63 275501297 v3
In certain embodiments, the 5- to 6-membered heteroaryl has 1 ring heteroatom selected from nitrogen, oxygen, and sulfur. Unless otherwise specified, each instance of a heteroaryl group is independently optionally substituted, i.e., unsubstituted (an “unsubstituted heteroaryl”) or substituted (a “substituted heteroaryl”) with one or more substituents. In certain embodiments, the heteroaryl group is unsubstituted 5- to 14-membered heteroaryl. In certain embodiments, the heteroaryl group is substituted 5- to 14-membered heteroaryl. [000205] Exemplary 5-membered heteroaryl containing one heteroatom include, without limitation, pyrrolyl, furanyl and thiophenyl. Exemplary 5-membered heteroaryl containing two heteroatoms include, without limitation, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl. Exemplary 5-membered heteroaryl containing three heteroatoms include, without limitation, triazolyl, oxadiazolyl, and thiadiazolyl. Exemplary 5-membered heteroaryl containing four heteroatoms include, without limitation, tetrazolyl. Exemplary 6-membered heteroaryl containing one heteroatom include, without limitation, pyridinyl. Exemplary 6- membered heteroaryl containing two heteroatoms include, without limitation, pyridazinyl, pyrimidinyl, and pyrazinyl. Exemplary 6-membered heteroaryl containing three or four heteroatoms include, without limitation, triazinyl and tetrazinyl, respectively. Exemplary 7- membered heteroaryl containing one heteroatom include, without limitation, azepinyl, oxepinyl, and thiepinyl. Exemplary 5,6-bicyclic heteroaryl include, without limitation, indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzoisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzthiazolyl, benzisothiazolyl, benzthiadiazolyl, indolizinyl, and purinyl. Exemplary 6,6- bicyclic heteroaryl include, without limitation, naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl. [000206] “Heteroaralkyl” is a subset of alkyl and heteroaryl, as defined herein, and refers to an optionally substituted alkyl group substituted by an optionally substituted heteroaryl group. [000207] “Carbocyclyl” refers to a radical of a non-aromatic cyclic hydrocarbon group having from 3 to 12 ring carbon atoms (“C3-12 carbocyclyl”) and zero heteroatoms in the nonaromatic ring system. In certain embodiments, a carbocyclyl group has 3 to 10 ring carbon atoms (“C3- 10 carbocyclyl”). In certain embodiments, a carbocyclyl group has 3 to 8 ring carbon atoms (“C3-8 carbocyclyl”). In certain embodiments, a carbocyclyl group has 3 to 6 ring carbon atoms (“C3-6 carbocyclyl”). In certain embodiments, a carbocyclyl group has 5 to 12 ring carbon atoms (“C5-12 carbocyclyl”). In certain embodiments, a carbocyclyl group has 5 to 10 ring carbon atoms (“C5-10 carbocyclyl”). In certain embodiments, a carbocyclyl group has 5 to 8 ring carbon atoms (“C5-8 carbocyclyl”). In certain embodiments, a carbocyclyl group has 5 or 6 ring carbon 64 275501297 v3
atoms (“C5-6 carbocyclyl”). Exemplary C3-6 carbocyclyl include, without limitation, cyclopropyl (C3), cyclopropenyl (C3), cyclobutyl (C4), cyclobutenyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclohexyl (C6), cyclohexenyl (C6), cyclohexadienyl (C6), and the like. Exemplary C3-8 carbocyclyl include, without limitation, the aforementioned C3-6 carbocyclyl groups as well as cycloheptyl (C7), cycloheptenyl (C7), cycloheptadienyl (C7), cycloheptatrienyl (C7), cyclooctyl (C8), cyclooctenyl (C8), bicyclo[2.2.1]heptanyl (C7), bicyclo[2.2.2]octanyl (C8), and the like. Exemplary C3-10 carbocyclyl include, without limitation, the aforementioned C3-8 carbocyclyl groups as well as cyclononyl (C9), cyclononenyl (C9), cyclodecyl (C10), cyclodecenyl (C10), octahydro-1H-indenyl (C9), decahydronaphthalenyl (C10), spiro[4.5]decanyl (C10), and the like. [000208] In certain embodiments, “carbocyclyl” is a monocyclic, saturated carbocyclyl group having from 3 to 12 ring carbon atoms (“C3-12 carbocyclyl”). In certain embodiments, “carbocyclyl” is a monocyclic, saturated carbocyclyl group having from 3 to 10 ring carbon atoms (“C3-10 carbocyclyl”). In certain embodiments, “carbocyclyl” is a monocyclic, saturated carbocyclyl group having from 3 to 8 ring carbon atoms (“C3-8 carbocyclyl”). In certain embodiments, “carbocyclyl” is a monocyclic, saturated carbocyclyl group having from 3 to 6 ring carbon atoms (“C3-6 carbocyclyl”). In certain embodiments, “carbocyclyl” is a monocyclic, saturated carbocyclyl group having from 5 to 12 ring carbon atoms (“C5-12 carbocyclyl”). In certain embodiments, a carbocyclyl group has 5 to 10 ring carbon atoms (“C5-10 carbocyclyl”). In certain embodiments, a carbocyclyl group has 5 to 8 ring carbon atoms (“C5-8 carbocyclyl”). In certain embodiments, “carbocyclyl” is a monocyclic, saturated carbocyclyl group having 5 or 6 ring carbon atoms (“C5-6 carbocyclyl”). Examples of C5-6 carbocyclyl include cyclopentyl (C5) and cyclohexyl (C5). Examples of C3-6 carbocyclyl include the aforementioned C5-6 carbocyclyl groups as well as cyclopropyl (C3) and cyclobutyl (C4). Examples of C3-8 carbocyclyl include the aforementioned C3-6 carbocyclyl groups as well as cycloheptyl (C7) and cyclooctyl (C8). Unless otherwise specified, each instance of a carbocyclyl group is independently unsubstituted (an “unsubstituted carbocyclyl”) or substituted (a “substituted carbocyclyl”) with one or more substituents. In certain embodiments, the carbocyclyl group is unsubstituted C3-12 carbocyclyl. In certain embodiments, the carbocyclyl group is substituted C3-12 carbocyclyl. [000209] As the foregoing examples illustrate, in certain embodiments, the carbocyclyl group is either monocyclic (“monocyclic carbocyclyl”) or polycyclic (“polycyclic carbocyclyl”) that contains a fused, bridged or spiro ring system and can be saturated or can be partially unsaturated. Unless otherwise specified, each instance of a carbocyclyl group is independently 65 275501297 v3
optionally substituted, i.e., unsubstituted (an “unsubstituted carbocyclyl”) or substituted (a “substituted carbocyclyl”) with one or more substituents. In certain embodiments, the carbocyclyl group is unsubstituted C3-12 carbocyclyl. In certain embodiments, the carbocyclyl group is a substituted C3-12 carbocyclyl. [000210] “Fused carbocyclyl” or “fused carbocycle” refers to ring systems wherein the carbocyclyl group, as defined above, is fused with, i.e., share one common bond with, one or more carbocyclyl groups, as defined above, wherein the point of attachment is on any of the fused rings. In such instances, the number of carbons designates the total number of carbons in the fused ring system. When substitution is indicated, unless otherwise specified, substitution can occur on any of the fused rings. [000211] “Spiro carbocyclyl” or or “spiro carbocycle” refers to ring systems wherein the carbocyclyl group, as defined above, form spiro structure with, i.e., share one common atom with, one or more carbocyclyl groups, as defined above, wherein the point of attachment is on the carbocyclyl rings in which the spiro structure is embeded. In such instances, the number of carbons designates the total number of carbons of the carbocyclyl rings in which the spiro structure is embeded. When substitution is indicated, unless otherwise specified, substitution can occur on the carbocyclyl rings in which the spiro structure is embeded. [000212] “Bridged carbocyclyl” or or “bridged carbocycle” refers to ring systems wherein the carbocyclyl group, as defined above, form bridged structure with, i.e., share more than one atoms (as such, share more than one bonds) with, one or more carbocyclyl groups, as defined above, wherein the point of attachment is on any of the carbocyclyl rings in which the bridged structure is embeded. In such instances, the number of carbons designates the total number of carbons of the bridged rings. When substitution is indicated, unless otherwise specified, substitution can occur on any of the carbocyclyl rings in which the bridged structure is embeded. [000213] “Heterocyclyl” refers to a radical of a 3- to 12-membered non-aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus, and silicon (“3- to 12-membered heterocyclyl”). In heterocyclyl groups that contain one or more nitrogen atoms, the point of attachment can be a carbon or nitrogen atom, as valency permits. Exemplary 3- membered heterocyclyl groups containing one heteroatom include, without limitation, azirdinyl, oxiranyl, thiorenyl. Exemplary 4-membered heterocyclyl groups containing one heteroatom include, without limitation, azetidinyl, oxetanyl and thietanyl. Exemplary 5membered heterocyclyl groups containing one heteroatom include, without limitation, 66 275501297 v3
tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, pyrrolidinyl, dihydropyrrolyl and pyrrolyl-2,5-dione. Exemplary 5-membered heterocyclyl groups containing two heteroatoms include, without limitation, dioxolanyl, oxasulfuranyl, disulfuranyl, and oxazolidin-2-one. Exemplary 5-membered heterocyclyl groups containing three heteroatoms include, without limitation, triazolinyl, oxadiazolinyl, and thiadiazolinyl. Exemplary 6-membered heterocyclyl groups containing one heteroatom include, without limitation, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl. Exemplary 6- membered heterocyclyl groups containing two heteroatoms include, without limitation, piperazinyl, morpholinyl, dithianyl, dioxanyl. Exemplary 6-membered heterocyclyl groups containing two heteroatoms include, without limitation, triazinanyl. Exemplary 7-membered heterocyclyl groups containing one heteroatom include, without limitation, azepanyl, oxepanyl and thiepanyl. Exemplary 8-membered heterocyclyl groups containing one heteroatom include, without limitation, azocanyl, oxecanyl and thiocanyl. Exemplary 5-membered heterocyclyl groups fused to a C6 aryl ring (also referred to herein as a 5,6-bicyclic heterocyclic ring) include, without limitation, indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, benzoxazolinonyl, and the like. Exemplary 6-membered heterocyclyl groups fused to an aryl ring (also referred to herein as a 6,6-bicyclic heterocyclic ring) include, without limitation, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and the like. [000214] In certain embodiments, a heterocyclyl group is a 5- to 12-membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus, and silicon (“5- to 12-membered heterocyclyl”). In certain embodiments, a heterocyclyl group is a 5- to 10- membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus, and silicon (“5- to 10-membered heterocyclyl”). In certain embodiments, a heterocyclyl group is a 5- to 8-membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5- to 8-membered heterocyclyl”). In certain embodiments, a heterocyclyl group is a 5- to 6-membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5- to 6-membered heterocyclyl”). In certain embodiments, the 5- to 6-membered heterocyclyl has 1-3 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In certain embodiments, the 5- to 6-membered heterocyclyl has 1-2 ring heteroatoms selected from 67 275501297 v3
nitrogen, oxygen, and sulfur. In certain embodiments, the 5- to 6-membered heterocyclyl has one ring heteroatom selected from nitrogen, oxygen, and sulfur. [000215] As the foregoing examples illustrate, in certain embodiments, a heterocyclyl group can either be monocyclic (“monocyclic heterocyclyl”) or polycyclic (“polycyclic heterocyclyl”) that contains a fused, bridged or spiro ring system, and can be saturated or can be partially unsaturated. Heterocyclyl polycyclic ring systems can include one or more heteroatoms in one or both rings. “Heterocyclyl” also includes ring systems wherein the heterocyclyl group, as defined above, is fused with one or more carbocyclyl groups wherein the point of attachment is either on the carbocyclyl or heterocyclyl ring, and in such instances, the number of ring members designates the total number of ring members in the entire ring system. When substitution is indicated in such instances, unless otherwise specified, substitution can occur on either the heterocyclyl or the one or more carbocyclyl groups. Unless otherwise specified, each instance of heterocyclyl is independently optionally substituted, i.e., unsubstituted (an “unsubstituted heterocyclyl”) or substituted (a “substituted heterocyclyl”) with one or more substituents. In certain embodiments, the heterocyclyl group is unsubstituted 3- to 12-membered heterocyclyl. In certain embodiments, the heterocyclyl group is substituted 3- to 12-membered heterocyclyl. [000216] “Fused heterocyclyl” or “fused heterocycle” refers to ring systems wherein the heterocyclyl group, as defined above, is fused with, i.e., share one common bond with, one or more heterocyclyl or carbocyclyl groups, as defined above, wherein the point of attachment is on any of the fused rings. In such instances, the number of carbons designates the total number of ring members in the fused ring system. When substitution is indicated, unless otherwise specified, substitution can occur on any of the fused rings. [000217] “Spiro heterocyclyl” or “spiro heterocycle” refers to ring systems wherein the heterocyclyl group, as defined above, form spiro structure with, i.e., share one common atom with, one or more heterocyclyl or carbocyclyl groups, as defined above, wherein the point of attachment is on the heterocyclyl or carbocyclyl rings in which the spiro structure is embeded. In such instances, the number of ring members designates the total number of ring members of the heterocyclyl or carbocyclyl rings in which the spiro structure is embeded. When substitution is indicated, unless otherwise specified, substitution can occur on any of the heterocyclyl or carbocyclyl rings in which the spiro structure is embeded. [000218] “Bridged heterocyclyl” or “bridged heterocycle” refers to ring systems wherein the heterocyclyl group, as defined above, form bridged structure with, i.e., share more than one atoms (as such, share more than one bonds) with, one or more heterocyclyl or carbocyclyl 68 275501297 v3
groups, as defined above, wherein the point of attachment is on the heterocyclyl or carbocyclyl rings in which the bridged structure is embeded. In such instances, the number of ring members designates the total number of ring members of the heterocyclyl or carbocyclyl rings in which the bridged structure is embeded. When substitution is indicated, unless otherwise specified, substitution can occur on any of the bridged rings. [000219] “Hetero” when used to describe a compound or a group present on a compound means that one or more carbon atoms in the compound or group have been replaced by a nitrogen, oxygen, sulfur, boron, phosphorus, and silicon heteroatom, as valency permits. Hetero may be applied to any of the hydrocarbyl groups described above having from 1 to 5, and particularly from 1 to 3 heteroatoms. [000220] “Alkoxy” as used herein, refers to the group -OR, wherein R is alkyl as defined herein. C1-6 alkoxy refers to the group -OR, wherein each R is C1-6 alkyl, as defined herein. Exemplary C1-6 alkyl is set forth above. [000221] “Alkylamino” as used herein, refers to the group -NHR or -NR2, wherein each R is independently alkyl, as defined herein. C1-6 alkylamino refers to the group -NHR or -NR2, wherein each R is independently C1-6 alkyl, as defined herein. Exemplary C1-6 alkyl is set forth above. [000222] “Oxo” refers to =O. When a group other than aryl and heteroaryl or an atom is substituted with an oxo, it is meant to indicate that two geminal radicals on that group or atom form a double bond with an oxygen radical. When a heteroaryl is substituted with an oxo, it is meant to indicate that a resonance structure/tautomer involving a heteroatom provides a carbon atom that is able to form two geminal radicals, which form a double bond with an oxygen radical. [000223] “Azido” refers to the radical -N3. [000224] “Amino” refers to the radical -NH2. [000225] “Hydroxy” refers to the radical -OH. [000226] “Thioketo” refers to the group =S. [000227] “Carboxy” refers to the radical -C(=O)OH. [000228] “Cyano” refers to the radical -CN. [000229] “Halo” or “halogen” refers to fluoro (F), chloro (Cl), bromo (Br), and iodo (I). In certain embodiments, the halo group is either fluoro or chloro. [000230] “Nitro” refers to the radical -NO2. [000231] “Protecting group” as used herein is art-recognized and refers to a chemical moiety introduced into a molecule by chemical modification of a functional group (e.g., hydroxyl, 69 275501297 v3
amino, thio, and carboxylic acid) to obtain chemoselectivity in a subsequent chemical reaction, during which the unmodified functional group may not survive or may interfere with the chemical reaction. Common functional groups that need to be protected include but not limited to hydroxyl, amino, thiol, and carboxylic acid. Accordingly, the protecting groups are termed hydroxyl-protecting groups, amino-protecting groups, thiol-protecting groups, and carboxylic acid-protecting groups, respectively. [000232] Common types of hydroxyl-protecting groups include but not limited to ethers (e.g., methoxymethyl (MOM), β-Methoxyethoxymethyl (MEM), tetrahydropyranyl (THP), p- methoxyphenyl (PMP), t-butyl, triphenylmethyl (Trityl), allyl, and benzyl ether (Bn)), silyl ethers (e.g., t-butyldiphenylsilyl (TBDPS), trimethylsilyl (TMS), triisopropylsilyl (TIPS), tri- iso-propylsilyloxymethyl (TOM), and t-butyldimethylsilyl (TBDMS)), and esters (e.g., pivalic acid ester (Piv) and benzoic acid ester (benzoate; Bz)). [000233] Common types of amino-protecting groups include but not limited to carbamates (e.g., t-butyloxycarbonyl (Boc), 9-fluorenylmethyloxycarbonyl (Fmoc), p-methoxybenzyl carbonyl (Moz or MeOZ), 2,2,2-trichloroehtoxycarbonyl (Troc), and benzyl carbamate (Cbz)), esters (e.g., acetyl (Ac); benzoyl (Bz), trifluoroacetyl, and phthalimide), amines (e.g, benzyl (Bn), p-methoxybenzyl (PMB), p-methoxyphenyl (PMP), and triphenylmethyl (trityl)), and sulfonamides (e.g., tosyl (Ts), N-alkyl nitrobenzenesulfonamides (Nosyl), and 2- nitrophenylsulfenyl (Nps)). [000234] Common types of thiol-protecting groups include but not limited to sulfide (e.g., p- methylbenzyl (Meb), t-butyl, acetamidomethyl (Acm), and triphenylmethyl (Trityl)). [000235] Common types of carboxylic acid-protecting groups include but not limited to esters (e.g., methyl ester, triphenylmethyl (Trityl), t-butyl ester, benzyl ester (Bn), S-t-butyl ester, silyl esters, and orthoesters) and oxazoline. [000236] These and other exemplary substituents are described in more detail in the Detailed Description, Examples, and claims. The invention is not intended to be limited in any manner by the above exemplary listing of substituents. Other Definitions [000237] “Pharmaceutically acceptable” means approved or approvable by a regulatory agency of the Federal or a state government or the corresponding agency in countries other than the United States, or that is listed in the U.S. Pharmacopoeia or other generally recognized pharmacopoeia for use in animals, and more particularly, in humans. 70 275501297 v3
[000238] “Pharmaceutically acceptable salt” refers to a salt of a compound of the invention that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. In particular, such salts are non-toxic may be inorganic or organic acid addition salts and base addition salts. Specifically, such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2- hydroxyethanesulfonic acid, benzenesulfonic acid, chlorobenzenesulfonic acid, 2- naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo [2.2.2]-oct-2-ene-1-carboxylic acid, glucoheptonic acid , 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid , gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, and the like; or (2) salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion , an alkaline earth ion , or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, N-methylglucamine and the like. Salts further include, by way of example only, sodium potassium, calcium, magnesium, ammonium, tetraalkylammonium, and the like; and when the compound contains a basic functionality, salts of nontoxic organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate and the like. [000239] The term “pharmaceutically acceptable cation” refers to an acceptable cationic counterion of an acidic functional group. Such cations are exemplified by sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium cations, and the like (see, e.g., Berge, et al., J. Pharm. Sci.66 (1):1-79 (January 77). [000240] “Pharmaceutically acceptable vehicle” refers to a diluent, adjuvant, excipient or carrier with which a compound of the invention is administered. [000241] “Pharmaceutically acceptable metabolically cleavable group” refers to a group which is cleaved in vivo to yield the parent molecule of the structural formula indicated herein. Examples of metabolically cleavable groups include -COR, -COOR, -CONR2 and -CH2OR radicals, where R is selected independently at each occurrence from alkyl, trialkylsilyl, carbocyclic aryl or carbocyclic aryl substituted with one or more of alkyl, halogen, hydroxy or 71 275501297 v3
alkoxy. Specific examples of representative metabolically cleavable groups include acetyl, methoxycarbonyl, benzoyl, methoxymethyl and trimethylsilyl groups. [000242] “Solvate” refers to forms of the compound that are associated with a solvent or water (also referred to as “hydrate”), usually by a solvolysis reaction. This physical association includes hydrogen bonding. Conventional solvents include water, ethanol, acetic acid and the like. The compounds of the invention may be prepared e.g., in crystalline form and may be solvated or hydrated. Suitable solvates include pharmaceutically acceptable solvates, such as hydrates, and further include both stoichiometric solvates and non-stoichiometric solvates. In certain instances, the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. “Solvate” encompasses both solution-phase and isolable solvates. Representative solvates include hydrates, ethanolates and methanolates. [000243] A “subject” to which administration is contemplated includes, but is not limited to, humans (i.e., a male or female of any age group, e.g., a pediatric subject (e.g, infant, child, adolescent) or an adult subject (e.g., young adult, middle aged adult or senior adult) and/or a non-human animal, e.g., a mammal such as primates (e.g., cynomolgus monkeys, rhesus monkeys), cattle, pigs, horses, sheep, goats, rodents, cats, and/or dogs. In certain embodiments, the subject is a human. In certain embodiments, the subject is a non-human animal. [000244] An “effective amount” means the amount of a compound that, when administered to a subject for treating or preventing a disease, is sufficient to effect such treatment or prevention. The “effective amount” can vary depending on the compound, the disease and its severity, and the age, weight, etc., of the subject to be treated. A “therapeutically effective amount” refers to the effective amount for therapeutic treatment. A “prophylatically effective amount” refers to the effective amount for prophylactic treatment. [000245] “Preventing”, “prevention” or “prophylactic treatment” refers to a reduction in risk of acquiring or developing a disease or disorder (i.e., causing at least one of the clinical symptoms of the disease not to develop in a subject not yet exposed to a disease-causing agent, or in a subject who is predisposed to the disease in advance of disease onset). [000246] The term “prophylaxis” is related to “prevention,” and refers to a measure or procedure the purpose of which is to prevent, rather than to treat or cure a disease. Non limiting examples of prophylactic measures may include the administration of vaccines; the administration of low molecular weight heparin to hospital patients at risk for thrombosis due, for example, to immobilization, and the administration of an anti-malarial agent such as 72 275501297 v3
chloroquine, in advance of a visit to a geographical region where malaria is endemic or the risk of contracting malaria is high. [000247] “Treating” or “treatment” or “therapeutic treatment” of any disease or disorder refers, in one embodiment, to ameliorating the disease or disorder (i.e., arresting the disease or reducing the manifestation, extent or severity of at least one of the clinical symptoms thereof). In another embodiment, “treating” or “treatment” refers to ameliorating at least one physical parameter, which may not be discernible by the subject. In yet another embodiment, “treating” or “treatment” refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both. In a further embodiment, “treating” or “treatment” relates to slowing the progression of the disease. [000248] “Cereblon E3 ubiquitin ligase protein complex” is art recognized and refers to an association of proteins in which CRBN, a 442-amino acid protein, forms a Cullin-4-RING E3 ubiquitin ligase (CRL4) complex and interacts with the adaptor protein damaged DNA–binding protein 1 (DDB1), Cullin-4A (CUL4A), and regulator of cullins 1 (ROC1). Within the CRL4 complex, CRBN acts as a substrate-specificity receptor. [000249] It is also to be understood that compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed “isomers.” Isomers that only differ in the arrangement of their atoms in space are termed “stereoisomers.” [000250] Stereoisomers that are not mirror images of one another are termed “diastereomers” and those that are non-superimposable mirror images of each other are termed “enantiomers.” When a compound has an asymmetric center, for example, it is bonded to four different groups, a pair of enantiomers is possible. An enantiomer can be characterized by the absolute configuration of its asymmetric center and is described by the R - and S - sequencing rules of Cahn and Prelog, or by the manner in which the molecule rotates the plane of polarized light and designated as dextrorotatory or levorotatory (i.e., as (+)- or (-)- isomers respectively). A chiral compound can exist as either individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is termed a “racemic mixture”. [000251] “Tautomers” refer to compounds that are interchangeable forms of a particular compound structure, and that vary in the displacement of hydrogen atoms and electrons. Thus, two structures may be in equilibrium through the movement of its electrons and an atom (usually H). For example, enols and ketones are tautomers because they are rapidly interconverted by treatment with either acid or base. Another example of tautomerism is the 73 275501297 v3
aci- and nitro-forms of phenylnitromethane, that are likewise formed by treatment with acid or base. Tautomeric forms may be relevant to the attainment of the optimal chemical reactivity and biological activity of a compound of interest. [000252] As used herein a pure enantiomeric compound is substantially free from other enantiomers or stereoisomers of the compound (i.e., in enantiomeric excess). In other words, an “S” form of the compound is substantially free from the “R” form of the compound and is, thus, in enantiomeric excess of the “R” form. The term “enantiomerically pure” or “pure enantiomer” denotes that the compound comprises more than 95% by weight, more than 96% by weight, more than 97% by weight, more than 98% by weight, more than 98.5% by weight, more than 99% by weight, more than 99.2% by weight, more than 99.5% by weight, more than 99.6% by weight, more than 99.7% by weight, more than 99.8% by weight or more than 99.9% by weight, of the enantiomer. In certain embodiments, the weights are based upon total weight of all enantiomers or stereoisomers of the compound. [000253] As used herein and unless otherwise indicated, the term “enantiomerically pure (R)- compound” refers to at least about 95% by weight (R)-compound and at most about 5% by weight (S)-compound, at least about 99% by weight (R)-compound and at most about 1% by weight (S)-compound, or at least about 99.9 % by weight (R)-compound and at most about 0.1% by weight (S)-compound. In certain embodiments, the weights are based upon total weight of compound. [000254] As used herein and unless otherwise indicated, the term “enantiomerically pure (S)- compound” refers to at least about 95% by weight (S)-compound and at most about 5% by weight (R)-compound, at least about 99% by weight (S)-compound and at most about 1% by weight (R)-compound or at least about 99.9% by weight (S)-compound and at most about 0.1% by weight (R)-compound. In certain embodiments, the weights are based upon total weight of compound. [000255] In the compositions provided herein, an enantiomerically pure compound or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof can be present with other active or inactive ingredients. For example, a pharmaceutical composition comprising enantiomerically pure (R)-compound can comprise, for example, about 90% excipient and about 10% enantiomerically pure (R)-compound. In certain embodiments, the enantiomerically pure (R)-compound in such compositions can, for example, comprise, at least about 95% by weight (R)-compound and at most about 5% by weight (S)-compound, by total weight of the compound. For example, a pharmaceutical composition comprising enantiomerically pure (S)- compound can comprise, for example, about 90% excipient and about 10% enantiomerically 74 275501297 v3
pure (S)-compound. In certain embodiments, the enantiomerically pure (S)-compound in such compositions can, for example, comprise, at least about 95% by weight (S)-compound and at most about 5% by weight (R)-compound, by total weight of the compound. In certain embodiments, the active ingredient can be formulated with little or no excipient or carrier. [000256] Unless indicated otherwise, the description or naming of a particular compound in the specification and claims is intended to include both individual enantiomers and mixtures, racemic or otherwise, thereof. The methods for the determination of stereochemistry and the separation of stereoisomers are well-known in the art. [000257] The term “about” when referring to a number or a numerical range means that the number or numerical range referred to is an approximation within experimental variability or within statistical experimental error, and thus the number or numerical range, in some instances, will vary between 1% and 15% of the stated number or numerical range. In certain embodiments, the number or numerical range vary by 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, or 15% of the stated number or numerical range. [000258] The term “comprising” (and related terms such as “comprise” or “comprises” or “having” or “including”) is not intended to exclude that in other certain embodiments, for example, an embodiment of any composition of matter, composition, method, or process, or the like, described herein, “consist of” or “consist essentially of” the described features. [000259] The phrase “and/or,” as used herein in the specification and in the claims, should be understood to mean “either or both” of the elements so conjoined, i.e., elements that are conjunctively present in some cases and disjunctively present in other cases. Multiple elements listed with “and/or” should be construed in the same fashion, i.e., “one or more” of the elements so conjoined. Other elements may optionally be present other than the elements specifically identified by the “and/or” clause, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, a reference to “A and/or B”, when used in conjunction with open-ended language such as “comprising” may refer, in one embodiment, to A only (optionally including elements other than B); in another embodiment, to B only (optionally including elements other than A); in yet another embodiment, to both A and B (optionally including other elements); etc. [000260] As used herein in the specification and in the claims, “or” should be understood to have the same meaning as “and/or” as defined above. For example, when separating items in a list, “or” or “and/or” shall be interpreted as being inclusive, i.e., the inclusion of at least one, but also including more than one, of a number or list of elements, and, optionally, additional unlisted items. Only terms clearly indicated to the contrary, such as “only one of” or “exactly 75 275501297 v3
one of,” or, when used in the claims, “consisting of,” will refer to the inclusion of exactly one element of a number or list of elements. In general, the term “or” as used herein shall only be interpreted as indicating exclusive alternatives (i.e., “one or the other but not both”) when preceded by terms of exclusivity, such as “either,” “one of,” “only one of,” or “exactly one of.” “Consisting essentially of,” when used in the claims, shall have its ordinary meaning as used in the field of patent law. [000261] As used herein in the specification and in the claims, the phrase “at least one,” in reference to a list of one or more elements, should be understood to mean at least one element selected from any one or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed within the list of elements and not excluding any combinations of elements in the list of elements. This definition also allows that elements may optionally be present other than the elements specifically identified within the list of elements to which the phrase “at least one” refers, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, “at least one of A and B” (or, equivalently, “at least one of A or B,” or, equivalently “at least one of A and/or B”) may refer, in one embodiment, to at least one, optionally including more than one, A, with no B present (and optionally including elements other than B); in another embodiment, to at least one, optionally including more than one, B, with no A present (and optionally including elements other than A); in yet another embodiment, to at least one, optionally including more than one, A, and at least one, optionally including more than one, B (and optionally including other elements); etc. [000262] While the present teachings have been described in conjunction with various embodiments and examples, it is not intended that the present teachings be limited to such embodiments or examples. On the contrary, the present teachings encompass various alternatives, modifications, and equivalents, as will be appreciated by those of skill in the art. [000263] While various inventive embodiments have been described and illustrated herein, those of ordinary skill in the art will readily envision a variety of other means and/or structures for performing the function and/or obtaining the results and/or one or more of the advantages described herein, and each of such variations and/or modifications is deemed to be within the scope of the inventive embodiments described herein. More generally, those skilled in the art will readily appreciate that all parameters, dimensions, materials, and configurations described herein are meant to be exemplary and that the actual parameters, dimensions, materials, and/or configurations will depend upon the specific application or applications for which the inventive teachings is/are used. Those skilled in the art will recognize many equivalents to the specific 76 275501297 v3
inventive embodiments described herein. It is, therefore, to be understood that the foregoing embodiments are presented by way of example only and that, within the scope of the appended claims and equivalents thereto, inventive embodiments may be practiced otherwise than as specifically described and claimed. Inventive embodiments of the present disclosure are directed to each individual feature, system, article, material, kit, and/or method described herein. In addition, any combination of two or more such features, systems, articles, materials, kits, and/or methods, if such features, systems, articles, materials, kits, and/or methods are not mutually inconsistent, is included within the inventive scope of the present disclosure. [000264] The claims should not be read as limited to the described order or elements unless stated to that effect. It should be understood that various changes in form and detail may be made by one of ordinary skill in the art without departing from the spirit and scope of the appended claims. All embodiments that come within the spirit and scope of the following claims and equivalents thereto are claimed. EXAMPLES [000265] In order that the invention described herein may be more fully understood, the following examples are set forth. The examples described in this application are offered to illustrate the compounds, pharmaceutical compositions, and methods provided herein and are not to be construed in any way as limiting their scope. I. Cereblon Ligands ^ Synthesis and Characterization Compound 1: 3-(3-(hydroxymethyl)-3-methyl-6-oxo-2,3,6,8-tetrahydro-7H-furo[2,3- e]isoindol-7-yl)piperidine-2,6-dione
[000266] To a solution of NaH (60% suspend in oil) (1.44 g, 60.0 mmol, 1.0 eq) in THF (10 mL) were added benzyl alcohol (4.56 g, 40.00 mmol, 1.0 eq) and DMF (40 mL) at 0 °C. The mixture was stirred at room temperature for 45 min, and then warmed to reflux and stirred for 1 h. The mixture was allowed to cool to room temperature and then transferred into a dropping funnel. The resulting solution was added dropwise to a solution of 3-chloro-2- (chloromethyl)prop-1-ene (4.63 mL, 40.00 mmol, 1.0 eq) in THF (100 mL) over 1 h. The 77 275501297 v3
mixture was stirred at room temperature overnight. The mixture was quenched with ice water (200 mL) and exacted with EA (300 mL x 3). The organic layer was washed with brine (150 mL x 4), and dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (ethyl acetate in petroleum ether, from 0% to 10%) to give the (((2-(chloromethyl)allyl)oxy)methyl)benzene (3.5 g, yield 44%) as a light yellow solid. LC-MS (ESI): mass calcd. for C11H13ClO, 196.07; m/z found, 197.1 [M+H]+.1H NMR (400 MHz, DMSO-d6) δ 7.35 - 7.28 (m, 5H), 5.32 (d, J = 1.2 Hz, 1H), 5.27 (d, J = 1.2 Hz, 1H), 4.52 (s, 2H), 4.12 (d, J = 1.2 Hz, 4H). Step B: 4-((2-((benzyloxy)methyl)allyl)oxy)-5-bromoisobenzofuran-1(3H)-one [000267] To a solution of 5-bromo-4-hydroxyisobenzofuran-1(3H)-one (5 g, 21.83 mmol, 1.0 eq) in DMF (50 mL) were added (((2-(chloromethyl)allyl)oxy)methyl)benzene (5.58 g, 28.38 mmol, 1.25 eq) and K2CO3 (5.43 g, 39.29 mmol, 1.8 eq). The mixture was stirred at 80 oC for 5 h. After cooled to room temperature, the mixture was diluted with H2O (150 mL) and extracted with ethyl acetate (100 mL x 3). The organic layer was washed with brine (100 mL x 4), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (ethyl acetate in petroleum ether, from 30% to 70%) to give 4-((2-((benzyloxy)methyl)allyl)oxy)-5-bromoisobenzofuran- 1(3H)-one (4.3 g, yield 50%) as a light yellow oil. LC-MS (ESI): mass calcd. for C19H17BrO4, 388.03; m/z found, 389.3 [M+H]+. Step C: 3-((benzyloxy)methyl)-3-methyl-2,3-dihydrobenzo[2,1-b:3,4-c']difuran-6(8H)-one [000268] To a solution of 4-((2-((benzyloxy)methyl)allyl)oxy)-5-bromoisobenzofuran-1(3H)- one (4.3 g, 11.05 mmol, 1.0 eq) in Toluene (40 mL) were added tributylstannane (14.89 mL, 55.23 mmol, 4.5 eq) and AIBN (0.36 g, 2.21 mmol, 0.2 eq). The mixture was stirred at 110 oC in a sealed tube overnight. After cooled to room temperature, the mixture was diluted with aqueous KF solution (2 N) (100 mL) and stirred for 1 h. After separation, the aqueous layer was extracted with ethyl acetate (40 mL x 3). The combined extracts were washed with water (40 mL x 3), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (ethyl acetate in petroleum ether, from 0% to 50%) to give 3-((benzyloxy)methyl)-3-methyl-2,3- dihydrobenzo[2,1-b:3,4-c']difuran-6(8H)-one (3.2 g, yield 93%) as a light yellow solid. LC- MS (ESI): mass calcd. for C19H18O4, 310.12; m/z found, 311.2 [M+H]+.1H NMR (400 MHz, DMSO-d6) δ 7.46 (d, J = 7.6 Hz, 1H), 7.40 (d, J = 7.6 Hz, 1H), 7.34 - 7.24 (m, 5H), 5.35 (s, 2H), 4.66 (d, J = 9.0 Hz, 1H), 4.48 (d, J = 5.0 Hz, 2H), 4.36 (d, J = 9.0 Hz, 1H), 3.54 - 3.51 (m, 2H), 1.37 (s, 3H). 78 275501297 v3
Step D: 3-((benzyloxy)methyl)-7-(hydroxymethyl)-3-methyl-2,3-dihydrobenzofuran-6- carboxylic acid [000269] To a solution of 3-((benzyloxy)methyl)-3-methyl-2,3-dihydrobenzo[2,1-b:3,4- c']difuran-6(8H)-one (3.2 g, 10.31 mmol, 1.0 eq) in THF (20 mL) and MeOH (5 mL), was added a solution of sodium hydroxide (0.82 g, 20.62 mmol, 2.0 eq) and water (5 mL). The mixture was stirred at 40 oC for 3 h. After evaporation, the residue was diluted with water (100 mL), adjusted to pH 5 with aqueous HCl solution (2 N), and extracted with EtOAc (100 mL x 3). The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give 3-((benzyloxy)methyl)-7-(hydroxymethyl)-3-methyl-2,3- dihydrobenzofuran-6-carboxylic acid (2.8 g, yield 82%) as a light yellow oil. The crude product was directly used in the next step without further purification. LC-MS (ESI): mass calcd. for C19H20O5, 328.132; m/z found, 329.2 [M+H]+. [000270] 1HNMR (400 MHz, DMSO-d6) δ 7.34 - 7.25 (m, 6H), 6.96 (d, J = 8.0 Hz, 1H), 4.48 (s, 2H), 4.44 (d, J = 8.8 Hz, 1H), 4.39 (s, 2H), 4.10 (d, J = 8.8 Hz, 1H), 3.44 - 3.39 (m, 2H), 1.30 (s, 3H). Step E: 3-((benzyloxy)methyl)-7-formyl-3-methyl-2,3-dihydrobenzofuran-6-carboxylic acid [000271] To a solution of 3-((benzyloxy)methyl)-7-(hydroxymethyl)-3-methyl-2,3- dihydrobenzofuran-6-carboxylic acid (2.8 g, 8.53 mmol, 1.0 eq) in DCM (50 mL) was added Dess-Martin Periodinane (7.24 g, 17.06 mmol, 2.0 eq). The mixture was stirred at room temperature overnight. After evaporation, the residue was purified by flash column chromatography on silica gel (ethyl acetate in petroleum ether, from 40% to 80%) to give 3- ((benzyloxy)methyl)-7-formyl-3-methyl-2,3-dihydrobenzofuran-6-carboxylic acid (1.3 g, yield 46%) as a light yellow solid. LC-MS (ESI): mass calcd. for C19H18O5, 326.12; m/z found, 327.3 [M+H]+. Step F: 3-(3-((benzyloxy)methyl)-3-methyl-6-oxo-2,3,6,8-tetrahydro-7H-furo[2,3-e]isoindol- 7-yl)piperidine-2,6-dione [000272] To a solution of 3-[(benzyloxy)methyl]-7-formyl-3-methyl-2,3-dihydro-1- benzofuran-6-carboxylic acid (1.3 g, 3.98 mmol, 1.0 eq) in DMF (30 mL) and AcOH (10 mL) were added 3-aminopiperidine-2,6-dione hydrochloride (0.56 g, 4.38 mmol, 1.5 eq) and NaBH(OAc)3 (1.68 g, 7.97 mmol, 2.0 eq). The mixture was stirred at room temperature overnight. The mixture was quenched with aqueous NH4Cl solution (50 mL) and diluted with ethyl acetate (100 mL x 3). The organic layer was washed with brine (50 mL x 3), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (ethyl acetate in petroleum ether, from 0% to 79 275501297 v3
50%) to give 3-(3-((benzyloxy)methyl)-3-methyl-6-oxo-2,3,6,8-tetrahydro-7H-furo[2,3- e]isoindol-7-yl)piperidine-2,6-dione (1 g, yield 74%) as a light yellow solid. LC-MS (ESI): mass calcd. for C24H24N2O5, 420.17; m/z found, 421.2 [M+H]+ . Step G: 3-(3-(hydroxymethyl)-3-methyl-6-oxo-2,3,6,8-tetrahydro-7H-furo[2,3-e]isoindol-7- yl)piperidine-2,6-dione [000273] To a solution of 3-{3-[(benzyloxy)methyl]-3-methyl-6-oxo-2H,3H,6H,7H,8H- furo[2,3-e]isoindol-7-yl}piperidine-2,6-dione (1 g, 2.38 mmol, 1.0 eq) in Ethyl acetate (10 mL) was added 10% Pd/C (200 mg). The mixture was stirred under hydrogen (1 atm) at room temperature for 5 h. After filtration, the filtrate was concentrated to give 3-(3-(hydroxymethyl)- 3-methyl-6-oxo-2,3,6,8-tetrahydro-7H-furo[2,3-e]isoindol-7-yl)piperidine-2,6-dione (680 mg, yield 86%) as an off-white solid. LC-MS (ESI): mass calcd. for C17H18N2O5, 330; m/z found, 331.3 [M+H]+ .1H NMR (400 MHz, DMSO-d6) δ 10.97 (s, 1H), 7.34 (d, J = 7.6 Hz, 1H), 7.26 (d, J = 7.6 Hz, 1H), 5.11 - 5.04 (m, 2H), 4.64 - 4.62 (md, 1H), 4.37 (d, J = 16.4 Hz, 1H), 4.25 - 4.18 (m, 2H), 3.55 - 3.39 (m, 2H), 2.97 - 2.80 (m, 1H), 2.65 - 2.58 (m, 1H), 2.49 - 2.42 (m, 1H), 1.99 - 1.96 (m, 1H), 1.319 (d, J = 3.2 Hz, 3H). Compound 2: 3-(3-(2-hydroxyethyl)-3-methyl-6-oxo-2,3,6,8-tetrahydro-7H-furo[2,3- e]isoindol-7-yl)piperidine-2,6-dione
Step A: methyl 4-bromo-2-formyl-3-hydroxybenzoate [000274] A solution of methyl 4-bromo-3-hydroxybenzoate (5 g, 21.64 mmol, 1.0 eq) and Hexamethylenetetramine (11.53 g, 82.24 mmol, 3.8 eq) in TFA (50 mL) was stirred at 90 oC for 18 h. After cooled to room temperature, the mixture was diluted with water (200 mL), stirred for 1 h, and filtered. The cake was slurried with methanol (50 mL), filtered, and dried to obtain methyl 4-bromo-2-formyl-3-hydroxybenzoate (3 g, yield 54%) as a white solid. LC- MS (ESI): mass calcd. for C9H7BrO4, 259.06; m/z found, 260.2 [M+H]+.1H NMR (400 MHz, DMSO-d6) δ 12.06 (s, 1H), 10.39 (s, 1H), 8.01 (d, J = 8.2 Hz, 1H), 7.32 (d, J = 8.2 Hz, 1H), 3.88 (s, 3H). Step B: 5-bromo-4-hydroxyisobenzofuran-1(3H)-one [000275] To a solution of methyl 4-bromo-2-formyl-3-hydroxybenzoate (3 g, 11.58 mmol, 1.0 eq) in MeOH (30 mL) was added NaBH4 (1.17 g, 34.74 mmol, 3.0 eq) in portions at 0 oC. Then 80 275501297 v3
the mixture was stirred at 65 oC for 16 h. After cooled to room temperature and the mixture was filtered. The filtration was concentrated under reduced pressure. The residue was diluted with water (60 mL) and extracted with DCM (100 mL x 3). The combined organic layers were dried anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a crude product. The crude product was slurried with MTBE (50 mL), filtered and dried to obtain 5- bromo-4-hydroxy-1,3-dihydro-2-benzofuran-1-one (2 g, yield 75%) as a white solid. LC-MS (ESI): mass calcd. for C8H5BrO3, 229.03; m/z found, 230.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 10.93 (s, 1H), 7.72 (d, J = 8.0 Hz, 1H), 7.23 (d, J = 8.0 Hz, 1H), 5.34 (s, 2H). Step C: 4-(benzyloxy)-2-methylenebutanal [000276] To a solution of oxalic dichloride (2.859 mL, 33.287 mmol, 1.5 eq) in anhydrous DCM (160 mL) was added dropwise DMSO (4.73 mL, 66.57 mmol, 3.0 eq) under N2 at - 78 oC. After stirring for 20 min, a solution of 5-(benzyloxy)pentan-1-ol (4.0 g, 22.19 mmol, 1.0 eq) in DCM (30 mL) was added dropwise to above solution over 20 min and the resulting mixture was stirred at -78 oC for 1 h. TEA (15.42 mL, 110.95 mmol, 5.0 eq) was added to above mixture at -78 oC and the resulting mixture was stirred at 0 oC for 30 min. CH2NMe2Cl (4.13 g, 44.383 mmol, 2.0 eq) and DBU (3.31 mL, 22.19 mmol, 1.0 eq) were added to above mixture and the mixture was stirred 25 oC for 22 h. The reaction mixture was quenched with saturated aqueous NH4Cl solution (150 mL) and extracted with DCM (300 mL x 2). The combined organic extracts were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (ethyl acetate in petroleum ether, from 0% to 9%) to provide 4-(benzyloxy)-2-methylidenebutanal (1.7 g, yield 40%) as a colorless oil. LC-MS (ESI): mass calcd. for C12H14O2, 190.2; m/z found, 191.3 [M+H]+. Step D: 4-(benzyloxy)-2-methylenebutan-1-ol [000277] To a solution of 2-[(benzyloxy)methyl]prop-2-enal (1.7 g, 9.64 mmol, 1.0 eq) in THF (50 mL) was added LiAlH4 (0.55 g, 14.47 mmol, 1.5 eq) in small portions over 5 min at 0 oC and the mixture was stirred at 0 oC for 30 min. The reaction mixture was cautiously quenched with saturated aqueous NH4Cl solution (50 mL) and extracted with EtOAc (200 mL x 2). The combined organic extracts were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (ethyl acetate (EA) in petroleum ether, from 20% to 30%) to provide 2- [(benzyloxy)methyl]prop-2-en-1-ol (1.5 g, yield 87%) as a colorless oil. LC-MS (ESI): mass calcd. for C12H16O2, 192.2; m/z found, 193.3 [M+H]+.1H NMR (400 MHz, DMSO-d6) δ 7.38 - 7.27 (m, 5H), 4.99 (d, J = 2.0 Hz, 1H), 4.83 - 4.75 (m, 2H), 4.46 (s, 2H), 3.87 (d, J = 5.6 Hz, 81 275501297 v3
2H), 3.53 (t, J = 6.8 Hz, 2H), 2.27 (t, J = 6.8 Hz, 2H). Step E: 4-(4-(benzyloxy)-2-methylenebutoxy)-5-bromoisobenzofuran-1(3H)-one [000278] A solution of 5-bromo-4-hydroxy-1,3-dihydro-2-benzofuran-1-one (1.8 g, 7.80 mmol, 1.0 eq), 4-(benzyloxy)-2-methylidenebutan-1-ol (1.5 g, 7.80 mmol, 1.0 eq), and PPh3 (3.0 g, 11.70 mmol, 1.5 equiv) in dry THF (20 mL) was stirred under N2 atmosphere at 0 oC for 10 min. Then DIAD (2.32 mL, 11.70 mmol, 1.5 equiv) was added dropwise to above mixture and the resulting solution was stirred at room temperature for 2 h. After evaporation, the residue was purified by flash column chromatography on silica gel (ethl acetate in petroleum ether, from 9% to 50%) to afford 4-(4-(benzyloxy)-2-methylenebutoxy)-5- bromoisobenzofuran-1(3H)-one (1.9 g, yield 61%) as a light-yellow oil. LC-MS (ESI): mass calcd. for C20H19BrO4, 402.05; m/z found, 231.2 [M+H]+. Step F: 3-(2-(benzyloxy)ethyl)-3-methyl-2,3-dihydrobenzo[2,1-b:3,4-c']difuran-6(8H)-one and 3-(2-(benzyloxy)ethyl)-3,4-dihydro-2H-furo[3,4-h]chromen-7(9H)-one [000279] To a solution of 4-(4-(benzyloxy)-2-methylenebutoxy)-5-bromoisobenzofuran- 1(3H)-one (7.7 g, 19.09 mmol, 1.0 eq) in toluene (100 mL) were added AIBN (627.3 mg, 3.82 mmol, 0.2 eq) and tributyltin hydride (15.4 mL, 57.28 mmol, 3.0 eq). The mixture was stirred under N2 at 110 oC in a sealed tube overnight. After cooled to room temperature, the mixture was quenched with saturated aqueous potassium fluoride solution (150 mL) and stirred for 2 h. Then the mixture was extracted with EA (150 mL x 3). The organic layer was washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (ethl acetate in petroleum ether, from 9% to 50%) to give 3-(2-(benzyloxy)ethyl)-3-methyl-2,3- dihydrobenzo[2,1-b:3,4-c']difuran-6(8H)-one (1.7 g, yield 27%) as a white solid and 3-(2- (benzyloxy)ethyl)-3,4-dihydro-2H-furo[3,4-h]chromen-7(9H)-one (2.1 g, yield 34%) as a white solid. [000280] 3-(2-(benzyloxy)ethyl)-3-methyl-2,3-dihydrobenzo[2,1-b:3,4-c']difuran-6(8H)-one: LC-MS (ESI): mass calcd. for C20H20O4, 324.14; m/z found, 325.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 7.48 (d, J = 7.6 Hz, 1H), 7.42 (d, J = 7.6 Hz, 1H), 7.36 - 7.28 (m, 5H), 5.37 (s, 2H), 4.68 (d, J = 9.0 Hz, 1H), 4.44 (s, 2H), 4.37 (d, J = 9.0 Hz, 1H), 3.57 - 3.47 (m, 2H), 2.07 - 2.01 (m, 2H), 1.37 (s, 3H). [000281] 3-(2-(benzyloxy)ethyl)-3,4-dihydro-2H-furo[3,4-h]chromen-7(9H)-one: LC-MS (ESI): mass calcd. for C20H20O4, 324.14; m/z found, 325.2 [M+H]+.1H NMR (400 MHz, DMSO-d6) δ 7.37 - 7.28 (m, 7H), 5.30 (s, 2H), 4.52 (s, 2H), 4.39 - 4.31 (m, 1H), 3.90 (t, J = 9.2 Hz, 1H), 3.63 - 3.54 (m, 2H), 3.02 - 2.90 (m, 1H), 2.65 - 2.58 (m, 1H), 2.24 - 2.10 (m, 1H), 82 275501297 v3
1.72 – 1.52 (m, 2H). Step G: 3-(2-(benzyloxy)ethyl)-7-(hydroxymethyl)-3-methyl-2,3-dihydrobenzofuran-6- carboxylic acid [000282] To a solution of 3-(2-(benzyloxy)ethyl)-3-methyl-2,3-dihydrobenzo[2,1-b:3,4- c']difuran-6(8H)-one (100 mg, 0.307 mmol, 1.0 eq) in THF/MeOH/H2O (3/3/1, 7 mL) was added NaOH (49 mg, 1.233 mmol, 4.0 eq) and the mixture was stirred at room temperature for 0.5 h. The mixture was diluted with water (4 mL), acidified to pH 5-6 with diluted aqueous HCl solution (2 N), and extracted with EA (10 mL x 3). The combined organic layers were washed with brine (5 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give 3-(2-(benzyloxy)ethyl)-7-(hydroxymethyl)-3-methyl-2,3- dihydrobenzofuran-6-carboxylic acid (274.4 mg, yield 100%) as a brown oil. The crude product was directly used in the next step without further purification. LC-MS (ESI): mass calcd. for C20H22O5, 342.15; m/z found, 341.2 [M-H]-. Step H: 3-(2-(benzyloxy)ethyl)-7-formyl-3-methyl-2,3-dihydrobenzofuran-6-carboxylic acid [000283] To a solution of 3-(2-(benzyloxy)ethyl)-7-(hydroxymethyl)-3-methyl-2,3- dihydrobenzofuran-6-carboxylic acid (274.44 mg, 0.802 mmol, 1.0 eq) in DCM (10 mL) was added Dess-Martin periodinane (680 mg, 1.603 mmol, 2.0 eq) in portions at 0 oC and the mixture was stirred for 1 h, After evaporation, the residue was purified by flash silica gel column chromatography (ethyl acetate in petroleum ether, from 0% to 30%) to give 3-(2- (benzyloxy)ethyl)-7-(hydroxymethyl)-3-methyl-2,3-dihydrobenzofuran-6-carboxylic acid (210 mg, yield 77%) as a colorless oil. LC-MS (ESI): mass calcd. for C20H20O5, 340.13; m/z found, 341.2 [M+H]+. Step I: 3-(2-(benzyloxy)ethyl)-7-(((2,6-dioxopiperidin-3-yl)amino)methyl)-3-methyl-2,3- dihydrobenzofuran-6-carboxylic acid [000284] To a mixture of 3-(2-(benzyloxy)ethyl)-7-(hydroxymethyl)-3-methyl-2,3- dihydrobenzofuran-6-carboxylic acid (210 mg, 0.617 mmol, 1.0 eq) in methanol (5 mL) and DCM (5 mL) were added 3-aminopiperidine-2,6-dione hydrochloride (158.10 mg, 1.23 mmol, 2.0 eq), sodium acetate (202.44 mg, 2.468 mmol, 4.0 eq), and AcOH (0.354 mL, 6.170 mmol, 10.0 eq). The mixture was stirred at 20 oC for 30 min. Then sodium cyanoborohydride (116.31 mg, 1.851 mmol, 3.0 eq) was added to above mixture and the mixture was further stirred for 30 min. The reaction mixture was quenched with water (3 mL) and concentrated under reduced pressure to give a crude product. The crude product was purified by Prep-TLC (DCM/MeOH = 10/1) to give 3-(2-(benzyloxy)ethyl)-7-(((2,6-dioxopiperidin-3-yl)amino)methyl)-3-methyl- 2,3-dihydrobenzofuran-6-carboxylic acid (150 mg, yield 54%) as a blue solid. LC-MS (ESI): 83 275501297 v3
mass calcd. for C25H28N2O6, 452.19; m/z found, 453.2 [M+H]+. Step J: 3-(3-(2-(benzyloxy)ethyl)-3-methyl-6-oxo-2,3,6,8-tetrahydro-7H-furo[2,3-e]isoindol- 7-yl)piperidine-2,6-dione [000285] To a solution of 3-(2-(benzyloxy)ethyl)-7-(((2,6-dioxopiperidin-3-yl)amino)methyl)- 3-methyl-2,3-dihydrobenzofuran-6-carboxylic acid (150 mg, 0.331 mmol, 1.0 eq) in DMF (3 mL) were added HATU (189.06 mg, 0.497 mmol, 1.5 eq) and N,N-Diisopropylethylamine (0.274 mL, 1.657 mmol, 5.0 eq) and the reaction mixture was stirred at room temperature for 10 min. The reaction was quenched with water (1 mL) and concentrated under reduced pressure. The residue was purified by Prep-TLC (100% EA) to give 3-{3-[2-(benzyloxy)ethyl]- 3-methyl-6-oxo-2H,3H,6H,7H,8H-furo[2,3-e]isoindol-7-yl}piperidine-2,6-dione (100 mg, yield 69%) as a white solid. LC-MS (ESI): mass calcd. for C25H26N2O5, 434.18; m/z found, 435.4 [M+H]+. Step K: 3-(3-(2-hydroxyethyl)-3-methyl-6-oxo-2,3,6,8-tetrahydro-7H-furo[2,3-e]isoindol-7- yl)piperidine-2,6-dione [000286] A mixture of 3-{3-[2-(benzyloxy)ethyl]-3-methyl-6-oxo-2H,3H,6H,7H,8H-furo[2,3- e]isoindol-7-yl}piperidine-2,6-dione (100 mg, 0.230 mmol, 1 equiv) and 10% Pd/C (25 mg) in 2,2,2-trifluoroethanol (20 mL) was stirred under H2 (1 atm) at room temperature for 1 h. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by Pprep-HPLC with YMC-Actus Triart C18 (5 µm, 21.2 x 250 mm), and mobile phase of 5-95% ACN in water (0.1% FA) over 23 min and then hold at 95% ACN for 3 min, at a flow rate of 20 mL/min to give 3-[3-(2-hydroxyethyl)-3-methyl-6-oxo-2H,3H,6H,7H,8H-furo[2,3- e]isoindol-7-yl]piperidine-2,6-dione (79.2 mg, yield 100%) as a white solid. LC-MS (ESI): mass calcd. for C18H20N2O5, 344.13; m/z found, 345.4 [M+H]+. 1H NMR (400 MHz, DMSO- d6) δ 10.97 (s, 1H), 7.35 (d, J = 7.6 Hz, 1H), 7.28 (d, J = 7.6 Hz, 1H), 5.11 - 5.06 (m, 1H), 4.59 (d, J = 8.8 Hz, 1H), 4.48 (t, J = 5.0 Hz, 1H), 4.39 (d, J = 17.2 Hz, 1H), 4.30 (d, J = 8.8 Hz, 1H), 4.21 (d, J = 17.2 Hz, 1H), 3.56 - 3.45 (m, 1H), 3.42 - 3.36 (m, 1H), 2.97 - 2.84 (m, 1H), 2.63 - 2.60 (m, 1H), 2.44 - 2.39 (m, 1H), 1.99 - 1.93 (m, 1H), 1.88 - 1.80 (m, 2H), 1.51 - 1.41 (m, 1H), 1.33 (s, 3H). Compound 3: 3-(3-(3-hydroxypropyl)-3-methyl-6-oxo-2,3,6,8-tetrahydro-7H-furo[2,3- e]isoindol-7-yl)piperidine-2,6-dione 84 275501297 v3
Step A: 5-(benzyloxy)-2-methylenepentanal [000287] To a solution of Oxalyl Chloride (6.6 mL, 77.2 mmol, 1.5 eq) in anhydrous DCM (300 mL) was slowly added DMSO (10.9 mL, 154.4 mmol, 3.0 eq) at -78 oC and the mixture was stirred for 20 min. A solution of 5-(Benzyloxy)pentan-1-ol (10 g, 51.4 mmol, 1.0 eq) in anhydrous DCM (70 mL) was added dropwise to above mixture and the resulting mixture was stirred at -78 oC for 1 h. TEA (35.7 mL, 257.3 mmol, 5.0 eq) was added dropwise to above mixture at -78 oC and the mixture was heated to 0 oC. After 30 min, ESCHENMOSER'S SALT (9.63 g, 102.9 mmol, 2.0 eq) and DBU (7.84 g, 7.7 mL, 51.4 mmol, 1.0 eq) was added to above mixture and the mixture was stirred for 30 min. The reaction mixture was quenched with saturated aqueous NH4Cl solution (120 mL) and extracted with DCM (120 mL x 3). The organic layer was washed with brine (300 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel (ethyl acetate in petroleum ether, from 0% to 5%) to give 5- (benzyloxy)-2-methylenepentanal (4.3 g, yield 40%) as a yellow oil. LC-MS (ESI): mass calcd. for C13H16O2, 204.27; m/z found, 205.27 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 9.53 (s, 1H), 7.38 - 7.30 (m, 5H), 6.25 (s, 1H), 5.99 (s, 1H), 4.49 (s, 2H), 3.49 - 3.46 (m, 2H), 2.37 - 2.32 (m, 2H), 1.81 - 1.74 (m, 2H). Step B: 5-(benzyloxy)-2-methylenepentan-1-ol [000288] To a solution of 5-(benzyloxy)-2-methylenepentanal (4.3 g, 21.0 mmol, 1.0 eq) in THF (50 mL) was added LiAlH4 (0.4 g, 10.5 mmol, 0.5 eq) at 0 oC and the reaction mixture was stirred at room temperature for 30 min. The reaction mixture was quenched with Na2SO4 .10H2O and filtered. The filtrate was concentrated under reduced pressure to give crude 5-(benzyloxy)-2-methylenepentan-1-ol (3.5 g, yield 80%) as a colorless oil. LC-MS (ESI): mass calcd. for C13H18O2, 206.29; m/z found, 207.3 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 7.37 - 7.27 (m, 5H), 5.05 - 5.00 (m, 1H), 4.87 (d, J = 1.2 Hz, 1H), 4.50 (s, 2H), 4.06 (s, 2H), 3.50 (t, J = 6.4 Hz, 2H), 2.18 - 2.13 (m, 2H), 1.81 - 1.77 (m, 2H). Step C: 4-((5-(benzyloxy)-2-methylenepentyl)oxy)-5-bromoisobenzofuran-1(3H)-one [000289] To a solution of 5-bromo-4-hydroxy-1,3-dihydro-2-benzofuran-1-one (3.87 g, 16.9 mmol, 1.0 eq) and 5-(benzyloxy)-2-methylidenepentan-1-ol (3.49 g, 16.9 mmol, 1.0 eq), and PPh3 (5.32 g, 20.3 mmol, 1.2 eq) in dry THF (40 mL) was added dropwise DIAD (4.10 g, 85 275501297 v3
20.3 mmol, 1.2 eq) and the reaction mixture was stirred under N2 at room temperature for 16 h. The reaction mixture was quenched with water (50 ml) and extracted with EA (50 mL x 3). The organic layer was washed with brine (100 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel (ethyl acetate in petroluem ether, from 0% to 11%) to give 4-((5- (benzyloxy)-2-methylenepentyl)oxy)-5-bromoisobenzofuran-1(3H)-one (6.8 g, yield 96%) as a colorless oil. LC-MS (ESI): mass calcd. for C H BrO , 417.3; m/z found, 418 + 21 21 4 .3 [M+H]. 1H NMR (400 MHz, DMSO-d6) δ 7.83 (d, J = 8.0 Hz, 1H), 7.44 (d, J = 8.0 Hz, 1H), 7.35 - 7.27 (m, 5H), 5.05 - 5.00 (m, 1H), 5.68 (s, 2H), 5.25 (s, 1H), 5.02 (s, 1H), 4.71 (s, 2H), 4.46 (s, 2H), 4.06 (s, 2H), 3.48 (t, J = 6.4 Hz, 2H), 2.29 - 2.21 (m, 2H), 1.80 - 1.73 (m, 2H). Step D: 3-(3-(benzyloxy)propyl)-3-methyl-2,3-dihydrobenzo[2,1-b:3,4-c']difuran-6(8H)-one [000290] To a solution of 4-((5-(benzyloxy)-2-methylenepentyl)oxy)-5-bromoisobenzofuran- 1(3H)-one (1.0 g, 2.4 mmol, 1.0 eq) in toluene (25 mL) were added Bu3SnH (2.38 g, 9.6 mmol, 4.0 eq) and AIBN (80 mg, 479 µmol, 0.2 eq). The mixture was stirred at 100 oC in a sealed tube for 16 h. After cooled to room temperature, the reaction mixture was quenched with aqueous KF solution (20 mL), stirred for 2 h, and extracted with EA (20 mL x 3). The organic layer was washed with brine (40 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified by reverse phase chromatography with C18 spherical (20-35 µm, 100A), and mobile phase of 5%-70% ACN in H2O (0.1% FA) over 16 min and then hold at 100% ACN for 2 min, at a flow rate of 25 mL/min to give 3-(3- (benzyloxy)propyl)-3-methyl-2,3-dihydrobenzo[2,1-b:3,4-c']difuran-6(8H)-one (370 mg, yield 45%) as a white solid. LC-MS (ESI): mass calcd. for C21H22O4, 338.4; m/z found, 339.4 [M+H]+.1H NMR (400 MHz, DMSO-d6) δ 7.41 (q, J = 7.6 Hz, 2H), 7.35 - 7.26 (m, 5H), 5.35 (s, 2H), 4.55 (d, J = 9.0 Hz, 1H), 4.40 (s, 2H), 4.32 (d, J = 9.0 Hz, 1H), 3.37 (t, J = 6.4 Hz, 2H), 1.70 - 1.60 (m, 2H), 1.59 - 1.53 (m, 1H), 1.35 (s, 3H), 1.32 - 1.23 (m, 1H). Step E: 3-(3-(benzyloxy)propyl)-7-(hydroxymethyl)-3-methyl-2,3-dihydrobenzofuran-6- carboxylic acid [000291] To a solution of 3-(3-(benzyloxy)propyl)-3-methyl-2,3-dihydrobenzo[2,1-b:3,4- c']difuran-6(8H)-one (370 mg, 1.1 mmol, 1.0 eq) in THF (3 mL) and water (1.5 mL) were added NaOH (174.9 mg, 4.4 mmol, 4.0 eq). The mixture was stirred at 40 °C for 2 h. The mixture was cooled to room temperature, adjusted to pH 6 with aqueous HCl solution (1 N), and extracted with EA (30 mL x 3). The organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give crude 3-(3- 86 275501297 v3
(benzyloxy)propyl)-7-(hydroxymethyl)-3-methyl-2,3-dihydrobenzofuran-6-carboxylic acid (400 mg, yield 102%) as a yellow oil. LC-MS (ESI): mass calcd. for C21H24O5, 356.42; m/z found, 355.4 [M-H]-. Step F: 3-(3-(benzyloxy)propyl)-7-formyl-3-methyl-2,3-dihydrobenzofuran-6-carboxylic acid [000292] To a solution of 3-(3-(benzyloxy)propyl)-7-(hydroxymethyl)-3-methyl-2,3- dihydrobenzofuran-6-carboxylic acid (210 mg, 589 µmol, 1.0 eq) in DCM (10 mL) were added MnO2 (1.02 g, 11.7 mmol, 20.0 eq). The mixture was stirred at room temperature for 1 h. After filtered to remove MnO2, the filtrate was collected and concentrated under reduced pressure to give crude 3-(3-(benzyloxy)propyl)-7-formyl-3-methyl-2,3-dihydrobenzofuran-6-carboxylic acid (160 mg, yield 76%) as a yellow oil. LC-MS (ESI): mass calcd. for C21H22O5, 354.4; m/z found, 353.4 [M-H]-. Step G: 3-(3-(3-(benzyloxy)propyl)-3-methyl-6-oxo-2,3,6,8-tetrahydro-7H-furo[2,3- e]isoindol-7-yl)piperidine-2,6-dione [000293] To a solution of 3-(3-(benzyloxy)propyl)-7-formyl-3-methyl-2,3- dihydrobenzofuran-6-carboxylic acid (250 mg, 705 µmol, 1.0 eq) in DMF (2.5 mL) and AcOH (0.2 mL) were added 3-aminopiperidine-2,6-dione hydrochloride (135.5 mg, 1.06 mmol, 1.5 eq) and the mixture was stirred at 30 oC for 30 min. Sodium triacetoxyborohydride (446.4 mg, 2.1 mmol, 3.0 eq) was added to above mixture and the resulting mixture was stirred at 30 oC for 16 h. The reaction mixture was quenched with aqueous NH4Cl solution (10 mL) and extracted with EA (5 mL x 4). The organic layer was washed with brine (10 mL x 4), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel (ethyl acetate in petroleum ether, from 0% to 70%) to give 3-(3-(3-(benzyloxy)propyl)-3-methyl-6-oxo-2,3,6,8-tetrahydro-7H- furo[2,3-e]isoindol-7-yl)piperidine-2,6-dione (240 mg, yield 75%) as a blue solid. LC-MS (ESI): mass calcd. for C26H28N2O5, 448.52; m/z found, 449.5 [M+H]+. Step H: 3-(3-(3-hydroxypropyl)-3-methyl-6-oxo-2,3,6,8-tetrahydro-7H-furo[2,3-e]isoindol-7- yl)piperidine-2,6-dione [000294] To a solution of 3-(3-(3-(benzyloxy)propyl)-3-methyl-6-oxo-2,3,6,8-tetrahydro-7H- furo[2,3-e]isoindol-7-yl)piperidine-2,6-dione (40 mg, 89 µmol, 1.0 eq) in 2,2,2- trifluoroethanol (2 mL) was added 10% Pd/C (630 mg). The mixture was stirred in H2 atmosphere (1 atm) at 40 °C for 2 h. After evaporation, the filtrate was collected and concentrated under reduced pressure. The crude product was purified by Prep-TLC (DCM/MeOH = 10/1) to give 3-(3-(3-hydroxypropyl)-3-methyl-6-oxo-2,3,6,8-tetrahydro-7H- furo[2,3-e]isoindol-7-yl)piperidine-2,6-dione (24.2 g, yield 75%) as a white solid. LC-MS 87 275501297 v3
(ESI): mass calcd. for C19H22N2O5, 358.39; m/z found, 359.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 10.97 (s, 1H), 7.33 (d, J = 7.4 Hz, 1H), 7.28 (d, J = 7.4 Hz, 1H), 5.10 - 5.06 (m, 1H), 4.51 - 4.47 (m, 1H), 4.41 - 4.18 (m, 4H), 3.34 (s, 2H), 2.97 - 2.83 (m, 1H), 2.61 - 2.56 (m, 1H), 2.44 - 2.39 (m, 1H), 2.00 - 1.96 (m, 1H), 1.66 - 1.61 (m, 2H), 1.48 - 1.39 (m, 1H), 1.34 (d, J = 3.4 Hz, 3H), 1.18 - 1.172 (m, 1H). Compound 4: 3-(4-(2-hydroxyethyl)-8-oxo-2,3,4,5,8,10-hexahydro-9H-oxepino[2,3- e]isoindol-9-yl)piperidine-2,6-dione
Step A: (((5-bromo-3-methylenepentyl)oxy)methyl)benzene [000295] To a solution of 5-(benzyloxy)-3-methylidenepentan-1-ol (1 g, 4.8 mmol, 1.0 eq) and PPh3 (1.4 g, 5.3 mmol, 1.1 eq) in DCM (10 mL) was added CBr4 (1.8 g, 5.3 mmol, 1.1 eq) at 0 oC. The reaction mixture was stirred at room temperature for 2 h. The reaction mixture was quenched with water (20 mL) and extracted with DCM (30 mL x 3). The organic layer was washed with brine (30 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (PE/EA = 20/1) to give (((5-bromo-3-methylenepentyl)oxy)methyl)benzene (1.0 g, yield 77%) as a yellow oil. LC-MS (ESI): mass calced for: C13H17BrO 268.0; m/z found, 269.0 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 7.28 - 7.15 (m, 5H), 4.84 (s, 1H), 4.80 (s, 1H), 4.45 (s, 2H), 3.50 (t, J = 6.8 Hz, 2H), 3.38 (t, J = 7.4 Hz, 2H), 2.52 (t, J = 7.4 Hz, 2H), 2.27 (t, J = 6.8 Hz, 2H). Step B: 4-((5-(benzyloxy)-3-methylenepentyl)oxy)-5-bromoisobenzofuran-1(3H)-one [000296] To a mixture of 5-bromo-4-hydroxy-1,3-dihydro-2-benzofuran-1-one (200 mg, 0.9 mmol, 1.0 eq) in DMF (5 mL) was added (((5-bromo-3-methylenepentyl)oxy)methyl)benzene (234.99 mg, 0.9 mmol, 1.0 eq) and K2CO3 (362 mg, 2.6 mmol, 3.0 eq) at room temperature. The reaction mixture was stirred at 80 oC overnight. The reaction mixture was cooled to room temperature, quenched with water (50 mL), and extracted with EtOAc (50 mL x 3). The organic layer was washed with brine (30 mL x 4), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (ethyl acetate in petroleum ether, from 0% to 50%) to give 4-((5- (benzyloxy)-3-methylenepentyl)oxy)-5-bromoisobenzofuran-1(3H)-one (200 mg, yield 55%) as a yellow oil. LC-MS (ESI): mass calced for: C21H21BrO4416.06; m/z found, 417.3 [M+H]+.1H 88 275501297 v3
NMR (400 MHz, CDCl3) δ 7.63 (d, J = 8.0 Hz, 1H), 7.41 (d, J = 8.0 Hz, 1H), 7.26 - 7.19 (m, 5H), 5.23 (s, 2H), 4.88 (d, J = 5.2 Hz, 2H), 4.44 (s, 2H), 4.14 (t, J = 6.8 Hz, 2H), 3.55 (t, J = 6.8 Hz, 2H), 2.51 (t, J = 6.8 Hz, 2H), 2.36 (t, J = 6.8 Hz, 2H). Step C: 4-(2-(benzyloxy)ethyl)-2,3,4,5-tetrahydrooxepino[2,3-e]isobenzofuran-8(10H)-one [000297] To a mixture of 4-{[5-(benzyloxy)-3-methylidenepentyl]oxy}-5-bromo-1,3-dihydro- 2-benzofuran-1-one (2.2 g, 5.272 mmol, 1.0 eq) and AIBN (1.73 g, 10.544 mmol, 2.0 eq) in Toluene (30 mL) was added Bu3SnH (5.37 mL, 10.544 mmol, 2.0 eq) at room temperature. The reaction mixture was stirred under N2 at 100 oC in a sealed tube overnight. The reaction mixture was cooled to room temperature, quenched with aqueous KF solution (50 mL), stirred for 2 h, and extracted with EtOAc (30 mL x 3). The organic layer was washed with brine (30 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (ethyl acetate in petroleum ether, from 0% to 50%) to afford 4-(2-(benzyloxy)ethyl)-2,3,4,5-tetrahydrooxepino[2,3- e]isobenzofuran-8(10H)-one (1.5 g, yield 84%) as a yellow oil. LC-MS (ESI): mass calced for: C21H22O4338.15; m/z found, 339.2 [M+H]+ .1HNMR (400 MHz, CDCl3) δ 7.43 (d, J = 8.0 Hz, 1H), 7.30 - 7.20 (m, 5H), 7.14 (d, J = 8.0 Hz, 1H), 5.18 (s, 2H), 4.45 (s, 2H), 4.27 - 4.44 (m, 1H), 3.84 - 3.78 (m, 1H), 3.51 - 3.47 (m, 2H), 2.79 - 2.75 (m, 2H), 1.98 - 1.90 (m, 2H), 1.75 - 1.59 (m, 2H), 1.32 - 1.28 (m, 1H). Step D: 4-(2-(benzyloxy)ethyl)-9-(hydroxymethyl)-2,3,4,5-tetrahydrobenzo[b]oxepine-8- carboxylic acid [000298] To a solution of 4-(2-(benzyloxy)ethyl)-2,3,4,5-tetrahydrooxepino[2,3- e]isobenzofuran-8(10H)-one (1.5 g, 4.433 mmol, 1.0 eq) in THF (20 mL) and MeOH (20 mL) was added dropwise aqueous NaOH solution (886.5 mg, 22.163 mmol, 5.0 eq) in water (10 mL) and the resulting mixture was stirred at 40 ℃ for 2 h. After evaporation, the residue was diluted with water (30 mL), acidified to pH 5-6 with diluted HCl solution (1 N), and extracted with EA (100 mL x 3). The combined organic layers were washed with brine (100 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give 4-[2- (benzyloxy)ethyl]-9-(hydroxymethyl)-2,3,4,5-tetrahydro-1-benzoxepine-8-carboxylic acid (1.5 g, yield 93%) as a yellow solid. The crude product was directly used in the next step without further purification. LC-MS (ESI): mass calced for: C21H24O5356.16; m/z found, 357.0 [M+H]+. Step E: 4-(2-(benzyloxy)ethyl)-9-formyl-2,3,4,5-tetrahydrobenzo[b]oxepine-8-carboxylic acid [000299] To a solution of 4-[2-(benzyloxy)ethyl]-9-(hydroxymethyl)-2,3,4,5-tetrahydro-1- 89 275501297 v3
benzoxepine-8-carboxylic acid (1.5 g, 4.489 mmol,1.0 eq) in DCM (50 mL) was added active manganese dioxide (7.8 g, 89.782 mmol, 20.0 eq) in one portion at room temperature. The reaction mixture was stirred at room temperature for 1 h. After filtration, the filtrate was concentrated under reduced pressure to give 4-[2-(benzyloxy)ethyl]-9-formyl-2,3,4,5- tetrahydro-1-benzoxepine-8-carboxylic acid (1.3 g, yield 82%) as a yellow solid. The crude product was directly used in next step without further purification. LC-MS (ESI): mass calced for: C21H22O5354.15; m/z found, 355.0 [M+H]+. Step F: 3-(4-(2-(benzyloxy)ethyl)-8-oxo-2,3,4,5,8,10-hexahydro-9H-oxepino[2,3-e]isoindol-9- yl)piperidine-2,6-dione [000300] To a solution of 4-[2-(benzyloxy)ethyl]-9-formyl-2,3,4,5-tetrahydro-1-benzoxepine- 8-carboxylic acid (1.3 g, 3.668 mmol, 1.0 eq) and 3-aminopiperidine-2,6-dione hydrochloride (0.71 g, 5.502 mmol, 1.5 eq) in DMF (20 mL) was added AcOH (2.11 mL, 37 mmol, 10.0 eq). The mixture was stirred at room temperature for 1 h. Then NaBH(OAc)3 (2.33 g, 11.00 mmol, 3.0 eq) was added to above mixture and the resulting reaction mixture was stirred at 40 oC overnight. After cooled to room temperature, the reaction was quenched with water (20 mL) and extracted with EA (50 mL x 3). The organic layer was washed with brine (30 mL x 4), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (DCM/MeOH = 10/1) to give 3-(4- (2-(benzyloxy)ethyl)-8-oxo-2,3,4,5,8,10-hexahydro-9H-oxepino[2,3-e]isoindol-9- yl)piperidine-2,6-dione (780 mg, yield 55%) as a yellow solid. LC-MS (ESI): mass calced for: C26H28N2O5448.20; m/z found, 449.2 [M+H]+. Step G: 3-(4-(2-hydroxyethyl)-8-oxo-2,3,4,5,8,10-hexahydro-9H-oxepino[2,3-e]isoindol-9- yl)piperidine-2,6-dione [000301] To a solution of 3-(4-(2-(benzyloxy)ethyl)-8-oxo-2,3,4,5,8,10-hexahydro-9H- oxepino[2,3-e]isoindol-9-yl)piperidine-2,6-dione (610 mg, 1.360 mmol, 1.0 eq) in 2,2,2- trifluoroethanol (20 mL) was added 10% Pd/C (100 mg) at room temperature. The mixture was stirred under H2 (1 atm) at room temperature for 3 h. After filtration, the filtrate was concentrated under reduced pressure. The crude product was purified by Prep-HPLC with YMC-Actus Triart C18 (5 um, 20 x 250 mm), and mobile phase of 5-95% ACN in water (0.1% HCOOH) over 20 min and then hold at 100% ACN for 2 min, at a flow rate of 25 mL/min to give 3-(4-(2-hydroxyethyl)-8-oxo-2,3,4,5,8,10-hexahydro-9H-oxepino[2,3-e]isoindol-9- yl)piperidine-2,6-dione (390 mg, yield 80%) as a white solid. LC-MS (ESI): mass calced for: C19H22N2O5358.15; m/z found, 359.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 10.97 (s, 90 275501297 v3
1H), 7.42 - 7.24 (m, 2H), 5.11 - 5.06 (m, 1H), 4.40 - 4.18 (m, 4H), 3.92 - 3.77 (m, 1H), 3.49 (t, J = 5.4 Hz, 2H), 2.97 - 2.82 (m, 2H), 2.83 - 2.69 (m, 1H), 2.67 - 2.56 (m, 1H), 2.45 - 2.42 (m, 1H), 2.00 - 1.95 (m, 2H), 1.84 - 1.81 (m, 1H), 1.77 - 1.67 (m, 1H), 1.49 - 1.42 (m, 2H). Compound 5: 3-(3-(2-hydroxyethyl)-7-oxo-3,4,7,9-tetrahydropyrano[2,3-e]isoindol- 8(2H)-yl)piperidine-2,6-dione
Step A: 3-(2-(benzyloxy)ethyl)-8-(hydroxymethyl)chromane-7-carboxylic acid [000302] To a solution of 3-(2-(benzyloxy)ethyl)-3,4-dihydro-2H-furo[3,4-h]chromen-7(9H)- one (320 mg, 0.986 mmol, 1.0 eq) in THF/MeOH/H2O (3/3/1, 7 mL) was added NaOH (158 mg, 3.946 mmol, 4.0 eq) and the mixture was stirred at room temperature for 0.5 h. The mixture was diluted with water (4 mL), acidified to pH 5-6 with diluted aqueous HCl solution (2 N), and extracted with EA (10 mL x 3). The combined organic layers were washed with brine (5 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give 3-(2-(benzyloxy)ethyl)-8-(hydroxymethyl)chromane-7-carboxylic acid (337.8 mg, yield 100%) as a brown oil. The crude product was directly used in the next step without further purification. LC-MS (ESI): mass calcd. for C20H22O5, 342.15; m/z found, 341.2 [M-H]-. Step B: 3-(2-(benzyloxy)ethyl)-8-formylchromane-7-carboxylic acid [000303] To a solution of 3-(2-(benzyloxy)ethyl)-8-(hydroxymethyl)chromane-7-carboxylic acid (338 mg, 0.987 mmol, 1.0 eq) in DCM (10 mL) was added Dess-Martin periodinane (837 mg, 1.974 mmol, 2.0 eq) in portions at 0 oC and the mixture was stirred for 1 h, After evapoation, the residue was purified by flash silica gel column chromatography (ethyl acetate in petroleum ether, from 0% to 30%) to give 3-(2-(benzyloxy)ethyl)-8-formylchromane-7- carboxylic acid (180 mg, yield 54%) as a colorless oil. LC-MS (ESI): mass calcd. for C20H20O5, 340.13; m/z found, 341.2 [M+H]+. Step C: 3-(2-(benzyloxy)ethyl)-8-(((2,6-dioxopiperidin-3-yl)amino)methyl)chromane-7- carboxylic acid [000304] To a mixture of 3-(2-(benzyloxy)ethyl)-8-formylchromane-7-carboxylic acid (180 mg, 0.529 mmol, 1.0 eq) in methanol (5 mL) and DCM (5 mL) were added 3-aminopiperidine- 2,6-dione hydrochloride (135.5 mg, 1.06 mmol, 2.0 eq), sodium acetate (100 mg, 1.586 mmol, 4.0 eq), and AcOH (0.303 mL, 5.288 mmol, 10.0 eq). The mixture was stirred at 20 oC for 30 91 275501297 v3
min. Then sodium cyanoborohydride (173.58 mg, 1.586 mmol, 3.0 eq) was added to above mixture and the mixture was further stirred for 30 min. The reaction mixture was quenched with water (3 mL) and concentrated under reduced pressure to give a crude product. The crude product was purified by Prep-TLC (DCM/MeOH = 10/1) to give 3-(2-(benzyloxy)ethyl)-8- (((2,6-dioxopiperidin-3-yl)amino)methyl)chromane-7-carboxylic acid (150 mg, yield 63%) as a blue solid. LC-MS (ESI): mass calcd. for C25H28N2O6, 452.19; m/z found, 453.2 [M+H]+. Step D: 3-(3-(2-(benzyloxy)ethyl)-7-oxo-3,4,7,9-tetrahydropyrano[2,3-e]isoindol-8(2H)- yl)piperidine-2,6-dione [000305] To a solution of 3-(2-(benzyloxy)ethyl)-8-(((2,6-dioxopiperidin-3- yl)amino)methyl)chromane-7-carboxylic acid (750 mg, 1.657 mmol, 1.0 eq) in DMF (2 mL) were added HATU (945.3 mg, 2.486 mmol, 1.5 eq) and N,N-Diisopropylethylamine (1.370 mL, 8.287 mmol, 5.0 eq) and the reaction mixture was stirred at room temperature for 10 min. The reaction was quenched with water (1 mL) and concentrated under reduced pressure. The residue was purified by prep-TLC (100% EA) to give 3-(3-(2-(benzyloxy)ethyl)-7-oxo-3,4,7,9- tetrahydropyrano[2,3-e]isoindol-8(2H)-yl)piperidine-2,6-dione (600 mg, yield 83%) as a white solid. LC-MS (ESI): mass calcd. for C25H26N2O5, 434.18; m/z found, 435.4 [M+H]+. Step E: 3-(3-(2-hydroxyethyl)-7-oxo-3,4,7,9-tetrahydropyrano[2,3-e]isoindol-8(2H)- yl)piperidine-2,6-dione [000306] A mixture of 3-(3-(2-(benzyloxy)ethyl)-7-oxo-3,4,7,9-tetrahydropyrano[2,3- e]isoindol-8(2H)-yl)piperidine-2,6-dione (30 mg, 0.069 mmol, 1 equiv) and 10% Pd/C (10 mg) in 2,2,2-trifluoroethanol (10 mL) was stirred under H2 (1 atm) at room temperature for 1 h. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by Prep-HPLC with YMC-Actus Triart C18 (5 µm, 21.2 x 250 mm), and mobile phase of 5- 95% ACN in water (0.1% FA) over 23 min and then hold at 95% ACN for 3 min, at a flow rate of 20 mL/min to give 3-(3-(2-hydroxyethyl)-7-oxo-3,4,7,9-tetrahydropyrano[2,3-e]isoindol- 8(2H)-yl)piperidine-2,6-dione (23 mg, yield 99%) as a white solid. LC-MS (ESI): mass calcd. for C18H20N2O5, 344.13; m/z found, 345.4 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 10.96 (s, 1H), 7.24 - 7.16 (m, 2H), 5.32 (t, J = 4.8 Hz, 1H), 5.10 - 5.05 (m, 1H), 4.36 - 4.10 (m, 3H), 3.92 - 3.79 (m, 1H), 3.55 (t, J = 5.4 Hz, 2H), 2.99 - 2.86 (m, 2H), 2.62 - 2.57 (m, 1H), 2.45 - 2.37 (m, 1H), 2.20 - 2.10 (m, 1H), 2.02 - 1.95 (m, 1H), 1.53 - 1.42 (m, 2H), 1.36 - 1.30 (m, 1H). Compound 8: 8-(2,6-dioxopiperidin-3-yl)-2,2-dimethyl-2,3,8,9-tetrahydropyrano[2,3- e]isoindole-4,7-dione 92 275501297 v3
[000307] To a solution of 3-(2,2-dimethyl-7-oxo-2,3,7,9-tetrahydro-8H-spiro[pyrano[2,3- e]isoindole-4,2'-[1,3]dioxolan]-8-yl)piperidine-2,6-dione (2.6 g, 6.7 mmol, 1.0 eq) in acetone (15 mL) was added aqueous HCl solution (4 N) (5 mL, 20.0 mmol, 3.0 eq) and the reaction mixture was stirred at room temperature for 3 h. The reaction was diluted with EA (60 mL), washed with saturated NaHCO3 solution (10 mL x 3) and brine (10 mL x 3), dried over anhydrous Na2SO4, and filtered. The filtrate was concentrated under reduced pressure to afford 8-(2,6-dioxopiperidin-3-yl)-2,2-dimethyl-2,3,8,9-tetrahydropyrano[2,3-e]isoindole-4,7-dione (1.9 g, yield 82%) as an off-white solid. LC-MS (ESI): mass calcd. for C18H18N2O5, 342.12; m/z found, 343.0 [M+H]+.1H NMR (400 MHz, DMSO-d6) δ 11.01 (s, 1H), 7.88 (d, J = 8.0 Hz, 1H), 7.36 (d, J = 8.0 Hz, 1H), 5.16 - 5.11 (m, 1H), 4.45 (d, J = 17.2 Hz, 1H), 4.28 (d, J = 17.2 Hz, 1H), 2.97 - 2.85 (m, 3H), 2.68 - 2.54 (m, 1H), 2.45 - 2.40 (m, 1H), 1.98 - 1.93 (m, 1H), 1.44 (d, J = 2.0 Hz, 6H). Compound 9: 3-(4-hydroxy-2,2-dimethyl-7-oxo-3,4,7,9-tetrahydropyrano[2,3-e]isoindol- 8(2H)-yl)piperidine-2,6-dione
[000308] To a solution of 8-(2,6-dioxopiperidin-3-yl)-2,2-dimethyl-2,3,8,9- tetrahydropyrano[2,3-e]isoindole-4,7-dione (40 mg, 0.12 mmol, 1.0 eq) in THF (5 mL) was added NaBH4 (14 mg, 0.36 mmol, 3.0 eq) in portions. The reaction mixture was stirred at 40 ℃ for 3 h. After cooled to room temperature, the reaction mixture was diluted with EA (30 mL) and quenched with water (10 mL). The organic layer was washed with brine (10 mL x 3), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified with Prep-HPLC with YMC-Actus Triart C18 (5 µm, 21.2 x 250 mm), and mobile phase of 5-95% ACN in water (0.1% FA) over 23 min and then hold at 95% ACN for 3 min, at a flow rate of 20 mL/min to afford 3-(4-hydroxy-2,2-dimethyl-7-oxo-3,4,7,9- tetrahydropyrano[2,3-e]isoindol-8(2H)-yl)piperidine-2,6-dione (17.4 mg, yield 43%) as an off- 93 275501297 v3
white solid. LC-MS (ESI): mass calcd. for C18H20N2O5, 344.14; m/z found, 345.2 [M+H]+.1H NMR (400 MHz, DMSO-d6) δ 10.95 (s, 1H), 7.58 (d, J = 7.8 Hz, 1H), 7.24 (d, J = 7.8 Hz, 1H), 5.57 (d, J = 6.2 Hz, 1H), 5.10 - 5.06 (m, 1H), 4.81 - 4.67 (m, 1H), 4.29 (d, J = 17.23 Hz, 1H), 4.13 (d, J = 17.2 Hz, 1H), 2.99 - 2.82 (m, 1H), 2.60 - 2.54 (m, 1H), 2.47 - 2.38 (m, 1H), 2.21 - 2.11 (m, 1H), 1.99 - 1.97 (m, 1H), 1.85 - 1.72 (m, 1H), 1.41 (s, 3H), 1.29 (s, 3H). Compound 10: 3-(4-amino-2,2-dimethyl-7-oxo-3,4,7,9-tetrahydropyrano[2,3-e]isoindol- 8(2H)-yl)piperidine-2,6-dione
Step A: (E)-3-(4-(hydroxyimino)-2,2-dimethyl-7-oxo-3,4,7,9-tetrahydropyrano[2,3-e]isoindol- 8(2H)-yl)piperidine-2,6-dione [000309] To a solution of 8-(2,6-dioxopiperidin-3-yl)-2,2-dimethyl-2,3,8,9- tetrahydropyrano[2,3-e]isoindole-4,7-dione (350 mg, 1.0 mmol, 1.0 eq) in EtOH (10 mL) were added pyridine (0.25 mL, 3.1 mmol, 3.1 eq) and hydroxylamine hydrochloride (0.25 mL, 3.1 mmol, 3.1 eq). The reaction mixture was stirred under N2 at 70 ℃ for 3 h. After cooled to room temperature, the reaction mixture was evaporated and the residue was diluted with EA (100 mL). The organic layer was washed with saturated NH4Cl solution (20 mL x 3) and brine(20 mL x 3), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (EA/PE = 2/1) to afford (E)-3-(4-(hydroxyimino)-2,2-dimethyl-7-oxo-3,4,7,9-tetrahydropyrano[2,3-e]isoindol-8(2H)- yl)piperidine-2,6-dione (342 mg, yield 94%) as an off-white solid. LC-MS (ESI): mass calcd. for C18H19N3O5, 357.13; m/z found, 358.2 [M+H]+. Step B: 3-(4-amino-2,2-dimethyl-7-oxo-3,4,7,9-tetrahydropyrano[2,3-e]isoindol-8(2H)- yl)piperidine-2,6-dione [000310] To a solution of (E)-3-(4-(hydroxyimino)-2,2-dimethyl-7-oxo-3,4,7,9- tetrahydropyrano[2,3-e]isoindol-8(2H)-yl)piperidine-2,6-dione (342 mg, 0.96 mmol, 1.0 eq) in AcOH (10 mL) was added Zn powder (936 mg, 14.4 mmol, 15.0 eq). The reaction mixture was stirred at 120 ℃ for 1.5 h. After cooled to room temperature, the reaction mixture was filtered and the filtrate was concentrated under reduced pressure. The residue was diluted with EA (100 mL), washed with saturated aqueous NaHCO3 solution (20 mL x 3) and brine (20 mL), dried 94 275501297 v3
over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (DCM/EtOH = 10/1) to afford 3- (4-amino-2,2-dimethyl-7-oxo-3,4,7,9-tetrahydropyrano[2,3-e]isoindol-8(2H)-yl)piperidine- 2,6-dione (150 mg, yield 45%) as an off-white solid. LC-MS (ESI): mass calcd. for C18H21N3O4, 343.15; m/z found, 344.3 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 10.95 (s, 1H), 7.72 (d, J = 7.8 Hz, 1H), 7.27 (d, J = 7.8 Hz, 1H), 5.11 - 5.06 (m, 1H), 4.29 (d, J = 17.2 Hz, 1H), 4.21 - 4.10 (m, 2H), 2.96 - 2.85 (m, 1H), 2.61 - 2.55 (m, 1H), 2.49 - 2.37 (m, 1H), 2.22 - 2.12 (m, 1H), 2.01 - 1.93 (m, 1H), 1.76 - 1.61 (m, 1H), 1.42 (s, 3H), 1.26 (s, 3H). Compound 11: N-(8-(2,6-dioxopiperidin-3-yl)-2,2-dimethyl-7-oxo-2,3,4,7,8,9-hexahydro pyrano[2,3-e]isoindol-4-yl)acetamide
[000311] To a solution of 3-(4-amino-2,2-dimethyl-7-oxo-3,4,7,9-tetrahydropyrano[2,3- e]isoindol-8(2H)-yl)piperidine-2,6-dione (50 mg, 146 ummol, 1.0 eq) in DCM (5 mL) were added DIPEA (0.072 mL, 437 umol, 3.0 eq) and Ac2O (0.021 mL, 218 umol, 1.5 eq). The reaction was stirred at room temperature for 1.5 h. The mixture was diluted with DCM (20 mL), washed with water (15 mL) and brine (15 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by Prep-TLC (DCM/MeCN = 1/1) to give N-(8-(2,6-dioxopiperidin-3-yl)-2,2-dimethyl-7-oxo-2,3,4,7,8,9- hexahydropyrano[2,3-e]isoindol-4-yl)acetamide (39.5 mg, yield 70%) as an off-white solid. LC-MS (ESI): mass calcd. for C20H23N3O5, 385.16; m/z found, 386.3 [M+H]+.1H NMR (400 MHz, DMSO-d6) δ 10.96 (d, J = 4.4 Hz, 1H), 8.32 (d, J = 8.6 Hz, 1H), 7.29 (d, J = 8.0 Hz, 1H), 7.25 (d, J = 8.0 Hz, 1H), 5.16 - 5.07 (m, 2H), 4.30 (d, J = 17.4 Hz, 1H), 4.20 - 4.14 (m, 1H), 2.99 - 2.81 (m, 1H), 2.62 - 2.54 (m, 1H), 2.44 - 2.35 (m, 1H), 2.13 - 2.05 (m, 1H), 2.02 - 1.95 (m, 1H), 1.94 (s, 3H), 1.83 - 1.72 (m, 1H), 1.42 (s, 3H), 1.30 (s, 3H). Compound 12: N-(8-(2,6-dioxopiperidin-3-yl)-2,2-dimethyl-7-oxo-2,3,4,7,8,9-hexahydro pyrano[2,3-e]isoindol-4-yl)methanesulfonamide 95 275501297 v3
[000312] To a solution of 3-(4-amino-2,2-dimethyl-7-oxo-3,4,7,9-tetrahydropyrano[2,3- e]isoindol-8(2H)-yl)piperidine-2,6-dione (50 mg, 146 ^mmol, 1.0 eq) in DCM (5 mL) were added DIPEA (0.028 mL, 218 ^mol, 1.5 eq) and Ms2O (0.021 mL, 218 ^mol, 1.5 eq). The reaction was stirred at room temperature for 1.5 h. The mixture was diluted with DCM (20 mL), washed with water (15 mL) and brine (15 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by Prep-TLC (DCM/MeCN = 1/2) to give N-(8-(2,6-dioxopiperidin-3-yl)-2,2-dimethyl-7-oxo-2,3,4,7,8,9- hexahydropyrano[2,3-e]isoindol-4-yl)methanesulfonamide (7.0 mg, yield 11%) as an off-white solid. LC-MS (ESI): mass calcd. for C19H23N3O6S, 421.13; m/z found, 422.4 [M+H]+.1H NMR (400 MHz, DMSO-d6) δ 11.97 (s, 1H), 7.71 - 7.67 (m, 1H), 7.61 (d, J = 8.0 Hz, 1H), 7.29 (d, J = 8.0 Hz, 1H), 5.12 - 5.07 (m, 1H), 4.71 - 4.55 (m, 1H), 4.30 (d, J = 17.4 Hz, 1H), 4.22 - 4.10 (m, 1H), 3.13 (s, 3H), 2.99 - 2.83 (m, 1H), 2.61 - 2.55 (m, 1H), 2.47 - 2.41 (m, 1H), 2.35 - 2.29 (m, 1H), 2.00 - 1.95 (m, 1H), 1.91 - 1.81 (m, 1H), 1.43 (s, 3H), 1.31 (s, 3H). Compound 13: 3-(4-(aminomethyl)-2,2-dimethyl-7-oxo-3,4,7,9-tetrahydropyrano[2,3- e]isoindol-8(2H)-yl)piperidine-2,6-dione
Step A: 8-(2,6-dioxopiperidin-3-yl)-2,2-dimethyl-7-oxo-4-((trimethylsilyl)oxy)-2,3,4,7,8,9- hexahydropyrano[2,3-e]isoindole-4-carbonitrile [000313] To a solution of 8-(2,6-dioxopiperidin-3-yl)-2,2-dimethyl-2,3,8,9- tetrahydropyrano[2,3-e]isoindole-4,7-dione (750 mg, 2.19 mmol, 1.0 eq) in anhydrous DCM (15.0 mL) were added anhydrous ZnI2 (210 mg, 657 µmol, 0.3 eq) and TMSCN (2.17 g, 2.87 mL, 21.9 mmol, 10.0 eq). The reaction mixture was stirred under N2 at room temperature for 36 h. The reaction mixture was diluted with EA (150 mL), washed with saturated aqueous NaHCO3 solution (15 mL x 2) and brine (15 mL x 3), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column 96 275501297 v3
chromatography on silica gel (ethyl acetate in petroleum ether, from 0% to 50%) to afford 8- (2,6-dioxopiperidin-3-yl)-2,2-dimethyl-7-oxo-4-((trimethylsilyl)oxy)-2,3,4,7,8,9- hexahydropyrano[2,3-e]isoindole-4-carbonitrile (950 mg, yield 98%) as a yellow solid. LC- MS (ESI): mass calcd. for C22H27N3O5Si, 441.17; m/z found, 442.2 [M+H]+. Step B: 3-(4-(aminomethyl)-2,2-dimethyl-7-oxo-3,4,7,9-tetrahydropyrano[2,3-e]isoindol- 8(2H)-yl)piperidine-2,6-dione [000314] To a solution of 8-(2,6-dioxopiperidin-3-yl)-2,2-dimethyl-7-oxo-4- ((trimethylsilyl)oxy)-2,3,4,7,8,9-hexahydropyrano[2,3-e]isoindole-4-carbonitrile (50.0 mg, 113 µmol, 1.0 eq) in EtOH (4.00 mL) were added con. HCl (1.00 mL, 12.0 mmol, 106 Eq) and 10% Pd/C (12.1 mg, 113 µmol, 1.0 eq). The reaction mixture was stirred under H2 atmosphere (1 atm) at 12 °C for 18 h. After filtration, the filtrate was concentrated under reduced pressure and the residue was purified by flash column chromatography on silica gel (EtOH in DCM, from 0% to 20%) to afford a crude product (30 mg). The crude product was further purified by Prep-HPLC with YMC-Actus Triart C18 (5 µm, 21.2 x 250 mm), and mobile phase of 5-95% ACN in water (0.1% FA) over 23 min and then hold at 95% ACN for 3 min, at a flow rate of 20 mL/min to afford 3-(4-(aminomethyl)-2,2-dimethyl-7-oxo-3,4,7,9- tetrahydropyrano[2,3-e]isoindol-8(2H)-yl)piperidine-2,6-dione formate (1.70 mg, yield 4.2%) as a white solid. LC-MS (ESI): mass calcd. for C19H23N3O4, 357.17; m/z found, 358.3 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 10.92 (s, 1H), 8.31 (s, 1H), 7.52 (d, J = 7.8 Hz, 1H), 7.23 (d, J = 7.8 Hz, 1H), 5.10 - 5.05 (m, 1H), 4.28 (d, J = 17.2 Hz, 1H), 4.12 (d, J = 17.3 Hz, 1H), 3.06 - 3.01 (m, 1H), 2.93 - 2.84 (m, 2H), 2.63 - 2.54 (m, 1H), 2.48 - 2.38 (m, 2H), 2.11 - 2.03 (m, 1H), 2.02 - 1.93 (m, 1H), 1.74 - 1.62 (m, 1H), 1.43 (s, 3H), 1.22 (s, 3H). Compound 14: 8-(2,6-dioxopiperidin-3-yl)-2,2-dimethyl-7-oxo-2,7,8,9- tetrahydropyrano[2,3-e]isoindole-4-carbonitrile
[000315] To a solution of 8-(2,6-dioxopiperidin-3-yl)-2,2-dimethyl-7-oxo-4- ((trimethylsilyl)oxy)-2,3,4,7,8,9-hexahydropyrano[2,3-e]isoindole-4-carbonitrile (30.0 mg, 67.9 µmol, 1.0 eq) in Toluene (4.00 mL) was added p-toluenesulfonic acid (2.34 mg, 13.6 µmol, 0.2 eq). The reaction mixture was stirred under N2 at 100 °C for 18 h. After evaporation, 97 275501297 v3
the residue was purified by Prep-HPLC with YMC-Actus Triart 18C (5 µm, 20 x 250 mm), and mobile phase of 5-99% ACN in water (0.1% FA) over 10 min and then hold at 100% ACN for 2 min, at a flow rate of 25 mL/min to afford 8-(2,6-dioxopiperidin-3-yl)-2,2-dimethyl-7-oxo- 2,7,8,9-tetrahydropyrano[2,3-e]isoindole-4-carbonitrile (8.00 mg, yield 33%) as a white solid. LC-MS (ESI): mass calcd. for C19H17N3O4, 351.12; m/z found, 352.2 [M+H]+.1H NMR (400 MHz, DMSO-d6) δ 10.99 (s, 1H), 7.41 (s, 2H), 7.06 (s, 1H), 5.13 - 5.08 (m, 1H), 4.40 (d, J = 17.4 Hz, 1H), 4.23 (d, J = 17.4 Hz, 1H), 2.97 - 2.83 (m, 1H), 2.64 - 2.54 (m, 1H), 2.47 - 2.36 (m, 1H), 2.04 - 1.94 (m, 1H), 1.49 (s, 6H). Compound 15: 3-(7- (hydroxymethyl)-7-methyl-3-oxo-1,3,7,8-tetrahydro-2H-furo[3,2- e]isoindol-2-yl)piperidine-2,6-dione
Step A: 5-((2- methylallyl)oxy)isobenzofuran-1(3H)-one [000316] To a solution of 5-hydroxyisobenzofuran-1(3H)-one (5.00 g, 33.3 mmol, 1.0 eq) in DMF (30.0 mL) were added cesium carbonate (32.6 g, 99.9 mmol, 3.0 eq) and 3-bromo-2- methylprop-1-ene (4.37 mL, 43.3 mmol, 1.3 eq) at room temperature and the reaction mixture was stirred at room temperature for 2 h. The reaction mixture was diluted with EA (80 mL) and filtered. The filtrate was washed with brine (60 mL x 3), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (ethyl acetate in petroleum ether, from 0% to 20%) to afford 5- ((2- methylallyl)oxy)isobenzofuran-1(3H)-one (6 g, yield 88%) as a white solid. LC-MS (ESI): mass calcd. for C12H12O3, 204.1; m/z found, 205.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 7.75 (d, J = 8.4 Hz, 1H), 7.21 (d, J = 2.0 Hz, 1H), 7.14 (dd, J = 8.4, 2.0 Hz, 1H), 5.33 (s, 2H), 5.07 (s, 1H), 4.99 (s, 1H), 4.61 (s, 2H), 1.78 (s, 3H). Step B: 5-hydroxy-4-(2- methylallyl)isobenzofuran-1(3H)-one [000317] A solution of 5-((2-methylallyl)oxy)isobenzofuran-1(3H)-one (220 mg, 1.08 mmol, 1.0 eq) in 1-methylpyrrolidin-2-one (6.00 mL) was stirred under microwave at 150 oC for 1 h. After cooled to room temperature, the reaction mixture was diluted with EA (30 mL), washed with brine (30 mL x 3), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (ethyl acetate 98 275501297 v3
in petroleum ether, from 0% to 20%) to afford 5-hydroxy-4-(2- methylallyl)isobenzofuran- 1(3H)-one (100 mg, yield 50%) as a white solid. LC-MS (ESI): mass calcd. for C12H12O3, 204.1; m/z found, 205.2 [M+H]+.1H NMR (400 MHz, DMSO-d6) δ 10.59 (s, 1H), 7.57 (d, J = 8.4 Hz, 1H), 7.03 (d, J = 8.4 Hz, 1H), 5.22 (s, 2H), 4.73 (s, 1H), 4.54 (s, 1H), 3.30 (s, 2H), 1.68 (s, 3H) Step C: 5-hydroxy-4-((2-methyloxiran-2-yl)methyl)isobenzofuran-1(3H)-one [000318] To a solution of 5-hydroxy-4-(2-methylallyl)isobenzofuran-1(3H)-one (670 mg, 3.28 mmol, 1.0 eq) in DCM (15.0 mL) was added m-CPBA (85%) (906 mg, 5.25 mmol, 1.6 eq). The reaction was stirred at 40 oC for 1 h. After cooled to room temperature, the reaction was diluted with EA (40 mL), washed with saturated aqueous NaHCO3 solution (20 mL x 2) and brine (30 mL x 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to get 5-hydroxy-4-((2-methyloxiran-2-yl)methyl)isobenzofuran-1(3H)-one (700 mg, yield 98%) as a yellow solid. The crude product was directly used in next step without further purification. LC-MS (ESI): mass calcd. for C12H12O4, 220.2; m/z found, 221.1 [M+H]+. Step D: (7-methyl-3-oxo-1,3,7,8-tetrahydrobenzo[1,2-b:3,4-c']difuran-7-yl)methyl formate [000319] A solution of 5-hydroxy-4-((2-methyloxiran-2-yl)methyl)isobenzofuran-1(3H)-one (700 mg, 3.18 mmol, 1 eq) in HCOOH (8.00 mL) was stirred at 90 oC for 30 min. After evaporation, the residue was diluted with EA (40 mL), washed with saturated aqueous NaHCO3 solution (20 mL x 2) and brine (30 mL x 3), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (ethyl acetate in petroleum ether, from 0% to 30%) to afford (7- methyl-3-oxo-1,3,7,8-tetrahydrobenzo[1,2-b:3,4-c']difuran-7-yl)methyl formate (370 mg, yield 46%) as a colorless oil. LC-MS (ESI): mass calcd. for C13H12O5, 248.2; m/z found, 249.2 [M+H]+.1H NMR (400 MHz, DMSO-d6) δ 8.27 (s, 1H), 7.64 (d, J = 8.4 Hz, 1H), 6.96 (d, J = 8.4 Hz, 1H), 5.32 (s, 2H), 4.31 (s, 2H), 3.24 (d, J = 16.4 Hz, 1H), 3.05 (d, J = 16.4 Hz, 1H), 1.49 (s, 3H). Step E: 2,4-bis(hydroxymethyl)-2-methyl-2,3-dihydrobenzofuran-5- carboxylic acid [000320] To a solution of (7-methyl-3-oxo-1,3,7,8-tetrahydrobenzo[1,2-b:3,4-c']difuran-7- yl)methyl formate (680 mg, 2.74 mmol, 1.0 eq) and NaOH (0.55 g, 13.7 mmol, 5.0 eq) in THF/MeOH/H2O (7.0 mL 3 mL/3 mL/1 mL) and the reaction mixture was stirred at 50 oC for 1 h. After cooled to room temperature, the reaction mixture was diluted with EA (50 mL), adjusted to pH 4-5 with diluted aqueous HCl solution (3 M), and extracted with EA (40 mL x 4). The organic layer was washed with brine (20 mL x 2), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to afford 2,4-bis(hydroxymethyl)-2-methyl- 99 275501297 v3
2,3-dihydrobenzofuran-5-carboxylic acid (600 mg, yield 92%) as a colorless oil. The crude product was directly used in next step without further purification. LC-MS (ESI): mass calcd. for C12H14O5, 238.2; m/z found, 237.1 [M-H]-. Step F: 1-hydroxy-7-(hydroxymethyl)-7-methyl-7,8-dihydrobenzo[1,2-b:3,4-c']difuran-3(1H)- one [000321] To a solution of 2,4-bis(hydroxymethyl)-2-methyl-2,3-dihydrobenzofuran-5- carboxylic acid (600 mg, 2.52 mmol, 1.0 eq) in DMF (20.0 mL) was added MnO2 (4.38 g, 13.7 mmol, 20.0 eq). The mixture was stirred at room temperature for 12 h. After filtration, the filtrate was collected and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (methanol in dichloromethane, from 0% to 10%) to afford 1-hydroxy-7-(hydroxymethyl)-7-methyl-7,8-dihydrobenzo[1,2-b:3,4-c']difuran-3(1H)- one (310 mg, yield 52%) as a white solid. LC-MS (ESI): mass calcd. for C12H12O5, 236.2; m/z found, 235.0 [M-H]-.1H NMR (400 MHz, DMSO-d6) δ 8.03 (s, 1H), 7.61 (d, J = 8.2 Hz, 1H), 6.95 (d, J = 8.2 Hz, 1H), 6.57 (s, 1H), 5.17 (t, J = 5.6 Hz, 1H), 3.52 - 3.44 (m, 2H), 3.28 (d, J = 16.4 Hz, 1H), 2.90 (d, J = 16.4 Hz, 1H), 1.38 (s, 3H). Step G: 3-(7- (hydroxymethyl)-7-methyl-3-oxo-1,3,7,8-tetrahydro-2H-furo[3,2-e]isoindol-2- yl)piperidine-2,6-dione [000322] To a solution of 3-aminopiperidine-2,6-dione hydrochloride (418 mg, 2.54 mmol, 1.5 eq) in DMF (10.0 mL) was added TEA (257 mg, 2.54 mmol, 0.35 mL, 2.0 eq) and the reaction mixture was stirred at 40 oC for 10 min. Then 1-hydroxy-7-(hydroxymethyl)-7-methyl-7,8- dihydrobenzo[1,2-b:3,4-c']difuran-3(1H)-one (300 mg, 1.27 mmol, 1.0 eq) and acetic acid (0.52 g, 8.7 mmol, 0.50 mL, 6.8 eq) were added to above mixture and the resulting mixture was stirred at 40 oC for 2 h. Then Sodium triacetoxyborohydride (565 mg, 2.67 mmol, 3.0 eq) was added to above mixture and the resulting mixture was stirred at 40 oC for 16 h. After cooled to room temperature, the mixture was diluted with EA (50 mL), washed with brine (30 mL x 3), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (methanol in dichloromethane, from 0% to 10%) to afford 3-(7- (hydroxymethyl)-7-methyl-3-oxo-1,3,7,8- tetrahydro-2H-furo[3,2-e]isoindol-2-yl)piperidine-2,6-dione (340.0 mg, yield 81%) as a gray solid. LC-MS (ESI): mass calcd. for C17H18N2O5, 330.3; m/z found, 331.1 [M+H]+.1H NMR (400 MHz, DMSO-d6) δ 10.96 (s, 1H), 7.47 (d, J = 8.2 Hz, 1H), 6.83 (d, J = 8.2 Hz, 1H), 5.12 - 5.06 (m, 2H), 4.34 (d, J = 17.2 Hz, 1H), 4.21 (d, J = 17.2 Hz, 1H), 3.50 - 3.45 (m, 2H), 3.21 (d, J = 16.0 Hz, 1H), 2.97 - 2.85 (m, 2H), 2.61 - 2.56 (m, 1H), 2.44 - 2.30 (m, 1H), 2.01 - 1.92 (m, 1H), 1.38 (s, 3H). 100 275501297 v3
Compound 16: 3-(4-(2-aminoethyl)-4-methyl-6-oxo-3,4,6,8-tetrahydropyrano[2,3- f]isoindol-7(2H)-yl)piperidine-2,6-dione
[000323] To a solution of freshly distilled TMEDA (13.9 g, 120 mmol, 2.0 eq) in THF (30 mL) was added dropwise n-BuLi (2.5 M in hexane) (75 mL, 120 mmol) at 0 °C and the mixture was stirred for 15 min. A solution of 3-methylbut-3-en-1-ol (6.1 mL, 60 mmol, 1.0 eq) in THF (20 mL) was added dropwise to above mixture over 15 min and the reaction mixture allowed to warm to temperature over 30 min. The reaction mixture was then vigorously stirred for 15 h at room temperature to give a pale yellow suspension, diluted with freshly distilled THF (30 mL), and cooled to –78 °C before addition of dry paraformaldehyde (1.9 g, 63.0 mmol, 1.05 eq) in one portion. The reaction mixture was then allowed to warm to room temperature over 1 h and stirred vigorously overnight. The reaction mixture was quenched with saturated aqueous NH4Cl solution (50 mL) and the aqueous layer was extracted with CHCl3/i-PrOH (8/2, 100 mL x 5). The combined organic layers were dried over anhydrous MgSO4, filtered and concentrated under reduced pressure. The residue purified by flash column chromatography on silica gel (100% EA) to give 3-methylidenepentane-1,5-diol (1.7 g, yield 24%) as a light yellow oil. LC- MS (ESI): C6H12O2 mass calcd. for 116.1; m/z found, 117.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 4.97 (s, 2H), 3.75 (t, J = 6.2 Hz, 4H), 2.32 (t, J = 6.2 Hz, 4H). Step B: 5-(benzyloxy)-3-methylenepentan-1-ol [000324] To a solution of 3-methylidenepentane-1,5-diol (1.7 g, 15 mmol, 1.0 eq) in DCM (30 mL) were added Silver(I) Oxide (6.8 g, 30 mmol, 2.0 eq) and Benzyl bromide (2.7 g, 15 mmol, 1.0 eq) at room temperature. The reaction mixture was stirred at room temperature overnight. The reaction mixture was quenched with water (50 mL) and extracted with EtOAc (30 mL x 3). The organic layer was washed with brine (30 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (100% EA) to give 5-(benzyloxy)-3-methylidenepentan-1-ol (2.1 g, yield 70%) as a yellow oil. LC-MS (ESI): C13H18O2 mass calcd. for 206.1; m/z found, 207.1 [M+H]+.1H NMR (400 MHz, CDCl3) δ 7.27 - 7.18 (m, 5H), 4.88 - 4.81 (m, 2H), 4.44 (s, 2H), 3.63 (t, J = 6.2 Hz, 2H), 3.53 (t, J = 6.8 Hz, 2H), 2.31 - 2.22 (m, 4H). 101 275501297 v3
Step C: methyl 5-((5-(benzyloxy)-3-methylenepentyl)oxy)-4-bromo-2-methylbenzoate [000325] To a solution of methyl 4-bromo-5-hydroxy-2-methylbenzoate (4.2 g, 17.1 mmol, 1.0 eq),5-(benzyloxy)-3-methylidenepentan-1-ol (4.24 g, 20.6 mmol, 1.2 eq), and PPh3 (5.39 g, 20.6 mmol, 1.2 eq) in THF (45 mL) was added dropwise DIAD (4.16 g, 20.6 mmol, 1.2 eq). The mixture was stirred under N2 at room temperature for 16 h. The reaction mixture was quenched with water (50 mL) and extracted with EA (50 mL x 3). The organic layer was washed with brine (80 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel (ethyl acetate in petroleum ether, from )5 to 6%) to give methyl 5-((5-(benzyloxy)-3- methylenepentyl)oxy)-4-bromo-2-methylbenzoate (6.6 g, yield 88%) as a colorless oil. LC-MS (ESI): mass calcd. for C22H25BrO4, 433.34; m/z found, 434.3 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 7.59 (s, 1H), 7.44 (s, 1H), 7.34 - 7.25 (m, 5H), 4.91 (d, J = 13.8 Hz, 2H), 4.47 (s, 2H), 4.16 (t, J = 6.6 Hz, 2H), 3.83 (s, 3H), 3.58 (t, J = 6.8 Hz, 2H), 2.49 (d, J = 8.0 Hz, 2H), 2.42 (s, 3H), 2.39 (t, J = 6.8 Hz, 2H). Step D: methyl 4-(2-(benzyloxy)ethyl)-4,6-dimethylchromane-7-carboxylate [000326] To a solution of methyl 5-((5-(benzyloxy)-3-methylenepentyl)oxy)-4-bromo-2- methylbenzoate (6.6 g, 15.2 mmol, 1.0 eq) in DMF (66 mL) were added NaOAc (3.37 g, 41.1 mmol, 2.7 eq), sodium formate (1.35 g, 19.8 mmol, 1.3 eq), Tetraethylammonium chloride monohydrate (3.64 g, 19.8 mmol, 1.3 eq), and Pd(OAc)2 (340 mg, 1.5 mmol, 0.1 eq). The mixture was stirred under N2 at 90 oC for 3 h. After cooled to room temperature, the reaction mixture was quenched with water (120 mL) and extracted with EA (90 mL x 3). The organic layer was washed with brine (100 mL x 4), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel (ethyl acetate in petroluem ether, from 0% to 5%) to give methyl 4-(2-(benzyloxy)ethyl)-4,6-dimethylchromane-7-carboxylate (3.5 g, yield 64%) as a colorless oily. LC-MS (ESI): mass calcd. for C22H26O4, 354.45; m/z found, 355.45 [M+H]+. 1HNMR (400 MHz, DMSO-d6) δ 7.38 - 7.30 (m, 6H), 7.22 (s, 1H), 4.46 (s, 2H), 4.24 - 4.20 (m, 1H), 4.16 - 4.10 (m, 1H), 3.85 (s, 3H), 3.54 - 3.44 (m, 2H), 2.46 (s, 3H), 2.10 - 1.97 (m, 3H), 2.07 - 2.00 (m, 1H), 1.36 (s, 3H). Step E: methyl 4-(2-hydroxyethyl)-4,6-dimethylchromane-7-carboxylate [000327] To a solution of methyl 4-(2-(benzyloxy)ethyl)-4,6-dimethylchroman-7-carboxylate (3.0 g, 8.5 mmol, 1.0 eq) in MeOH (30 mL) was added 10% Pd/C (300 mg). The mixture was stirred under H2 (1 atm) at room temperature for 10 h. After filtration, the filtrate was 102 275501297 v3
concentrated under reduced pressure to afford methyl 4-(2-hydroxyethyl)-4,6- dimethylchroman-7-carboxylate (2.0 g, yield 89%) as a colorless oil. The crude product was directly used in next step without further purification. LC-MS (ESI): mass calcd. for C15H20O4, 264.1; m/z found, 265.1 [M+H]+. Step F: methyl 4-(2-bromoethyl)-4,6-dimethylchroman-7-carboxylate [000328] To a solution of methyl 4-(2-hydroxyethyl)-4,6-dimethylchroman-7-carboxylate (1.5 g, 5.67 mmol, 1.0 eq) and PPh3 (1.94 g, 7.38 mmol, 1.3 eq) in DCM (30 mL) was added CBr4 (2.26 g, 6.81 mmol, 1.2 eq) at 0 oC. The mixture was stirred under N2 at 25 oC overnight. After evaporation, the residue was poured into water (100 mL) and extracted with EtOAc (100 mL x 3). The organic layer was washed with brine (100 mL), dried over anhydrous MgSO4, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel (ethyl acetate in petroleum ether, from 0% to 10%) to give methyl 4-(2-bromoethyl)-4,6-dimethylchroman-7-carboxylate (1.6 g, yield 86%) as a colorless oil. LC-MS (ESI): mass calcd. for C + 15H19BrO3, 326.05; m/z found, 327.3 [M+H].1H NMR (400 MHz, CDCl3) δ 7.37 (s, 1H), 7.01 (s, 1H), 4.34 - 4.02 (m, 2H), 3.86 (s, 3H), 3.33 - 3.27 (m, 1H), 3.20 - 3.15 (m, 1H), 2.52 (s, 3H), 2.44 - 2.14 (m, 2H), 2.11 - 1.93 (m, 1H), 1.74 - 1.68 (m, 1H), 1.37 (s, 3H). Step G: methyl 4-(2-azidoethyl)-4,6-dimethylchroman-7-carboxylate [000329] To a solution of methyl 4-(2-bromoethyl)-4,6-dimethylchroman-7-carboxylate (1.5 g, 4.60 mmol, 1.0 eq) in DMF (30 mL) was added NaN3 (598 mg, 9.2 mmol, 2.0 eq). The mixture was stirred at 60 oC for 12 h. The reaction mixture was cooled to room temperature, quenched with water (60 mL), and extracted with EtOAc (60 mL x 3). The organic layer was washed with brine (40 mL x 4), dried over anhydrous MgSO4, and filtered. The filtrate was concentrated under reduced pressure to afford methyl 4-(2-azidoethyl)-4,6-dimethylchroman- 7-carboxylate (1.1 g, yield 83%) as a colorless oil. The crude product was directly used in next step without further purification. LC-MS (ESI): mass calcd. for C15H19N3O3, 289.1; m/z found, 290.2 [M+H]+. Step H: methyl 4-(2-aminoethyl)-4,6-dimethylchroman-7-carboxylate [000330] To a solution of methyl 4-(2-azidoethyl)-4,6-dimethylchroman-7-carboxylate (1.1 g, 3.8 mmol, 1.0 eq) in MeOH (15 mL) was added 10% Pd/C (110 mg). The mixture was stirred under H2 (1 atm) at room temperature for 10 h. After filtration, the filtrate was concentrated under reduced pressure to afford methyl 4-(2-aminoethyl)-4,6-dimethylchroman-7-carboxylate (940 mg, yield 94%) as a colorless oil. The crude product was directly used in next step without 103 275501297 v3
further purification. LC-MS (ESI): mass calcd. for C15H21NO3, 263.2; m/z found, 264.2 [M+H]+. Step I: methyl 4-(2-((tert-butoxycarbonyl)amino)ethyl)-4,6-dimethylchroman-7-carboxylate [000331] To a solution of methyl 4-(2-aminoethyl)-4,6-dimethylchroman-7-carboxylate (940 mg, 3.56 mmol, 1.0 eq) in DCM (25 mL) were added Boc2O (1.1 g, 5.34 mmol, 1.5 eq), DMAP (43 mg, 0.356 mmol, 0.1 eq), and TEA (719 mg, 7.12 mmol, 2.0 eq). The mixture was stirred at room temperature for 2 h. The reaction mixture was quenched with water (30 mL) and extracted with DCM (40 mL x 3). The organic layer was washed with brine (30 mL), dried over anhydrous MgSO4, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel (ethyl acetate in petroleum ether, from 0% to 20%) to methyl 4-(2-((tert-butoxycarbonyl)amino)ethyl)-4,6-dimethylchroman-7- carboxylate (1.1 g, yield 83%) as a colorless oil. LC-MS (ESI): mass calcd. for C20H29NO5, 363.2; m/z found, 364.2 [M+H]+. [000332] 1H NMR (400 MHz, DMSO-d6) δ 7.19 (s, 1H), 7.15 (s, 1H), 6.73 (d, J = 5.0 Hz, 1H), 4.25 - 4.01 (m, 2H), 3.78 (s, 3H), 3.00 - 2.69 (m, 2H), 2.45 (s, 3H), 1.98 - 1.87 (m, 1H), 1.82 - 1.60 (m, 3H), 1.35 (s, 9H), 1.27 (s, 3H). Step J: methyl 6-(bromomethyl)-4-(2-((tert-butoxycarbonyl)amino)ethyl)-4-methyl chroman- 7-carboxylate [000333] To a solution of methyl 4-(2-((tert-butoxycarbonyl)amino)ethyl)-4,6-dimethylchr oman-7-carboxylate (500 mg, 1.38 mmol, 1.0 eq) in CCl4 (15 mL) were added NBS (269 mg, 1.51 mmol, 1.1 eq) and BPO (100 mg, 0.413 mmol, 0.3 eq). The mixture was stirred at 80 oC for 4 h. After evaporation, the residue was purified by flash column chromatography on silica gel (ethyl acetate in petroluem ether, from 0% to 10%) to afford methyl 6-(bromomethyl)-4- (2-((tert-butoxycarbonyl)amino)ethyl)-4-methylchroman-7-carboxylate (410 mg, yield 67%) as a yellow solid. LC-MS (ESI): mass calcd. for C20H28BrNO5, 441.2; m/z found, 464.3 [M+23]+. Step K: tert-butyl(2-(7-(2,6-dioxopiperidin-3-yl)-4-methyl-8-oxo-2,3,4,6,7,8-hexahy dropyrano[2,3-f]isoindol-4-yl)ethyl)carbamate [000334] To a solution of methyl 6-(bromomethyl)-4-(2-((tert-butoxycarbonyl)amino)ethyl)- 4-methylchroman-7-carboxylate (280 mg, 0.633 mmol, 1.0 eq) in ACN (50 mL) was added DIEA (245 mg, 1.9 mmol, 3.0 eq) and 3-aminopiperidine-2,6-dione hydrochloride (104 mg, 0.633 mmol, 1.0 eq). The mixture was stirred at 80 oC for 12 h. After evaporation, the crude product was purified by flash column chromatography on silica gel (ethyl acetate in petroleum 104 275501297 v3
ether, from 0% to 80%) to afford tert-butyl(2-(7-(2,6-dioxopiperidin-3-yl)-4-methyl-8-oxo- 2,3,4,6,7,8-hexahydro pyrano[2,3-f]isoindol-4-yl)ethyl)carbamate (200 mg, yield 69%) as a white solid. LC-MS (ESI): mass calcd. for C24H31N3O6, 457.2; m/z found, 402.2 [M+H-56]+. 1H NMR (400 MHz, CDCl3) δ 10.98 (s, 1H), 7.52 (s, 1H), 7.01 (s, 1H), 6.75 (s, 1H), 5.11 - 5.06 (m, 1H), 4.35 (dd, J = 16.6, 2.0 Hz, 1H), 4.27 - 4.09 (m, 3H), 3.00 - 2.76 (m, 3H), 2.65 - 2.54 (m, 1H) , 2.46 - 2.34 (m, 1H), 2.00 - 1.95 (m, 2H), 1.85 - 1.67 (m, 3H), 1.36 (d, J = 2.8 Hz, 9H), 1.32 (d, J = 4.8 Hz, 3H). Step L: 3-(4-(2-aminoethyl)-4-methyl-8-oxo-3,4-dihydropyrano[2,3-f]isoindol-7(2H,6H,8H)- yl)piperidine-2,6-dione hydrochloride [000335] To a solution of tert-butyl (2-(7-(2,6-dioxopiperidin-3-yl)-4-methyl-8-oxo - 2,3,4,6,7,8-hexahydropyrano[2,3-f]isoindol-4-yl)ethyl)carbamate (200 mg, 0.437 mmol, 1.0 eq) in 1,4-dioxane (5 mL) was added HCl-dioxane (4 M) (5 mL, 20 mmol, 45 eq). The mixture was stirred at room temperature for 1 h. After filtration, the filter cake was washed with ACN (10 mL x 3) and dried to afford 3-(4-(2-aminoethyl)-4- methyl-8-oxo-3,4-dihydropyrano[2,3- f]isoindol-7(2H,6H,8H)-yl)piperidine-2,6-dione hydrochloride (125 mg, yield 69%) as a light blue solid. LC-MS (ESI): mass calcd. for C19H23N3O4, 357.2; m/z found, 358.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 10.98 (s, 1H), 8.11 (s, 3H), 7.54 (d, J = 6.0 Hz, 1H), 7.03 (s, 1H), 5.11 - 5.06 (m, 1H), 4.47 - 4.08 (m, 4H), 2.99 - 2.72 (m, 2H), 2.61 - 2.57 (m, 2H), 2.41 - 2.36 (m, 1H), 2.09 - 2.06 (m, 1H), 2.02 - 1.94 (m, 3H) , 1.77 - 1.66 (m, 1H), 1.34 (d, J = 4.6 Hz, 3H). ^ Biological Actvity of Cereblon Ligands Cereblon Binding Assay [000336] In vitro Assay: IC50 Measurements for binding to CRBN/DDB1 (Table E1) [000337] The binding potency was determined using HTRF assay technology (Perkin Elmer). Compounds were serially diluted in DMSO and 0.2 µL volume was transferred to white 384- well plate. The reaction was conducted in total volume of 20 µL with addition of 2 nM His tagged CRBN+DDB-DLS7+CXU4 (Wuxi, catalogue # RP210521GA) to compounds followed by addition of 60 nM Fluorescent probe Cy5-labeled Thalidomide (Tenova Pharma, catalogue # T52461), and 0.4 nM of MAb Anti-6HIS Tb cryptate Gold (Cisbio, catalogue # 61HI2TLA in the assay buffer (50 mM HEPES pH 7.5, 1 mM TCEP, 0.01% Brij-35, 50 mM NaCl, and 0.1% BSA). After one hour incubation at room temperature, the HTRF signals were read on Envision reader (Perkin Elemer). Data was analyzed using XLfit using four parameters dose response curve to determine IC50s. 105 275501297 v3
Table E1.
Note: A: IC50 < 0.01 ^M; B: 0.01 ^M < IC50 < 0.1 ^M; C: 0.1 ^M < IC50 < 1 ^M 106 275501297 v3
INCORPORATION BY REFERENCE [000338] All publications and patents mentioned herein are hereby incorporated by reference in their entirety as if each individual publication or patent was specifically and individually indicated to be incorporated by reference. In case of conflict, the present application, including any definitions herein, will control. EQUIVALENTS [000339] As used herein and in the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “an agent” includes a plurality of such agents, and reference to “the cell” includes reference to one or more cells (or to a plurality of cells) and equivalents thereof known to those skilled in the art, and so forth. [000340] While specific embodiments of the subject invention have been discussed, the above specification is illustrative and not restrictive. Many variations of the invention will become apparent to those skilled in the art upon review of this specification and the claims below. The full scope of the invention should be determined by reference to the claims, along with their full scope of equivalents, and the specification, along with such variations. 107 275501297 v3
Claims
CLAIMS WHAT IS CLAIMED IS: 1. A compound of Formula I:
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein: R1 is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, 3- to 12- membered heterocyclyl, -SRb, -S(=O)Ra, -S(=O)2Ra, -S(=O)2ORb, -S(=O)2NRcRd, - NRcS(=O)2Ra, -NRcS(=O)Ra, -NRcS(=O)2ORb, -NRcS(=O)2NRcRd, -NRbC(=O)NRcRd, - NRbC(=O)Ra, -NRbC(=O)ORb, -OS(=O)2Ra, -OS(=O)2ORb, -OS(=O)2NRcRd, -OC(=O)Ra, -OC(=O)ORb, -OC(=O)NRcRd, -C(=O)Ra, -C(=O)ORb, or -C(=O)NRcRd, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more Ru; or R1 and R2, together with the intervening carbon atoms, form Ring A; Y” is N or CR3; R3 is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, 3- to 12- membered heterocyclyl, -SRb, -S(=O)Ra, -S(=O)2Ra, -S(=O)2ORb, -S(=O)2NRcRd, - NRcS(=O)2Ra, -NRcS(=O)Ra, -NRcS(=O)2ORb, -NRcS(=O)2NRcRd, -NRbC(=O)NRcRd, - NRbC(=O)Ra, -NRbC(=O)ORb, -OS(=O)2Ra, -OS(=O)2ORb, -OS(=O)2NRcRd, -OC(=O)Ra, -OC(=O)ORb, -OC(=O)NRcRd, -C(=O)Ra, -C(=O)ORb, or -C(=O)NRcRd, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more Ru; or R2 and R3, together with the intervening carbon atoms, form Ring A; provided that either R1 and R2 or R2 and R3 form Ring A, Y’ is N or CRY’; RY’ is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, or 3- to 12-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl is optionally substituted with one or more Ru; 108 275501297 v3
denotes an optional covalent bond between Y and U; when the bond between Y and U is absent: r is 0 or 1; X is O or N; wherein when X is O, then U is absent; Y is N or CRY; RY is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, or 3- to 12-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl is optionally substituted with one or more Ru; and U is absent, hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, 3- to 12-membered heterocyclyl, -S(=O)Ra, -S(=O)2Ra, - S(=O)2ORb, -S(=O)2NRcRd, -C(=O)Ra, -C(=O)ORb, or -C(=O)NRcRd, wherein the alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more Ru; when the bond between Y and U is present: r is 1; X is N; Y is C; and U is -CH2- or -C(=O)- R4 is hydrogen, deuterium, C1-6 haloalkyl, or C1-6 alkyl; q is an integer from 0 to 2, Ring A is
wherein: each Ri independently is oxo, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, 3- to 12-membered heterocyclyl, -SRb, -S(=O)Ra, -S(=O)2Ra, -S(=O)2ORb, - S(=O)2NRcRd, -NRcS(=O)2Ra, -NRcS(=O)Ra, -NRcS(=O)2ORb, -NRcS(=O)2NRcRd, - NRbC(=O)NRcRd, -NRbC(=O)Ra, -NRbC(=O)ORb, -OS(=O)2Ra, -OS(=O)2ORb, - OS(=O)2NRcRd, -OC(=O)Ra, -OC(=O)ORb, -OC(=O)NRcRd, -C(=O)Ra, -C(=O)ORb, or - 109 275501297 v3
C(=O)NRcRd, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more Ru; s is an integer selected from 0 to 5; m is an integer selected from 0 to 2; Rcp is , wherein: Rend is -ORH1, -N(RH2)2, -SRH3, or -C(=O)ORH4; RH1 is hydrogen, C1-6 alkyl, -S(=O)2Ra, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, or a hydroxyl- protecting group, wherein the C1-6 alkyl is optionally substituted with one or more Ru; RH2 is hydrogen, C1-6 alkyl, -S(=O)2Ra, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, or an amino- protecting group, wherein the C1-6 alkyl is optionally substituted with one or more Ru; RH3 is hydrogen, C1-6 alkyl, -C(=O)Ra, or a thiol-protecting group, wherein the C1-6 alkyl is optionally substituted with one or more Ru; RH4 is hydrogen, C1-6 alkyl, or a carboxylic acid-protecting group, wherein the C1-6 alkyl is optionally substituted with one or more Ru; each occurrence of G is independently -C(RG1)2-, -O-, -NRG2-, -C(=O)-, -S-, or -S(=O)2-; each RG1 is independently hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, or 3- to 12-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl is optionally substituted with one or more Ru; each RG2 is independently hydrogen or C1-6 alkyl optionally substituted with one or more Ru; and p is an integer selected from 0 to 5, wherein: each Ru is independently oxo, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, 3- to 12-membered heterocyclyl, -SRb, -S(=O)Ra, -S(=O)2Ra, -S(=O)2ORb, - S(=O)2NRcRd, -NRcS(=O)2Ra, -NRcS(=O)Ra, -NRcS(=O)2ORb, -NRcS(=O)2NRcRd, - NRbC(=O)NRcRd, -NRbC(=O)Ra, -NRbC(=O)ORb, -OS(=O)2Ra, -OS(=O)2ORb, - OS(=O)2NRcRd, -OC(=O)Ra, -OC(=O)ORb, -OC(=O)NRcRd, -C(=O)Ra, -C(=O)ORb, or - 110 275501297 v3
C(=O)NRcRd; wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more substituents selected from oxo, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C3-6 carbocyclyl, and 3- to 6-membered heterocyclyl; or two Ru, together with the one or more intervening atoms, form C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl or 3- to 12-membered heterocyclyl; each Ra is independently C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-12 carbocyclyl, 3- to 12- membered heterocyclyl, C6-10 aryl, or 5- to 10-membered heteroaryl; each Rb is independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-12 carbocyclyl, 3- to 12-membered heterocyclyl, C6-10 aryl, or 5- to 10-membered heteroaryl; and each Rc and Rd is independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-12 carbocyclyl, 3- to 12-membered heterocyclyl, C6-10 aryl, or 5- to 10-membered heteroaryl; or Rc and Rd, together with the nitrogen atom to which they are attached, form 3- to 12-membered heterocyclyl, wherein each occurrence of Ra, Rb, Rc, and Rd is independently and optionally substituted with one or more Rz; and each Rz is independently oxo, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C3-6 carbocyclyl, or 3- to 6-memberred heterocyclyl. 2. The compound of claim 1, wherein the compound is not
3. The compound of claim 1 or 2, wherein Rend is -ORH1 or -N(RH2)2. 4. The compound of any one of claims 1-3, wherein each occurrence of G is independently -C(RG1)2-, -O-, -NRG2- or -C(=O)-, and each RG1 is independently hydrogen, halogen, or C1-6 alkyl. 111 275501297 v3
5. The compound of any one of claims 1-4, wherein Rcp is -(CH2)nOH, or -(CH2)nNH2, wherein n is an integer selected from 0 to 4. 6. A conjugate of Formula I:
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein: R1 is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, 3- to 12- membered heterocyclyl, -SRb, -S(=O)Ra, -S(=O)2Ra, -S(=O)2ORb, -S(=O)2NRcRd, - NRcS(=O)2Ra, -NRcS(=O)Ra, -NRcS(=O)2ORb, -NRcS(=O)2NRcRd, -NRbC(=O)NRcRd, - NRbC(=O)Ra, -NRbC(=O)ORb, -OS(=O)2Ra, -OS(=O)2ORb, -OS(=O)2NRcRd, -OC(=O)Ra, -OC(=O)ORb, -OC(=O)NRcRd, -C(=O)Ra, -C(=O)ORb, or -C(=O)NRcRd, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more Ru; R1 and R2, together with the intervening carbon atoms, form Ring A’; Y” is N or CR3; R3 is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, 3- to 12- membered heterocyclyl, -SRb, -S(=O)Ra, -S(=O)2Ra, -S(=O)2ORb, -S(=O)2NRcRd, - NRcS(=O)2Ra, -NRcS(=O)Ra, -NRcS(=O)2ORb, -NRcS(=O)2NRcRd, -NRbC(=O)NRcRd, - NRbC(=O)Ra, -NRbC(=O)ORb, -OS(=O)2Ra, -OS(=O)2ORb, -OS(=O)2NRcRd, -OC(=O)Ra, -OC(=O)ORb, -OC(=O)NRcRd, -C(=O)Ra, -C(=O)ORb, or -C(=O)NRcRd, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more Ru; or R2 and R3, together with the intervening carbon atoms, form Ring A’; provided that either R1 and R2, or R2 and R3, form Ring A’; Y’ is N or CRY’; RY’ is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, or 3- to 112 275501297 v3
12-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl is optionally substituted with one or more Ru; denotes an optional covalent bond between Y and U; when the bond between Y and U is absent: r is 0 or 1; X is O or N; wherein when X is O, then U is absent; Y is N or CRY; RY is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, or 3- to 12-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl is optionally substituted with one or more Ru; and U is absent, hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, 3- to 12-membered heterocyclyl, -S(=O)Ra, -S(=O)2Ra, - S(=O)2ORb, -S(=O)2NRcRd, -C(=O)Ra, -C(=O)ORb, or -C(=O)NRcRd, wherein the alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more Ru; when the bond between Y and U is present: r is 1; X is N; Y is C; and U is -CH2- or -C(=O)-; R4 is hydrogen, deuterium, C1-6 haloalkyl, or C1-6 alkyl; q is an integer from 0 to 2, Ring A’ is
, wherein: each Ri independently is oxo, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, 3- to 12-membered heterocyclyl, -SRb, -S(=O)Ra, -S(=O)2Ra, -S(=O)2ORb, - S(=O)2NRcRd, -NRcS(=O)2Ra, -NRcS(=O)Ra, -NRcS(=O)2ORb, -NRcS(=O)2NRcRd, - NRbC(=O)NRcRd, -NRbC(=O)Ra, -NRbC(=O)ORb, -OS(=O)2Ra, -OS(=O)2ORb, - 113 275501297 v3
OS(=O)2NRcRd, -OC(=O)Ra, -OC(=O)ORb, -OC(=O)NRcRd, -C(=O)Ra, -C(=O)ORb, or - C(=O)NRcRd, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more Ru; s is an integer selected from 0 to 5; m is an integer selected from 0 to 2; Rcp’ is
, wherein: Rv is -O-, -N(RG3)-, -S-, or -C(=O)O-; RG3 is hydrogen or C1-6 alkyl optionally substituted with one or more Ru; each occurrence of G is independently -C(RG1)2-, -O-, -NRG2-, -C(=O)-, -S-, or -S(=O)2-; each RG1 is independently hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, or 3- to 12-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl is optionally substituted with one or more Ru; each RG2 is independently hydrogen or C1-6 alkyl optionally substituted with one or more Ru; p is an integer selected from 0 to 5, L is a linker, and T is a ligand for a protein, wherein: each Ru is independently oxo, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, 3- to 12-membered heterocyclyl, -SRb, -S(=O)Ra, -S(=O)2Ra, -S(=O)2ORb, - S(=O)2NRcRd, -NRcS(=O)2Ra, -NRcS(=O)Ra, -NRcS(=O)2ORb, -NRcS(=O)2NRcRd, - NRbC(=O)NRcRd, -NRbC(=O)Ra, -NRbC(=O)ORb, -OS(=O)2Ra, -OS(=O)2ORb, - OS(=O)2NRcRd, -OC(=O)Ra, -OC(=O)ORb, -OC(=O)NRcRd, -C(=O)Ra, -C(=O)ORb, or - C(=O)NRcRd; wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more substituents 114 275501297 v3
selected from oxo, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C3-6 carbocyclyl, and 3- to 6-membered heterocyclyl; or two Ru, together with the one or more intervening atoms, form C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl or 3- to 12-membered heterocyclyl; each Ra is independently C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-12 carbocyclyl, 3- to 12- membered heterocyclyl, C6-10 aryl, or 5- to 10-membered heteroaryl; each Rb is independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-12 carbocyclyl, 3- to 12-membered heterocyclyl, C6-10 aryl, or 5- to 10-membered heteroaryl; and each Rc and Rd is independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-12 carbocyclyl, 3- to 12-membered heterocyclyl, C6-10 aryl, or 5- to 10-membered heteroaryl; or Rc and Rd, together with the nitrogen atom to which they are attached, form 3- to 12-membered heterocyclyl, wherein each occurrence of Ra, Rb, Rc, and Rd is independently and optionally substituted with one or more Rz; and each Rz is independently oxo, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C3-6 carbocyclyl, or 3- to 6-memberred heterocyclyl. 7. The conjugate of claim 6, wherein Rv is -O- or -N(RG3)-. 8. The conjugate of claim 6 or 7 , wherein each occurrence of G is independently -C(RG1)2- , -O-, -NRG2- or -C(=O)-, and each RG1 is independently hydrogen, halogen, or C1-6 alkyl. 9. The conjugate of any one of claims 6-8, wherein -RV-[G]p- is *-(CH2)nO- or *- (CH2)nNH-, wherein n is an integer selected from 0 to 4, and * denotes attachment to Ring A’. 10. The conjugate of claim 9, wherein -RV-[G]p- is *-CH2O-. 11. The compound or conjugate of any one of claims 1-10, wherein the compound or conjugate of Formula I is a compound or conjugate of Formula I-1
115 275501297 v3
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. 12. The compound or conjugate of any one of claims 1-10, wherein the compound or conjugate of Formula I is a compound or conjugate of Formula I-2
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. 13. The compound or conjugate of claim 12, wherein U is hydrogen or C1-6 alkyl. 14. The compound or conjugate of claim 12 or 13, wherein Y is CRY, and RY is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, or 3- to 12-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl is optionally substituted with one or more Ru. 15. The compound or conjugate of claim 14, wherein RY is hydrogen. 16. The compound or conjugate of any one of claims 1-15, wherein R1 and R2, together with the intervening carbon atoms, form Ring A or Ring A’. 17. The compound or conjugate of claim 16, wherein the compound of Formula I-1 is a compound of Formula I-1-i’, I-1-ii’, I-1-iii’, or I-1-iv’:
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, or 116 275501297 v3
the conjugate of Formula I-1 is a conjugate of Formula I’-1-i’ or I’-1-ii’
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. 18. The compound or conjugate of claim 16, wherein the compound of Formula I-2 is a compound of Formula I-2-i’, I-2-ii’, I-2-iii’, or I-2-iv’:
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, or the conjugate of Formula I-2 is a conjugate of Formula I’-2-i’ or I’-2-ii’
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. 19. The compound or conjugate of any one of claims 16-18, wherein Y” is CR3, and R3 is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, or 3- to 12- membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl is optionally substituted with one or more Ru. 20. The compound or conjugate of claim 19, wherein Y” is CR3, and R3 is hydrogen. 21. The compound or conjugate of any one of claims 1-15, wherein R2 and R3, together with the intervening carbon atoms, form Ring A or Ring A’. 117 275501297 v3
22. The compound or conjugate of claim 21, wherein the compound of Formula I-1 is a compound of Formula I-1-v’, I-1-vi’, I-1-vii’, or I-1-viii’:
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, or wherein the conjugate of Formula I-1 is a conjugate of Formula I’-1-iii’ or I’-1-iv’
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. 23. The compound or conjugate of claim 21, wherein the compound of Formula I-2 is a compound of Formula I-2-v’, I-2-vi’, I-2-vii’, or I-2-viii’:
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, or the conjugate of Formula I-2 is a conjugate of Formula I’-2-iii’ or I’-2-iv’ 118 275501297 v3
(I’-2-iii’) or (I’-2-iv’), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. 24. The compound or conjugate of any one of claims 21-23, wherein R1 is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, or 3- to 12-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl is optionally substituted with one or more Ru. 25. The compound or conjugate of claim 24, wherein R1 is hydrogen. 26. The compound or conjugate of any one of claims 1-25, wherein Y’ is CRY’, and RY’ is hydrogen, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, or 3- to 12- membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl is optionally substituted with one or more Ru. 27. The compound or conjugate of claim 26, wherein RY’ is hydrogen. 28. The compound or conjugate of any one of claims 1-27, wherein each Ri is independently oxo, halogen, -CN, -NO2, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C2-6 alkenyl, C2- 6 alkynyl, C6-10 aryl, 5- to 10-membered heteroaryl, C3-12 carbocyclyl, or 3- to 12-membered heterocyclyl, wherein the alkyl, alkoxy, alkylamino, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl is optionally substituted with one or more Ru. 29. The compound or conjugate of any one of claims 1-27, wherein each Ri is independently oxo, -CN, -OH, -NH2, C1-6 alkyl, -NRcS(=O)2Ra, or -NRbC(=O)Ra, , wherein the alkyl is optionally substituted with one or more Ru. 30. The compound or conjugate of any one of claims 1-29, wherein s is 0. 119 275501297 v3
31. The compound or conjugate of any one of claims 1-30, wherein R4 is hydrogen. 32. The compound or conjugate of any one of claims 1-31, wherein q is 1. 33. A compound selected from the compounds in Table 1 and pharmaceutically acceptable salts thereof. 34. A pharmaceutical composition comprising the compound or conjugate of any one of claims 1-33, and a pharmaceutically acceptable excipient. 35. A method of binding cereblon E3 ubiquitin ligase protein complex in a subject or biological sample comprising administering the compound of any one of claims 1-33 to the subject or contacting the biological sample with the compound of any one of claims 1-33. 36. Use of the compound of any one of claims 1-33 in the manufacture of a medicament for binding cereblon E3 ubiquitin ligase protein complex in a subject or biological sample. 37. A compound of any one of claims 1-33 for use in binding cereblon E3 ubiquitin ligase protein complex in a subject or biological sample. 38. A method of degrading a protein in a subject or biological sample comprising administering a conjugate described herein to the subject or contacting the biological sample with a conjugate of any one of claims 6-32. 39. Use of a conjugate of any one of claims 6-32 in the manufacture of a medicament for degrading a protein in a subject or biological sample. 40. A conjugate of any one of claims 6-32 for use in degrading a protein in a subject or biological sample. 41. The method, use, or compound for use of any one of claims 38-40, wherein the protein is an androgen receptor (AR), an estrogen receptor (ER), signal transducer and activator of transcription 3 (STAT3), signal transducer and activator of transcription 5 120 275501297 v3
(STAT5), CREB-binding protein/EP300(E1A) binding protein (CBP/p300), SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A, Member 2/4 (SMARCA2/4), Kirsten rat sarcoma viral oncogene homolog G12D (KRAS G12D), Src homology region 2-containing protein tyrosine phosphatase 2 (SHP2), or bromodomain-containing protein 4 (BRD4). 121 275501297 v3
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263417198P | 2022-10-18 | 2022-10-18 | |
US63/417,198 | 2022-10-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024086644A1 true WO2024086644A1 (en) | 2024-04-25 |
Family
ID=88833656
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/077191 WO2024086644A1 (en) | 2022-10-18 | 2023-10-18 | Cereblon ligands and uses thereof |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024086644A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017161119A1 (en) * | 2016-03-16 | 2017-09-21 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Small molecules against cereblon to enhance effector t cell function |
WO2019043214A1 (en) * | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | Glutarimide |
WO2021143822A1 (en) * | 2020-01-16 | 2021-07-22 | 江苏恒瑞医药股份有限公司 | Bicyclic imide derivative, preparation method thereof, and application thereof in medicine |
-
2023
- 2023-10-18 WO PCT/US2023/077191 patent/WO2024086644A1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017161119A1 (en) * | 2016-03-16 | 2017-09-21 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Small molecules against cereblon to enhance effector t cell function |
WO2019043214A1 (en) * | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | Glutarimide |
WO2021143822A1 (en) * | 2020-01-16 | 2021-07-22 | 江苏恒瑞医药股份有限公司 | Bicyclic imide derivative, preparation method thereof, and application thereof in medicine |
Non-Patent Citations (28)
Title |
---|
"CID 65969820 - PubChem", 24 December 2012, article N-(2 ET AL: "CID 65969820 - PubChem", XP093133485 * |
"Handbook of Chemistry and Physics", article "Periodic Table of the Elements" |
"N-(2,6-dioxopiperidin-3-yl)-2,2-dimethyl-4-oxo-3H-chromene-6-carboxamide | C17H18N2O5 | CID 154810741 - PubChem", 24 November 2020, article N-(2 ET AL: "N-(2,6-dioxopiperidin-3-yl)-2,2-dimethyl-4-oxo-3H-chromene-6-carboxamide | C17H18N2O5 | CID 154810741 - PubChem", XP093133482 * |
"Organic Reactions", vol. 55, 1942, JOHN WILEY & SONS |
BERGE ET AL., J. PHARM. SCI., vol. 66, no. 1, pages 1 - 79 |
CARRUTHERS: "Some Modern Methods of Organic Synthesis", 1987, CAMBRIDGE UNIVERSITY PRESS |
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE OHIO; 11 July 2016 (2016-07-11), XP093134631, retrieved from STN Database accession no. 1949072-70-1 * |
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE OHIO; 15 December 2019 (2019-12-15), XP093134636, retrieved from STN Database accession no. 2390556-23-5 * |
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE OHIO; 2 September 2020 (2020-09-02), XP093134640, retrieved from STN Database accession no. 2470206-59-6 * |
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE OHIO; 2 September 2020 (2020-09-02), XP093134647, retrieved from STN Database accession no. 2470158-52-0 * |
DATABASE REGISTRY [online] chemical abstracts service OHIO; 8 December 2013 (2013-12-08), XP093134629, retrieved from STN Database accession no. 1489606-35-0 * |
E. L. ELIELS. H. WILENL. N. MANDER: "Organic Synthesis: Concepts, Methods, Starting Materials", 1994, WILEY-INTERSCIENCE |
ELIEL: "Stereochemistry of Carbon Compounds", 1962, MCGRAW-HILL |
GENNARO: "Remington: The Science and Practice of Pharmacy", 2005, MACK PUB. CO. |
H. O. HOUSE: "Tables of Resolving Agents and Optical Resolutions", 1972, UNIV. OF NOTRE DAME PRESS, pages: 268 |
HOFFMAN, R.V.: "Organic Chemistry, An Intermediate Text", 1996, OXFORD UNIVERSITY PRESS |
JACQUES ET AL.: "Enantiomers, Racemates and Resolutions", 1981, WILEY INTERSCIENCE |
LAROCK: "Comprehensive Organic Transformations", 1989, VCH PUBLISHERS, INC. |
P. H. STAHLC. G. WERMUTH: "Handbook of Pharmaceutical Salts", vol. 73, 2002, VERLAG HELVETICA CHIMICA ACTA |
S. R. SANDLER ET AL.: "Organic Functional Group Preparations", 1983, JOHN WILEY & SONS, INC. |
SCIENCE, vol. 327, 2010, pages 1345 |
SCIENCE, vol. 343, 2014, pages 305 |
SMITHMARCH: "March's Advanced Organic Chemistry", 2001, JOHN WILEY & SONS, INC. |
SOLOMONS, T. W. G: "Modern Carbonyl Chemistry", 2000, JOHN WILEY & SONS |
STOWELL, J.C.: "Intermediate Organic Chemistry", 1993, WILEY-INTERSCIENCE |
T. L. GILCHRIST: "Advanced Organic Chemistry: Reactions, Mechanisms, and Structure", 1992, WILEY-INTERSCIENCE |
THOMAS SORRELL: "Industrial Organic Chemicals: Starting Materials and Intermediates: An Ullmann's Encyclopedia", vol. 8, 1999, UNIVERSITY SCIENCE BOOKS |
WILEN ET AL., TETRAHEDRON, vol. 33, 1977, pages 2725 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2931730B1 (en) | 4-pyridinonetriazine derivatives as hiv integrase inhibitors | |
KR20170138998A (en) | Fused-ring compounds, pharmaceutical compositions and uses thereof | |
NZ588031A (en) | Bridged heterocycles as hiv integrase inhibitors | |
TW200800182A (en) | Nitrogen-containing heterocyclic derivatives substituted by ring-type groups | |
CA3049816A1 (en) | Thienopyrimidine derivative and use thereof in medicine | |
US11691981B2 (en) | Heterocyclic compounds, preparation methods therefor, and methods of uses thereof | |
AU2019353144B2 (en) | Compounds and compositions for treating conditions associated with APJ receptor activity | |
EP2877469A1 (en) | Substituted naphthyridinedione derivatives as hiv integrase inhibitors | |
CN113474333A (en) | Novel substituted sulfonylurea derivatives | |
WO2023183607A1 (en) | Cereblon ligands and uses thereof | |
WO2024086644A1 (en) | Cereblon ligands and uses thereof | |
WO2023183540A1 (en) | Ikzf2 degraders and uses thereof | |
WO2023069720A1 (en) | Compounds that mediate protein degradation and methods of use thereof | |
WO2023069708A1 (en) | Compounds that mediate protein degradation and uses thereof | |
WO2024015346A1 (en) | Cereblon ligands and uses thereof | |
WO2022111621A1 (en) | Aminoheteroaryl kinase inhibitors | |
WO2024073475A1 (en) | Cereblon ligands and uses thereof | |
EP4069702A1 (en) | Sstr5 antagonists | |
WO2024103069A1 (en) | COMPOUNDS AND COMPOSITIONS AS eIF4E INHIBITORS AND USES THEREOF | |
US20240059711A1 (en) | Cereblon Ligands and Uses Thereof | |
WO2024103067A1 (en) | COMPOUNDS AND COMPOSITIONS AS eIF4E INHIBITORS AND USES THEREOF | |
US20240059704A1 (en) | Cereblon Ligands and Uses Thereof | |
WO2023201012A1 (en) | Ikzf2 degraders and uses thereof | |
WO2024015340A1 (en) | Cereblon ligands and uses thereof | |
WO2024064316A1 (en) | Compounds and compositions as smarca2/4 inhibitors and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23806139 Country of ref document: EP Kind code of ref document: A1 |